
<html lang="en"     class="pb-page"  data-request-id="ffba2fb5-11e5-4b25-aa57-da72e991169c"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.9b00132;website:website:acspubs;issue:issue:10.1021/jmcmar.2019.62.issue-10;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of Potent, Selective, and Short-Acting Peptidic V2 Receptor Agonists" /></meta><meta name="dc.Creator" content="Kazimierz  Wiśniewski" /></meta><meta name="dc.Creator" content="Steve  Qi" /></meta><meta name="dc.Creator" content="John  Kraus" /></meta><meta name="dc.Creator" content="Brian  Ly" /></meta><meta name="dc.Creator" content="Karthik  Srinivasan" /></meta><meta name="dc.Creator" content="Hiroe  Tariga" /></meta><meta name="dc.Creator" content="Glenn  Croston" /></meta><meta name="dc.Creator" content="Erin  La" /></meta><meta name="dc.Creator" content="Halina  Wiśniewska" /></meta><meta name="dc.Creator" content="Carlos  Ortiz" /></meta><meta name="dc.Creator" content="Régent  Laporte" /></meta><meta name="dc.Creator" content="Pierre J.-M.  Rivière" /></meta><meta name="dc.Creator" content="Gebhard  Neyer" /></meta><meta name="dc.Creator" content="Diane M.  Hargrove" /></meta><meta name="dc.Creator" content="Claudio D.  Schteingart" /></meta><meta name="dc.Description" content="The vasopressin analogue desmopressin (desamino-d-arginine8 vasopressin, dDAVP, 1) is a potent vasopressin 2 (V2) receptor (V2R) agonist approved in many countries for the treatment of diabetes ins..." /></meta><meta name="Description" content="The vasopressin analogue desmopressin (desamino-d-arginine8 vasopressin, dDAVP, 1) is a potent vasopressin 2 (V2) receptor (V2R) agonist approved in many countries for the treatment of diabetes ins..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 25, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b00132" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00132" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b00132" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00132" /></link>
        
    
    

<title>Discovery of Potent, Selective, and Short-Acting Peptidic V2 Receptor Agonists | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b00132" /></meta><meta property="og:title" content="Discovery of Potent, Selective, and Short-Acting Peptidic V2 Receptor Agonists" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00132/20190516/images/large/jm-2019-001323_0010.jpeg" /></meta><meta property="og:description" content="The vasopressin analogue desmopressin (desamino-d-arginine8 vasopressin, dDAVP, 1) is a potent vasopressin 2 (V2) receptor (V2R) agonist approved in many countries for the treatment of diabetes insipidus, primary nocturnal enuresis, nocturia, and coagulation disorders. Since 1 is primarily excreted via the kidneys, an age-related decline in kidney function leads to slower elimination, prolonged antidiuresis, and hyponatremia. In search of novel, potent, selective, and short-acting peptidic V2R agonists, we synthesized a series of C-terminally truncated analogues of [Val4]dDAVP, 2, modified in positions 2, 3, and 7 and/or at the disulfide bridge. The peptides were evaluated for in vitro potency at the human V2 receptor, selectivity versus the related receptors (human vasopressin 1a receptor, human vasopressin 1b receptor, and human oxytocin receptor), and pharmacokinetic profiles in rodents and other higher species. The truncated analogues show excellent potency at the V2R, increased systemic clearance, and shorter half-life in rats. Two compounds 19 (c(Bua-Cpa-Thi-Val-Asn-Cys)-Pro-Agm) and 38 (c(Bua-Cpa-Thi-Val-Asn-Cys)-Pro-d-Arg-NEt2) have been selected for clinical development for nocturia." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b00132"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00132">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b00132&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b00132&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b00132&amp;href=/doi/10.1021/acs.jmedchem.9b00132" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 10</span><span class="cit-fg-pageRange">, 4991-5005</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/10" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b00123" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b00176" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Potent, Selective, and Short-Acting Peptidic V<sub>2</sub> Receptor Agonists</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Kazimierz Wiśniewski</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kazimierz Wiśniewski</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Ferring Research Institute Inc., San Diego, California 92121, United States</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#236842594a4e4a4651590d744a504d4a465450484a63454651514a4d440d404c4e"><span class="__cf_email__" data-cfemail="460d273c2f2b2f23343c68112f35282f2331352d2f06202334342f28216825292b">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kazimierz++Wi%C5%9Bniewski">Kazimierz Wiśniewski</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0002-5411" title="Orcid link">http://orcid.org/0000-0003-0002-5411</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Steve Qi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Steve Qi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Ferring Research Institute Inc., San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Steve++Qi">Steve Qi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">John Kraus</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">John Kraus</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Ferring Research Institute Inc., San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=John++Kraus">John Kraus</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Brian Ly</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Brian Ly</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Ferring Research Institute Inc., San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Brian++Ly">Brian Ly</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Karthik Srinivasan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Karthik Srinivasan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Ferring Research Institute Inc., San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Karthik++Srinivasan">Karthik Srinivasan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hiroe Tariga</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hiroe Tariga</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Ferring Research Institute Inc., San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hiroe++Tariga">Hiroe Tariga</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Glenn Croston</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Glenn Croston</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Ferring Research Institute Inc., San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Glenn++Croston">Glenn Croston</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Erin La</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Erin La</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Ferring Research Institute Inc., San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Erin++La">Erin La</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Halina Wiśniewska</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Halina Wiśniewska</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Ferring Research Institute Inc., San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Halina++Wi%C5%9Bniewska">Halina Wiśniewska</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Carlos Ortiz</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Carlos Ortiz</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Ferring Research Institute Inc., San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Carlos++Ortiz">Carlos Ortiz</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Régent Laporte</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Régent Laporte</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Ferring Research Institute Inc., San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=R%C3%A9gent++Laporte">Régent Laporte</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Pierre J.-M. Rivière</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Pierre J.-M. Rivière</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Ferring Research Institute Inc., San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Pierre+J.-M.++Rivi%C3%A8re">Pierre J.-M. Rivière</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gebhard Neyer</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gebhard Neyer</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Ferring Research Institute Inc., San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gebhard++Neyer">Gebhard Neyer</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Diane M. Hargrove</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Diane M. Hargrove</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Ferring Research Institute Inc., San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Diane+M.++Hargrove">Diane M. Hargrove</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Claudio D. Schteingart</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Claudio D. Schteingart</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Ferring Research Institute Inc., San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Claudio+D.++Schteingart">Claudio D. Schteingart</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00132&amp;href=/doi/10.1021%2Facs.jmedchem.9b00132" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 10</span><span class="cit-pageRange">, 4991–5005</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 25, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>22 January 2019</li><li><span class="item_label"><b>Published</b> online</span>25 April 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 23 May 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b00132" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00132</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4991%26pageCount%3D15%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DKazimierz%2BWi%25C5%259Bniewski%252C%2BSteve%2BQi%252C%2BJohn%2BKraus%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D10%26contentID%3Dacs.jmedchem.9b00132%26title%3DDiscovery%2Bof%2BPotent%252C%2BSelective%252C%2Band%2BShort-Acting%2BPeptidic%2BV2%2BReceptor%2BAgonists%26numPages%3D15%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D5005%26publicationDate%3DMay%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b00132"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1089</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">2</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b00132" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Potent, Selective, and Short-Acting Peptidic V2 Receptor Agonists&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Kazimierz&quot;,&quot;last_name&quot;:&quot;Wiśniewski&quot;},{&quot;first_name&quot;:&quot;Steve&quot;,&quot;last_name&quot;:&quot;Qi&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;Kraus&quot;},{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;Ly&quot;},{&quot;first_name&quot;:&quot;Karthik&quot;,&quot;last_name&quot;:&quot;Srinivasan&quot;},{&quot;first_name&quot;:&quot;Hiroe&quot;,&quot;last_name&quot;:&quot;Tariga&quot;},{&quot;first_name&quot;:&quot;Glenn&quot;,&quot;last_name&quot;:&quot;Croston&quot;},{&quot;first_name&quot;:&quot;Erin&quot;,&quot;last_name&quot;:&quot;La&quot;},{&quot;first_name&quot;:&quot;Halina&quot;,&quot;last_name&quot;:&quot;Wiśniewska&quot;},{&quot;first_name&quot;:&quot;Carlos&quot;,&quot;last_name&quot;:&quot;Ortiz&quot;},{&quot;first_name&quot;:&quot;Régent&quot;,&quot;last_name&quot;:&quot;Laporte&quot;},{&quot;first_name&quot;:&quot;Pierre&quot;,&quot;last_name&quot;:&quot;J.-M. Rivière&quot;},{&quot;first_name&quot;:&quot;Gebhard&quot;,&quot;last_name&quot;:&quot;Neyer&quot;},{&quot;first_name&quot;:&quot;Diane&quot;,&quot;last_name&quot;:&quot;M. Hargrove&quot;},{&quot;first_name&quot;:&quot;Claudio&quot;,&quot;last_name&quot;:&quot;D. Schteingart&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;25&quot;,&quot;issue&quot;:&quot;10&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;4991-5005&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b00132&quot;},&quot;abstract&quot;:&quot;The vasopressin analogue desmopressin (desamino-d-arginine8 vasopressin, dDAVP, 1) is a potent vasopressin 2 (V2) receptor (V2R) agonist approved in many countries for the treatment of diabetes insipidus, primary nocturnal enuresis, nocturia, and coagulation disorders. Since 1 is primarily excreted via the kidneys, an age-related decline in kidney function leads to slower elimination, prolonged antidiuresis, and hyponatremia. In search of novel, potent, selective, and short-acting peptidic V2R agonists, we synthesized a series of C-terminally truncated analogues of [Val4]dDAVP, 2, modified in positions 2, 3, and 7 and/or at the disulfide bridge. The peptides were evaluated for in vitro potency at the human V2 receptor, selectivity versus the related receptors (human vasopressin 1a receptor, human vasopressin 1b receptor, and human oxytocin receptor), and pharmacokinetic profiles in rodents and other higher species. The truncated analogues show excellent potency at the V2R, increased systemic clearance, and sh&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00132&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00132" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00132&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00132" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00132&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00132" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00132&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00132&amp;href=/doi/10.1021/acs.jmedchem.9b00132" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b00132" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b00132" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (1 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b00132%26sid%3Dliteratum%253Aachs%26pmid%3D31022340%26genre%3Darticle%26aulast%3DWi%25C5%259Bniewski%26date%3D2019%26atitle%3DDiscovery%2Bof%2BPotent%252C%2BSelective%252C%2Band%2BShort-Acting%2BPeptidic%2BV2%2BReceptor%2BAgonists%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D10%26spage%3D4991%26epage%3D5005%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292589" title="Agonists">Agonists</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/10" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/jmcmar.2019.62.issue-10/20190523/jmcmar.2019.62.issue-10.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00132/20190516/images/medium/jm-2019-001323_0010.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00132/20190516/images/large/jm-2019-001323_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00132&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The vasopressin analogue desmopressin (desamino-<span class="smallcaps smallerCapital">d</span>-arginine<sup>8</sup> vasopressin, dDAVP, <b>1</b>) is a potent vasopressin 2 (V<sub>2</sub>) receptor (V<sub>2</sub>R) agonist approved in many countries for the treatment of diabetes insipidus, primary nocturnal enuresis, nocturia, and coagulation disorders. Since <b>1</b> is primarily excreted via the kidneys, an age-related decline in kidney function leads to slower elimination, prolonged antidiuresis, and hyponatremia. In search of novel, potent, selective, and short-acting peptidic V<sub>2</sub>R agonists, we synthesized a series of C-terminally truncated analogues of [Val<sup>4</sup>]dDAVP, <b>2</b>, modified in positions 2, 3, and 7 and/or at the disulfide bridge. The peptides were evaluated for in vitro potency at the human V<sub>2</sub> receptor, selectivity versus the related receptors (human vasopressin 1a receptor, human vasopressin 1b receptor, and human oxytocin receptor), and pharmacokinetic profiles in rodents and other higher species. The truncated analogues show excellent potency at the V<sub>2</sub>R, increased systemic clearance, and shorter half-life in rats. Two compounds <b>19</b> (c(Bua-Cpa-Thi-Val-Asn-Cys)-Pro-Agm) and <b>38</b> (c(Bua-Cpa-Thi-Val-Asn-Cys)-Pro-<span class="smallcaps smallerCapital">d</span>-Arg-NEt<sub>2</sub>) have been selected for clinical development for nocturia.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43738" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43738" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Arginine vasopressin, AVP, acts on the vasopressin 2 (V<sub>2</sub>) receptor (V<sub>2</sub>R) subtype expressed on principal cells in the collecting ducts of the kidney to induce translocation of aquaporin 2 channels to their apical membrane. This drives an increase in the reabsorption of free water, resulting in the production of more concentrated urine and water conservation. Secretion of AVP by the pituitary gland in response to an increase in plasma osmolality is the primary determinant of water homeostasis in animals and humans.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Its synthetic analogue desmopressin (desamino-<span class="smallcaps smallerCapital">d</span>-Arginine<sup>8</sup> vasopressin, dDAVP), <b>1</b>,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> is the only antidiuretic peptide available on the market to treat conditions where the secretion of endogenous AVP hormone is deficient or absent. Compound <b>1</b> is a potent V<sub>2</sub> agonist, more selective, and devoid of vasopressin 1a receptor (V<sub>1a</sub>R) mediated pressor effects, and with longer plasma half-life than AVP, which makes possible its therapeutic use by bolus administration by the intravenous (iv), oral, and intranasal routes. Since its discovery and first approval in 1972 for diabetes insipidus, <b>1</b> has gained approval over time for the treatment of conditions affecting much larger numbers of patients such as primary nocturnal enuresis (PNE)<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> and nocturia.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> In addition, <b>1</b> is approved for the treatment of coagulation disorders including hemophilia A and von Willebrand’s disease.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5,6)</a> Compound <b>1</b> is generally well tolerated, with most reported adverse effects related to hyponatremia. Hyponatremia is defined as a serum sodium concentration of less than 135 mmol/L,<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> but clinically significant hyponatremia is observed with sodium serum levels below 130 mmol/L.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Symptoms of mild hyponatremia are headache and nausea, but in severe cases, they can progress to confusion, seizures, and coma.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> It is thought that V<sub>2</sub> agonists cause dilutional hyponatremia, which requires two factors to be present simultaneously: protracted duration of antidiuretic activity, that does not allow sufficient time for the kidneys to excrete accumulated water, and higher intake of fluids than necessary for the condition.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> PNE is a multifactorial condition, with a significant polyuria component in many patients. In normal children, plasma concentrations of AVP increase during the night, causing urine concentration and decrease in urine flow to below the functional capacity of the bladder. Polyuric PNE patients appear to lack this diurnal rhythm in the secretion of AVP; thus, nocturnal urine production exceeds functional bladder capacity, and because they do not wake up, they experience enuresis.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Treatment with an appropriate dose of desmopressin before bedtime restores urine concentration for the duration of the night, with no or little effect expected during the following morning due to washout of the drug.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> In children treated with desmopressin for PNE, the incidence of hyponatremia is very low.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> The small number of serious cases appear to have occurred due to the presence of intercurrent illnesses, other medications, longer plasma half-life, or unexpectedly higher drug bioavailability, combined in many cases with documented excessive intake of fluids.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div><div class="NLM_p">Nocturia is defined as the complaint of waking up to void one or more times per night. Its prevalence increases with age, and when the frequency is two or more voids per night, it becomes bothersome due to sleep fragmentation. This may result in reduced quality of life, mood disturbances, poorer overall health, and an increase in falls and fractures.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> The causes of nocturia are multifactorial, but a strong association with nocturnal polyuria has been found<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> and in many patients it can also be treated with desmopressin before bedtime, suggesting that they may also have insufficient release of AVP during the night.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> However, the incidence of clinical and subclinical hyponatremia in this older population is higher than in PNE, which has been mitigated by reduction of the dose and more careful evaluation of patients.<a onclick="showRef(event, 'ref8 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref8 ref17 ref18">(8,17,18)</a> Although hyponatremia may also be multifactorial, one contributing factor may be extended duration of antidiuretic action in the elderly population (together with inappropriate fluid intake). The elimination of <b>1</b> is primarily via passive glomerular filtration into urine by the kidneys,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> and renal impairment or age-related decline in kidney function (glomerular filtration rate, GFR) might lead to slower elimination and extended half-life,<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19,20)</a> which may result in prolonged antidiuresis and ultimately hyponatremia.<a onclick="showRef(event, 'ref10 ref20'); return false;" href="javascript:void(0);" class="ref ref10 ref20">(10,20)</a> The pharmacokinetic (PK) profile of <b>1</b> in humans has been extensively studied.<a onclick="showRef(event, 'ref19 ref21 ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref19 ref21 ref22 ref23 ref24">(19,21−24)</a> In healthy subjects, the systemic clearance (CL) of <b>1</b> was determined to be 7.1 L/h (1.7 mL/(min kg) for 70 kg) with <i>t</i><sub>1/2el</sub> of 2.8 h.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> In patients with severe renal impairment, the CL can be reduced to as low as 0.69 mL/(min kg) and its elimination half-life lengthened to as long as 10 h.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> With the intent of providing antidiuretics with an improved profile in the elderly population, we launched a drug discovery program to identify potent and selective V<sub>2</sub> agonists with shorter half-life than <b>1</b> and elimination mechanism substantially less dependent on passive glomerular filtration by the kidneys.</div><div class="NLM_p">Small-molecule V<sub>2</sub>R agonists have been reported in the literature. Despite the promise of having V<sub>2</sub>R agonists with considerable oral bioavailability, the small molecules VNA-932<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> and OPC-51803<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> have not advanced beyond phase 1 in clinical trials and their current status is unknown. Two other small-molecule compounds appear to be advancing at a slow pace: fedovapagon (VA106483)<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> is currently undergoing a phase 2b/3 study to treat nocturia in men with benign prostatic hyperplasia (<a href="https://clinicaltrials.gov/ct2/show/NCT02637960" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02637960</a>) and ASP-7035<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> is in a phase 2 clinical trial for nocturnal polyuria (<a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003701-25" class="extLink">https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003701-25</a>).</div><div class="NLM_p">Given the modest clinical progress with small-molecule V<sub>2</sub>R agonists and their potential for drug–drug interactions in a population simultaneously treated with a considerable number of other drugs, we decided to undertake a peptide-based drug discovery program.</div><div class="NLM_p">In reporter gene assays (RGAs) at human receptors, <b>1</b> is a very potent V<sub>2</sub> agonist, fairly selective against the oxytocin and V<sub>1b</sub> receptors and completely devoid of V<sub>1a</sub> activity. Its rat plasma protein binding (PPB) is low, and its CL in rats is 7.5 mL/(min kg), which is similar to the GFR in rats (∼9 mL/(min kg)),<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> suggesting that <b>1</b> is cleared mostly by passive glomerular filtration in these animals, confirmed by the very low proportion of nonrenal clearance remaining in nephrectomized rats (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00132/20190516/images/medium/jm-2019-001323_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00132/20190516/images/large/jm-2019-001323_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of reference compounds <b>1</b> (left) and <b>2</b> (right). Sequence positions are numbered at α-carbons.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00132/20190516/images/large/jm-2019-001323_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00132&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Pharmacological Profiles of Reference Peptides <b>1</b> and <b>2</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="char" char="." /></col><col align="char" char="(" /></col><col align="char" char="(" /></col><col align="char" char="(" /></col><col align="char" char="(" /></col><col align="char" char="(" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="±" /></col><col align="left" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">compound</th><th class="colsep0 rowsep0" align="center" char="(">hV<sub>2</sub>R EC<sub>50</sub> (nM) (95%CI, nM)</th><th class="colsep0 rowsep0" align="center" char="(">hOTR EC<sub>50</sub> (nM) (95%CI, nM)</th><th class="colsep0 rowsep0" align="center" char="(">hOTR efficacy (%) (95%CI, %)</th><th class="colsep0 rowsep0" align="center" char="(">hV<sub>1b</sub>R EC<sub>50</sub> (nM) (95%CI, nM)</th><th class="colsep0 rowsep0" align="center" char="(">hV<sub>1b</sub>R efficacy (%) (95%CI, %)</th><th class="colsep0 rowsep0" align="center" char=".">selectivity vs hOTR<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">selectivity vs hV<sub>1b</sub>R<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char="±">rat iv CL ± STD (mL/(min kg))<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">nonrenal CL (%)<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char="±">rat PPB ± STD (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>1</b></td><td class="colsep0 rowsep0" align="char" char="(">0.20 (0.19–0.21)</td><td class="colsep0 rowsep0" align="char" char="(">110 (60–200)</td><td class="colsep0 rowsep0" align="char" char="(">79 (61–97)</td><td class="colsep0 rowsep0" align="char" char="(">11 (6.5–20)</td><td class="colsep0 rowsep0" align="char" char="(">94 (86–101)</td><td class="colsep0 rowsep0" align="char" char=".">550</td><td class="colsep0 rowsep0" align="char" char=".">55</td><td class="colsep0 rowsep0" align="char" char="±">7.5 ± 0.33</td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="char" char="±">41 ± 8.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>2</b></td><td class="colsep0 rowsep0" align="char" char="(">0.05 (0.01–0.20)</td><td class="colsep0 rowsep0" align="char" char="(">350 (220–570)</td><td class="colsep0 rowsep0" align="char" char="(">27 (20–34)</td><td class="colsep0 rowsep0" align="char" char="(">24 (1.1–554)</td><td class="colsep0 rowsep0" align="char" char="(">98 (54–140)</td><td class="colsep0 rowsep0" align="char" char=".">7000</td><td class="colsep0 rowsep0" align="char" char=".">480</td><td class="colsep0 rowsep0" align="char" char="±">9.6 ± 0.87</td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="char" char="±">31 ± 6.3</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">No activity at the human V<sub>1a</sub>R (hV<sub>1a</sub>R) up to 1000 nM; compounds fully efficacious at the human V<sub>2</sub>R (hV<sub>2</sub>R); EC<sub>50</sub> (receptor)/EC<sub>50</sub> (hV<sub>2</sub>R).</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Four animals per compound were used.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Nonrenal CL fraction is calculated as described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>. The CL values in nephrectomized and sham-operated rats are given in <a href="/doi/suppl/10.1021/acs.jmedchem.9b00132/suppl_file/jm9b00132_si_001.pdf" class="ext-link">Table S3</a>, Supporting Information.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">NT: not tested.</p></div></div></div><div class="NLM_p">In-house experience revealed that conservative amino acid modifications of <b>1</b> resulted in peptides with rat CL similar or lower than rat GFR (data not shown). We concluded that to obtain peptides with higher CL in rats and humans we would need to introduce more severe modifications in <b>1</b> in the hope of adding extra-renal mechanisms of clearance, while preserving potency and selectivity at the hV<sub>2</sub> receptor.</div><div class="NLM_p">Structure–activity relationship (SAR) studies to identify peptidic analogues of <b>1</b> with improved pharmacological profiles have been reviewed in the literature.<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31,32)</a> The Val<sup>4</sup> analogue, [Val<sup>4</sup>]dDAVP, <b>2</b>, has been reported to be more potent and selective than <b>1</b> in vivo rat models.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Modifications of position 2 with bulky <span class="smallcaps smallerCapital">l</span>- and <span class="smallcaps smallerCapital">d</span>-β,β-diphenylalanine resulted in potent and selective V<sub>2</sub>R agonists in rat in vivo.<a onclick="showRef(event, 'ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref34 ref35">(34,35)</a> The replacement of Phe<sup>3</sup> with β-(2-thienyl)alanine (Thi) has been reported to increase potency at the V<sub>2</sub>R as compared to <b>2</b>.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Manning et al. investigated the impact of the C-terminal Gly residue removal on the antidiuretic activity of <b>1</b> and <b>2</b> and related peptides in rats. The corresponding desglycine analogues, especially the ones with the C-terminal amide function preserved, retained only 10–50% of the antidiuretic activity of their parent compounds.<a onclick="showRef(event, 'ref37 ref38 ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref37 ref38 ref39 ref40">(37−40)</a></div><div class="NLM_p last">Therefore, we designed and synthesized a series of C-terminally truncated analogues of <b>2</b> modified in positions 2, 3, and 7 and/or at the disulfide bridge. The peptides were evaluated for in vitro potency in RGAs at the human V<sub>2</sub> receptor (hV<sub>2</sub>R), selectivity versus related receptors (hV<sub>1a</sub>R, human vasopressin 1b receptor (hV<sub>1b</sub>R), and human oxytocin receptor (hOTR)), and systemic clearance in rat. The nonrenal component of CL was assessed in bilaterally nephrectomized rats. Plasma protein binding (PPB) in rat plasma was determined by an ultracetrifugation method to help interpret the PK data. Allometric scaling of CL in several species was performed to attempt to predict CL in humans.<a onclick="showRef(event, 'ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref41 ref42">(41,42)</a> Selected analogues were tested for in vivo potency and duration of action in a rat antidiuresis model. We report here on the identification of two promising peptidic V<sub>2</sub> agonists with different rat clearance and elimination half-lives as clinical candidates for the treatment of nocturia and other indications where short duration of antidiuretic action may be desirable.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72827" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72827" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The reference peptides <b>1</b> and <b>2</b> were evaluated for their in vitro potency and selectivity in RGA assays at the human receptors and for PK parameters in rats (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). The in vitro pharmacological profile of <b>1</b> determined in these assays was consistent with the literature data.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Compound <b>1</b> was particularly selective versus the V<sub>1a</sub>R (>1000-fold) presumably due to the desamino modification.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Compound <b>2</b> was more potent as hV<sub>2</sub>R agonist and slightly more selective versus hV<sub>1b</sub>R than <b>1</b>.</div><div class="NLM_p">Our drug discovery program aimed at identifying new analogues with in vitro potency at the hV<sub>2</sub>R similar to <b>1</b> and <b>2</b> and improved selectivity versus the related receptors (hV<sub>1a</sub>, hV<sub>1b</sub>, and hOT), increased CL (>10 mL/(min kg)) in rat, considerable nonrenal clearance component (>50%), and predicted CL in humans from allometric scaling in the range of 3–6 mL/(min kg), which is approximately 1.5–3 times the CL of <b>1</b> in healthy subjects. Assuming that the physiological volume of distribution of the new peptides is similar to that of <b>1</b>, i.e., extracellular fluid, this increase in CL would translate into decreased elimination half-life by a small factor to be determined experimentally. Since nonapeptides based on modified <b>1</b> tended to have similar CL to <b>1</b>, we decided to explore C-terminal desglycineamides as lead series to find out whether they could provide compounds with higher CL and shorter half-life while maintaining potency at the hV<sub>2</sub>R. The removal of the C-terminal Gly residue had been reported to be tolerated by the rat V<sub>2</sub>R (rV<sub>2</sub>R) as the corresponding analogues of <b>1</b> and <b>2</b> retained some activity (48 and 32%, respectively) in a rat antidiuretic assay.<a onclick="showRef(event, 'ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref39 ref40">(39,40)</a> Thus, the C-terminal glycine amide in <b>1</b> was replaced with various functionalities (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, R<sup>3</sup>═H, CH<sub>2</sub>OH, or C(═O)–NHR<sup>4</sup>). To compensate for the expected loss of potency due to the truncation, the Phe<sup>3</sup> residue was replaced with Thi<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> or β-(4-fluorophenyl)alanine (Fpa) and the Gln<sup>4</sup> residue was fixed with Val as <b>2</b> was 4-fold more potent as a hV<sub>2</sub>R agonist than <b>1</b> in our preliminary studies in vitro (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). In addition, the replacement of Gln<sup>4</sup> with Val results in more lipophilic peptide <b>2</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00132/suppl_file/jm9b00132_si_001.pdf" class="ext-link">Table S4</a>, <i>k</i>′ 4.56 for <b>2</b> vs 3.72 for <b>1</b>) and slightly higher rat CL (9.6 mL/(min kg)). In previous work with a family of similarly sized oxytocin analogues, we had found that increased lipophilicity correlated with higher systemic clearance, even when it could be expected to also increase PPB.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> By fixing position 4 with Val, we hoped that the increased lipophilicity of the analogues would result in higher CL values also in this series. For position 2, we employed conservative and more lipophilic replacements of Tyr (β-(4-chlorophenyl)alanine (Cpa), Phe(4-Me), and Phe(4-Et)). Since the Cpa analogue of desamino-arginine8 vasopressin (dAVP) was shown to be a weak antagonist of OTR in a rat uterotonic assay in vitro and was less active than the parent compound as V<sub>1a</sub>R agonist in a rat in vivo pressor assay,<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> these Tyr replacements appeared to be a good strategy to improve selectivity versus the related receptors. The modifications explored in this study, compounds <b>3</b>–<b>43</b>, are summarized in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00132/20190516/images/medium/jm-2019-001323_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00132/20190516/images/large/jm-2019-001323_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Modifications of <b>2</b> explored in this study. Sequence positions are numbered at α-carbons.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00132/20190516/images/large/jm-2019-001323_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00132&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Analogues <b>3</b>–<b>43</b> were synthesized by a combination of solid- and solution-phase chemistry. The linear precursors of <b>3</b>–<b>10</b>, <b>19</b>, <b>38</b>, <b>39</b>, and <b>41</b>–<b>43</b> were assembled on H-Aaa-O-2-ClTrt resins by standard Fmoc chemistry using <i>N</i>,<i>N</i>′-diisopropylcarbodiimide (DIC)/1-hydroxybenzotriazole (HOBt)-mediated couplings. The carba thioether modifications of the disulfide bridge (X or Y = CH<sub>2</sub>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) were introduced to the peptide sequence by coupling Fmoc-Cys((CH<sub>2</sub>)<sub>3</sub>-COOtBu)-OH or Fmoc-Hcy((CH<sub>2</sub>)<sub>2</sub>-COOtBu)-OH.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Fully protected peptide C-terminal acids were cleaved from the resin with 30% 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP)/dichloromethane (DCM). For compounds <b>3</b>–<b>10</b>, the carboxylic group was reduced to the hydroxymethyl group using the mixed anhydride method.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> For Agm compounds <b>38</b>, <b>39</b>, and <b>41</b>–<b>43</b>, the C-terminal acids were coupled with agmatine, and for analogue <b>19</b>, the linear fragment was coupled with H-<span class="smallcaps smallerCapital">d</span>-Arg-NEt<sub>2</sub>. The linear precursor of peptide <b>40</b> was assembled on 1,4-diaminobutane-2-ClTrt resin. After the cleavage from the resin, the C-terminal amino function was temporarily protected with the trifluoroacetyl (TFA)-resistant Z(2-Cl) group and the peptide was deprotected with TFA. The linear precursors of compounds <b>11</b>–<b>18</b> and <b>20</b>–<b>37</b> were synthesized on BAL resin, which was reductively aminated with an appropriate primary amine prior to the peptide assembly (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). The peptides were cleaved with concomitant side chain protecting group removal using the TFA/triisopropylsilane (TIPS)/H<sub>2</sub>O 95/2.5/2.5 cocktail. All peptides with the thioether modifications of the SS bridge were cyclized in solution using the pseudodilution method<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> and 2-(1<i>H</i>-bezotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU)/<i>N</i>-methylmorpholine (NMM) as coupling reagents. The partially protected, cyclic precursor of analogue <b>40</b> was treated with TMSBr/thioanisole/TFA (1/1/6)<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> to remove the Z(2-Cl) group. Peptides <b>11</b> and <b>14</b>, containing the disulfide bridge, were cyclized with iodine in 5% aqueous TFA. All peptides were purified by preparative high-performance liquid chromatography (HPLC) and lyophilized.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00132/20190516/images/medium/jm-2019-001323_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00132/20190516/images/large/jm-2019-001323_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Synthesis of peptide amides <b>11</b>–<b>18</b> and <b>20</b>–<b>37</b>. Synthesis of other compounds discussed in the text (<b>3</b>–<b>10</b>, <b>19</b>, and <b>38</b>–<b>43</b>) is depicted in <a href="/doi/suppl/10.1021/acs.jmedchem.9b00132/suppl_file/jm9b00132_si_001.pdf" class="ext-link">Figures S2 and S3</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00132/20190516/images/large/jm-2019-001323_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00132&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The first chemical series we explored in this study comprised octapeptide alcohols (compounds <b>3</b>–<b>10</b>, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>), in which the C-terminal group R<sup>3</sup> (−C(═O)–Gly–NH<sub>2</sub>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) in compound <b>2</b> was replaced with the hydroxymethyl function and the analogues were also modified in positions 2 and 3 and at the disulfide bridge. The disulfide bridge modifications (X, Y) as well as the configuration of the *C chiral carbon in position 8 had very little impact on V<sub>2</sub>R potency in vitro (compare <b>3</b>–<b>7</b>), but the carba-6 compounds <b>4</b> and <b>6</b> (X = S, Y = CH<sub>2</sub>) were less selective versus hV<sub>1b</sub>R than their carba-1 counterparts <b>3</b>, <b>5</b>, and <b>7</b>–<b>10</b>. Analogues in this series were potent V<sub>2</sub>R agonists with <b>8</b> (Ar = 4-fluorophenyl), <b>9</b>, and <b>10</b> (R<sup>1</sup> = alkyl) being about 5-fold less potent than <b>2</b>. Analogues <b>3</b>–<b>10</b> displayed improved selectivity versus both the V<sub>1b</sub>R (all partial agonists) and OTR except for the native Tyr<sup>2</sup> compounds <b>3</b> and <b>4</b> (R<sup>1</sup> = OH) that were less selective versus hOTR than <b>2</b>, as suggested by literature data.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Since the replacement of the C-terminal group R<sup>3</sup> with the hydroxymethyl group resulted in potent and selective hV<sub>2</sub>R agonists, we evaluated the compounds for their PK properties in male rats. Similarly to <b>1</b>, the Tyr<sup>2</sup> compounds (<b>3</b>, <b>4</b>, R<sup>1</sup> = OH) showed low PPB in rats, whereas the 4-chloro analogues <b>6</b>–<b>8</b> exhibited surprisingly high binding. The 4-alkyl-substituted analogues had intermediate PPB values. Despite their low free fraction (<15%), which should result in a proportionally lower rate of elimination by glomerular filtration, the total clearance in rats of analogues <b>7</b>, <b>9</b>, and <b>10</b> was still markedly high, suggesting that a new, nonrenal, elimination mechanism was operating.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Pharmacological Properties of Peptide Alcohols <b>3</b>–<b>10</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00132/20190516/images/medium/jm-2019-001323_0007.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="(" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char="."> </th><th class="rowsep1 colsep0" colspan="5" align="center">structure</th><th class="rowsep1 colsep0" colspan="6" align="center" char="(">pharmacological data<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char="±"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">compound</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">Ar</th><th class="colsep0 rowsep0" align="center">X</th><th class="colsep0 rowsep0" align="center">Y</th><th class="colsep0 rowsep0" align="center">C* config</th><th class="colsep0 rowsep0" align="center" char="(">hV<sub>2</sub>R EC<sub>50</sub> (nM) (95%CI, nM)</th><th class="colsep0 rowsep0" align="center">hOTR EC<sub>50</sub> (nM) (95%CI, nM)</th><th class="colsep0 rowsep0" align="center">hV<sub>1b</sub>R EC<sub>50</sub> (nM) (95%CI, nM)</th><th class="colsep0 rowsep0" align="center">selectivity<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a> vs hV<sub>1b</sub>R</th><th class="colsep0 rowsep0" align="center" char="±">rat iv CL ± STD (mL/(min kg))<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">nonrenal CL (%)<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center" char="±">rat PPB ± STD (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>3</b></td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">2Thi</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="char" char="(">0.10 (0.04–0.22)</td><td class="colsep0 rowsep0" align="left">230<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a> (100–540)</td><td class="colsep0 rowsep0" align="left">520 (180–1500)</td><td class="colsep0 rowsep0" align="left">5200</td><td class="colsep0 rowsep0" align="char" char="±">8.1 ± 0.77</td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t2fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="char" char="±">15 ± 3.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>4</b></td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">2Thi</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">R</td><td class="colsep0 rowsep0" align="char" char="(">0.08 (0.03–0.19)</td><td class="colsep0 rowsep0" align="left">160<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a> (46–520)</td><td class="colsep0 rowsep0" align="left">58 (26–130)</td><td class="colsep0 rowsep0" align="left">720</td><td class="colsep0 rowsep0" align="char" char="±">6.9 ± 0.83</td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t2fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="char" char="±">26 ± 1.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>5</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">2Thi</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">R</td><td class="colsep0 rowsep0" align="char" char="(">0.10 (0.04–0.27)</td><td class="colsep0 rowsep0" align="left">>10 000<a class="ref internalNav" href="#t2fn7" aria-label="g">g</a> N/A</td><td class="colsep0 rowsep0" align="left">140 (51–390)</td><td class="colsep0 rowsep0" align="left">1400</td><td class="colsep0 rowsep0" align="char" char="±">4.0 ± 1.7</td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t2fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="char" char="±">80 ± 1.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>6</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">2Thi</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">R</td><td class="colsep0 rowsep0" align="char" char="(">0.08 (0.03–0.21)</td><td class="colsep0 rowsep0" align="left">>10 000<a class="ref internalNav" href="#t2fn7" aria-label="g">g</a> N/A</td><td class="colsep0 rowsep0" align="left">64 (11–360)</td><td class="colsep0 rowsep0" align="left">800</td><td class="colsep0 rowsep0" align="char" char="±">2.8 ± 0.46</td><td class="colsep0 rowsep0" align="left">66</td><td class="colsep0 rowsep0" align="char" char="±">89 ± 5.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>7</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">2Thi</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="char" char="(">0.14 (0.10–0.19)</td><td class="colsep0 rowsep0" align="left">>10 000<a class="ref internalNav" href="#t2fn7" aria-label="g">g</a> N/A</td><td class="colsep0 rowsep0" align="left">380 (140–1000)</td><td class="colsep0 rowsep0" align="left">2700</td><td class="colsep0 rowsep0" align="char" char="±">8.1 ± 0.43</td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t2fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="char" char="±">81 ± 0.53</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>8</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">Fpa</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">R</td><td class="colsep0 rowsep0" align="char" char="(">0.35 (0.12–1.1)</td><td class="colsep0 rowsep0" align="left">>10 000<a class="ref internalNav" href="#t2fn7" aria-label="g">g</a> N/A</td><td class="colsep0 rowsep0" align="left">220 (95–530)</td><td class="colsep0 rowsep0" align="left">620</td><td class="colsep0 rowsep0" align="char" char="±">3.8 ± 0.14</td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t2fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="char" char="±">93 ± 0.23</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>9</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">2Thi</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">R</td><td class="colsep0 rowsep0" align="char" char="(">0.39 (0.23–0.66)</td><td class="colsep0 rowsep0" align="left">>10 000<a class="ref internalNav" href="#t2fn7" aria-label="g">g</a> N/A</td><td class="colsep0 rowsep0" align="left">810 (250–2600)</td><td class="colsep0 rowsep0" align="left">2000</td><td class="colsep0 rowsep0" align="char" char="±">5.3 ± 0.41</td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="char" char="±">68 ± 0.69</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>10</b></td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">2Thi</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="char" char="(">0.35 (0.19–0.65)</td><td class="colsep0 rowsep0" align="left">>10 000<a class="ref internalNav" href="#t2fn7" aria-label="g">g</a> N/A</td><td class="colsep0 rowsep0" align="left">>10 000<a class="ref internalNav" href="#t2fn6" aria-label="f">f</a> N/A</td><td class="colsep0 rowsep0" align="left">>28 000</td><td class="colsep0 rowsep0" align="char" char="±">9.4 ± 1.3</td><td class="colsep0 rowsep0" align="left">80</td><td class="colsep0 rowsep0" align="char" char="±">84 ± 0.29</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">No activity at the hV<sub>1a</sub>R up to 1000 nM.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">EC<sub>50</sub> (hV<sub>1b</sub>R)/EC<sub>50</sub> (hV<sub>2</sub>R).</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">Four animals per compound were used.</p></div><div class="footnote" id="t2fn4"><sup><sup>d</sup></sup><p class="last">See footnote (c), <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</p></div><div class="footnote" id="t2fn5"><sup><sup>e</sup></sup><p class="last">Partial agonist.</p></div><div class="footnote" id="t2fn6"><sup><sup>f</sup></sup><p class="last">NT: not tested.</p></div><div class="footnote" id="t2fn7"><sup><sup>g</sup></sup><p class="last">No activity at the hOTR or hV<sub>1b</sub>R up to 10 000 nM, the highest concentration tested. Efficacy values are given in <a href="/doi/suppl/10.1021/acs.jmedchem.9b00132/suppl_file/jm9b00132_si_001.pdf" class="ext-link">Table S1</a>.</p></div></div></div><div class="NLM_p">Next, we explored if the C-terminal glycine amide (R<sup>3</sup> = −C(═O)–Gly–NH<sub>2</sub>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) in <b>2</b> could be replaced with alkyl groups (R<sup>3</sup> = −C(═O)–NR<sup>4</sup>R<sup>5</sup>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>; compounds <b>11</b>–<b>37</b>, <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Based on the results for the hydroxymethyl series, we selected the structure of the cyclic part as the one in compounds <b>5</b>–<b>7</b> (R<sup>1</sup> = Cl, Ar = 2-thienyl). Thus, one compound with that ring structure and the carba-1 modification (X = CH<sub>2</sub>, Y = S) was initially prepared for each alkyl group R<sup>4</sup> (R<sup>5</sup> = H). In addition, we prepared analogue <b>19</b> (where R<sup>4</sup> = R<sup>5</sup> = Et). For some more promising leads (R<sup>4</sup> = Et, <i>i</i>-Bu, Bn), compounds with other combinations of groups R<sup>1</sup>, Ar, X, and Y were also synthesized. In addition, we tested two modifications of Pro<sup>7</sup> (Z = CH<sub>2</sub>): thiaproline (Thz) (Z = S) and <i>trans</i>-hydroxyproline (Hyp) (Z = CH(OH), R configuration). Surprisingly, a variety of substituents R<sup>4</sup> (i.e., Bn) were well tolerated by the hV<sub>2</sub>R and a rather shallow SAR for in vitro potency at this receptor was observed. Even the diethyl amide <b>19</b> (R<sup>4</sup> = R<sup>5</sup> = Et) was only a slightly less potent hV<sub>2</sub>R agonist than <b>1</b>. The isopropyl compound <b>23</b> (R<sup>4</sup> = <i>i</i>-Pr) was the least potent hV<sub>2</sub>R agonist in this subset. The Thz<sup>7</sup> and Hyp<sup>7</sup> modifications were somewhat advantageous for hV<sub>2</sub> potency as exemplified by compounds <b>16</b> and <b>17</b>, the most potent analogues in this series. Compounds <b>3</b>–<b>37</b> were all less potent and therefore more selective vs. the hV<sub>1b</sub>R than the reference compounds <b>1</b> and <b>2</b>. This reduced potency/increased selectivity could possibly be explained by the binding model of AVP to the hV<sub>1b</sub>R.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> According to the model, all residues in the AVP molecule including C-terminal Gly contribute to binding to the hV<sub>1b</sub>R, so its removal may lead to the reduced binding and agonistic potency. Similarly to the peptide alcohol series, the carba-1 analogues in the amide series (<b>11</b>–<b>37</b>) were more selective vs. the hV<sub>1b</sub>R than their carba-6 counterparts (compare <b>12</b> vs <b>13</b> or <b>17</b> vs <b>18</b>) with the exception of isobutyl amides <b>27</b> and <b>28</b> where the carba-6 compound <b>28</b> was more selective than the carba-1 analogue <b>27</b>.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Structure and Pharmacological Properties of Peptide Alkylamides <b>11</b>–<b>37</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00132/20190516/images/medium/jm-2019-001323_0008.gif" alt="" id="fx2" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="(" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char="."> </th><th class="rowsep1 colsep0" colspan="6" align="center">structure<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="3" align="center">pharmacological data<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">compound</th><th class="colsep0 rowsep0" align="center">Ar</th><th class="colsep0 rowsep0" align="center">X</th><th class="colsep0 rowsep0" align="center">Y</th><th class="colsep0 rowsep0" align="center">Z</th><th class="colsep0 rowsep0" align="center">R<sup>4 </sup><a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char="(">hV<sub>2</sub>R EC<sub>50</sub> (nM) (95%CI, nM)</th><th class="colsep0 rowsep0" align="center">hV<sub>1b</sub>R EC<sub>50</sub> (nM) (95%CI, nM)</th><th class="colsep0 rowsep0" align="center">selectivity vs hV<sub>1b</sub>R<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center">rat iv CL ± STD (mL/(min kg))<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a></th><th class="colsep0 rowsep0" align="center">nonrenal CL (%)<a class="ref internalNav" href="#t3fn6" aria-label="f">f</a></th><th class="colsep0 rowsep0" align="center">rat PPB ± STD (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>11</b></td><td class="colsep0 rowsep0" align="left">2-thienyl</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="char" char="(">0.32 (0.16–0.61)</td><td class="colsep0 rowsep0" align="left">>10 000<a class="ref internalNav" href="#t3fn7" aria-label="g">g</a> N/A</td><td class="colsep0 rowsep0" align="left">>31 000</td><td class="colsep0 rowsep0" align="left">11 ± 0.78</td><td class="colsep0 rowsep0" align="left">81</td><td class="colsep0 rowsep0" align="left">88 ± 1.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>12</b></td><td class="colsep0 rowsep0" align="left">2-thienyl</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="char" char="(">0.29 (0.10–0.82)</td><td class="colsep0 rowsep0" align="left">170 (71–420)</td><td class="colsep0 rowsep0" align="left">5800</td><td class="colsep0 rowsep0" align="left">10 ± 2.5</td><td class="colsep0 rowsep0" align="left">49</td><td class="colsep0 rowsep0" align="left">84 ± 1.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>13</b></td><td class="colsep0 rowsep0" align="left">2-thienyl</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="char" char="(">0.19 (0.09–0.38)</td><td class="colsep0 rowsep0" align="left">120 (49–310)</td><td class="colsep0 rowsep0" align="left">630</td><td class="colsep0 rowsep0" align="left">5.3 ± 0.79</td><td class="colsep0 rowsep0" align="left">67</td><td class="colsep0 rowsep0" align="left">90 ± 1.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>14</b></td><td class="colsep0 rowsep0" align="left">Ph</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="char" char="(">0.38 (0.29–0.51)</td><td class="colsep0 rowsep0" align="left">>10 000<a class="ref internalNav" href="#t3fn7" aria-label="g">g</a> N/A</td><td class="colsep0 rowsep0" align="left">>26 000</td><td class="colsep0 rowsep0" align="left">7.1 ± 0.42</td><td class="colsep0 rowsep0" align="left">47</td><td class="colsep0 rowsep0" align="left">95 ± 0.30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>15</b></td><td class="colsep0 rowsep0" align="left">Ph</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">CH(OH)</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="char" char="(">0.29 (0.15–0.55)</td><td class="colsep0 rowsep0" align="left">150 (28–820)</td><td class="colsep0 rowsep0" align="left">510</td><td class="colsep0 rowsep0" align="left">3.3 ± 0.19</td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t3fn8" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="left">91 ± 0.53</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>16</b></td><td class="colsep0 rowsep0" align="left">2-thienyl</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">CH(OH)</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="char" char="(">0.10 (0.04–0.28)</td><td class="colsep0 rowsep0" align="left">260 (70–960)</td><td class="colsep0 rowsep0" align="left">2600</td><td class="colsep0 rowsep0" align="left">4.0 ± 0.53</td><td class="colsep0 rowsep0" align="left">58</td><td class="colsep0 rowsep0" align="left">90 ± 0.86</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>17</b></td><td class="colsep0 rowsep0" align="left">2-thienyl</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="char" char="(">0.10 (0.07–0.15)</td><td class="colsep0 rowsep0" align="left">160 (120–220)</td><td class="colsep0 rowsep0" align="left">1600</td><td class="colsep0 rowsep0" align="left">28 ± 12</td><td class="colsep0 rowsep0" align="left">80</td><td class="colsep0 rowsep0" align="left">93 ± 2.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>18</b></td><td class="colsep0 rowsep0" align="left">2-thienyl</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="char" char="(">0.11 (0.06–0.20)</td><td class="colsep0 rowsep0" align="left">40 (15–110)</td><td class="colsep0 rowsep0" align="left">360</td><td class="colsep0 rowsep0" align="left">11 ± 1.2</td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t3fn8" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="left">92 ± 0.84</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>19</b></td><td class="colsep0 rowsep0" align="left">2-thienyl</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">Et<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char="(">0.25 (0.14–0.44)</td><td class="colsep0 rowsep0" align="left">530 (420–690)</td><td class="colsep0 rowsep0" align="left">2100</td><td class="colsep0 rowsep0" align="left">42 ± 5.2</td><td class="colsep0 rowsep0" align="left">60</td><td class="colsep0 rowsep0" align="left">92 ± 9.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>20</b></td><td class="colsep0 rowsep0" align="left">2-thienyl</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char="(">0.27 (0.14–0.44)</td><td class="colsep0 rowsep0" align="left">350 (170–730)</td><td class="colsep0 rowsep0" align="left">1200</td><td class="colsep0 rowsep0" align="left">9.1 ± 0.57</td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t3fn8" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="left">82 ± 0.79</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>21</b></td><td class="colsep0 rowsep0" align="left">2-thienyl</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">Pr</td><td class="colsep0 rowsep0" align="char" char="(">0.33 (0.06–1.7)</td><td class="colsep0 rowsep0" align="left">250 (100–620)</td><td class="colsep0 rowsep0" align="left">750</td><td class="colsep0 rowsep0" align="left">26 ± 1.9</td><td class="colsep0 rowsep0" align="left">59</td><td class="colsep0 rowsep0" align="left">84 ± 1.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>22</b></td><td class="colsep0 rowsep0" align="left">2-thienyl</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">Pr</td><td class="colsep0 rowsep0" align="char" char="(">0.21 (0.09–0.49)</td><td class="colsep0 rowsep0" align="left">120 (85–180)</td><td class="colsep0 rowsep0" align="left">570</td><td class="colsep0 rowsep0" align="left">31 ± 11</td><td class="colsep0 rowsep0" align="left">90</td><td class="colsep0 rowsep0" align="left">83 ± 0.85</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>23</b></td><td class="colsep0 rowsep0" align="left">2-thienyl</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left"><i>i</i>-Pr</td><td class="colsep0 rowsep0" align="char" char="(">0.45 (0.16–1.2)</td><td class="colsep0 rowsep0" align="left">580 (330–1000)</td><td class="colsep0 rowsep0" align="left">1200</td><td class="colsep0 rowsep0" align="left">15 ± 0.88</td><td class="colsep0 rowsep0" align="left">58</td><td class="colsep0 rowsep0" align="left">85 ± 0.67</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>24</b></td><td class="colsep0 rowsep0" align="left">2-thienyl</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">cPr</td><td class="colsep0 rowsep0" align="char" char="(">0.23 (0.10–0.51)</td><td class="colsep0 rowsep0" align="left">480 (190–1200)</td><td class="colsep0 rowsep0" align="left">2000</td><td class="colsep0 rowsep0" align="left">10 ± 3.8</td><td class="colsep0 rowsep0" align="left">67</td><td class="colsep0 rowsep0" align="left">91 ± 3.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>25</b></td><td class="colsep0 rowsep0" align="left">2-thienyl</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>cPr</td><td class="colsep0 rowsep0" align="char" char="(">0.21 (0.13–0.34)</td><td class="colsep0 rowsep0" align="left">320 (160–660)</td><td class="colsep0 rowsep0" align="left">1500</td><td class="colsep0 rowsep0" align="left">21 ± 1.5</td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t3fn8" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="left">84 ± 2.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>26</b></td><td class="colsep0 rowsep0" align="left">2-thienyl</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">Bu</td><td class="colsep0 rowsep0" align="char" char="(">0.26 (0.18–0.38)</td><td class="colsep0 rowsep0" align="left">190 (140–250)</td><td class="colsep0 rowsep0" align="left">730</td><td class="colsep0 rowsep0" align="left">31 ± 2.9</td><td class="colsep0 rowsep0" align="left">57</td><td class="colsep0 rowsep0" align="left">89 ± 1.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>27</b></td><td class="colsep0 rowsep0" align="left">2-thienyl</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left"><i>i</i>-Bu</td><td class="colsep0 rowsep0" align="char" char="(">0.22 (0.12–0.41)</td><td class="colsep0 rowsep0" align="left">210 (170–270)</td><td class="colsep0 rowsep0" align="left">950</td><td class="colsep0 rowsep0" align="left">24 ± 4.2</td><td class="colsep0 rowsep0" align="left">63</td><td class="colsep0 rowsep0" align="left">86 ± 0.72</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>28</b></td><td class="colsep0 rowsep0" align="left">2-thienyl</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left"><i>i</i>-Bu</td><td class="colsep0 rowsep0" align="char" char="(">0.22 (0.10–0.50)</td><td class="colsep0 rowsep0" align="left">>10 000<a class="ref internalNav" href="#t3fn7" aria-label="g">g</a> N/A</td><td class="colsep0 rowsep0" align="left">>45 000</td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t3fn8" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t3fn8" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t3fn8" aria-label="h">h</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>29</b><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">2-thienyl</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left"><i>i</i>-Bu</td><td class="colsep0 rowsep0" align="char" char="(">0.29 (0.12–0.67)</td><td class="colsep0 rowsep0" align="left">>10 000<a class="ref internalNav" href="#t3fn7" aria-label="g">g</a> N/A</td><td class="colsep0 rowsep0" align="left">>34 000</td><td class="colsep0 rowsep0" align="left">51 ± 1.9</td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t3fn8" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="left">84 ± 2.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>30</b></td><td class="colsep0 rowsep0" align="left">2-thienyl</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">CH(OH)</td><td class="colsep0 rowsep0" align="left"><i>i</i>-Bu</td><td class="colsep0 rowsep0" align="char" char="(">0.23 (0.06–0.84)</td><td class="colsep0 rowsep0" align="left">480 (130–1800)</td><td class="colsep0 rowsep0" align="left">2000</td><td class="colsep0 rowsep0" align="left">7.8 ± 1.6</td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t3fn8" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="left">87 ± 1.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>31</b></td><td class="colsep0 rowsep0" align="left">Ph</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left"><i>i</i>-Bu</td><td class="colsep0 rowsep0" align="char" char="(">0.27 (0.10–0.68)</td><td class="colsep0 rowsep0" align="left">46 (10–210)</td><td class="colsep0 rowsep0" align="left">170</td><td class="colsep0 rowsep0" align="left">5.4 ± 0.98</td><td class="colsep0 rowsep0" align="left">88</td><td class="colsep0 rowsep0" align="left">95 ± 0.81</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>32</b></td><td class="colsep0 rowsep0" align="left">2-thienyl</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">CH(OH)</td><td class="colsep0 rowsep0" align="left"><i>i</i>-Bu</td><td class="colsep0 rowsep0" align="char" char="(">0.20 (0.09–0.46)</td><td class="colsep0 rowsep0" align="left">130 (50–360)</td><td class="colsep0 rowsep0" align="left">650</td><td class="colsep0 rowsep0" align="left">5.9 ± 0.35</td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t3fn8" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="left">92 ± 0.60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>33</b></td><td class="colsep0 rowsep0" align="left">2-thienyl</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">Bn</td><td class="colsep0 rowsep0" align="char" char="(">0.19 (0.13–0.29)</td><td class="colsep0 rowsep0" align="left">150 (100–220)</td><td class="colsep0 rowsep0" align="left">780</td><td class="colsep0 rowsep0" align="left">23 ± 3.3</td><td class="colsep0 rowsep0" align="left">84</td><td class="colsep0 rowsep0" align="left">90 ± 1.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>34</b><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">2-thienyl</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">Bn</td><td class="colsep0 rowsep0" align="char" char="(">0.26 (0.21–0.32)</td><td class="colsep0 rowsep0" align="left">150 (82–270)</td><td class="colsep0 rowsep0" align="left">570</td><td class="colsep0 rowsep0" align="left">14 ± 1.1</td><td class="colsep0 rowsep0" align="left">71</td><td class="colsep0 rowsep0" align="left">45 ± 0.82</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>35</b></td><td class="colsep0 rowsep0" align="left">2-thienyl</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">Bn</td><td class="colsep0 rowsep0" align="char" char="(">0.31 (0.20–0.49)</td><td class="colsep0 rowsep0" align="left">330 (160–660)</td><td class="colsep0 rowsep0" align="left">1000</td><td class="colsep0 rowsep0" align="left">38 ± 20</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">91 ± 1.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>36</b></td><td class="colsep0 rowsep0" align="left">2-thienyl</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">EtThi</td><td class="colsep0 rowsep0" align="char" char="(">0.17 (0.12–0.24)</td><td class="colsep0 rowsep0" align="left">96 (73–130)</td><td class="colsep0 rowsep0" align="left">560</td><td class="colsep0 rowsep0" align="left">34 ± 0.89</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">93 ± 0.30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>37</b></td><td class="colsep0 rowsep0" align="left">Ph(4-F)</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">EtThi</td><td class="colsep0 rowsep0" align="char" char="(">0.30 (0.16–0.56)</td><td class="colsep0 rowsep0" align="left">100 (96–110)</td><td class="colsep0 rowsep0" align="left">330</td><td class="colsep0 rowsep0" align="left">27 ± 5.9</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">96 ± 1.0</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">All compounds of R configuration at C* except for <b>29</b>. Compounds <b>15</b>, <b>16</b>, <b>30</b>, and <b>32</b> contain Hyp (Z = CH(OH), the carbon atom of R configuration). R<sup>1</sup> is Cl for all compounds except for <b>34</b> for which it is OH.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">No activity at the hV<sub>1a</sub>R up to 1000 nM, no activity at the hOTR up to 10 000 nM, the highest concentration tested for all compounds except for <b>35</b> (EC<sub>50</sub> = 140 nM at 32% efficacy); efficacy values at the hV<sub>1b</sub>R in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b00132/suppl_file/jm9b00132_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">R<sup>5</sup> = H for all compounds except for <b>19</b> where R<sup>5</sup> = Et.</p></div><div class="footnote" id="t3fn4"><sup><sup>d</sup></sup><p class="last">EC<sub>50</sub> (hV<sub>1b</sub>R)/EC<sub>50</sub> (hV<sub>2</sub>R).</p></div><div class="footnote" id="t3fn5"><sup><sup>e</sup></sup><p class="last">Four animals per compound were used.</p></div><div class="footnote" id="t3fn6"><sup><sup>f</sup></sup><p class="last">See footnote (c), <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</p></div><div class="footnote" id="t3fn7"><sup><sup>g</sup></sup><p class="last">No activity up to 10 000 nM, the highest concentration tested.</p></div><div class="footnote" id="t3fn8"><sup><sup>h</sup></sup><p class="last">NT: not tested.</p></div></div></div><div class="NLM_p">A wide range of total systemic CL values in the rat were observed in this alkylamide series. Generally, rat CL increased with the increasing lipophilicity/number of carbon atoms in the alkyl groups. Within the compounds of the substructure c(Bua-Cpa-2Thi-Val-Asn-Cys)-Pro-<span class="smallcaps smallerCapital">d</span>-Arg-NR<sup>4</sup>R<sup>5</sup> (<b>12</b>, <b>19</b>–<b>21</b>, <b>23</b>–<b>27</b>, and <b>33</b>), the methyl amide analogue <b>20</b> displayed the lowest CL (9.1 mL/(min kg)) and the diethyl analogue <b>19</b> had the highest CL (42 mL/(min kg)). Cyclic or branched alkyl groups resulted in lower CL than their straight alkyl equivalents (compare propyl peptides <b>21</b>, <b>23</b>, and <b>24</b> or butyl analogues <b>25</b>–<b>27</b>). The modifications of the disulfide bridge had considerable effect on rat CL. As we observed in our previous study with OT analogues,<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> the carba-6 modification (X = CH<sub>2</sub>, Y = S) yielded compounds with lower CL than their carba-1 and disulfide bridged counterparts. For instance, for the carba-6 ethyl amide <b>13</b>, the CL value was 5.3 mL/(min kg), whereas its disulfide bridge analogue <b>11</b> and the carba-1 counterpart <b>12</b> showed higher CL values of 11 and 10 mL/(min kg), respectively. In all cases where the pair was available, the carba-1 analogue had markedly higher CL than the corresponding carba-6 analogue (compare <b>17</b> and <b>18</b>, <b>27</b> and <b>28</b>, or <b>30</b> and <b>32</b>). The Pro<sup>7</sup> modification with a more polar amino acid Hyp (Z = CH(OH)) resulted in analogues with drastically reduced CL (compare <b>15</b> vs <b>12</b> or <b>30</b> vs <b>27</b>), whereas the replacement with less polar Thz (Z = S) led in most cases to CL increases (e.g., <b>17</b> vs <b>12</b> or <b>22</b> vs <b>21</b>). Changing the configuration of the C-terminal Arg residue in compound <b>27</b> to S resulted in analogue <b>29</b> with the second highest CL in the series.</div><div class="NLM_p">Selected compounds were tested for nonrenal contributions to CL in rats. All new analogues tested in the series showed high (>50%) extra-renal CL. Some compounds (<b>35</b>–<b>37</b>) were cleared exclusively by nonrenal mechanisms (CL<sub>nr</sub> = 100%), a rather unusual phenomenon for small peptides. The presence of an aromatic ring in the amide alkyl and the sulfur atom in the pyrrolidine ring (Z = S) were the structural motifs facilitating high CL<sub>nr</sub>. All compounds in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, except <b>34</b>, had similar rat PPB, which was higher than 80%. Since the passive glomerular elimination rate should be proportional to the free fraction of the peptide, it would be expected that its contribution to the total clearance in rats would be less than ∼2 mL/(min kg) (CL<sub>r</sub> = <i>f</i><sub>u</sub>·GFR). We can rationalize the observed total rat CL values as arising from this residual kidney clearance of the free peptide plus the contribution of nonrenal clearance, which clearly depends on the structure of the peptide, can be very high, and apparently not hindered by PPB. We note that removing the kidneys from the circulation in nephrectomized rats eliminates not only passive glomerular filtration but also the possibility of active kidney tubular excretion of any drug. However, to the best of our knowledge, active tubular secretion of peptides has not been described in the literature. In this work, we will refer to renal clearance as a synonym of passive glomerular filtration. The mechanisms of the extra-renal clearance of peptides <b>3</b>–<b>43</b> are not known at this time, but the most likely candidates are proteolysis and transport into organs. Other than the tendency for more lipophilic compounds to have higher total rat clearance and the carba-1 modification, a clear SAR correlation for CL is not immediately apparent.</div><div class="NLM_p">Finally, we investigated if the substituent R<sup>3</sup> in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> is actually required to preserve high agonist potency at the hV<sub>2</sub>R (compounds <b>38</b>–<b>43</b>, <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>) and the consequences of its removal on PK. To design such compounds, we applied the SAR lessons learned with the hydroxymethyl and <i>N</i>-alkylamide series (<b>3</b>–<b>37</b>). In this subset, only the carba-1-modified analogues (X = CH<sub>2</sub>, Y = S in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) were prepared. Somewhat surprisingly, the compounds in this series turned out to be potent hV<sub>2</sub>R agonists in vitro. Particularly, <b>38</b> was found to be very potent as a hV<sub>2</sub>R agonist (EC<sub>50</sub> = 0.07 nM) and considerably more selective than <b>1</b> or <b>2</b> versus the related receptors. Interestingly, we found that the guanidine function (R<sup>6</sup> = C(═NH)–NH<sub>2</sub>) was not essential for hV<sub>2</sub>R activation. Analogue <b>40</b> in which the guanidine function was replaced with a less basic primary amine (R<sup>6</sup> = H in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>) retained very good potency in vitro and displayed an excellent selectivity profile. All compounds were inactive at the hV<sub>1a</sub> and hOT receptors, including <b>41</b>, which carries a Tyr<sup>2</sup> (R<sup>1</sup> = OH). CL values in this series were similar to the ones of small alkylamide compounds (compare <b>38</b> with <b>12</b> or <b>20</b>) and generally followed the trends observed in the previous series. As expected, the Thz<sup>7</sup>-containing peptide <b>42</b> (Z = S) showed the highest CL (16 mL/(min kg)) in the subset. Compound <b>40</b> displayed a similar PK profile (CL = 7.2 mL/(min kg), CL<sub>nr</sub> = 19%) to that of <b>1</b>, which suggests that the presence of the native Tyr<sup>2</sup> (R<sup>1</sup> = OH), which severely reduces PPB, should be avoided if a reduction in renal CL is desired.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Structure and Pharmacological Properties of Peptides <b>38</b>–<b>43</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00132/20190516/images/medium/jm-2019-001323_0009.gif" alt="" id="fx3" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="(" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char="."> </th><th class="rowsep1 colsep0" colspan="4" align="center">structure</th><th class="rowsep1 colsep0" colspan="5" align="center" char="(">pharmacological data<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char="±"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">compound</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">Ar</th><th class="colsep0 rowsep0" align="center">Z</th><th class="colsep0 rowsep0" align="center">R<sup>6</sup></th><th class="colsep0 rowsep0" align="center" char="(">hV<sub>2</sub>R EC<sub>50</sub> (nM) (95%CI, nM)</th><th class="colsep0 rowsep0" align="center">hV<sub>1b</sub>R EC<sub>50</sub> (nM) (95%CI, nM)</th><th class="colsep0 rowsep0" align="center">selectivity vs hV<sub>1b</sub>R<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char="±">rat iv CL ± STD (mL/(min kg))<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">nonrenal CL (%)<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center" char="±">rat PPB ± STD (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>38</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">2Thi</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">C(═NH)NH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char="(">0.07 (0.04–0.11)</td><td class="colsep0 rowsep0" align="left">110 (87–130)</td><td class="colsep0 rowsep0" align="left">1500</td><td class="colsep0 rowsep0" align="char" char="±">14 ± 1.3</td><td class="colsep0 rowsep0" align="left">57</td><td class="colsep0 rowsep0" align="char" char="±">85 ± 1.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>39</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">Fpa</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">C(═NH)NH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char="(">0.31 (0.10–0.98)</td><td class="colsep0 rowsep0" align="left">140 (98–210)</td><td class="colsep0 rowsep0" align="left">450</td><td class="colsep0 rowsep0" align="char" char="±">7.5 ± 2.0</td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="char" char="±">94 ± 0.29</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>40</b></td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">2Thi</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char="(">0.19 (0.08–0.46)</td><td class="colsep0 rowsep0" align="left">>10 000<a class="ref internalNav" href="#t4fn6" aria-label="f">f</a> N/A</td><td class="colsep0 rowsep0" align="left">>52 000</td><td class="colsep0 rowsep0" align="char" char="±">7.2 ± 0.8</td><td class="colsep0 rowsep0" align="left">18</td><td class="colsep0 rowsep0" align="char" char="±">42 ± 30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>41</b></td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">Fpa</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">C(═NH)NH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char="(">0.10 (0.03–0.35)</td><td class="colsep0 rowsep0" align="left">180 (120–260)</td><td class="colsep0 rowsep0" align="left">1800</td><td class="colsep0 rowsep0" align="char" char="±">8.7 ± 0.52</td><td class="colsep0 rowsep0" align="left">45</td><td class="colsep0 rowsep0" align="char" char="±">31 ± 20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>42</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">2Thi</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">C(═NH)NH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char="(">0.12 (0.08–0.20)</td><td class="colsep0 rowsep0" align="left">140 (94–210)</td><td class="colsep0 rowsep0" align="left">1100</td><td class="colsep0 rowsep0" align="char" char="±">16 ± 4.2</td><td class="colsep0 rowsep0" align="left">90</td><td class="colsep0 rowsep0" align="char" char="±">84 ± 0.79</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>43</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">Fpa</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">C(═NH)NH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char="(">0.22 (0.10–0.45)</td><td class="colsep0 rowsep0" align="left">110 (96–140)</td><td class="colsep0 rowsep0" align="left">500</td><td class="colsep0 rowsep0" align="char" char="±">9.9 ± 0.63</td><td class="colsep0 rowsep0" align="left">85</td><td class="colsep0 rowsep0" align="char" char="±">96 ± 0.23</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">No activity at the hV<sub>1a</sub>R up to 1000 nM, no activity at the hOTR up to 10 000 nM, the highest concentration tested for all compounds except for <b>40</b> (EC<sub>50</sub> = 650 nM at 28% efficacy).</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">EC<sub>50</sub> (hV<sub>1b</sub>R)/EC<sub>50</sub> (hV<sub>2</sub>R).</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">Four animals per compound were used.</p></div><div class="footnote" id="t4fn4"><sup><sup>d</sup></sup><p class="last">See footnote (c), <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</p></div><div class="footnote" id="t4fn5"><sup><sup>e</sup></sup><p class="last">NT: not tested.</p></div><div class="footnote" id="t4fn6"><sup><sup>f</sup></sup><p class="last">No activity up to 10 000 nM, the highest concentration tested.</p></div></div></div><div class="NLM_p">The SAR studies described above produced a relatively high number of compounds, which are potent and selective at hV<sub>2</sub>R and have moderately high PPB, high total rat CL, and significant contribution from extra-renal CL, but with no easy way to identify those that might have human CL in the 3–6 mL/(min kg) range we desired. We then decided to investigate whether allometric scaling<a onclick="showRef(event, 'ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref41 ref42">(41,42)</a> of CL might offer an avenue for selection. Compounds with no or low PPB and exclusive elimination by passive glomerular filtration would be expected to exhibit reasonable allometric scaling of their CL because GFR itself scales allometrically.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> However, the compounds of our interest were designed and selected to have a low proportion of total CL from elimination by passive glomerular filtration, and a priori there was no expectation that the extra-renal component of elimination would also scale allometrically. Moreover, we had no evidence that the PPB of the peptides would be similar in various animal species and in humans. Rather than trying to dissect the various factors that could determine CL in animals and humans, we decided to attempt an empirical correlation of total CL versus body weight (BW) in rats (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Tables <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>), dogs, cynomolgus monkeys, and pigs (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00132/suppl_file/jm9b00132_si_001.pdf" class="ext-link">Table S2</a> in the Supporting Information). The rationale being that if we found compounds with good allometric scaling of CL across four species, they would also have a high probability of continuing the correlation to humans. This would increase our confidence that the value of CL extrapolated allometrically to humans might be observed in the clinic. We selected for this study compounds with rat total CL ≥ 10 mL/(min kg), excellent potency/selectivity profile in vitro, high (>50%) nonrenal CL component in rats (<b>11</b>, <b>12</b>, <b>17</b>, <b>19</b>, <b>21</b>, <b>23</b>, <b>24</b>, <b>26</b>, <b>27</b>, <b>33</b>, and <b>38</b>), and two carba-6 peptides with low rat CL (<b>16</b> and <b>31</b>) as they might be informative on the scope of any emerging allometric scaling relationship. We excluded peptides with very high CL in rat (>45 mL/(min kg), e.g., <b>29</b>) as well as the few ones with very high fraction (≥85%) of nonrenal CL in rat (e.g., <b>35</b>–<b>37</b>, <b>42</b>). Whole-body CL was graphed as a function of body weight in log–log allometric scaling plots (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>), and the data fitted to the standard allometric equation<span class="NLM_disp-formula" id="ueq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00132/20190516/images/medium/jm-2019-001323_m001.gif" alt="" id="_i8" /></img></span>The values of the allometric coefficient <i>a</i> and the exponent <i>b</i> were obtained from the corresponding trend lines from rat, cyno, dog, and pig CL data. The regression coefficient of the correlation <i>R</i><sup>2</sup> and the value of <i>b</i> were used as measures of goodness of the allometric correlation. The predicted values of whole-body CL (CL<sub>wb</sub>) and the CL per kg body weight for humans were calculated assuming a BW = 70 kg (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00132/20190516/images/medium/jm-2019-001323_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00132/20190516/images/large/jm-2019-001323_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Allometric scaling for selected compounds. Panel A (compound <b>31</b>, carba-6), B (<b>11</b>, disulfide), C (<b>19</b>, carba-1), and D (<b>38</b>, carba-1). The CL values used to construct the graphs are listed in the Supporting Information (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00132/suppl_file/jm9b00132_si_001.pdf" class="ext-link">Tables S1 and S2</a>). The CL values are represented by blue diamonds (rat), red dots (cyno), orange squares (dog), and green triangles (pig). Three animals per compound were used with the exception of rat experiments where four animals were used. Additional allometric scaling plots are shown in <a href="/doi/suppl/10.1021/acs.jmedchem.9b00132/suppl_file/jm9b00132_si_001.pdf" class="ext-link">Figure S1</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00132/20190516/images/large/jm-2019-001323_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00132&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Allometric Scaling Parameters and Predicted CL in Humans for Selected Compounds</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">compound</th><th class="colsep0 rowsep0" align="center" char="."><i>a</i><a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char="."><i>b</i><a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char="."><i>R</i><sup>2</sup></th><th class="colsep0 rowsep0" align="center" char=".">whole-body CL (predicted, mL/min)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">CL (predicted, mL/(min kg))<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>1</b></td><td class="colsep0 rowsep0" align="char" char=".">5.338</td><td class="colsep0 rowsep0" align="char" char=".">0.742</td><td class="colsep0 rowsep0" align="char" char=".">0.981</td><td class="colsep0 rowsep0" align="char" char=".">129</td><td class="colsep0 rowsep0" align="char" char=".">1.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>11</b></td><td class="colsep0 rowsep0" align="char" char=".">9.220</td><td class="colsep0 rowsep0" align="char" char=".">0.786</td><td class="colsep0 rowsep0" align="char" char=".">0.962</td><td class="colsep0 rowsep0" align="char" char=".">260</td><td class="colsep0 rowsep0" align="char" char=".">3.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>12</b></td><td class="colsep0 rowsep0" align="char" char=".">6.950</td><td class="colsep0 rowsep0" align="char" char=".">0.722</td><td class="colsep0 rowsep0" align="char" char=".">0.942</td><td class="colsep0 rowsep0" align="char" char=".">151</td><td class="colsep0 rowsep0" align="char" char=".">2.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>16</b></td><td class="colsep0 rowsep0" align="char" char=".">4.576</td><td class="colsep0 rowsep0" align="char" char=".">0.992</td><td class="colsep0 rowsep0" align="char" char=".">0.989</td><td class="colsep0 rowsep0" align="char" char=".">310</td><td class="colsep0 rowsep0" align="char" char=".">4.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>17</b></td><td class="colsep0 rowsep0" align="char" char=".">17.064</td><td class="colsep0 rowsep0" align="char" char=".">0.678</td><td class="colsep0 rowsep0" align="char" char=".">0.996</td><td class="colsep0 rowsep0" align="char" char=".">305</td><td class="colsep0 rowsep0" align="char" char=".">4.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>19</b></td><td class="colsep0 rowsep0" align="char" char=".">24.685</td><td class="colsep0 rowsep0" align="char" char=".">0.633</td><td class="colsep0 rowsep0" align="char" char=".">0.999</td><td class="colsep0 rowsep0" align="char" char=".">365</td><td class="colsep0 rowsep0" align="char" char=".">5.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>27</b></td><td class="colsep0 rowsep0" align="char" char=".">16.063</td><td class="colsep0 rowsep0" align="char" char=".">0.673</td><td class="colsep0 rowsep0" align="char" char=".">0.964</td><td class="colsep0 rowsep0" align="char" char=".">280</td><td class="colsep0 rowsep0" align="char" char=".">4.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>31</b></td><td class="colsep0 rowsep0" align="char" char=".">7.689</td><td class="colsep0 rowsep0" align="char" char=".">0.910</td><td class="colsep0 rowsep0" align="char" char=".">0.912</td><td class="colsep0 rowsep0" align="char" char=".">368</td><td class="colsep0 rowsep0" align="char" char=".">5.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>33</b></td><td class="colsep0 rowsep0" align="char" char=".">19.092</td><td class="colsep0 rowsep0" align="char" char=".">0.798</td><td class="colsep0 rowsep0" align="char" char=".">0.968</td><td class="colsep0 rowsep0" align="char" char=".">568</td><td class="colsep0 rowsep0" align="char" char=".">8.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>38</b></td><td class="colsep0 rowsep0" align="char" char=".">10.917</td><td class="colsep0 rowsep0" align="char" char=".">0.787</td><td class="colsep0 rowsep0" align="char" char=".">0.995</td><td class="colsep0 rowsep0" align="char" char=".">309</td><td class="colsep0 rowsep0" align="char" char=".">4.4</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Allometry equation parameters.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">For CL calculations, 70 kg body weight was assumed. For corresponding graphs, see <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.9b00132/suppl_file/jm9b00132_si_001.pdf" class="ext-link">S1</a>.</p></div></div></div><div class="NLM_p">The values of <i>R</i><sup>2</sup> and visual inspection of the plots in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.9b00132/suppl_file/jm9b00132_si_001.pdf" class="ext-link">S1</a> show that many compounds did not scale allometrically, e.g. <b>11</b> and <b>31</b>, while others did it very well, e.g., <b>19</b> and <b>38</b>. Given the small number of peptides tested, we could not establish an effect of the bridge substitution pattern (carba-1, carba-6, disulfide) on the correlation. However, the analogues with the best allometric scaling, <b>17</b>, <b>19</b>, and <b>38</b> (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>, <i>b</i> < 0.85, <i>R</i><sup>2</sup> > 0.98), have the carba-1 substitution. They also extrapolate to a predicted CL in humans in the 3–6 mL/(min kg) range. With both <b>17</b> and <b>38</b> having the same predicted CL in humans (4.4 mL/(min kg)), compound <b>38</b> was preferred over <b>17</b> due to its marginally better potency in vitro (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Tables <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). Therefore, two analogues, <b>19</b> (higher predicted CL in humans, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, panel C) and <b>38</b> (lower predicted CL in humans, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, panel D), were chosen for further evaluation in vivo.</div><div class="NLM_p">To confirm that the lead peptides were potent and short-acting in vivo, we tested the reference <b>1</b> and compounds <b>19</b> and <b>38</b> in a rat model of antidiuresis, which required knowing their potency at the rV<sub>2</sub> receptor. The in vitro potency of the three compounds at the rat V<sub>2</sub>R was similar (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>) but substantially higher than at the human V<sub>2</sub> receptor (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>, and <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). A constant intravenous infusion of the peptide was instituted in euvolemic rats to establish a known steady-state plasma concentration (<i>C</i><sub>ss</sub>), and the antidiuretic activity was determined by measuring cumulative weight of urine output from 0 to 180 min. The infusion rate <i>R</i><sub>0</sub> required to establish each <i>C</i><sub>ss</sub> was calculated using the value of CL for the compound (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>) with the equation <i>R</i><sub>0</sub> = CL. <i>C</i><sub>ss</sub>. It was not possible to verify the established plasma concentrations <i>C</i><sub>ss</sub> experimentally as they are well below the limit of quantification of even modern liquid chromatography–mass spectrometry (LC–MS) methods when only a small volume of blood sample is available.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Rat Pharmacological Profiles of Compounds Selected for in Vivo Testing</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="char" char="." /></col><col align="char" char="(" /></col><col align="char" char="(" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">compound</th><th class="colsep0 rowsep0" align="center" char="(">rV<sub>2</sub>R EC<sub>50</sub> (nM) (95%CI, nM)</th><th class="colsep0 rowsep0" align="center" char="(">rV<sub>2</sub>R efficacy (%) (95%CI, %)</th><th class="colsep0 rowsep0" align="center" char="±">rat iv CL ± STD (mL/(min kg))<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char="±">rat iv <i>t</i><sub>1/2el</sub> ± STD (min)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char="±">rat PPB ± STD (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>1</b></td><td class="colsep0 rowsep0" align="char" char="(">0.03 (0.03–0.04)</td><td class="colsep0 rowsep0" align="char" char="(">100 (N/A–N/A)<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">7.5 ± 0.33</td><td class="colsep0 rowsep0" align="char" char="±">40 ± 5.2</td><td class="colsep0 rowsep0" align="char" char="±">41 ± 8.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>19</b></td><td class="colsep0 rowsep0" align="char" char="(">0.05 (0.03–0.11)</td><td class="colsep0 rowsep0" align="char" char="(">91 (80–102)</td><td class="colsep0 rowsep0" align="char" char="±">42 ± 5.2</td><td class="colsep0 rowsep0" align="char" char="±">6.4 ± 0.65</td><td class="colsep0 rowsep0" align="char" char="±">92 ± 9.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>38</b></td><td class="colsep0 rowsep0" align="char" char="(">0.02 (0.01–0.04)</td><td class="colsep0 rowsep0" align="char" char="(">99 (89–110)</td><td class="colsep0 rowsep0" align="char" char="±">14 ± 1.3</td><td class="colsep0 rowsep0" align="char" char="±">16 ± 3.0</td><td class="colsep0 rowsep0" align="char" char="±">85 ± 1.0</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">Four animals per compound were used.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">Reference compound.</p></div></div></div><div class="NLM_p">The results of the in vivo study are summarized in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> and <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a> and tabulated in <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>. Analogues <b>19</b> and <b>38</b>, infused at a range of doses to achieve target <i>C</i><sub>ss</sub> of 0.3–100 pM, produced dose-related decreases in urine output with similar maximal efficacy to <b>1</b>.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00132/20190516/images/medium/jm-2019-001323_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00132/20190516/images/large/jm-2019-001323_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Comparison of in vivo antidiuretic potency and maximal effect of <b>1</b> and <b>19</b> (left graph) and <b>1</b> and <b>38</b> (right graph) in normal euvolemic rats assessed by measuring the weight of cumulative urine output at 3 h of intravenous infusion. Shown are mean ± standard error values of the mean (SEM) for urine output in <i>N</i> = 200 vehicle-treated animals and 15–20 compound-treated animals at each target <i>C</i><sub>ss</sub> (error bars that are not visible are encompassed within the symbol). Fitted parameters for dose–response are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00132/20190516/images/large/jm-2019-001323_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00132&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00132/20190516/images/medium/jm-2019-001323_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00132/20190516/images/large/jm-2019-001323_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Rat antidiuretic time course at maximally effective target <i>C</i><sub>ss</sub>. Time courses of <b>19</b> (left graph) and <b>38</b> (right graph) (30 and 100 pM) compared to <b>1</b>. Peptides were infused iv through 180 min at doses to rapidly achieve and maintain the indicated target <i>C</i><sub>ss</sub>, and cumulative urine weight was measured. At 180 min, peptide infusion was stopped and urine output was measured for an additional 300 min. Shown are the mean urine output values in <i>N</i> = 200 vehicle-treated animals and 16–20 compound-treated animals. Error bars (only shown at 60 min intervals for clarity) indicate ±SEM in each treatment group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00132/20190516/images/large/jm-2019-001323_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00132&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Dose–Response Analysis of Compound <b>1</b>, <b>19</b>, or <b>38</b> Effect on Urine Output at 3 h of Intravenous Infusion in Normal Euvolemic Rats<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="–" /></col><col align="char" char="." /></col><col align="char" char="–" /></col><col align="char" char="." /></col><col align="char" char="–" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">compound</th><th class="colsep0 rowsep0" align="center" char=".">ECp<sub>50</sub> (target <i>C</i><sub>ss</sub>, pM)</th><th class="colsep0 rowsep0" align="center" char="–">95% confidence interval for ECp<sub>50</sub> (target <i>C</i><sub>ss</sub>, pM)</th><th class="colsep0 rowsep0" align="center" char=".">top (g)</th><th class="colsep0 rowsep0" align="center" char="–">95% confidence interval for top (g/3 h)</th><th class="colsep0 rowsep0" align="center" char=".">maximal effect (bottom) (g/3 h)</th><th class="colsep0 rowsep0" align="center" char="–">95% confidence interval for maximal effect (g/3 h)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>1</b></td><td class="colsep0 rowsep0" align="char" char=".">0.32</td><td class="colsep0 rowsep0" align="char" char="–">0.28–0.40</td><td class="colsep0 rowsep0" align="char" char=".">5.2</td><td class="colsep0 rowsep0" align="char" char="–">5.0–5.3</td><td class="colsep0 rowsep0" align="char" char=".">0.99</td><td class="colsep0 rowsep0" align="char" char="–">0.91–1.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>19</b></td><td class="colsep0 rowsep0" align="char" char=".">0.43</td><td class="colsep0 rowsep0" align="char" char="–">0.10–1.8</td><td class="colsep0 rowsep0" align="char" char=".">5.0</td><td class="colsep0 rowsep0" align="char" char="–">3.7–6.4</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td><td class="colsep0 rowsep0" align="char" char="–">0.26–1.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>38</b></td><td class="colsep0 rowsep0" align="char" char=".">0.64</td><td class="colsep0 rowsep0" align="char" char="–">0.26–1.5</td><td class="colsep0 rowsep0" align="char" char=".">5.0</td><td class="colsep0 rowsep0" align="char" char="–">4.2–5.8</td><td class="colsep0 rowsep0" align="char" char=".">1.3</td><td class="colsep0 rowsep0" align="char" char="–">0.82–1.8</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">Reported are best-fit values and 95% confidence intervals (CIs) from dose–response curve analysis. Potency was expressed as the ECp<sub>50</sub>, the effective plasma concentration of the compound causing half-maximal suppression of urine output; maximal effect to suppress urine output was reported as the bottom in the dose–response fit, and 16–20 animals were used at each target <i>C</i><sub>ss</sub>.</p></div></div></div><div class="NLM_p">When expressed in terms of effective plasma concentrations (ECp<sub>50</sub>), the potencies of <b>19</b> and <b>38</b> were also similar to <b>1</b>. Notably, the values of in vivo ECp<sub>50</sub> were in the subpicomolar range, whereas their in vitro potencies were in the 20–50 pM range (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). This result was not unexpected as both AVP<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> and <b>1</b><a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> are known to have single-digit pM potency in humans and animals. This appears to be a consequence of the exquisite downstream amplification of the effect relayed via the V<sub>2</sub> receptor in the principal cells of the collecting ducts of the kidney, which is not fully reflected in artificial-cell-based assays. It is interesting to note that <b>1</b> is about a 100-fold more potent in vivo in rats than in the cell-based assay, while <b>19</b> and <b>38</b> are only 10 times more potent (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a> vs <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). This may be due to the much higher PPB of <b>19</b> and <b>38</b> in rats than of <b>1</b>.</div><div class="NLM_p last">To investigate whether the higher CL of <b>19</b> and <b>38</b> in rats translated into a shorter duration of antidiuretic action compared to <b>1</b>, we examined the time required to restore urine output after stopping an intravenous infusion of <b>19</b> and <b>38</b> at 180 min (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). Vehicle-treated animals exhibited normal diuresis with increasing cumulative urine output throughout the 8 h time course. During the compound infusion period (0–180 min), maximally effective doses of <b>1</b>, <b>19</b>, and <b>38</b> suppressed urine output by ∼80% compared to vehicle treatment. After stopping an infusion of <b>1</b> at a rate to target <i>C</i><sub>ss</sub> of 30 pM, the compound continued suppressing urine output for an additional 5 h, as could be reasonably expected from its half-life of 60 min and its ECp<sub>50</sub> of 0.32 pM in these animals. By contrast, after terminating an infusion of <b>19</b> to target <i>C</i><sub>ss</sub> of 30 or 100 pM, the diuresis recovered in about 1 h, in accordance with its much shorter 12 min half-life. After terminating an infusion of <b>38</b> targeted to <i>C</i><sub>ss</sub> of 100 pM, diuresis recovered within about 1 h, but at a reduced urine production rate for the following hours, which can be rationalized by its intermediate half-life of 20 min and slightly lower potency ECp<sub>50</sub> of 0.64 pM in rats. At the end of an infusion of <b>38</b> to target <i>C</i><sub>ss</sub> of 30 pM, the recovery of diuresis was almost immediate and at a faster urine production rate. We concluded that at least in this rat antidiuresis model compounds <b>19</b> and <b>38</b> are very potent antidiuretics with sub-pM ECp<sub>50</sub> values in spite of their higher PPB and exhibit shorter duration of action than <b>1</b> in response to their higher CL and shorter half-lives.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02455" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02455" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">A series of novel C-terminally truncated analogues of <b>1</b> and <b>2</b> with improved in vitro pharmacological profile and higher systemic clearance have been identified. These novel compounds retain the potent V<sub>2</sub> receptor agonistic activity of <b>1</b> and display substantially improved selectivities versus the related hV<sub>1a</sub>R, hV<sub>1b</sub>R, and hOTR as compared to <b>1</b>. The C-terminal modifications described herein resulted in analogues with desirable PK profiles (CL<sub>analogue</sub> > CL<sub><b>1</b></sub>, nonrenal CL > 50%) and, in some cases, good allometric scaling in four species. However, as it would be unreasonable to expect that allometric scaling would predict the CL of these peptides in humans with any great accuracy, two compounds from different chemical series, <b>19</b> (FE 202217) and <b>38</b> (FE 201836), have been selected for clinical development as potential treatments for nocturia and other indications requiring short duration of antidiuretic action.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54340" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54340" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Chemistry</h3><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15"> General</h4><div class="NLM_p">Amino acid derivatives were purchased from commercial providers (Aapptec, EMD Millipore, Bachem, and Peptides International). Resins were purchased from commercial suppliers (PCAS BioMatrix Inc. and EMD Millipore). All additional reagents, chemicals, and solvents were purchased from Sigma-Aldrich and VWR. Fmoc-Cys((CH<sub>2</sub>)<sub>3</sub>-COOtBu)-OH (the carba-1 derivative) and Fmoc-Hcy((CH<sub>2</sub>)<sub>2</sub>-COOtBu)-OH (the carba-6 derivative) were synthesized as described previously.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Noncommercial H-Aaa-2ClTrt resins were prepared according to a literature procedure.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a></div><div class="NLM_p">Preparative HPLC was performed on a Waters Prep LC System using a PrepPack cartridge Delta-Pack C18, 300 Å, 15 μm, 47 × 300 mm<sup>2</sup>, at a flow rate of 100 mL/min and/or on a Phenomenex Luna C18 column, 100 Å, 5 μm, 30 × 100 mm<sup>2</sup>, at a flow rate of 40 mL/min. Analytical reverse-phase HPLC was performed on an Agilent Technologies 1200rr series liquid chromatograph using an Agilent Zorbax C18 column, 1.8 μm, 4.6 × 110 mm<sup>2</sup>, at a flow rate of 1.5 mL/min.</div><div class="NLM_p last">Final purity of analogues was assessed on a 1100 Agilent liquid chromatograph using the following analytical method: column: Vydac C18, 5 μm, 2.1 × 250 mm<sup>2</sup>; column temperature: 40 °C; flow rate: 0.3 mL/min; solvent A: 0.01% aqueous TFA; solvent B, 70% CH<sub>3</sub>CN, 0.01% TFA; and gradient: 0–20% B in 1 min, then 20–40% B in 20 min, and then held at 100% B for 5 min; when necessary, the first two segments of the gradient were adjusted for compound lipophilicity; UV detection at 214 nm; injection volume: 5 μL, and sample concentration: 0.5 mg/mL in 0.1% TFA. The purity of all analogues exceeded 95% (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00132/suppl_file/jm9b00132_si_001.pdf" class="ext-link">Table S4</a>). Mass spectra were recorded on a MAT Finnigan LCQ electrospray mass spectrometer.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> Synthesis of Peptide Alcohols <b>3</b>–<b>10</b></h4><div class="NLM_p last">The linear precursors of the peptides were assembled on H-Arg(Pbf)-2ClTrt resin (commercially available) or H-<span class="smallcaps smallerCapital">d</span>-Arg(Pbf)-2ClTrt resin using a Tribute peptide synthesizer (Protein Technologies Inc.). The Fmoc protecting group was removed with multiple 20% PIP/dimethylformamide (DMF) treatments. The couplings were mediated by HBTU/NMM or DIC/HOBt for Cys. The Boc-protecting group was used at the N-terminus. The fully protected linear peptides were cleaved from resin with 30% HFIP/DCM. The C-terminal carboxylic group was reduced to the hydroxymethyl function by the mixed anhydride method.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> The peptide alcohols were deprotected with the TFA/TIPS/H<sub>2</sub>O 96:2:2 cocktail, and the linear peptides were cyclized in DMF under pseudo-high dilution conditions<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> using the HBTU/NMM coupling method. The cyclization reaction mixture was diluted with 10 volumes of 0.1% aqueous TFA and loaded onto the HPLC column. The peptides were purified in a TFA-based buffer and eluted from the column with a gradient of acetonitrile. Where necessary, a second purification in a TFA-based buffer was performed.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> Synthesis of Peptide Secondary Amides <b>11</b>–<b>18</b> and <b>20</b>–<b>37</b></h4><div class="NLM_p last">FMPB AM resin (EMD Millipore, cat # 855028) was suspended in the DCM/trimethyl orthoformate 1:1 mixture. An appropriate primary amine and solid sodium triacetoxyborohydride were subsequently added to the suspension. The resins were shaken overnight and washed with MeOH and DMF. The desired sequences were assembled on the Tribute synthesizer. The crude peptide amides were cleaved with the TFA/TIPS/H<sub>2</sub>O 96:2:2 cocktail and cyclized and purified as described above.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> Synthesis of Compound <b>19</b></h4><div class="NLM_p last">A detailed protocol to prepare the compound has been recently published by us.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> The protected linear peptide was assembled manually starting from 7.8 g (6.9 mmol) of H-Pro-2ClTrt AM resin (EMD Millipore, cat # 856057, 0.88 mmol/g) using single, DIC/HOBt-mediated couplings in DMF with a 3-fold excess of activated Fmoc-protected amino acids. The following amino acid derivatives were used to assemble the resin-bound peptide: Fmoc-Cys((CH<sub>2</sub>)<sub>3</sub>COOtBu)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Val-OH, Fmoc-Thi-OH, and Boc-Cpa-OH. Removal of the Fmoc protecting group was achieved with a single 30 min wash of the peptide resin with 20% piperidine in DMF. The fully protected peptide was cleaved with the DCM/HFIP 7:3 (v/v) cocktail (2 × 1 h, 30 mL each). The cleavage cocktails were pooled, the solvents were evaporated, and the crude peptide was precipitated with ethyl ether, filtered, and dried in vacuo. Then, 5.79 g (4.63 mmol, 67%) of the product was obtained.</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> H-<span class="smallcaps smallerCapital">d</span>-Arg-NEt<sub>2</sub> × 2TFA</h4><div class="NLM_p last">First, 2.81 g (5.4 mmol) of Boc-<span class="smallcaps smallerCapital">d</span>-Arg(Pbf)-OH (Chem Impex, cat # 05282), 1.95 mL (11.2 mmol) of <i>N</i>,<i>N</i>-diisopropyl-<i>N</i>-ethylamine (DIPEA), and 2.13 g (5.6 mmol) of HBTU were dissolved in 10 mL of DMF, and 0.62 mL (6 mmol) of diethylamine was subsequently added to the solution. No substrate was detected by analytical HPLC after 5 min. The reaction mixture was poured into 500 mL of water, and the precipitate was separated by centrifugation/decantation and dried in vacuo. The residue was treated with 20 mL of TFA/TIPS/H<sub>2</sub>O (96/2/2, v/v/v) for 1 h, and the solvents were evaporated. The residue was treated with diethyl ether, decanted, and dried. Then, 1.65 g (3.6 mmol, 67%) of a semisolid derivative was obtained, which was used in the subsequent step without purification.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> Boc-Cpa-Thi-Val-Asn(Trt)-Cys((CH<sub>2</sub>)<sub>3</sub>-COOtBu)-Pro-<span class="smallcaps smallerCapital">d</span>-Arg-NEt<sub>2</sub></h4><div class="NLM_p last">The linear protected peptide (2.3 g, ca. 1.86 mmol) and 0.76 g (2 mmol) of HBTU were dissolved in 10 mL of DMF containing 1.46 mL (8.4 mmol) of DIPEA. Then, 0.93 g (2.05 mmol) of H-<span class="smallcaps smallerCapital">d</span>-Arg(Pbf)-OH × 2TFA in 1 mL of DMF was subsequently added to the reaction mixture. No substrate-protected peptide was detected after 5 min by HPLC. The product was precipitated with 1 L of water, filtered off, and dried in vacuo. Then, 2.6 g (1.78 mmol, 96%) of crude protected linear peptide was obtained.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> c(Bua-Cpa-Thi-Val-Asn-Cys)-Pro-<span class="smallcaps smallerCapital">d</span>-Arg-NEt<sub>2</sub>, <b>19</b></h4><div class="NLM_p last">The fully protected peptide was treated with 20 mL of TFA/TIPS/H<sub>2</sub>O (96/2/2, v/v/v) for 1 h, and the solvents were evaporated. The unprotected linear peptide was precipitated with ethyl ether and lyophilized. The entire amount of the linear peptide (1.82 g, 1.55 mmol) was dissolved in 50 mL of DMF. A solution of 0.59 g (ca. 1.55 mmol) of HBTU in 10 mL of DMF was also prepared. The peptide solution and the activator solution were added interchangeably to 50 mL of vigorously stirred DMF containing 200 μL of DIPEA in 10 portions of 5 mL and 1 mL, respectively. The pH was maintained at 9–10 with the addition of neat DIPEA. No substrate peak was detected by HPLC after the last portions of the activator and peptide solutions have been added. The reaction mixture was diluted with 0.1% AcOH to 1 L. The obtained solution was loaded directly onto an HPLC prep column and purified as described above. The fractions with a purity exceeding 93%, determined by reverse-phase analytical HPLC, were pooled, diluted with two volumes of water, and reloaded onto the column. The column was washed with five volumes of 0.1 M AcONH<sub>4</sub> and one volume of 1% AcOH. The compound was subsequently eluted with a fast gradient of acetonitrile in 1% AcOH buffer to provide acetate salt. The fractions exceeding 95% purity were pooled and lyophilized. Then, 703.1 mg (0.60 mmol, 22% overall based on 89.6% peptide content) of white peptide powder was obtained (see <a href="/doi/suppl/10.1021/acs.jmedchem.9b00132/suppl_file/jm9b00132_si_001.pdf" class="ext-link">Table S4</a> for physicochemical properties).</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> Synthesis of Agmatine Peptides <b>39</b> and <b>41</b>–<b>43</b></h4><div class="NLM_p">The linear precursors of the peptides were assembled on H-Pro-2ClTrt resin (commercially available, <b>39</b>, <b>41</b>) or H-Thz-2ClTrt resin (<b>42</b>, <b>43</b>) using a Tribute peptide synthesizer using synthetic protocols described above. The fully protected linear peptides were cleaved from resin with 30% HFIP/DCM. The fully protected peptide was coupled with agmatine (see the <a href="/doi/suppl/10.1021/acs.jmedchem.9b00132/suppl_file/jm9b00132_si_001.pdf" class="ext-link">Supporting Information</a> for synthesis of compound <b>38</b>). The protected linear analogues were deprotected, cyclized, and purified as described above.</div><div class="NLM_p last">The synthesis of compound <b>40</b> and additional synthetic protocols can be found in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b00132/suppl_file/jm9b00132_si_001.pdf" class="ext-link">Supporting Information</a>.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Biological Methods</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> In Vitro Receptor Assays</h4><div class="NLM_p last">The agonist activity and potency of compounds at the human and rat vasopressin V<sub>2</sub>R receptor (hV<sub>2</sub>R) were determined in a transcriptional reporter gene assay (RGA) by transiently cotransfecting recombinant human or rat V<sub>2</sub> receptor expression DNA construct into a human embryonic kidney (HEK-293) cell line with a reporter DNA construct containing a luciferase gene under the control of cAMP-responsive promoter elements. Two days following transfection, cells were treated with appropriate concentrations of peptides, incubated for 5 h, followed by lysis of cells in the presence of luciferin, and the total luminescence was measured. To determine receptor selectivity, compounds were also tested in luciferase-based transcriptional reporter assays in HEK-293 cells expressing the human V<sub>1a</sub>R and human V<sub>1b</sub>R. Assays for human OTR activity were performed in CHO-K1 cells stably expressing the human OT receptor and transiently transfected with the NFAT-luciferase reporter construct. Compound <b>1</b> was used as an internal control for the V<sub>2</sub>R assays, AVP was used as an internal control for the vasopressin V<sub>1a</sub>R and V<sub>1b</sub>R assays, and carbetocin (carba-1-[Tyr(Me)<sup>2</sup>]dOT) was used as an internal control for the OTR assays. The assays were standardized by including these controls in every experiment. In all assays, compounds were tested in at least three independent experiments performed in duplicates. Dose–response curves were analyzed using a one-site, four-parameter model from Xlfit (IDBS) and used to estimate EC<sub>50</sub> and efficacy values. Agonist potencies determined from multiple independent experiments are reported by first calculating pEC<sub>50</sub> values from EC<sub>50</sub> (pEC<sub>50</sub> = −log(EC<sub>50</sub> in M)) for each individual value and then determining the 95% CI of pEC<sub>50</sub>. These values are then transformed back to linear scale. This is based on the assumption that the data follows a Gaussian distribution, the values are randomly sampled, and the sample assumes the same distribution as the theoretical full statistical population. Agonist efficacy is presented as the arithmetic means in percentage of internal control efficacy. The final efficacy is reported as arithmetic mean ± 95% CI. Selectivity values are given as ratios of the EC<sub>50</sub> values at the receptor of interest to the corresponding EC<sub>50</sub> values at the V<sub>2</sub>R.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> PK and PD Studies: Animals</h4><div class="NLM_p last">All procedures involving the use of animals were approved by the Ferring Research Institute or Contract Research Organization Institutional Animal Care and Use Committee and were in accordance with the Guide for the Care and Use of Laboratory Animals published by the National Research Council. The single-dose pharmacokinetic profile and antidiuretic activity of V<sub>2</sub> analogues were investigated following iv administration in male Sprague–Dawley rats (230–380 g, age commensurate with body weight) at Ferring Research Institute. Naïve rats or rats with chronic jugular vein and carotid artery catheters inserted surgically were obtained from Harlan Laboratories Inc. (Indianapolis). The rats were given free access to food (18% protein Rodent Diet, Harlan Teklad, Madison) and water. They were housed in a conventional animal facility in individually ventilated caging (LabProducts Inc., Seaford) with appropriate air flow under controlled environmental conditions (20–22 °C, 12 h light/dark cycle). In-life portions of the monkey, dog, and minipig single-dose pharmacokinetic studies were conducted at Sinclair Research Centre (Auxvasse, MO). Cynomolgus monkey (male, average body weight 5 kg, age commensurate with body weight), Beagle dog (male, average body weight 9 kg, age 15 months), and Yucatan minipig (castrated male, average body weight 70 kg, age 3.5 years) were used in the studies.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> In-Life Experimental Protocol for Nonrenal CL Determination in Nephrectomized Rats</h4><div class="NLM_p last">These experiments were conducted in terminally anesthetized rats. On each experimental day, animals were lightly anesthetized with isoflurane and then injected with the long-acting esthetic thiobutabarbital. Once under anesthesia, each animal was placed on a heating pad and implanted with jugular vein and carotid artery catheters, for compound administration and blood sampling, respectively, and a tracheostomy tube for assisted respiration. Bilateral kidney occlusion was performed by making an abdominal incision and ligating the renal blood vessels and ureter with sutures. Sham surgery was performed using identical procedures including kidney manipulation and placement of sutures without ligation. Following the surgical procedures, animals were connected to ventilators (Harvard apparatus) through their tracheostomy tubes and allowed to stabilize for 30 min before compound administration.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> PK Studies: Dosing and Sampling</h4><div class="NLM_p last">The analogues were dissolved in 5% mannitol in water. Each rat was given a single dose of 0.1 mg/kg of each test compound in cassette mode through the jugular vein.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Cassettes were constituted of 3–6 V<sub>2</sub> analogues with each compound at a concentration of 0.1 mg/mL. Blood samples (250 μL) were collected from the carotid artery catheter at nominal times of either 2, 6, 10, 15, 20, 30, 45, 60, 90, and 120 min or 2, 6, 10, 15, 20, 40, 60, 90, 135, and 180 min after administration into prechilled tubes containing K<sub>2</sub>EDTA as the anticoagulant. Blood that was drawn from the animal was replaced with an equal volume of saline. The samples were centrifuged at 4 °C, and plasma was separated. All samples were immediately frozen on dry ice and stored at −50 °C until further analysis. Similar formulation and intravenous dosing procedures were used for monkey, dog, and minipig studies. Monkeys and dogs were dosed intravenously at 0.05 mg/kg, whereas minipigs were dosed at 0.01 mg/kg. Eleven blood samples were taken between 3 and 180 min postdose.</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> Bioanalysis</h4><div class="NLM_p last">The concentrations of compounds in rat monkey, dog, and minipig plasma were determined using a liquid chromatography tandem mass spectrometry (LC/MS/MS) method. The dynamic range of the assays was 1–1000 ng/mL. Standard and internal standard solutions were prepared in 0.1% TFA in 100% acetonitrile. Typically, 50 μL of the rat plasma sample was mixed with 30 μL of the internal standard and 200 μL of the crashing solution (0.1% TFA in 100% acetonitrile). After shaking for 2 min and centrifugation at 5700<i>g</i> for 45 min, 250 μL of supernatant was concentrated by evaporation under nitrogen at 35 °C for 15 min. Samples were then reconstituted with 100 μL of 0.01% TFA in 14% acetonitrile. Reconstituted samples were centrifuged again for 30 min at 5700<i>g</i>. The supernatant (40 μL) was injected into a Phenomenex Luna 3 μm, 100 Å, C18(2), 50 × 2.0 mm<sup>2</sup> HPLC column (Phenomenex, Torrance) coupled to a Shimadzu Nexera LC (Shimadzu, Kyoto, Japan) system. The analytes were eluted using a gradient of solvent B (solvent A, 0.01% TFA and 1% formic acid in water; solvent B, 0.01% TFA, 1% formic acid, and 70% acetonitrile in water) at a flow rate of 0.6 mL/min and detected using an API-5500 triple quadrupole mass spectrometer (Applied Biosystems, Ontario, Canada) in the positive electrospray ionization mode. Analyte concentrations were calculated by linear regression analysis using the peak area ratio of the analyte to the internal standard on Applied Biosystems Analyst software version 1.4.2.</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> PK Data Analysis</h4><div class="NLM_p last">PK parameters were calculated using a noncompartmental (NCA) method with Phoenix WinNonlin 6.1 (Certara, St. Louis). The area under the plasma concentration–time curve to infinity (AUC<sub>∞</sub>) was calculated by combining the area under the curve to the last time point (AUC<sub>0–<i>t</i></sub>) with the extrapolated AUC value of the terminal phase. Body-weight-normalized CL values (mL/(min kg)) were calculated as dose divided by AUC<sub>(0–∞)</sub> and rat body weight. The percentage of nonrenal clearance (% CL<sub>nr</sub>) was determined by comparing whole-body compound clearance in functionally nephrectomized animals to sham-operated animals<span class="NLM_disp-formula" id="ueq2"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00132/20190516/images/medium/jm-2019-001323_m002.gif" alt="" id="_i30" /></img></span></div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> Determination of Rat Plasma Protein Binding</h4><div class="NLM_p last">Rat plasma protein binding (PPB) analysis was performed by an ultracentrifugation (UC) method. Briefly, 5 μL of a 20–100 μg/mL solution of the V<sub>2</sub> analogue in 0.01% TFA in 35% acetonitrile was added to a 1 mL Sorvall polycarbonate thick-walled UC tube (Fisher Scientific, product number 45237) containing 495 μL of rat plasma (Bioreclamation, Westbury, NY) to a final peptide concentration of 200–1000 ng/mL. The peptide plasma mixture was incubated at 37 °C for 15 min in a Sorvall S140-AT 35° fixed angle rotor and then spun at 120 000 rpm (773 000<i>g</i>) for 30 min at 37 °C in a Sorvall MX150 micro-ultracentrifuge (Asheville, NC). After centrifugation, 50 μL of the sample in the middle layer of the UC tube was collected at the 300 μL volume meniscus level with a 250 μL pipettor tip. The compound concentrations in the collected sample were quantified immediately by the LC/MS/MS method described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>. Each compound was assayed in quadruplicate. The percentage of binding was calculated as<span class="NLM_disp-formula" id="ueq3"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00132/20190516/images/medium/jm-2019-001323_m003.gif" alt="" id="_i32" /></img></span>where <i>C</i><sub>i</sub> is the initial concentration of peptide and <i>C</i><sub>m</sub> is the concentration of peptide remaining in the middle layer after ultracentrifugation.</div></div><div id="sec4_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> Rat Antidiuretic Activity Assay</h4><div class="NLM_p last">Antidiuretic activity of selected V<sub>2</sub> analogues was assessed in rats by measuring urine output during and after administration of compound.</div></div><div id="sec4_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> Compound Formulation and Dose Calculation</h4><div class="NLM_p last">Compounds were formulated in 2.5% (w/v) rat or bovine serum albumin in nanopure water. On the day prior to each experiment, compounds were formulated at the concentrations to be used in the experiment and all tubing, syringes, and vials to be used for compound formulation and animal dosing were pre-equilibrated overnight with compound solution in an attempt to mitigate potential compound nonspecific binding. On the day of study, the compound solution that was used for pre-equilibration was discarded and fresh compound was weighed into the pre-equilibrated vials. Whole-body clearance (CL) values determined from rat PK studies (preliminary PK, cassette dosing) and PK simulations (Phoenix WinNonlin 6.1, Certara, St. Louis) were used to calculate the iv infusion rates (with optional loading dose during the first 20 min) to achieve targeted steady-state concentrations (<i>C</i><sub>ss</sub>) ranging from 0.3 to 100 pM within 15–30 min of infusion.</div></div><div id="sec4_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> In-Life Experimental Protocol</h4><div class="NLM_p last">On each experimental day, animals were weighed, assigned to treatment groups to receive test compound or <b>1</b> at one target <i>C</i><sub>ss</sub> or vehicle, and placed into metabolic cages for urine collection with free access to water, but no food. Average total vehicle volume was 1.2 mL per rat over 3 h. Rat receiving compounds were infused with an identical volume of vehicle. Under these experimental conditions, rats are expected to be euvolemic as the volume used for compound administration was relatively low compared to antidiuresis studies that use acute large volume water-loading to induce hypervolemia. Each metabolic cage was set up for continuous measurement of spontaneous urine output via force transducers attached to the urine collection vials to monitor and record cumulative urine weight. Catheters were attached to a swivel/tether. Compounds or vehicles were administered by iv infusion using a syringe infusion pump for the first 180 min of urine output measurements. At 180 min, the compound infusion was stopped and the urine output was measured for an additional 300 min. At the end of the experiment, animals were returned to their home cages. Animals were used in up to three experiments separated by at least 1 week.</div></div><div id="sec4_2_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> Data Analysis</h4><div class="NLM_p last">Cumulative urine output time courses (time points at 10 min intervals from 0 to 8 h) collected over multiple experiments were compiled; mean, SEM, and <i>N</i> were determined for each treatment group and time point. Dose–response analysis was performed on the compiled urine output data at the 180 min time point (end of infusion) in each treatment group. Compound potency was expressed as the ECp<sub>50</sub> value, the effective plasma concentration of compound (targeted <i>C</i><sub>ss</sub> in pM) causing half-maximal suppression of urine output, calculated using a three-parameter concentration response logistic model.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i37"><a href="/doi/suppl/10.1021/acs.jmedchem.9b00132" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20604" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20604" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.9b00132" class="ext-link">10.1021/acs.jmedchem.9b00132</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">In vitro, PK, PPB data with statistical parameters; analytical methods including assessment of final purity of analogues, determination of HPLC capacity factors, and high-resolution mass spectrometry; and physiochemical properties of analogues <b>1</b>–<b>43</b> as well as the description of additional synthetic methods (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00132/suppl_file/jm9b00132_si_001.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00132/suppl_file/jm9b00132_si_001.pdf">jm9b00132_si_001.pdf (280.05 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b00132" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77468" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77468" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kazimierz Wiśniewski</span> - <span class="hlFld-Affiliation affiliation">Ferring Research Institute
Inc., San Diego, California 92121, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0002-5411" title="Orcid link">http://orcid.org/0000-0003-0002-5411</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#347f554e5d595d51464e1a635d475a5d5143475f5d74525146465d5a531a575b59"><span class="__cf_email__" data-cfemail="591238233034303c2b23770e302a37303c2e2a3230193f3c2b2b30373e773a3634">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steve Qi</span> - <span class="hlFld-Affiliation affiliation">Ferring Research Institute
Inc., San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John Kraus</span> - <span class="hlFld-Affiliation affiliation">Ferring Research Institute
Inc., San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian Ly</span> - <span class="hlFld-Affiliation affiliation">Ferring Research Institute
Inc., San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Karthik Srinivasan</span> - <span class="hlFld-Affiliation affiliation">Ferring Research Institute
Inc., San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hiroe Tariga</span> - <span class="hlFld-Affiliation affiliation">Ferring Research Institute
Inc., San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Glenn Croston</span> - <span class="hlFld-Affiliation affiliation">Ferring Research Institute
Inc., San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Erin La</span> - <span class="hlFld-Affiliation affiliation">Ferring Research Institute
Inc., San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Halina Wiśniewska</span> - <span class="hlFld-Affiliation affiliation">Ferring Research Institute
Inc., San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carlos Ortiz</span> - <span class="hlFld-Affiliation affiliation">Ferring Research Institute
Inc., San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Régent Laporte</span> - <span class="hlFld-Affiliation affiliation">Ferring Research Institute
Inc., San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pierre J.-M. Rivière</span> - <span class="hlFld-Affiliation affiliation">Ferring Research Institute
Inc., San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gebhard Neyer</span> - <span class="hlFld-Affiliation affiliation">Ferring Research Institute
Inc., San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Diane M. Hargrove</span> - <span class="hlFld-Affiliation affiliation">Ferring Research Institute
Inc., San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Claudio D. Schteingart</span> - <span class="hlFld-Affiliation affiliation">Ferring Research Institute
Inc., San Diego, California 92121, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e5094-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i38">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40785" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40785" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors thank Monica Mares and Ying Zhang for their excellent technical assistance and Jolene Lau for providing relevant intelligence information. We also wish to thank Leslie Callejas-Dominguez for her assistance in implementing the rat antidiuretic activity/duration of action assay and Denise Riedl for auditing the data and critical reading of the manuscript.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">Aaa</td><td class="NLM_def"><p class="first last">any amino acid residue</p></td></tr><tr><td class="NLM_term">Agm</td><td class="NLM_def"><p class="first last">agmatine, <i>N</i>-(4-aminobutyl)guanidine</p></td></tr><tr><td class="NLM_term">Bua</td><td class="NLM_def"><p class="first last">butyric acid</p></td></tr><tr><td class="NLM_term">BW</td><td class="NLM_def"><p class="first last">body weight</p></td></tr><tr><td class="NLM_term">CL</td><td class="NLM_def"><p class="first last">systemic clearance</p></td></tr><tr><td class="NLM_term">Cpa</td><td class="NLM_def"><p class="first last">β-(4-chlorophenyl)alanine</p></td></tr><tr><td class="NLM_term">cPr</td><td class="NLM_def"><p class="first last">cyclopropyl</p></td></tr><tr><td class="NLM_term">DIC</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>′-diisopropylcarbodiimide</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropyl-<i>N</i>-ethylamine</p></td></tr><tr><td class="NLM_term">EtThi</td><td class="NLM_def"><p class="first last">2-(2-thienyl)ethyl</p></td></tr><tr><td class="NLM_term">Fpa</td><td class="NLM_def"><p class="first last">β-(4-fluorophenyl)alanine</p></td></tr><tr><td class="NLM_term">GFR</td><td class="NLM_def"><p class="first last">glomerular filtration rate</p></td></tr><tr><td class="NLM_term">HBTU</td><td class="NLM_def"><p class="first last">2-(1<i>H</i>-bezotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate</p></td></tr><tr><td class="NLM_term">HFIP</td><td class="NLM_def"><p class="first last">1,1,1,3,3,3-hexafluoro-2-propanol</p></td></tr><tr><td class="NLM_term">HOBt</td><td class="NLM_def"><p class="first last">1-hydroxybenzotriazole</p></td></tr><tr><td class="NLM_term">hV<sub>1a</sub>R</td><td class="NLM_def"><p class="first last">human vasopressin 1a receptor</p></td></tr><tr><td class="NLM_term">hV<sub>1b</sub>R</td><td class="NLM_def"><p class="first last">human vasopressin 1b receptor</p></td></tr><tr><td class="NLM_term">hV<sub>2</sub>R</td><td class="NLM_def"><p class="first last">human vasopressin 2 receptor</p></td></tr><tr><td class="NLM_term">Hyp</td><td class="NLM_def"><p class="first last"><i>trans</i>-hydroxyproline, (2<i>S</i>,4<i>R</i>)-4-hydroxyproline</p></td></tr><tr><td class="NLM_term"><i>i</i>-Bu</td><td class="NLM_def"><p class="first last">isobutyl</p></td></tr><tr><td class="NLM_term">MeOH</td><td class="NLM_def"><p class="first last">methanol</p></td></tr><tr><td class="NLM_term">NMM</td><td class="NLM_def"><p class="first last"><i>N</i>-methylmorpholine, 4-methylmorpholine</p></td></tr><tr><td class="NLM_term">PPB</td><td class="NLM_def"><p class="first last">plasma protein binding</p></td></tr><tr><td class="NLM_term">RGA</td><td class="NLM_def"><p class="first last">reporter gene assay</p></td></tr><tr><td class="NLM_term">rV<sub>2</sub>R</td><td class="NLM_def"><p class="first last">rat vasopressin 2 receptor</p></td></tr><tr><td class="NLM_term">Thi</td><td class="NLM_def"><p class="first last">β-(2-thienyl)alanine</p></td></tr><tr><td class="NLM_term">Thz</td><td class="NLM_def"><p class="first last">thiaproline, (<i>S</i>)-thiazolidine-4-carboxylic acid</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i40">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77133" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77133" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 57 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manigrasso, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandberg, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verbalis, J. G.</span></span> <span> </span><span class="NLM_article-title">Sex Differences in Vasopressin V(2) Receptor Expression and Vasopressin-Induced Antidiuresis</span>. <i>Am. J. Physiol.: Renal Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>300</i></span>,  <span class="NLM_fpage">F433</span>– <span class="NLM_lpage">F440</span>, <span class="refDoi"> DOI: 10.1152/ajprenal.00199.2010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1152%2Fajprenal.00199.2010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=21123493" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=300&publication_year=2011&pages=F433-F440&author=J.+Liuauthor=N.+Sharmaauthor=W.+Zhengauthor=H.+Jiauthor=H.+Tamauthor=X.+Wuauthor=M.+B.+Manigrassoauthor=K.+Sandbergauthor=J.+G.+Verbalis&title=Sex+Differences+in+Vasopressin+V%282%29+Receptor+Expression+and+Vasopressin-Induced+Antidiuresis&doi=10.1152%2Fajprenal.00199.2010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1152%2Fajprenal.00199.2010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajprenal.00199.2010%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DSharma%26aufirst%3DN.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DJi%26aufirst%3DH.%26aulast%3DTam%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DManigrasso%26aufirst%3DM.%2BB.%26aulast%3DSandberg%26aufirst%3DK.%26aulast%3DVerbalis%26aufirst%3DJ.%2BG.%26atitle%3DSex%2520Differences%2520in%2520Vasopressin%2520V%25282%2529%2520Receptor%2520Expression%2520and%2520Vasopressin-Induced%2520Antidiuresis%26jtitle%3DAm.%2520J.%2520Physiol.%253A%2520Renal%2520Physiol.%26date%3D2011%26volume%3D300%26spage%3DF433%26epage%3DF440%26doi%3D10.1152%2Fajprenal.00199.2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zaoral, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolc, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorm, F.</span></span> <span> </span><span class="NLM_article-title">Amino Acids and Peptides. LXXI. Synthesis of 1-Deamino-8-<span class="smallcaps smallerCapital">d</span>-γ-Aminobutyrine Vasopressin, 1-Deamino-8-<span class="smallcaps smallerCapital">d</span>-Lysine Vasopressin, and 1-Deamino-8-<span class="smallcaps smallerCapital">d</span>-Arginine Vasopressin</span>. <i>Collect. Czech. Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1967</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">1250</span>– <span class="NLM_lpage">1257</span>, <span class="refDoi"> DOI: 10.1135/cccc19671250</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1135%2Fcccc19671250" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADyaF1cXhtlelug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1967&pages=1250-1257&author=M.+Zaoralauthor=J.+Kolcauthor=F.+Sorm&title=Amino+Acids+and+Peptides.+LXXI.+Synthesis+of+1-Deamino-8-d-%CE%B3-Aminobutyrine+Vasopressin%2C+1-Deamino-8-d-Lysine+Vasopressin%2C+and+1-Deamino-8-d-Arginine+Vasopressin&doi=10.1135%2Fcccc19671250"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Amino acids and peptides.  LXXI.  Synthesis of 1-deamino-8-D-γ-aminobutyrine vasopressin, 1-deamino-8-D-lysine vasopressin, and 1-deamino-8-D-arginine vasopressin</span></div><div class="casAuthors">Zaoral, Milan; Kolc, Jaroslav; Sorm, Frantisek</div><div class="citationInfo"><span class="NLM_cas:title">Collection of Czechoslovak Chemical Communications</span>
        (<span class="NLM_cas:date">1967</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1250-7</span>CODEN:
                <span class="NLM_cas:coden">CCCCAK</span>;
        ISSN:<span class="NLM_cas:issn">0010-0765</span>.
    </div><div class="casAbstract">All amino acids (except glycine) are of the L-series unless stated otherwise.  A mixt. of 9.2 g. PhCH2S(CH2)2CO2H and excess SOCl2 was refluxed 20 min., evapd., the residue dissolved in 20 ml. EtOAc, and the soln. added portionwise at 0° to a mixt. of 10.86 g. tyrosine Me ester-HCl, 50 ml. H2O, and 50 ml. EtOAc; the pH was kept at 7-8 by addns. of NaHCO3 to give 16.3 g. 3-(benzylthiopropionyl)tyrosine (I) Me ester (II), m. 89-90° (EtOAc-petroleum ether), [α]25D -3.4 ± 0.5° (c 0.5, HCONMe2).  A mixt. of 15.3 g. II, 60 ml. MeOH, and 6 ml. 80% aq. N2H4 was refluxed 2 hrs. and dild. with excess H2O to give 11.95 g. I hydrazide, m. 193-4° (aq. EtOH), [α]24D -6.0 ± 0.5° (c 0.5, HCONMe2), which was converted into I azide and this condensed with phenylalanine Me ester.  The resulting BTP-Tyr-Phe-OMe (BTP = 3-benzylthiopropionyl) (III), m. 151-2° (aq. MeOH), [α]24D -17.5 ± 0.5° (c 0.5, HCONMe2), was converted to the III hydrazide, m. 249-51° (sintering from 243°) (HCONMe2-H2O), [α]24D -21.9 ± 0.5° (c 0.55, HCONMe2), which was condensed with Gln-Asn-Cys(CH2Ph)-OMe to give 76% BTP-Tyr-Phe-Gln-Asn-Cys(CH2Ph) (IV) Me ester (V), m. 253-5° (HCONMe2-H2O), [α]25D -29.6 ± 0.5° (c 0.5, HCONMe2).  A mixt. of 10.8 g. V, 160 ml. HCONMe2, and 12 ml. 80% aq. N2H4 was kept at room temp. 12 hrs. to give 6.7 g. IV hydrazide, m. 266-8° (HCONMe2-H2O), [α]25D -33.4 ± 0.5° (c 0.5, HCONMe2).  IV azide was coupled with prolyl-Nγ-tosyl-D-α,γ-diaminobutyrylglycinamide, prolyl-Nεtosyl-D-lysyl-glycinamide, and prolyl-NG-tosyl-D-arginylglycinamide, resp., to give 73% 3-benzylthiopropionyltyrosylphenylalanylglutaminylasparaginyl-S-benzylcysteinylprolyl-Nγ-tosyl-D-α,γ-diaminobutyrylglycinamide, m. 238-40° (sintering from 215°), [α]25D -22.3 ± 1° (c 0.5, HCONMe2), 74% BTP-Tyr-Phe-Gln-Asn-Cys(CH2Ph)-Pro-D-Lys(O2SC6H4Me-p)-Gly-NH2, m. 232-6°, [α]25D -18.1 ± 1° (c 0.4, HCONMe2), and 68% BTP-Tyr-Phe-Gln-Asn-Cys(CH2Ph)-Pro-D-Arg(NG-O2SC6H4Me-p)-Gly-NH2, m. 223-5°, which compds. on redn. with Na in liq. NH3 and oxidn. with K3Fe(CN)6 yielded 1-deamino-8-D-γ-aminobutyrine vasopressin (VI), 1-deamino-8-D-lysine vasopressin, [α]25D -70.4 ± 2° (c 0.27, M AcOH), and 1-deamino-8-D-arginine vasopressin (VII), [α]25D -82.5 ± 2° (c 0.2, HCONMe2).  VI and VII showed a high and specific antidiuretic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq42bs-00ljALVg90H21EOLACvtfcHk0lh5hMXqIbmgpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1cXhtlelug%253D%253D&md5=b648bc14a64413812ea27b8ce4001bfd</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1135%2Fcccc19671250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1135%252Fcccc19671250%26sid%3Dliteratum%253Aachs%26aulast%3DZaoral%26aufirst%3DM.%26aulast%3DKolc%26aufirst%3DJ.%26aulast%3DSorm%26aufirst%3DF.%26atitle%3DAmino%2520Acids%2520and%2520Peptides.%2520LXXI.%2520Synthesis%2520of%25201-Deamino-8-d-%25CE%25B3-Aminobutyrine%2520Vasopressin%252C%25201-Deamino-8-d-Lysine%2520Vasopressin%252C%2520and%25201-Deamino-8-d-Arginine%2520Vasopressin%26jtitle%3DCollect.%2520Czech.%2520Chem.%2520Commun.%26date%3D1967%26volume%3D32%26spage%3D1250%26epage%3D1257%26doi%3D10.1135%2Fcccc19671250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rushton, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belman, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaontz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skoog, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sihelnik, S.</span></span> <span> </span><span class="NLM_article-title">Response to Desmopressin as a Function of Urine Osmolality in the Treatment of Monosymptomatic Nocturnal Enuresis: A Double-Blind Prospective Study</span>. <i>J. Urol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>154</i></span>,  <span class="NLM_fpage">749</span>– <span class="NLM_lpage">753</span>, <span class="refDoi"> DOI: 10.1016/S0022-5347(01)67153-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1016%2FS0022-5347%2801%2967153-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=7609170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A280%3ADyaK2MzjtlCjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=1995&pages=749-753&author=H.+G.+Rushtonauthor=A.+B.+Belmanauthor=M.+Zaontzauthor=S.+J.+Skoogauthor=S.+Sihelnik&title=Response+to+Desmopressin+as+a+Function+of+Urine+Osmolality+in+the+Treatment+of+Monosymptomatic+Nocturnal+Enuresis%3A+A+Double-Blind+Prospective+Study&doi=10.1016%2FS0022-5347%2801%2967153-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Response to desmopressin as a function of urine osmolality in the treatment of monosymptomatic nocturnal enuresis: a double-blind prospective study</span></div><div class="casAuthors">Rushton H G; Belman A B; Zaontz M; Skoog S J; Sihelnik S</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of urology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue">2 Pt 2</span>),
    <span class="NLM_cas:pages">749-53</span>
        ISSN:<span class="NLM_cas:issn">0022-5347</span>.
    </div><div class="casAbstract">To determine if urine osmolality parameters can predict whether children with primary monosymptomatic nocturnal enuresis will respond to desmopressin, we conducted a prospective, double-blind, placebo-controlled study in 96 children 8 to 14 years old.  Following a 2-week baseline screening interval patients with at least 6 of 14 net nights were randomized to double-blind regimens of desmopressin or placebo.  Urine specimens for osmolality were collected at 6 p.m. and 6 a.m. on 3 consecutive days during the baseline and the 2, 14-day treatment periods.  A significantly greater proportion of desmopressin treated children had an excellent (2 or fewer wet nights in 14 days) or good (greater than 50% reduction in wet nights) response compared with placebo treated children (p = 0.004 and p = 0.002 for treatment periods 1 and 2, respectively).  Children treated with desmopressin reported a significantly lower number of wet nights than placebo treated children during both treatment periods (p = 0.0258 and p = 0.0136, respectively).  Children treated with desmopressin had a significantly higher 6 a.m. urine osmolality during both treatment periods and a higher 6 a.m.-to-6 p.m. osmolality ratio (p = 0.004) in the first treatment period compared with the placebo group.  Within the desmopressin treatment group clinical responders had a higher 6 a.m. urine osmolality and 6 a.m.-to-6 p.m. urine osmolality ratio than nonresponders during both treatment periods but these differences did not achieve statistical significance.  In conclusion, treatment with desmopressin is associated with a significant decrease in the number of wet nights, and a significant increase in nocturnal urine osmolality and nocturnal/diurnal urine osmolality ratios.  However, clinical response was not predictable based on baseline or treatment osmolality parameters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQieP-KpA3_HVvAgqb2vdc5fW6udTcc2eaziMHRJanwcbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2MzjtlCjtA%253D%253D&md5=0129432c97fb41c6ca73d90599039fa7</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS0022-5347%2801%2967153-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0022-5347%252801%252967153-2%26sid%3Dliteratum%253Aachs%26aulast%3DRushton%26aufirst%3DH.%2BG.%26aulast%3DBelman%26aufirst%3DA.%2BB.%26aulast%3DZaontz%26aufirst%3DM.%26aulast%3DSkoog%26aufirst%3DS.%2BJ.%26aulast%3DSihelnik%26aufirst%3DS.%26atitle%3DResponse%2520to%2520Desmopressin%2520as%2520a%2520Function%2520of%2520Urine%2520Osmolality%2520in%2520the%2520Treatment%2520of%2520Monosymptomatic%2520Nocturnal%2520Enuresis%253A%2520A%2520Double-Blind%2520Prospective%2520Study%26jtitle%3DJ.%2520Urol.%26date%3D1995%26volume%3D154%26spage%3D749%26epage%3D753%26doi%3D10.1016%2FS0022-5347%2801%2967153-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fralick, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kesselheim, A. S.</span></span> <span> </span><span class="NLM_article-title">FDA Approval of Desmopressin for Nocturia</span>. <i>JAMA, J. Am. Med. Assoc.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>317</i></span>,  <span class="NLM_fpage">2059</span>– <span class="NLM_lpage">2060</span>, <span class="refDoi"> DOI: 10.1001/jama.2017.4316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1001%2Fjama.2017.4316" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=317&publication_year=2017&pages=2059-2060&author=M.+Fralickauthor=A.+S.+Kesselheim&title=FDA+Approval+of+Desmopressin+for+Nocturia&doi=10.1001%2Fjama.2017.4316"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1001%2Fjama.2017.4316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2017.4316%26sid%3Dliteratum%253Aachs%26aulast%3DFralick%26aufirst%3DM.%26aulast%3DKesselheim%26aufirst%3DA.%2BS.%26atitle%3DFDA%2520Approval%2520of%2520Desmopressin%2520for%2520Nocturia%26jtitle%3DJAMA%252C%2520J.%2520Am.%2520Med.%2520Assoc.%26date%3D2017%26volume%3D317%26spage%3D2059%26epage%3D2060%26doi%3D10.1001%2Fjama.2017.4316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawler, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riddell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nitu-Whalley, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermans, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, S. A.</span></span> <span> </span><span class="NLM_article-title">Response to Desmopressin of Factors XI, X and V in Patients with Factor VIII Deficiency and Von Willebrand Disease</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">100</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2141.2004.04988.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1111%2Fj.1365-2141.2004.04988.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=15198739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtl2rt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2004&pages=100-104&author=B.+Whiteauthor=P.+Lawlerauthor=A.+Riddellauthor=I.+C.+Nitu-Whalleyauthor=C.+Hermansauthor=C.+A.+Leeauthor=S.+A.+Brown&title=Response+to+Desmopressin+of+Factors+XI%2C+X+and+V+in+Patients+with+Factor+VIII+Deficiency+and+Von+Willebrand+Disease&doi=10.1111%2Fj.1365-2141.2004.04988.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Response to desmopressin of factors XI, X and V in patients with factor VIII deficiency and von Willebrand disease</span></div><div class="casAuthors">White, B.; Lawler, P.; Riddell, A.; Nitu-Whalley, I. C.; Hermans, C.; Lee, C. A.; Brown, S. A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">100-104</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Desmopressin [1-deamino-8-D-arginine vasopressin (DDAVP)] has been successfully used in the treatment of type 1 von Willebrand disease (VWD) and mild haemophilia A (MHA).  Data suggest that DDAVP can increase factor XI (FXI) plasma levels and may represent an effective treatment for mild FXI deficiency.  We assessed the DDAVP response of FXI coagulant activity (FXI:C), FXI antigen (FXI:Ag), factor V coagulant activity (FV:C), and factor X coagulant activity (FX:C) in 33 individuals with VWD or MHA.  DDAVP did not produce a clin. significant increase in FXI:C, FXI:Ag, FX:C or FV:C in any patient.  The mean ± SD FXI:C pre-DDAVP (time 0) and at 1 h post-DDAVP was 90.7 (±22.9) U/dL and 92.1 (±20.9) U/dL, resp.  The mean (±SD) FXI:Ag at time 0 and 1 h was 92.2 (±20.1) U/dL and 89.9 (±21.3) U/dL, resp.  There was a small redn. at 1 h post-DDAVP in both FV:C, from 1018 (±20.9) U/dL to 97.2 (±21.4) U/dL (P < 0.001), and FX:C from 103 (±19.5) U/dL to 98.8 (±18.7) U/dL (P < 0.001).  No significant increase in FXI:C, FXI:Ag, FV:C or FX:C levels was seen at 4 h post-DDAVP.  This study failed to demonstrate a clin. significant increase in the levels of FXI, FX or FV following administration of DDAVP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpExbXsewqfMLVg90H21EOLACvtfcHk0lisQ6WVezRVUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtl2rt7Y%253D&md5=0a58856ed1c3deadb2e9ee015ad0c3f6</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2141.2004.04988.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2141.2004.04988.x%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DB.%26aulast%3DLawler%26aufirst%3DP.%26aulast%3DRiddell%26aufirst%3DA.%26aulast%3DNitu-Whalley%26aufirst%3DI.%2BC.%26aulast%3DHermans%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DC.%2BA.%26aulast%3DBrown%26aufirst%3DS.%2BA.%26atitle%3DResponse%2520to%2520Desmopressin%2520of%2520Factors%2520XI%252C%2520X%2520and%2520V%2520in%2520Patients%2520with%2520Factor%2520VIII%2520Deficiency%2520and%2520Von%2520Willebrand%2520Disease%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2004%26volume%3D126%26spage%3D100%26epage%3D104%26doi%3D10.1111%2Fj.1365-2141.2004.04988.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mannucci, P. M.</span></span> <span> </span><span class="NLM_article-title">Treatment of Von Willebrand’s Disease</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>351</i></span>,  <span class="NLM_fpage">683</span>– <span class="NLM_lpage">694</span>, <span class="refDoi"> DOI: 10.1056/NEJMra040403</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1056%2FNEJMra040403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=15306670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADC%252BD2cXms1Okur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=2004&pages=683-694&author=P.+M.+Mannucci&title=Treatment+of+Von+Willebrand%E2%80%99s+Disease&doi=10.1056%2FNEJMra040403"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of von Willebrand's disease</span></div><div class="casAuthors">Mannucci, Pier Mannuccio</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">351</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">683-694</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  Treatment of von Willebrand's disease is reviewed here.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-Qb6sdZ6ILbVg90H21EOLACvtfcHk0lisQ6WVezRVUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXms1Okur0%253D&md5=3c5c2f90538cad85ae983f9075f5ee4f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1056%2FNEJMra040403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra040403%26sid%3Dliteratum%253Aachs%26aulast%3DMannucci%26aufirst%3DP.%2BM.%26atitle%3DTreatment%2520of%2520Von%2520Willebrand%25E2%2580%2599s%2520Disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D351%26spage%3D683%26epage%3D694%26doi%3D10.1056%2FNEJMra040403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schrier, R. W.</span></span> <span> </span><span class="NLM_article-title">Body Water Homeostasis: Clinical Disorders of Urinary Dilution and Concentration</span>. <i>J. Am. Soc. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1820</span>– <span class="NLM_lpage">1832</span>, <span class="refDoi"> DOI: 10.1681/ASN.2006030240</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1681%2FASN.2006030240" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=16738014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADC%252BD28Xntlantb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2006&pages=1820-1832&author=R.+W.+Schrier&title=Body+Water+Homeostasis%3A+Clinical+Disorders+of+Urinary+Dilution+and+Concentration&doi=10.1681%2FASN.2006030240"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Body water homeostasis: clinical disorders of urinary dilution and concentration</span></div><div class="casAuthors">Schrier, Robert W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Society of Nephrology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1820-1832</span>CODEN:
                <span class="NLM_cas:coden">JASNEU</span>;
        ISSN:<span class="NLM_cas:issn">1046-6673</span>.
    
            (<span class="NLM_cas:orgname">American Society of Nephrology</span>)
        </div><div class="casAbstract">A review on the role of body water balance in the development of clin. disorders with impaired urinary diln. and concn., with emphasis on aquaporins 1, 2, 3, and 4.  These disorders include hypothyroidism, Addison's disease and hypopituitarism, primary polydipsia or compulsive water drinking, cirrhosis, pregnancy complications, and nephrogenic diabetes insipidus (genetic and acquired).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZMAWSj4lj8LVg90H21EOLACvtfcHk0ljcnHQsHXFy8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xntlantb0%253D&md5=1927a02bf18d481b2f29829da3d9b0ed</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1681%2FASN.2006030240&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1681%252FASN.2006030240%26sid%3Dliteratum%253Aachs%26aulast%3DSchrier%26aufirst%3DR.%2BW.%26atitle%3DBody%2520Water%2520Homeostasis%253A%2520Clinical%2520Disorders%2520of%2520Urinary%2520Dilution%2520and%2520Concentration%26jtitle%3DJ.%2520Am.%2520Soc.%2520Nephrol.%26date%3D2006%26volume%3D17%26spage%3D1820%26epage%3D1832%26doi%3D10.1681%2FASN.2006030240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Juul, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malmberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Meulen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walle, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norgaard, J. P.</span></span> <span> </span><span class="NLM_article-title">Low-Dose Desmopressin Combined with Serum Sodium Monitoring Can Prevent Clinically Significant Hyponatraemia in Patients Treated for Nocturia</span>. <i>BJU Int.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">776</span>– <span class="NLM_lpage">784</span>, <span class="refDoi"> DOI: 10.1111/bju.13718</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1111%2Fbju.13718" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=27862898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlsleqtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2017&pages=776-784&author=K.+V.+Juulauthor=A.+Malmbergauthor=E.+van+der+Meulenauthor=J.+V.+Walleauthor=J.+P.+Norgaard&title=Low-Dose+Desmopressin+Combined+with+Serum+Sodium+Monitoring+Can+Prevent+Clinically+Significant+Hyponatraemia+in+Patients+Treated+for+Nocturia&doi=10.1111%2Fbju.13718"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Low-dose desmopressin combined with serum sodium monitoring can prevent clinically significant hyponatraemia in patients treated for nocturia</span></div><div class="casAuthors">Juul, Kristian Vinter; Malmberg, Anders; van der Meulen, Egbert; Vande Walle, Johan; Norgaard, Jens Peter</div><div class="citationInfo"><span class="NLM_cas:title">BJU International</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">776-784</span>CODEN:
                <span class="NLM_cas:coden">BJINFO</span>;
        ISSN:<span class="NLM_cas:issn">1464-410X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Objective: To explore risk factors for desmopressin-induced hyponatremia and evaluate the impact of a serum sodium monitoring plan.  Subjects and Methods: This was a meta-anal. of data from three clin. trials of desmopressin in nocturia.  Patients received placebo or desmopressin orally disintegrating tablet (ODT; 10-100 μg).  The incidence of serum sodium <130 mmol/L was recorded by age, sex and dose.  Potential predictors of clin. significant hyponatremia were identified using multivariate anal. in a Cox proportional hazards model.  Results: Dose, age, baseline serum sodium level and kidney function, according to estd. GFR clearance, were significant risk factors for hyponatremia in both sexes; similar to the known risk factors assocd. with hyponatremia in the general population.  In men, arthritis and use of drugs for bone disease were also predictive of hyponatremia, while in women, raised monocytes and absence of lipid-modifying drugs increased the risk of hyponatremia.  Use of the proposed monitoring scheme and the min. ED would have omitted all patients with clin. significant hyponatremia from further treatment.  Conclusions: The incidence of hyponatremia can be reduced by using min. effective gender-specific dosing with the ODT formulation of desmopressin (25 μg in women, 50 μg in men).  A sodium monitoring plan is proposed whereby baseline sodium must be ≥135 mmol/L (esp. important in the elderly), with addnl. monitoring at week 1 and month 1 for those at elevated risk because they are aged ≥65 years or receiving concomitant medication assocd. with hyponatremia.  This monitoring plan would help to prevent some at-risk patients developing hyponatremia; retrospective application of the monitoring plan showed that, once at-risk patients were appropriately screened out, only mild, non-clin. significant hyponatremia was obsd., within ranges of other drugs assocd. with hyponatremia and similar to the background prevalence in the treatment population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSmFFUAmtZkbVg90H21EOLACvtfcHk0ljcnHQsHXFy8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlsleqtr4%253D&md5=910cc992f2d2225cbf77c48c819f211c</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1111%2Fbju.13718&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbju.13718%26sid%3Dliteratum%253Aachs%26aulast%3DJuul%26aufirst%3DK.%2BV.%26aulast%3DMalmberg%26aufirst%3DA.%26aulast%3Dvan%2Bder%2BMeulen%26aufirst%3DE.%26aulast%3DWalle%26aufirst%3DJ.%2BV.%26aulast%3DNorgaard%26aufirst%3DJ.%2BP.%26atitle%3DLow-Dose%2520Desmopressin%2520Combined%2520with%2520Serum%2520Sodium%2520Monitoring%2520Can%2520Prevent%2520Clinically%2520Significant%2520Hyponatraemia%2520in%2520Patients%2520Treated%2520for%2520Nocturia%26jtitle%3DBJU%2520Int.%26date%3D2017%26volume%3D119%26spage%3D776%26epage%3D784%26doi%3D10.1111%2Fbju.13718" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spasovski, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanholder, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allolio, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annane, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bichet, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decaux, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenske, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoorn, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joannidis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soupart, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zietse, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Veer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Biesen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagler, E.</span></span> <span> </span><span class="NLM_article-title">Clinical Practice Guideline on Diagnosis and Treatment of Hyponatraemia</span>. <i>Intensive Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">320</span>– <span class="NLM_lpage">331</span>, <span class="refDoi"> DOI: 10.1007/s00134-014-3210-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1007%2Fs00134-014-3210-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2014&pages=320-331&author=G.+Spasovskiauthor=R.+Vanholderauthor=B.+Allolioauthor=D.+Annaneauthor=S.+Ballauthor=D.+Bichetauthor=G.+Decauxauthor=W.+Fenskeauthor=E.+J.+Hoornauthor=C.+Ichaiauthor=M.+Joannidisauthor=A.+Soupartauthor=R.+Zietseauthor=M.+Hallerauthor=S.+van+der+Veerauthor=W.+Van+Biesenauthor=E.+Nagler&title=Clinical+Practice+Guideline+on+Diagnosis+and+Treatment+of+Hyponatraemia&doi=10.1007%2Fs00134-014-3210-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1007%2Fs00134-014-3210-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00134-014-3210-2%26sid%3Dliteratum%253Aachs%26aulast%3DSpasovski%26aufirst%3DG.%26aulast%3DVanholder%26aufirst%3DR.%26aulast%3DAllolio%26aufirst%3DB.%26aulast%3DAnnane%26aufirst%3DD.%26aulast%3DBall%26aufirst%3DS.%26aulast%3DBichet%26aufirst%3DD.%26aulast%3DDecaux%26aufirst%3DG.%26aulast%3DFenske%26aufirst%3DW.%26aulast%3DHoorn%26aufirst%3DE.%2BJ.%26aulast%3DIchai%26aufirst%3DC.%26aulast%3DJoannidis%26aufirst%3DM.%26aulast%3DSoupart%26aufirst%3DA.%26aulast%3DZietse%26aufirst%3DR.%26aulast%3DHaller%26aufirst%3DM.%26aulast%3Dvan%2Bder%2BVeer%26aufirst%3DS.%26aulast%3DVan%2BBiesen%26aufirst%3DW.%26aulast%3DNagler%26aufirst%3DE.%26atitle%3DClinical%2520Practice%2520Guideline%2520on%2520Diagnosis%2520and%2520Treatment%2520of%2520Hyponatraemia%26jtitle%3DIntensive%2520Care%2520Med.%26date%3D2014%26volume%3D40%26spage%3D320%26epage%3D331%26doi%3D10.1007%2Fs00134-014-3210-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vande
Walle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stockner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norgaard, J. P.</span></span> <span> </span><span class="NLM_article-title">Desmopressin 30 Years in Clinical Use: A Safety Review</span>. <i>Curr. Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">232</span>– <span class="NLM_lpage">238</span>, <span class="refDoi"> DOI: 10.2174/157488607781668891</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.2174%2F157488607781668891" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=18690973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFGqtbnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=232-238&author=J.+Vande%0AWalleauthor=M.+Stocknerauthor=A.+Raesauthor=J.+P.+Norgaard&title=Desmopressin+30+Years+in+Clinical+Use%3A+A+Safety+Review&doi=10.2174%2F157488607781668891"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Desmopressin 30 years in clinical use: a safety review</span></div><div class="casAuthors">Vande Walle, Johan; Stockner, Mette; Raes, Ann; Norgaard, Jens P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Safety</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">232-238</span>CODEN:
                <span class="NLM_cas:coden">CDSUBQ</span>;
        ISSN:<span class="NLM_cas:issn">1574-8863</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Desmopressin acetate is the synthetic analog of the antidiuretic hormone arginine vasopressin.  It has been employed clin. for >30 years in a range of formulations: intranasal soln. (since 1972), injectable soln. (since 1981), tablets (since 1987), and most recently, an oral lyophilisate (since 2005).  The antidiuretic properties of desmopressin have led to its use in polyuric conditions including primary nocturnal enuresis, nocturia, and diabetes insipidus.  While a large body of clin. data is available for desmopressin, and despite its widespread use, comprehensive reviews of the safety of desmopressin are lacking (although some case series have attempted to correlate patient and/or dosing characteristics with the occurrence of adverse reactions).  The purpose of this paper is to review the safety of desmopressin, based on analyses of both published data (MedLine) and of adverse reactions reported to Ferring Pharmaceuticals, the major manufacturer of desmopressin.  Based on the findings, suggested strategies to reduce the risk of adverse reactions are proposed.  Treatment with intranasal and oral formulations of desmopressin is generally well tolerated, and side effects are usually minor.  The risk of hyponatremia, although small, can be reduced by adhering to the indications, dosing recommendations and precautions when prescribing desmopressin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeDBlWsJBUPbVg90H21EOLACvtfcHk0lg76ba13MSqSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFGqtbnO&md5=b4d1c195dd8ca89ca81206fb34bd707e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2174%2F157488607781668891&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157488607781668891%26sid%3Dliteratum%253Aachs%26aulast%3DVande%2BWalle%26aufirst%3DJ.%26aulast%3DStockner%26aufirst%3DM.%26aulast%3DRaes%26aufirst%3DA.%26aulast%3DNorgaard%26aufirst%3DJ.%2BP.%26atitle%3DDesmopressin%252030%2520Years%2520in%2520Clinical%2520Use%253A%2520A%2520Safety%2520Review%26jtitle%3DCurr.%2520Drug%2520Saf.%26date%3D2007%26volume%3D2%26spage%3D232%26epage%3D238%26doi%3D10.2174%2F157488607781668891" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rittig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knudsen, U. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norgaard, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djurhuus, J. C.</span></span> <span> </span><span class="NLM_article-title">Abnormal Diurnal Rhythm of Plasma Vasopressin and Urinary Output in Patients with Enuresis</span>. <i>Am. J. Physiol.: Renal Physiol.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>256</i></span>,  <span class="NLM_fpage">F664</span>– <span class="NLM_lpage">F671</span>, <span class="refDoi"> DOI: 10.1152/ajprenal.1989.256.4.F664</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1152%2Fajprenal.1989.256.4.F664" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=256&publication_year=1989&pages=F664-F671&author=S.+Rittigauthor=U.+B.+Knudsenauthor=J.+P.+Norgaardauthor=E.+B.+Pedersenauthor=J.+C.+Djurhuus&title=Abnormal+Diurnal+Rhythm+of+Plasma+Vasopressin+and+Urinary+Output+in+Patients+with+Enuresis&doi=10.1152%2Fajprenal.1989.256.4.F664"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1152%2Fajprenal.1989.256.4.F664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajprenal.1989.256.4.F664%26sid%3Dliteratum%253Aachs%26aulast%3DRittig%26aufirst%3DS.%26aulast%3DKnudsen%26aufirst%3DU.%2BB.%26aulast%3DNorgaard%26aufirst%3DJ.%2BP.%26aulast%3DPedersen%26aufirst%3DE.%2BB.%26aulast%3DDjurhuus%26aufirst%3DJ.%2BC.%26atitle%3DAbnormal%2520Diurnal%2520Rhythm%2520of%2520Plasma%2520Vasopressin%2520and%2520Urinary%2520Output%2520in%2520Patients%2520with%2520Enuresis%26jtitle%3DAm.%2520J.%2520Physiol.%253A%2520Renal%2520Physiol.%26date%3D1989%26volume%3D256%26spage%3DF664%26epage%3DF671%26doi%3D10.1152%2Fajprenal.1989.256.4.F664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vande
Walle, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogaert, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattsson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schurmans, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoebeke, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deboe, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norgaard, J. P.</span></span> <span> </span><span class="NLM_article-title">A New Fast-Melting Oral Formulation of Desmopressin: A Pharmacodynamic Study in Children with Primary Nocturnal Enuresis</span>. <i>BJU Int.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">603</span>– <span class="NLM_lpage">609</span>, <span class="refDoi"> DOI: 10.1111/j.1464-410X.2006.05999.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1111%2Fj.1464-410X.2006.05999.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=16469035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADC%252BD28XjsFOqt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2006&pages=603-609&author=J.+G.+Vande%0AWalleauthor=G.+A.+Bogaertauthor=S.+Mattssonauthor=T.+Schurmansauthor=P.+Hoebekeauthor=V.+Deboeauthor=J.+P.+Norgaard&title=A+New+Fast-Melting+Oral+Formulation+of+Desmopressin%3A+A+Pharmacodynamic+Study+in+Children+with+Primary+Nocturnal+Enuresis&doi=10.1111%2Fj.1464-410X.2006.05999.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">A new fast-melting oral formulation of desmopressin: a pharmacodynamic study in children with primary nocturnal enuresis</span></div><div class="casAuthors">Vande Walle, Johan G. J.; Bogaert, Guy A.; Mattsson, Sven; Schurmans, Thierry; Hoebeke, Piet; Deboe, Veerle; Norgaard, Jens Pater; Vande Walle, Johan; Mauel, Reiner; Raes, Ann; Vande Walle, Caroline; de Lille, Sofie; Catteeuw, Julie; Audenaert, Martine; Caluwaerts, Hilde; Bogaert, Guy A.; Goeman, Lieven Joost Dieter; Goossens, Els; Cleymen, Inge; Mertens, Johan; Mattsson, Sven; Gladh, Gunilla; Persson, Dorotha; Schurmans, Thierry; Hall, Michelle; Wenderickx, Bernard; Hoebeke, Piet; Van Laecke, E.; Caluwaerts, Hilde; Audenaert, Martine; Deboe, Veerle; Depont, Saskia; Vandemaele, Kris; Van Gool, Jan D.; Wyndaele, Jean Jacques; Hauwers, Kathleen D.; van Neyghen, Ingrid</div><div class="citationInfo"><span class="NLM_cas:title">BJU International</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">603-609</span>CODEN:
                <span class="NLM_cas:coden">BJINFO</span>;
        ISSN:<span class="NLM_cas:issn">1464-4096</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Objective: To det. the pharmacodynamic properties of a new oral lyophilisate formulation of desmopressin (in single doses of 30, 60, 120, 240, 360 or 480 μg) in children with known primary nocturnal enuresis (PNE) and thus identify those dosages that could provide a duration of action corresponding to a typical length of night-time sleep in children with PNE; addnl. objectives were to det. the safety and tolerability of desmopressin in this population.  Patients and methods: Children with PNE (mean three or more wet nights/wk), aged 6-12 years, were randomized into a double-blind, placebo-controlled study.  An overhydration technique was used before dosing to suppress endogenous vasopressin prodn. and thereby ensure that any antidiuresis could be attributed to treatment.  Dosing with desmopressin or placebo occurred when urinary prodn. was >0.13 mL/min/kg.  Urinary vol., osmolality and duration of urinary-concg. action (above three threshold levels: 125, 200 and 400 mOsm/kg) were detd. as endpoints.  Results: All 72 participants receiving desmopressin had a pharmacodynamic response to the drug, while there was no change in urinary output in the 12 placebo-treated patients.  There was a clear relationship between desmopressin dose and duration of action and osmolality during action, although the three highest-dose groups had similar results.  The mean duration of action of desmopressin at the lowest osmolality threshold level was 3.6-10.6 h, according to dose; for the highest threshold, the values were 1.3-8.6 h.  Conclusion: Desmopressin, as the oral lyophilisate, causes a marked decrease in urinary output in hydrated children with PNE.  A small dose range (120-240 μg) is likely to control diuresis for a period corresponding to a night's sleep (7-11 h) in most children with PNE.  However, some patients might require a higher dose to obtain antidiuresis for the complete night.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzWkrh9fDp9bVg90H21EOLACvtfcHk0lg76ba13MSqSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjsFOqt78%253D&md5=08faba58e83013ca40c3e88daacf4a99</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1111%2Fj.1464-410X.2006.05999.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1464-410X.2006.05999.x%26sid%3Dliteratum%253Aachs%26aulast%3DVande%2BWalle%26aufirst%3DJ.%2BG.%26aulast%3DBogaert%26aufirst%3DG.%2BA.%26aulast%3DMattsson%26aufirst%3DS.%26aulast%3DSchurmans%26aufirst%3DT.%26aulast%3DHoebeke%26aufirst%3DP.%26aulast%3DDeboe%26aufirst%3DV.%26aulast%3DNorgaard%26aufirst%3DJ.%2BP.%26atitle%3DA%2520New%2520Fast-Melting%2520Oral%2520Formulation%2520of%2520Desmopressin%253A%2520A%2520Pharmacodynamic%2520Study%2520in%2520Children%2520with%2520Primary%2520Nocturnal%2520Enuresis%26jtitle%3DBJU%2520Int.%26date%3D2006%26volume%3D97%26spage%3D603%26epage%3D609%26doi%3D10.1111%2Fj.1464-410X.2006.05999.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lucchini, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonetti, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceschi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lava, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fare, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchetti, M. G.</span></span> <span> </span><span class="NLM_article-title">Severe Signs of Hyponatremia Secondary to Desmopressin Treatment for Enuresis: A Systematic Review</span>. <i>J. Pediatr. Urol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1049</span>– <span class="NLM_lpage">1053</span>, <span class="refDoi"> DOI: 10.1016/j.jpurol.2013.02.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1016%2Fj.jpurol.2013.02.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=23619353" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A280%3ADC%252BC3srosVWksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=1049-1053&author=B.+Lucchiniauthor=G.+D.+Simonettiauthor=A.+Ceschiauthor=S.+A.+Lavaauthor=P.+B.+Fareauthor=M.+G.+Bianchetti&title=Severe+Signs+of+Hyponatremia+Secondary+to+Desmopressin+Treatment+for+Enuresis%3A+A+Systematic+Review&doi=10.1016%2Fj.jpurol.2013.02.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Severe signs of hyponatremia secondary to desmopressin treatment for enuresis: a systematic review</span></div><div class="casAuthors">Lucchini Barbara; Simonetti Giacomo D; Ceschi Alessandro; Lava Sebastiano A G; Fare Pietro B; Bianchetti Mario G</div><div class="citationInfo"><span class="NLM_cas:title">Journal of pediatric urology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6 Pt B</span>),
    <span class="NLM_cas:pages">1049-53</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  Dilutional hyponatremia is a serious adverse effect of desmopressin, a vasopressin analog that is widely prescribed to manage monosymptomatic enuresis.  The presentation of hyponatremia, largely related to cerebral dysfunction, can include severe signs like altered mental status and seizures.  METHODS:  We reviewed the literature dealing with altered mental status or seizures in enuretic subjects on desmopressin.  The retained publications included patients who were described individually, revealing data on mode of administration, further identifiable factors predisposing to hyponatremia, presentation and clinical course.  RESULTS:  We found 54 cases of hyponatremia secondary to desmopressin treatment presenting with altered mental status or seizures.  In most cases the complication developed 14 days or less after starting desmopressin.  An intranasal formulation had been used in 47 patients.  Excess fluid intake was documented as a contributing factor in at least 22 cases.  In 6 cases severe signs of hyponatremia developed in the context of intercurrent illnesses.  CONCLUSION:  Altered mental status or seizures are very rare but recognized complications of desmopressin in enuresis.  This complication mostly develops in subjects managed with the intranasal formulation 14 days or less after starting the medication, following excess fluid intake and during intercurrent illnesses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTsdqMfLXLyO2BAiYWy6n3SfW6udTcc2eb5BOPneAC18rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3srosVWksA%253D%253D&md5=90583891b647188903327144e347e676</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.jpurol.2013.02.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpurol.2013.02.012%26sid%3Dliteratum%253Aachs%26aulast%3DLucchini%26aufirst%3DB.%26aulast%3DSimonetti%26aufirst%3DG.%2BD.%26aulast%3DCeschi%26aufirst%3DA.%26aulast%3DLava%26aufirst%3DS.%2BA.%26aulast%3DFare%26aufirst%3DP.%2BB.%26aulast%3DBianchetti%26aufirst%3DM.%2BG.%26atitle%3DSevere%2520Signs%2520of%2520Hyponatremia%2520Secondary%2520to%2520Desmopressin%2520Treatment%2520for%2520Enuresis%253A%2520A%2520Systematic%2520Review%26jtitle%3DJ.%2520Pediatr.%2520Urol.%26date%3D2013%26volume%3D9%26spage%3D1049%26epage%3D1053%26doi%3D10.1016%2Fj.jpurol.2013.02.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bosch, J. L. H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, J. P.</span></span> <span> </span><span class="NLM_article-title">The Prevalence and Causes of Nocturia</span>. <i>J. Urol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>189</i></span>,  <span class="NLM_fpage">S86</span>– <span class="NLM_lpage">S92</span>, <span class="refDoi"> DOI: 10.1016/j.juro.2012.11.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1016%2Fj.juro.2012.11.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=23234639" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=189&publication_year=2013&pages=S86-S92&author=J.+L.+H.+R.+Boschauthor=J.+P.+Weiss&title=The+Prevalence+and+Causes+of+Nocturia&doi=10.1016%2Fj.juro.2012.11.033"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.juro.2012.11.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.juro.2012.11.033%26sid%3Dliteratum%253Aachs%26aulast%3DBosch%26aufirst%3DJ.%2BL.%2BH.%2BR.%26aulast%3DWeiss%26aufirst%3DJ.%2BP.%26atitle%3DThe%2520Prevalence%2520and%2520Causes%2520of%2520Nocturia%26jtitle%3DJ.%2520Urol.%26date%3D2013%26volume%3D189%26spage%3DS86%26epage%3DS92%26doi%3D10.1016%2Fj.juro.2012.11.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hofmeester, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kollen, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffens, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosch, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drake, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanker, M. H.</span></span> <span> </span><span class="NLM_article-title">The Association between Nocturia and Nocturnal Polyuria in Clinical and Epidemiological Studies: A Systematic Review and Meta-Analyses</span>. <i>J. Urol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>191</i></span>,  <span class="NLM_fpage">1028</span>– <span class="NLM_lpage">1033</span>, <span class="refDoi"> DOI: 10.1016/j.juro.2013.10.100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1016%2Fj.juro.2013.10.100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=24184367" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A280%3ADC%252BC2c7itVCjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2014&pages=1028-1033&author=I.+Hofmeesterauthor=B.+J.+Kollenauthor=M.+G.+Steffensauthor=J.+L.+Boschauthor=M.+J.+Drakeauthor=J.+P.+Weissauthor=M.+H.+Blanker&title=The+Association+between+Nocturia+and+Nocturnal+Polyuria+in+Clinical+and+Epidemiological+Studies%3A+A+Systematic+Review+and+Meta-Analyses&doi=10.1016%2Fj.juro.2013.10.100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The association between nocturia and nocturnal polyuria in clinical and epidemiological studies: a systematic review and meta-analyses</span></div><div class="casAuthors">Hofmeester Ilse; Steffens Martijn G; Kollen Boudewijn J; Blanker Marco H; Bosch J L H Ruud; Drake Marcus J; Weiss Jeffrey P</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of urology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1028-33</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  We determined the relationship between nocturia and nocturnal polyuria.  MATERIALS AND METHODS:  The PubMed® and Embase® databases were searched for studies written in English, German, French or Dutch with original data on adult participants in an investigation of the relationship between nocturia and nocturnal polyuria.  A meta-analysis of the difference in mean nocturnal voiding frequencies between patients with and without nocturnal polyuria was conducted.  Nocturnal polyuria risk was compared between participants with and without nocturia, and the resulting odds ratio was subsequently converted to relative risk with 95% CIs.  RESULTS:  From 511 references identified we selected 78 publications of 66 studies, 15 of which met the inclusion criteria for this study.  Quality scores of studies were generally high for internal validity but low for external validity.  In 7 studies (1,416 participants) we estimated a standardized mean difference of 0.59 (95% CI 0.29-0.89) for nocturnal voids between nocturnal polyuria and nonnocturnal polyuria cases.  In 8 other studies (with 2,320 participants) we calculated a pooled OR of 4.99 (3.92-6.37) for nocturnal polyuria in individuals with nocturia.  The corresponding RR, based on a nocturnal polyuria risk in the pooled population of 63.8%, was 1.41 (1.37-1.44).  CONCLUSIONS:  The association between nocturia and nocturnal polyuria is apparent and robust.  However, the clinical importance of the association appears to be less obvious than previously suggested based on single studies.  The observed high prevalence of nocturnal polyuria, as a result of the applied International Continence Society definition, may be responsible for this discrepancy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTFyJXfa-E_NROk4JA3soTqfW6udTcc2eatJ7XZ4DYA9Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c7itVCjsw%253D%253D&md5=75a0095cf6290e6e373d7f73077acf97</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.juro.2013.10.100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.juro.2013.10.100%26sid%3Dliteratum%253Aachs%26aulast%3DHofmeester%26aufirst%3DI.%26aulast%3DKollen%26aufirst%3DB.%2BJ.%26aulast%3DSteffens%26aufirst%3DM.%2BG.%26aulast%3DBosch%26aufirst%3DJ.%2BL.%26aulast%3DDrake%26aufirst%3DM.%2BJ.%26aulast%3DWeiss%26aufirst%3DJ.%2BP.%26aulast%3DBlanker%26aufirst%3DM.%2BH.%26atitle%3DThe%2520Association%2520between%2520Nocturia%2520and%2520Nocturnal%2520Polyuria%2520in%2520Clinical%2520and%2520Epidemiological%2520Studies%253A%2520A%2520Systematic%2520Review%2520and%2520Meta-Analyses%26jtitle%3DJ.%2520Urol.%26date%3D2014%26volume%3D191%26spage%3D1028%26epage%3D1033%26doi%3D10.1016%2Fj.juro.2013.10.100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
Kerrebroeck, P.</span></span> <span> </span><span class="NLM_article-title">Nocturia: Current Status and Future Perspectives</span>. <i>Curr. Opin. Obstet. Gynecol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">376</span>– <span class="NLM_lpage">385</span>, <span class="refDoi"> DOI: 10.1097/GCO.0b013e32834ac78c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1097%2FGCO.0b013e32834ac78c" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=21897234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A280%3ADC%252BC3MfhvFCntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2011&pages=376-385&author=P.+Van%0AKerrebroeck&title=Nocturia%3A+Current+Status+and+Future+Perspectives&doi=10.1097%2FGCO.0b013e32834ac78c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Nocturia: current status and future perspectives</span></div><div class="casAuthors">Van Kerrebroeck Philip</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in obstetrics & gynecology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">376-85</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE OF REVIEW:  Nocturia is a bothersome and highly prevalent condition characterized by the need to wake to void at night.  Nocturia is equally common in men and women, and although its prevalence increases with age, a significant proportion of younger people are also affected.  Nocturia leads to fragmentation of sleep and consequently to a serious decline in daytime functioning and in quality of life and health.  Its impact should not be underestimated by clinicians and therefore a review on nocturia is timely and relevant.  RECENT FINDINGS:  Traditionally, nocturia is regarded as a symptom of benign prostatic enlargement and/or overactive bladder syndrome, with treatment therefore directed toward increasing the capacity of the bladder to hold urine.  Such treatments have proven ineffective in many patients because nocturnal polyuria, an overproduction of urine at night, has been found to be present in the majority of patients.  Nocturia can be attributed to some underlying pathological factors but it can also be a distinct clinical entity with specific pathogenesis.  Frequency-volume charts are recommended for routine use in clinical practice, to determine whether nocturia is a result of excessive urine production at night, or of small voided volumes due to bladder problems, or a combination of these factors.  Desmopressin, a synthetic analogue of the antidiuretic hormone, should be considered in patients with nocturia where nocturnal polyuria is present.  SUMMARY:  Contrary to popular and medical misconception nocturia is an important condition leading to general morbidity and with serious impact on overall quality of life and health.  We advise clinicians to pay attention to nocturia and diagnostics should be offered.  Treatment modalities are available and have to be discussed with the patient.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTed0IQzZeNpmyYR5VtavbzfW6udTcc2eatJ7XZ4DYA9Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MfhvFCntA%253D%253D&md5=ab34c8c6bb6c2a004cad4bea2db34578</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1097%2FGCO.0b013e32834ac78c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FGCO.0b013e32834ac78c%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BKerrebroeck%26aufirst%3DP.%26atitle%3DNocturia%253A%2520Current%2520Status%2520and%2520Future%2520Perspectives%26jtitle%3DCurr.%2520Opin.%2520Obstet.%2520Gynecol.%26date%3D2011%26volume%3D23%26spage%3D376%26epage%3D385%26doi%3D10.1097%2FGCO.0b013e32834ac78c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sand, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dmochowski, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Meulen, E. A.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Low Dose Desmopressin Orally Disintegrating Tablet in Women with Nocturia: Results of a Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study</span>. <i>J. Urol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>190</i></span>,  <span class="NLM_fpage">958</span>– <span class="NLM_lpage">964</span>, <span class="refDoi"> DOI: 10.1016/j.juro.2013.02.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1016%2Fj.juro.2013.02.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=23454404" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFCktL3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=190&publication_year=2013&pages=958-964&author=P.+K.+Sandauthor=R.+R.+Dmochowskiauthor=J.+Reddyauthor=E.+A.+van+der%0AMeulen&title=Efficacy+and+Safety+of+Low+Dose+Desmopressin+Orally+Disintegrating+Tablet+in+Women+with+Nocturia%3A+Results+of+a+Multicenter%2C+Randomized%2C+Double-Blind%2C+Placebo+Controlled%2C+Parallel+Group+Study&doi=10.1016%2Fj.juro.2013.02.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and Safety of Low Dose Desmopressin Orally Disintegrating Tablet in Women with Nocturia: Results of a Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study</span></div><div class="casAuthors">Sand, Peter K.; Dmochowski, Roger R.; Reddy, Jyotsna; van der Meulen, Egbert A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Urology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">190</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">958-964</span>CODEN:
                <span class="NLM_cas:coden">JOURAA</span>;
        ISSN:<span class="NLM_cas:issn">0022-5347</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Purpose: Previous studies suggest a lower dose of desmopressin orally disintegrating tablet may be effective in females compared to males with nocturia.  We confirm the efficacy and safety of 25 μg desmopressin orally disintegrating tablet compared to placebo in female patients.  Materials and Methods: In this 3-mo, randomized, double-blind, parallel group study 25 μg desmopressin once daily was compared to placebo in women with nocturia (2 or more nocturnal voids).  The co-primary efficacy end points were change from baseline in mean no. of nocturnal voids and proportion of patients achieving at least a 33% redn. from baseline in the mean no. of nocturnal voids (33% responders).  Results: The full anal. set comprised 261 patients (age range 19 to 87 years).  Desmopressin significantly reduced the mean no. of nocturnal voids and increased the odds of a 33% or greater response compared to placebo during 3 mo, assessed by longitudinal anal. (-0.22, p = 0.028 and OR 1.85, p = 0.006, resp.).  Desmopressin increased the mean time to first nocturnal void by 49 min compared to placebo at 3 mo (p = 0.003).  The response to desmopressin was seen by week 1 of treatment and was sustained throughout the trial.  Significant increases in health related quality of life and sleep quality were obsd. compared to placebo.  Desmopressin was well tolerated.  Serum sodium levels remained greater than 125 mmol/L throughout the trial and 3 transient decreases to less than 130 mmol/L were recorded.  Conclusions: At a dose of 25 μg, desmopressin orally disintegrating tablet is an effective and well tolerated treatment for women with nocturia.  Treatment provides rapid and sustained improvement in nocturia and quality of life.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0lJIF_Ana3rVg90H21EOLACvtfcHk0ljH-Jc0WFBskA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFCktL3P&md5=0c47afe21c2de6b6fc8d92aa2f3f1dd1</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.juro.2013.02.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.juro.2013.02.037%26sid%3Dliteratum%253Aachs%26aulast%3DSand%26aufirst%3DP.%2BK.%26aulast%3DDmochowski%26aufirst%3DR.%2BR.%26aulast%3DReddy%26aufirst%3DJ.%26aulast%3Dvan%2Bder%2BMeulen%26aufirst%3DE.%2BA.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Low%2520Dose%2520Desmopressin%2520Orally%2520Disintegrating%2520Tablet%2520in%2520Women%2520with%2520Nocturia%253A%2520Results%2520of%2520a%2520Multicenter%252C%2520Randomized%252C%2520Double-Blind%252C%2520Placebo%2520Controlled%252C%2520Parallel%2520Group%2520Study%26jtitle%3DJ.%2520Urol.%26date%3D2013%26volume%3D190%26spage%3D958%26epage%3D964%26doi%3D10.1016%2Fj.juro.2013.02.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herschorn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albei, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Meulen, E. A.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Low Dose Desmopressin Orally Disintegrating Tablet in Men with Nocturia: Results of a Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study</span>. <i>J. Urol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>190</i></span>,  <span class="NLM_fpage">965</span>– <span class="NLM_lpage">972</span>, <span class="refDoi"> DOI: 10.1016/j.juro.2012.12.112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1016%2Fj.juro.2012.12.112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=23454402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFCrsr7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=190&publication_year=2013&pages=965-972&author=J.+P.+Weissauthor=S.+Herschornauthor=C.+D.+Albeiauthor=E.+A.+van+der+Meulen&title=Efficacy+and+Safety+of+Low+Dose+Desmopressin+Orally+Disintegrating+Tablet+in+Men+with+Nocturia%3A+Results+of+a+Multicenter%2C+Randomized%2C+Double-Blind%2C+Placebo+Controlled%2C+Parallel+Group+Study&doi=10.1016%2Fj.juro.2012.12.112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and Safety of Low Dose Desmopressin Orally Disintegrating Tablet in Men with Nocturia: Results of a Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study</span></div><div class="casAuthors">Weiss, Jeffrey P.; Herschorn, Sender; Albei, Cerasela D.; van der Meulen, Egbert A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Urology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">190</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">965-972</span>CODEN:
                <span class="NLM_cas:coden">JOURAA</span>;
        ISSN:<span class="NLM_cas:issn">0022-5347</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Purpose: We investigated the efficacy and safety of 50 and 75 μg desmopressin orally disintegrating tablets in men with nocturia (2 or more nocturnal voids).  Materials and Methods: In this 3-mo, randomized, double-blind, parallel study 50 and 75 μg desmopressin were compared with placebo.  The co-primary efficacy end points were changes from baseline in mean no. of nocturnal voids and proportions of patients achieving at least a 33% redn. from baseline in nocturnal voids (33% responders) during a 3-mo treatment period.  Results: The full anal. set comprised 385 men (age range 20 to 87 years).  The 50 and 75 μg doses significantly reduced the no. of nocturnal voids (-0.37, p <0.0001 and -0.41, p = 0.0003, resp.) and increased the odds of a 33% or greater response (OR 1.98, p = 0.0009 and OR 2.04, p = 0.0004, resp.) compared with placebo during 3 mo.  Desmopressin 50 and 75 μg increased the time to first void from baseline by approx. 40 min compared to placebo (p = 0.006 and p = 0.003, resp.).  The response to desmopressin was seen by 1 wk of treatment and was sustained.  Significant increases in health related quality of life and sleep quality were obsd. compared to placebo.  Desmopressin was well tolerated as only 2 subjects (age 74 and 79 years) on 50 μg had a serum sodium level of less than 130 mmol/L (vs 9 subjects on 75 μg).  Conclusions: Desmopressin (orally disintegrating tablet) is an effective and well tolerated treatment for men with nocturia.  Treatment with 50 μg desmopressin, the min. ED, provided sustained improvement of nocturia throughout the study and meaningful benefits to patients with an improved safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjfJbUfCU3aLVg90H21EOLACvtfcHk0ljDU2TlnHIkjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFCrsr7O&md5=88dd9cd6edeedab40bec2f6de726e992</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.juro.2012.12.112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.juro.2012.12.112%26sid%3Dliteratum%253Aachs%26aulast%3DWeiss%26aufirst%3DJ.%2BP.%26aulast%3DHerschorn%26aufirst%3DS.%26aulast%3DAlbei%26aufirst%3DC.%2BD.%26aulast%3Dvan%2Bder%2BMeulen%26aufirst%3DE.%2BA.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Low%2520Dose%2520Desmopressin%2520Orally%2520Disintegrating%2520Tablet%2520in%2520Men%2520with%2520Nocturia%253A%2520Results%2520of%2520a%2520Multicenter%252C%2520Randomized%252C%2520Double-Blind%252C%2520Placebo%2520Controlled%252C%2520Parallel%2520Group%2520Study%26jtitle%3DJ.%2520Urol.%26date%3D2013%26volume%3D190%26spage%3D965%26epage%3D972%26doi%3D10.1016%2Fj.juro.2012.12.112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agerso, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovgren, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senderovitz, T.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and Renal Excretion of Desmopressin after Intravenous Administration to Healthy Subjects and Renally Impaired Patients</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">352</span>– <span class="NLM_lpage">358</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.2004.02175.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1111%2Fj.1365-2125.2004.02175.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=15373927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsVSiu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2004&pages=352-358&author=H.+Agersoauthor=L.+S.+Larsenauthor=A.+Riisauthor=U.+Lovgrenauthor=M.+O.+Karlssonauthor=T.+Senderovitz&title=Pharmacokinetics+and+Renal+Excretion+of+Desmopressin+after+Intravenous+Administration+to+Healthy+Subjects+and+Renally+Impaired+Patients&doi=10.1111%2Fj.1365-2125.2004.02175.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients</span></div><div class="casAuthors">Agerso, Henrik; Larsen, Lotte Seiding; Riis, Anders; Lovgren, Ulf; Karlsson, Mats O.; Senderovitz, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">352-358</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">The aim was to evaluate the influence of renal impairment on the pharmacokinetics of desmopressin.  Twenty-four subjects were enrolled in the study, 18 with varying degrees of renal impairment and six healthy volunteers.  Each subject received a single i.v. dose of 2 pg desmopressin.  Blood and urine samples were collected for 24 h and assayed for desmopressin by RIA.  Plasma concns. and the amts. of desmopressin excreted in the urine were analyzed simultaneously by use of mixed effects modeling.  Only mild adverse events were obsd.  Both the renal and the nonrenal clearance of desmopressin were found to vary with the creatinine clearance (CrCL).  A decrease of 1.67% in the CrCL (corresponding to 1 mL min-1 from 60 mL min-1) was found to cause a 1.74% decrease in the renal clearance and a 0.93% decrease in the nonrenal clearance.  The fall in renal clearance caused the amt. of desmopressin excreted in urine to decrease from 47% in healthy subjects to 21% in the patients with severe renal impairment.  The mean systemic clearance of desmopressin was 10 L h-1 in healthy subjects and 2.9 L h-1 in patients with severe renal impairment (difference -7.5 L h-1, 95% CI [-11; -4.3] litres h-1).  Correspondingly, the mean terminal half-life, was 3.7 h in healthy subjects and 10 h in patients with severe renal impairment (difference 6.7 h, 95% CI [4.0; 9.4] h).  Although desmopressin appears to be safe and well-tolerated by patients with impaired renal function, great caution should be exercised when titrating towards an efficient dosage regimen if patients with moderately or severely impaired renal function are to be treated with desmopressin at all.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhCTemkYdoBrVg90H21EOLACvtfcHk0ljDU2TlnHIkjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsVSiu70%253D&md5=7fdf7a4ce804c9ecdf700cc453686155</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2004.02175.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2004.02175.x%26sid%3Dliteratum%253Aachs%26aulast%3DAgerso%26aufirst%3DH.%26aulast%3DLarsen%26aufirst%3DL.%2BS.%26aulast%3DRiis%26aufirst%3DA.%26aulast%3DLovgren%26aufirst%3DU.%26aulast%3DKarlsson%26aufirst%3DM.%2BO.%26aulast%3DSenderovitz%26aufirst%3DT.%26atitle%3DPharmacokinetics%2520and%2520Renal%2520Excretion%2520of%2520Desmopressin%2520after%2520Intravenous%2520Administration%2520to%2520Healthy%2520Subjects%2520and%2520Renally%2520Impaired%2520Patients%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2004%26volume%3D58%26spage%3D352%26epage%3D358%26doi%3D10.1111%2Fj.1365-2125.2004.02175.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Callréus, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, M.</span></span> <span> </span><span class="NLM_article-title">Hyponatremia in Elderly Patients Treated with Desmopressin for Nocturia: A Review of a Case Series</span>. <i>Eur. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">281</span>– <span class="NLM_lpage">284</span>, <span class="refDoi"> DOI: 10.1007/s00228-005-0919-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1007%2Fs00228-005-0919-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2005&pages=281-284&author=T.+Callr%C3%A9usauthor=E.+Ekmanauthor=M.+Andersen&title=Hyponatremia+in+Elderly+Patients+Treated+with+Desmopressin+for+Nocturia%3A+A+Review+of+a+Case+Series&doi=10.1007%2Fs00228-005-0919-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1007%2Fs00228-005-0919-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00228-005-0919-4%26sid%3Dliteratum%253Aachs%26aulast%3DCallr%25C3%25A9us%26aufirst%3DT.%26aulast%3DEkman%26aufirst%3DE.%26aulast%3DAndersen%26aufirst%3DM.%26atitle%3DHyponatremia%2520in%2520Elderly%2520Patients%2520Treated%2520with%2520Desmopressin%2520for%2520Nocturia%253A%2520A%2520Review%2520of%2520a%2520Case%2520Series%26jtitle%3DEur.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2005%26volume%3D61%26spage%3D281%26epage%3D284%26doi%3D10.1007%2Fs00228-005-0919-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fjellestad-Paulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoglund, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulsen, O.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics of 1-Deamino-8-<span class="smallcaps smallerCapital">d</span>-Arginine Vasopressin after Various Routes of Administration in Healthy Volunteers</span>. <i>Clin. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">177</span>– <span class="NLM_lpage">182</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2265.1993.tb00990.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1111%2Fj.1365-2265.1993.tb00990.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=8435898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADyaK3sXisVOqu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1993&pages=177-182&author=A.+Fjellestad-Paulsenauthor=P.+Hoglundauthor=S.+Lundinauthor=O.+Paulsen&title=Pharmacokinetics+of+1-Deamino-8-d-Arginine+Vasopressin+after+Various+Routes+of+Administration+in+Healthy+Volunteers&doi=10.1111%2Fj.1365-2265.1993.tb00990.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics of 1-deamino-8-D-arginine vasopressin after various routes of administration in healthy volunteers</span></div><div class="casAuthors">Fjellestad-Paulsen, A.; Hoeglund, P.; Lundin, S.; Paulsen, O.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Endocrinology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">177-82</span>CODEN:
                <span class="NLM_cas:coden">CLECAP</span>;
        ISSN:<span class="NLM_cas:issn">0300-0664</span>.
    </div><div class="casAbstract">The pharmacokinetics and biol. effects of 1-deamino-8-D-arginine vasopressin (dDAVP) were investigated in healthy adults after i.v. and s.c. (2 μg), intranasal and sublingual (20μg), intrarectal (50 μg), and oral (200 μg) administration.  An increase of urine osmolality was obsd. after all routes of administration, except the sublingual and intrarectal for up to 8 h after administration.  After i.v. administration, the half-life of elimination of dDVAP was 78 min.  An extensive adsorption of dDAVP to the plastic syringe was found with i.v., but not with s.c., administration.  Using the area under the curve of dDAVP from the s.c. administration as a ref., bioavailability was found to be 3.4% after intranasal administration and 0.1% after oral administration.  After sublingual and intrarectal routes of administration no detectable dDAVP was found in the blood; however, low amts. were found in the total 24-h urine.  The bioavailability of dDAVP seems lower than previously reported after intranasal and oral administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiR1LCUXrYgLVg90H21EOLACvtfcHk0ljDU2TlnHIkjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXisVOqu7c%253D&md5=a742cdc744a057c00d9df7d0c6544d99</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2265.1993.tb00990.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2265.1993.tb00990.x%26sid%3Dliteratum%253Aachs%26aulast%3DFjellestad-Paulsen%26aufirst%3DA.%26aulast%3DHoglund%26aufirst%3DP.%26aulast%3DLundin%26aufirst%3DS.%26aulast%3DPaulsen%26aufirst%3DO.%26atitle%3DPharmacokinetics%2520of%25201-Deamino-8-d-Arginine%2520Vasopressin%2520after%2520Various%2520Routes%2520of%2520Administration%2520in%2520Healthy%2520Volunteers%26jtitle%3DClin.%2520Endocrinol.%26date%3D1993%26volume%3D38%26spage%3D177%26epage%3D182%26doi%3D10.1111%2Fj.1365-2265.1993.tb00990.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Odeberg, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callreus, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoglund, P.</span></span> <span> </span><span class="NLM_article-title">A Pharmacokinetic and Pharmacodynamic Study of Desmopressin: Evaluating Sex Differences and the Effect of Pre-Treatment with Piroxicam, and Further Validation of an Indirect Response Model</span>. <i>J. Pharm. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">1389</span>– <span class="NLM_lpage">1398</span>, <span class="refDoi"> DOI: 10.1211/0022357044535</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1211%2F0022357044535" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=15525445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpvFOltb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2004&pages=1389-1398&author=J.+M.+Odebergauthor=T.+Callreusauthor=S.+Lundinauthor=E.+B.+Rothauthor=P.+Hoglund&title=A+Pharmacokinetic+and+Pharmacodynamic+Study+of+Desmopressin%3A+Evaluating+Sex+Differences+and+the+Effect+of+Pre-Treatment+with+Piroxicam%2C+and+Further+Validation+of+an+Indirect+Response+Model&doi=10.1211%2F0022357044535"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">A pharmacokinetic and pharmacodynamic study of desmopressin: Evaluating sex differences and the effect of pre-treatment with piroxicam, and further validation of an indirect response model</span></div><div class="casAuthors">Odeberg, Johanna Mercke; Callreus, Torbjoern; Lundin, Stefan; Roth, E. Bodil; Hoeglund, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacy and Pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1389-1398</span>CODEN:
                <span class="NLM_cas:coden">JPPMAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3573</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Press</span>)
        </div><div class="casAbstract">Desmopressin is a synthetic vasopressin analog mainly used in treatment of diabetes insipidus and nocturia.  Studies in rats have revealed a sex difference in the response to a vasopressin infusion, which was diminished after treatment with an NSAID.  This study was performed in man to investigate the influence of sex and concomitant treatment of piroxicam on the pharmacokinetics and dynamics of desmopressin, and to validate a previously described indirect response model.  Eight healthy males and 8 healthy females participated in the trial, which was conducted in a pharmacokinetic (PK) part followed by a pharmacodynamic (PD) part.  Desmopressin was administered i.v. as a single dose (PK = dose 2 μg, PD = dose 0.2 μg).  Piroxicam was administered to achieve steady state.  The pharmacokinetic parameters of desmopressin were estd. and calcd. by 2-compartmental anal.  In the dynamic part a study design based on an oral hydration model was used.  Parameters for urine flow and urine osmolality were estd.  Individual ests. of the pharmacokinetic parameters served as input to the indirect response model that subsequently was fitted to urine osmolality data.  The pharmacokinetics of desmopressin after a fixed bolus injection was neither influenced by piroxicam nor sex of the subject.  The pharmacodynamics of desmopressin showed a sex difference where females exhibited a more pronounced antidiuretic effect than males, which was statistically significant when the effects were submaximal (>4.5 h after dose).  The sex differences were diminished after pre-treatment with piroxicam, indicating a prostaglandin PGE2-mediated mechanism.  The indirect response model was confirmed, although the modeling could not distinguish a sex difference, indicating a limitation of this model compared with traditional descriptive statistics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhclsIssWT_7Vg90H21EOLACvtfcHk0lg63_5wKbvf1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpvFOltb4%253D&md5=382b5ebfbddfc064c5859ae617e8499b</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1211%2F0022357044535&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1211%252F0022357044535%26sid%3Dliteratum%253Aachs%26aulast%3DOdeberg%26aufirst%3DJ.%2BM.%26aulast%3DCallreus%26aufirst%3DT.%26aulast%3DLundin%26aufirst%3DS.%26aulast%3DRoth%26aufirst%3DE.%2BB.%26aulast%3DHoglund%26aufirst%3DP.%26atitle%3DA%2520Pharmacokinetic%2520and%2520Pharmacodynamic%2520Study%2520of%2520Desmopressin%253A%2520Evaluating%2520Sex%2520Differences%2520and%2520the%2520Effect%2520of%2520Pre-Treatment%2520with%2520Piroxicam%252C%2520and%2520Further%2520Validation%2520of%2520an%2520Indirect%2520Response%2520Model%26jtitle%3DJ.%2520Pharm.%2520Pharmacol.%26date%3D2004%26volume%3D56%26spage%3D1389%26epage%3D1398%26doi%3D10.1211%2F0022357044535" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nevéus, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Läckgren, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuvemo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stenberg, A.</span></span> <span> </span><span class="NLM_article-title">Osmoregulation and Desmopressin Pharmacokinetics in Enuretic Children</span>. <i>Pediatrics</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1542/peds.103.1.65</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1542%2Fpeds.103.1.65" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=1999&pages=65-70&author=T.+Nev%C3%A9usauthor=G.+L%C3%A4ckgrenauthor=T.+Tuvemoauthor=A.+Stenberg&title=Osmoregulation+and+Desmopressin+Pharmacokinetics+in+Enuretic+Children&doi=10.1542%2Fpeds.103.1.65"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1542%2Fpeds.103.1.65&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1542%252Fpeds.103.1.65%26sid%3Dliteratum%253Aachs%26aulast%3DNev%25C3%25A9us%26aufirst%3DT.%26aulast%3DL%25C3%25A4ckgren%26aufirst%3DG.%26aulast%3DTuvemo%26aufirst%3DT.%26aulast%3DStenberg%26aufirst%3DA.%26atitle%3DOsmoregulation%2520and%2520Desmopressin%2520Pharmacokinetics%2520in%2520Enuretic%2520Children%26jtitle%3DPediatrics%26date%3D1999%26volume%3D103%26spage%3D65%26epage%3D70%26doi%3D10.1542%2Fpeds.103.1.65" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruzicka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjorkman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lethagen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sterner, G.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and Antidiuretic Effect of High-Dose Desmopressin in Patients with Chronic Renal Failure</span>. <i>Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">137</span>– <span class="NLM_lpage">142</span>, <span class="refDoi"> DOI: 10.1034/j.1600-0773.2003.920306.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1034%2Fj.1600-0773.2003.920306.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=12753429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADC%252BD3sXislOqu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2003&pages=137-142&author=H.+Ruzickaauthor=S.+Bjorkmanauthor=S.+Lethagenauthor=G.+Sterner&title=Pharmacokinetics+and+Antidiuretic+Effect+of+High-Dose+Desmopressin+in+Patients+with+Chronic+Renal+Failure&doi=10.1034%2Fj.1600-0773.2003.920306.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and antidiuretic effect of high-dose desmopressin in patients with chronic renal failure</span></div><div class="casAuthors">Ruzicka, Hana; Bjorkman, Sven; Lethagen, Stefan; Sterner, Gunnar</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Toxicology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">137-142</span>CODEN:
                <span class="NLM_cas:coden">PHTOEH</span>;
        ISSN:<span class="NLM_cas:issn">0901-9928</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishers Ltd.</span>)
        </div><div class="casAbstract">High-dose desmopressin shortens the bleeding time in uremia.  The aim of this study was to investigate the pharmacokinetics and the antidiuretic effect of desmopressin when given in a dose normally used for hemostasis to patients with reduced renal function.  Ten patients with chronic renal failure of varying etiol. were enrolled in the study.  The age was 58 (20-76) years (median and range), serum creatinine 447 (309-691) μmol/l and plasma clearance of iohexol 16 (8-19) ml/min./1.73 m2 body surface.  After baseline measurements, desmopressin was infused at a dose of 0.3 μg/kg.  The plasma concn. of desmopressin was followed for 26 h during and after the infusion and the pharmacokinetic parameters were estd. by compartmental anal.  Urine vol. and osmolality, as well as body wt., blood pressure, heart rate, hematocrit, serum osmolality, electrolytes and creatinine, were measured repeatedly during the day before and for two days after the infusion.  The total clearance of desmopressin was 0.35 (0.21-0.47) ml/min./kg, the vol. of distribution at steady state was 0.30 (0.17-0.38) l/kg and the terminal half-life 9.7 (8.4-16) hr.  After administration of desmopressin, urine osmolality increased significantly, by approx. 10%, and this increase lasted for 48 h.  Concomitantly, there was a modest but significant decrease in hematocrit.  Thus, the clearance of desmopressin was on av. decreased to approx. one quarter, and the terminal half-life was prolonged 2-3 times in the patients as compared to previously published values for healthy adults.  The single hemostatic dose of desmopressin given to patients with severe renal failure did not cause fluid overload or changes in serum electrolytes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojdxVX_ZZn6rVg90H21EOLACvtfcHk0lg63_5wKbvf1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXislOqu70%253D&md5=acc1ffec8bc3195e82ac991646feea8c</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1034%2Fj.1600-0773.2003.920306.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1034%252Fj.1600-0773.2003.920306.x%26sid%3Dliteratum%253Aachs%26aulast%3DRuzicka%26aufirst%3DH.%26aulast%3DBjorkman%26aufirst%3DS.%26aulast%3DLethagen%26aufirst%3DS.%26aulast%3DSterner%26aufirst%3DG.%26atitle%3DPharmacokinetics%2520and%2520Antidiuretic%2520Effect%2520of%2520High-Dose%2520Desmopressin%2520in%2520Patients%2520with%2520Chronic%2520Renal%2520Failure%26jtitle%3DPharmacol.%2520Toxicol.%26date%3D2003%26volume%3D92%26spage%3D137%26epage%3D142%26doi%3D10.1034%2Fj.1600-0773.2003.920306.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rembratt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graugaard-Jensen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senderovitz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norgaard, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djurhuus, J. C.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and Pharmacodynamics of Desmopressin Administered Orally Versus Intravenously at Daytime Versus Night-Time in Healthy Men Aged 55-70 Years</span>. <i>Eur. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">397</span>– <span class="NLM_lpage">402</span>, <span class="refDoi"> DOI: 10.1007/s00228-004-0781-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1007%2Fs00228-004-0781-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=397-402&author=A.+Rembrattauthor=C.+Graugaard-Jensenauthor=T.+Senderovitzauthor=J.+P.+Norgaardauthor=J.+C.+Djurhuus&title=Pharmacokinetics+and+Pharmacodynamics+of+Desmopressin+Administered+Orally+Versus+Intravenously+at+Daytime+Versus+Night-Time+in+Healthy+Men+Aged+55-70+Years&doi=10.1007%2Fs00228-004-0781-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2Fs00228-004-0781-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00228-004-0781-9%26sid%3Dliteratum%253Aachs%26aulast%3DRembratt%26aufirst%3DA.%26aulast%3DGraugaard-Jensen%26aufirst%3DC.%26aulast%3DSenderovitz%26aufirst%3DT.%26aulast%3DNorgaard%26aufirst%3DJ.%2BP.%26aulast%3DDjurhuus%26aufirst%3DJ.%2BC.%26atitle%3DPharmacokinetics%2520and%2520Pharmacodynamics%2520of%2520Desmopressin%2520Administered%2520Orally%2520Versus%2520Intravenously%2520at%2520Daytime%2520Versus%2520Night-Time%2520in%2520Healthy%2520Men%2520Aged%252055-70%2520Years%26jtitle%3DEur.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2004%26volume%3D60%26spage%3D397%26epage%3D402%26doi%3D10.1007%2Fs00228-004-0781-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caggiano, T. J.</span></span> <span> </span><span class="NLM_article-title">WAY-VNA-932</span>. <i>Drugs Future</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">248</span>– <span class="NLM_lpage">253</span>, <span class="refDoi"> DOI: 10.1358/dof.2002.027.03.659890</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1358%2Fdof.2002.027.03.659890" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADC%252BD38XkslaitL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2002&pages=248-253&author=T.+J.+Caggiano&title=WAY-VNA-932&doi=10.1358%2Fdof.2002.027.03.659890"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">WAY-VNA-932</span></div><div class="casAuthors">Caggiano, Thomas J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">248-253</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review. WAY-VNA-932 is a novel, orally active nonpeptide small mol. which exhibits vasopressin V2 receptor agonism.  In CHO cells transfected with human V1a, V2, V1b and oxytocin receptors, WAY-VNA-932 is a potent agonist at the V2 receptor, with an EC50 for 2nd messenger (cAMP) generation of 0.7 nM.  In water-loaded normotensive rats, Brattleboro rats, dogs and cynomolgus monkeys WAY-VNA-932 lowers urine output in a dose-dependent manner with a concomitant increase in osmolality.  It is expected that WAY-VNA-932 will offer several advantages over desmopressin, a peptide vasopressin V2 agonist, including greater and more consistent bioavailability and the lack of pressor activity.  WAY-VNA-932 is expected to be useful in conditions characterized by excessive prodn. and/or diln. of urine such as central diabetes insipidus and nocturnal enuresis as well as in conditions characterized by inappropriate prodn. of vasopressin.  WAY-VNA-932 is the 1st nonpeptide vasopressin V2 agonist to enter phase I trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqod3Z1TipNcrVg90H21EOLACvtfcHk0ljAmn3I0TzRSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkslaitL4%253D&md5=4d8946fd3c506cd1b9d20658d5ca0d42</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1358%2Fdof.2002.027.03.659890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2002.027.03.659890%26sid%3Dliteratum%253Aachs%26aulast%3DCaggiano%26aufirst%3DT.%2BJ.%26atitle%3DWAY-VNA-932%26jtitle%3DDrugs%2520Future%26date%3D2002%26volume%3D27%26spage%3D248%26epage%3D253%26doi%3D10.1358%2Fdof.2002.027.03.659890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itoh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsujimae, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinohara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teramoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sumida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekiguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kambe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsujimoto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tominaga, M.</span></span> <span> </span><span class="NLM_article-title">Characterization of a Novel Nonpeptide Vasopressin V(2)-Agonist, OPC-51803, in Cells Transfected Human Vasopressin Receptor Subtypes</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">1700</span>– <span class="NLM_lpage">1706</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0703221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1038%2Fsj.bjp.0703221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10780976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjtV2ru7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2000&pages=1700-1706&author=S.+Nakamuraauthor=Y.+Yamamuraauthor=S.+Itohauthor=T.+Hiranoauthor=K.+Tsujimaeauthor=M.+Aoyamaauthor=K.+Kondoauthor=H.+Ogawaauthor=T.+Shinoharaauthor=K.+Kanauthor=Y.+Tanadaauthor=S.+Teramotoauthor=T.+Sumidaauthor=S.+Nakayamaauthor=K.+Sekiguchiauthor=T.+Kambeauthor=G.+Tsujimotoauthor=T.+Moriauthor=M.+Tominaga&title=Characterization+of+a+Novel+Nonpeptide+Vasopressin+V%282%29-Agonist%2C+OPC-51803%2C+in+Cells+Transfected+Human+Vasopressin+Receptor+Subtypes&doi=10.1038%2Fsj.bjp.0703221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of a novel nonpeptide vasopressin V2-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes</span></div><div class="casAuthors">Nakamura, Shigeki; Yamamura, Yoshitaka; Itoh, Shuji; Hirano, Takahiro; Tsujimae, Kenji; Aoyama, Masashi; Kondo, Kazumi; Ogawa, Hidenori; Shinohara, Tomoichi; Kan, Keizo; Tanada, Yoshihisa; Teramoto, Shuji; Sumida, Takumi; Nakayama, Sunao; Sekiguchi, Kazuo; Kambe, Toshimi; Tsujimoto, Gozoh; Mori, Toyoki; Tominaga, Michiaki</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1700-1706</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We discovered the first nonpeptide arginine-vasopressin (AVP) V2-receptor agonist, OPC-51803.  Pharmacol. properties of OPC-51803 were elucidated using HeLa cells expressing human AVP receptor subtypes (V2, V1a and V1b) and compared with those of 1-desamino-8-D-arginine vasopressin (dDAVP), a peptide V2-receptor agonist.  OPC-51803 and dDAVP displaced [3H]-AVP binding to human V2- and V1a-receptors with Ki values of 91.9±10.8 nM (n=6) and 3.12±0.38 nM (n=6) for V2-receptors, and 819±39 nM (n=6) and 41.5±9.9 nM (n=6) for V1a-receptors, indicating that OPC-51803 was about nine times more selective for V2-receptors, similar to the selectivity of dDAVP.  OPC-51803 scarcely displaced [3H]-AVP binding to human V1b-receptors even at 10-4 M, while dDAVP showed potent affinity to human V1b-receptors with the Ki value of 13.7±3.2 nM (n=4).  OPC-51803 concn.-dependently increased cyclic adenosine 3', 5'-monophosphate (cAMP) prodn. in HeLa cells expressing human V2-receptors with an EC50 value of 189±14 nM (n=6).  The concn.-response curve for cAMP prodn. induced by OPC-51803 was shifted to the right in the presence of a V2-antagonist, OPC-31260.  At 10-5 M, OPC-51803 did not increase the intracellular Ca2+ concn. ([Ca2+]i) in HeLa cells expressing human V1a-receptors.  On the other hand, dDAVP increased [Ca2+]i in HeLa cells expressing human V1a- and V1b-receptors in a concn.-dependent fashion.  From these results, OPC-51803 has been confirmed to be the first nonpeptide agonist for human AVP V2-receptors without agonistic activities for V1a- and V1b-receptors.  OPC-51803 may be useful for the treatment of AVP-deficient pathophysiol. states and as a tool for AVP researches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtP6Ey2VlQ77Vg90H21EOLACvtfcHk0ljAmn3I0TzRSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjtV2ru7k%253D&md5=435c824ff32701169445cb4a1c35a94c</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0703221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0703221%26sid%3Dliteratum%253Aachs%26aulast%3DNakamura%26aufirst%3DS.%26aulast%3DYamamura%26aufirst%3DY.%26aulast%3DItoh%26aufirst%3DS.%26aulast%3DHirano%26aufirst%3DT.%26aulast%3DTsujimae%26aufirst%3DK.%26aulast%3DAoyama%26aufirst%3DM.%26aulast%3DKondo%26aufirst%3DK.%26aulast%3DOgawa%26aufirst%3DH.%26aulast%3DShinohara%26aufirst%3DT.%26aulast%3DKan%26aufirst%3DK.%26aulast%3DTanada%26aufirst%3DY.%26aulast%3DTeramoto%26aufirst%3DS.%26aulast%3DSumida%26aufirst%3DT.%26aulast%3DNakayama%26aufirst%3DS.%26aulast%3DSekiguchi%26aufirst%3DK.%26aulast%3DKambe%26aufirst%3DT.%26aulast%3DTsujimoto%26aufirst%3DG.%26aulast%3DMori%26aufirst%3DT.%26aulast%3DTominaga%26aufirst%3DM.%26atitle%3DCharacterization%2520of%2520a%2520Novel%2520Nonpeptide%2520Vasopressin%2520V%25282%2529-Agonist%252C%2520OPC-51803%252C%2520in%2520Cells%2520Transfected%2520Human%2520Vasopressin%2520Receptor%2520Subtypes%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2000%26volume%3D129%26spage%3D1700%26epage%3D1706%26doi%3D10.1038%2Fsj.bjp.0703221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yea, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allan, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashworth, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnett, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxter, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broadbridge, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franklin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hampton, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horton, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penson, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitt, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riviere, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robson, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooker, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semple, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheppard, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haigh, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roe, M. B.</span></span> <span> </span><span class="NLM_article-title">New Benzylureas as a Novel Series of Potent, Nonpeptidic Vasopressin V2 Receptor Agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">8124</span>– <span class="NLM_lpage">8134</span>, <span class="refDoi"> DOI: 10.1021/jm8008162</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8008162" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=8124-8134&author=C.+M.+Yeaauthor=C.+E.+Allanauthor=D.+M.+Ashworthauthor=J.+Barnettauthor=A.+J.+Baxterauthor=J.+D.+Broadbridgeauthor=R.+J.+Franklinauthor=S.+L.+Hamptonauthor=P.+Hudsonauthor=J.+A.+Hortonauthor=P.+D.+Jenkinsauthor=A.+M.+Pensonauthor=G.+R.+Pittauthor=P.+Riviereauthor=P.+A.+Robsonauthor=D.+P.+Rookerauthor=G.+Sempleauthor=A.+Sheppardauthor=R.+M.+Haighauthor=M.+B.+Roe&title=New+Benzylureas+as+a+Novel+Series+of+Potent%2C+Nonpeptidic+Vasopressin+V2+Receptor+Agonists&doi=10.1021%2Fjm8008162"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm8008162&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8008162%26sid%3Dliteratum%253Aachs%26aulast%3DYea%26aufirst%3DC.%2BM.%26aulast%3DAllan%26aufirst%3DC.%2BE.%26aulast%3DAshworth%26aufirst%3DD.%2BM.%26aulast%3DBarnett%26aufirst%3DJ.%26aulast%3DBaxter%26aufirst%3DA.%2BJ.%26aulast%3DBroadbridge%26aufirst%3DJ.%2BD.%26aulast%3DFranklin%26aufirst%3DR.%2BJ.%26aulast%3DHampton%26aufirst%3DS.%2BL.%26aulast%3DHudson%26aufirst%3DP.%26aulast%3DHorton%26aufirst%3DJ.%2BA.%26aulast%3DJenkins%26aufirst%3DP.%2BD.%26aulast%3DPenson%26aufirst%3DA.%2BM.%26aulast%3DPitt%26aufirst%3DG.%2BR.%26aulast%3DRiviere%26aufirst%3DP.%26aulast%3DRobson%26aufirst%3DP.%2BA.%26aulast%3DRooker%26aufirst%3DD.%2BP.%26aulast%3DSemple%26aufirst%3DG.%26aulast%3DSheppard%26aufirst%3DA.%26aulast%3DHaigh%26aufirst%3DR.%2BM.%26aulast%3DRoe%26aufirst%3DM.%2BB.%26atitle%3DNew%2520Benzylureas%2520as%2520a%2520Novel%2520Series%2520of%2520Potent%252C%2520Nonpeptidic%2520Vasopressin%2520V2%2520Receptor%2520Agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D8124%26epage%3D8134%26doi%3D10.1021%2Fjm8008162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koshio, H.</span>; <span class="NLM_string-name">Tsukamoto, I.</span>; <span class="NLM_string-name">Kakefuda, A.</span>; <span class="NLM_string-name">Akamatsu, S.</span>; <span class="NLM_string-name">Saitoh, C.</span></span> <span> </span><span class="NLM_article-title">Preparation of 4,4-Difluoro-1,2,3,4-Tetrahydro-1(5H)-Benzazepine Derivatives for Treatment of Night Pollakisuria and Diabetes Insipidus</span>. <span class="NLM_patent">WO2004096775A1</span>, <span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=H.+Koshio&author=I.+Tsukamoto&author=A.+Kakefuda&author=S.+Akamatsu&author=C.+Saitoh&title=Preparation+of+4%2C4-Difluoro-1%2C2%2C3%2C4-Tetrahydro-1%285H%29-Benzazepine+Derivatives+for+Treatment+of+Night+Pollakisuria+and+Diabetes+Insipidus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKoshio%26aufirst%3DH.%26atitle%3DPreparation%2520of%25204%252C4-Difluoro-1%252C2%252C3%252C4-Tetrahydro-1%25285H%2529-Benzazepine%2520Derivatives%2520for%2520Treatment%2520of%2520Night%2520Pollakisuria%2520and%2520Diabetes%2520Insipidus%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satoh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamagishi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furuhama, K.</span></span> <span> </span><span class="NLM_article-title">Calculation of Glomerular Filtration Rate in Conscious Rats by the Use of a Bolus Injection of Iodixanol and a Single Blood Sample</span>. <i>J. Pharmacol. Toxicol. Methods</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">64</span>, <span class="refDoi"> DOI: 10.1016/j.vascn.2009.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1016%2Fj.vascn.2009.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=19854282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1WltbnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2010&pages=59-64&author=R.+Katayamaauthor=N.+Yamaguchiauthor=T.+Yamashitaauthor=S.+Watanabeauthor=H.+Satohauthor=N.+Yamagishiauthor=K.+Furuhama&title=Calculation+of+Glomerular+Filtration+Rate+in+Conscious+Rats+by+the+Use+of+a+Bolus+Injection+of+Iodixanol+and+a+Single+Blood+Sample&doi=10.1016%2Fj.vascn.2009.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Calculation of glomerular filtration rate in conscious rats by the use of a bolus injection of iodixanol and a single blood sample</span></div><div class="casAuthors">Katayama, Rieko; Yamaguchi, Nami; Yamashita, Tetsuro; Watanabe, Shuji; Satoh, Hiroshi; Yamagishi, Norio; Furuhama, Kazuhisa</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological and Toxicological Methods</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">59-64</span>CODEN:
                <span class="NLM_cas:coden">JPTMEZ</span>;
        ISSN:<span class="NLM_cas:issn">1056-8719</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Introduction: To establish a simple and convenient procedure for the detn. of glomerular filtration rate (GFR) in conscious rats, the authors developed a single-blood-sample method, in contrast to the conventional three-sample method, using a bolus injection of the nonionic contrast medium iodixanol.  Methods: Iodixanol was i.v. administered at 1500 mg I/kg to healthy or renal-impaired rats, and blood was collected 60, 120, and 180 min later.  Serum iodixanol concns. were measured by HPLC, and serum urea nitrogen (UN) and creatinine concns. were detd. as renal function tests.  Results: In rats subjected to 1/2 and 3/4 nephrectomies, GFR values decreased significantly without and with increases in serum UN and creatinine concns., resp.  In rats treated s.c. with gentamicin sulfate (GM) at 80 mg/kg/day or puromycin aminonucleoside (PAN) at 15 mg/kg/day for 10 consecutive days, the GFR values decreased or showed a tendency to decrease before increases in serum UN and creatinine concns.  Accordingly, when the GFR decreased to more than 60% of the basal value, serum UN or creatinine concns. became elevated.  The GFR values obtained from the three-sample method were closely correlated (r = 0.83) with those calcd. from the estd. distribution vol. (V) and serum iodixanol concn. 120 min after iodixanol injection in the single-blood-sample method in which serum iodixanol concns. ranged between 20 and 250 μg I/mL.  Discussion: These results suggest that the single-blood-sample method with a bolus injection of iodixanol, allowing for the repeated use of the same animals, is an expedient procedure without ensuring accurate urine collection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDMjSYiBEq27Vg90H21EOLACvtfcHk0lgH2o8X7xB0nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1WltbnL&md5=024c608eee322fd813c550cf274bc44b</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.vascn.2009.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vascn.2009.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DYamaguchi%26aufirst%3DN.%26aulast%3DYamashita%26aufirst%3DT.%26aulast%3DWatanabe%26aufirst%3DS.%26aulast%3DSatoh%26aufirst%3DH.%26aulast%3DYamagishi%26aufirst%3DN.%26aulast%3DFuruhama%26aufirst%3DK.%26atitle%3DCalculation%2520of%2520Glomerular%2520Filtration%2520Rate%2520in%2520Conscious%2520Rats%2520by%2520the%2520Use%2520of%2520a%2520Bolus%2520Injection%2520of%2520Iodixanol%2520and%2520a%2520Single%2520Blood%2520Sample%26jtitle%3DJ.%2520Pharmacol.%2520Toxicol.%2520Methods%26date%3D2010%26volume%3D61%26spage%3D59%26epage%3D64%26doi%3D10.1016%2Fj.vascn.2009.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manning, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoev, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chini, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durroux, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mouillac, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillon, G.</span></span> <span> </span><span class="NLM_article-title">Peptide and Non-Peptide Agonists and Antagonists for the Vasopressin and Oxytocin V1a, V1b, V2 and OT Receptors: Research Tools and Potential Therapeutic Agents</span>. <i>Prog. Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>170</i></span>,  <span class="NLM_fpage">473</span>– <span class="NLM_lpage">512</span>, <span class="refDoi"> DOI: 10.1016/S0079-6123(08)00437-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1016%2FS0079-6123%2808%2900437-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=18655903" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1CjtrfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2008&pages=473-512&author=M.+Manningauthor=S.+Stoevauthor=B.+Chiniauthor=T.+Durrouxauthor=B.+Mouillacauthor=G.+Guillon&title=Peptide+and+Non-Peptide+Agonists+and+Antagonists+for+the+Vasopressin+and+Oxytocin+V1a%2C+V1b%2C+V2+and+OT+Receptors%3A+Research+Tools+and+Potential+Therapeutic+Agents&doi=10.1016%2FS0079-6123%2808%2900437-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents</span></div><div class="casAuthors">Manning, Maurice; Stoev, Stoytcho; Chini, Bice; Durroux, Thierry; Mouillac, Bernard; Guillon, Gilles</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Brain Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue">Advances in Vasopressin and Oxytocin</span>),
    <span class="NLM_cas:pages">473-512</span>CODEN:
                <span class="NLM_cas:coden">PBRRA4</span>;
        ISSN:<span class="NLM_cas:issn">0079-6123</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Oxytocin (OT) and vasopressin (AVP) mediate their biol. actions by acting on four known receptors: The OT (uterine) and the AVP V1a (vasopressor), V1b (pituitary), V2 (renal) receptors and a fifth putative AVP V1c (vasodilating) receptor.  This presentation will summarize some highlights of the recent progress, in the design and synthesis of selective peptide agonists, antagonists, radioiodinated ligands, fluorescent ligands and bivalent ligands for these receptors.  Here we present published and unpublished pharmacol. data on the most widely used agonists, antagonists and labeled ligands.  The pharmacol. properties of promising new selective OT antagonists and V1b agonists are also presented.  This review should serve as a useful guide for the selection of the most appropriate ligand for a given study.  The current status of non-peptide OT and AVP antagonists and agonists is also summarized.  The relative merits of peptide and non-peptide AVP and OT agonists and antagonists as: (1) research tools and (2) therapeutic agents will be evaluated.  Many of the receptor selective peptide agonists and antagonists from this and other labs. are far more widely used as pharmacol. tools for studies on the peripheral and central effects of OT and AVP than their non-peptide counterparts.  In addn. to OT and to a lesser extent AVP (pitressin), a no. of OT and AVP analogs; such as carbetocin (OT agonist) dDAVP (desmopressin, V2 agonist), terlipressin (V1a agonist), felypressin (V1a agonist) and atosiban (Tractocile OT antagonist) are also in clin. use.  Despite much early promise, no non-peptide V1a or OT antagonists are currently in clin. trials.  While a no. of orally active non-peptide V2 antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clin. trials; to date, only the mixed V2/V1a, antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clin. use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.  Promising new non-peptide V1b and OT antagonists, as well as non-peptide V2 and OT agonists are now in pre-clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3jiQ5LZT5gLVg90H21EOLACvtfcHk0lgH2o8X7xB0nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1CjtrfJ&md5=c21ad467eaee4a2651232a16c7dc61c5</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2FS0079-6123%2808%2900437-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0079-6123%252808%252900437-8%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DM.%26aulast%3DStoev%26aufirst%3DS.%26aulast%3DChini%26aufirst%3DB.%26aulast%3DDurroux%26aufirst%3DT.%26aulast%3DMouillac%26aufirst%3DB.%26aulast%3DGuillon%26aufirst%3DG.%26atitle%3DPeptide%2520and%2520Non-Peptide%2520Agonists%2520and%2520Antagonists%2520for%2520the%2520Vasopressin%2520and%2520Oxytocin%2520V1a%252C%2520V1b%252C%2520V2%2520and%2520OT%2520Receptors%253A%2520Research%2520Tools%2520and%2520Potential%2520Therapeutic%2520Agents%26jtitle%3DProg.%2520Brain%2520Res.%26date%3D2008%26volume%3D170%26spage%3D473%26epage%3D512%26doi%3D10.1016%2FS0079-6123%2808%2900437-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manning, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misicka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bankowski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoev, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chini, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durroux, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mouillac, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillon, G.</span></span> <span> </span><span class="NLM_article-title">Oxytocin and Vasopressin Agonists and Antagonists as Research Tools and Potential Therapeutics</span>. <i>J. Neuroendocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">609</span>– <span class="NLM_lpage">628</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2826.2012.02303.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1111%2Fj.1365-2826.2012.02303.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=22375852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADC%252BC38XlsFKrtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2012&pages=609-628&author=M.+Manningauthor=A.+Misickaauthor=A.+Olmaauthor=K.+Bankowskiauthor=S.+Stoevauthor=B.+Chiniauthor=T.+Durrouxauthor=B.+Mouillacauthor=M.+Corbaniauthor=G.+Guillon&title=Oxytocin+and+Vasopressin+Agonists+and+Antagonists+as+Research+Tools+and+Potential+Therapeutics&doi=10.1111%2Fj.1365-2826.2012.02303.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics</span></div><div class="casAuthors">Manning, M.; Misicka, A.; Olma, A.; Bankowski, K.; Stoev, S.; Chini, B.; Durroux, T.; Mouillac, B.; Corbani, M.; Guillon, G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroendocrinology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">609-628</span>CODEN:
                <span class="NLM_cas:coden">JOUNE2</span>;
        ISSN:<span class="NLM_cas:issn">0953-8194</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  We recently reviewed the status of peptide and nonpeptide agonists and antagonists for the V1a, V1b and V2 receptors for arginine vasopressin (AVP) and the oxytocin receptor for oxytocin (OT).  In the present review, we update the status of peptides and nonpeptides as: (i) research tools and (ii) therapeutic agents.  We also present our recent findings on the design of fluorescent ligands for V1b receptor localization and for OT receptor dimerization.  We note the exciting discoveries regarding 2 novel naturally occurring analogs of OT.  Recent reports of a selective VP V1a agonist and a selective OT agonist point to the continued therapeutic potential of peptides in this field.  To date, only 2 nonpeptides, the V2/V1a antagonist, conivaptan and the V2 antagonist tolvaptan have received Food and Drug Administration approval for clin. use.  The development of nonpeptide AVP V1a, V1b and V2 antagonists and OT agonists and antagonists has recently been abandoned by Merck, Sanofi and Pfizer.  A promising OT antagonist, Retosiban, developed at Glaxo SmithKline is currently in a Phase II clin. trial for the prevention of premature labour.  A no. of the nonpeptide ligands that were not successful in clin. trials are proving to be valuable as research tools.  Peptide agonists and antagonists continue to be very widely used as research tools in this field.  In this regard, we present receptor data on some of the most widely used peptide and nonpeptide ligands, as a guide for their use, esp. with regard to receptor selectivity and species differences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvboATX-Tv3rVg90H21EOLACvtfcHk0ljXCESqhjPWrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlsFKrtrw%253D&md5=73b26be08e84e9daf8ac9136b472e6ad</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2826.2012.02303.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2826.2012.02303.x%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DM.%26aulast%3DMisicka%26aufirst%3DA.%26aulast%3DOlma%26aufirst%3DA.%26aulast%3DBankowski%26aufirst%3DK.%26aulast%3DStoev%26aufirst%3DS.%26aulast%3DChini%26aufirst%3DB.%26aulast%3DDurroux%26aufirst%3DT.%26aulast%3DMouillac%26aufirst%3DB.%26aulast%3DCorbani%26aufirst%3DM.%26aulast%3DGuillon%26aufirst%3DG.%26atitle%3DOxytocin%2520and%2520Vasopressin%2520Agonists%2520and%2520Antagonists%2520as%2520Research%2520Tools%2520and%2520Potential%2520Therapeutics%26jtitle%3DJ.%2520Neuroendocrinol.%26date%3D2012%26volume%3D24%26spage%3D609%26epage%3D628%26doi%3D10.1111%2Fj.1365-2826.2012.02303.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acosta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balaspiri, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judd, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, M.</span></span> <span> </span><span class="NLM_article-title">Structural Changes in the Arginine Vasopressin Molecule That Enhance Antidiuretic Activity and Specificity</span>. <i>Endocrinology</i> <span class="NLM_year" style="font-weight: bold;">1974</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">1106</span>– <span class="NLM_lpage">1115</span>, <span class="refDoi"> DOI: 10.1210/endo-94-4-1106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1210%2Fendo-94-4-1106" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1974&pages=1106-1115&author=W.+H.+Sawyerauthor=M.+Acostaauthor=L.+Balaspiriauthor=J.+Juddauthor=M.+Manning&title=Structural+Changes+in+the+Arginine+Vasopressin+Molecule+That+Enhance+Antidiuretic+Activity+and+Specificity&doi=10.1210%2Fendo-94-4-1106"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1210%2Fendo-94-4-1106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fendo-94-4-1106%26sid%3Dliteratum%253Aachs%26aulast%3DSawyer%26aufirst%3DW.%2BH.%26aulast%3DAcosta%26aufirst%3DM.%26aulast%3DBalaspiri%26aufirst%3DL.%26aulast%3DJudd%26aufirst%3DJ.%26aulast%3DManning%26aufirst%3DM.%26atitle%3DStructural%2520Changes%2520in%2520the%2520Arginine%2520Vasopressin%2520Molecule%2520That%2520Enhance%2520Antidiuretic%2520Activity%2520and%2520Specificity%26jtitle%3DEndocrinology%26date%3D1974%26volume%3D94%26spage%3D1106%26epage%3D1115%26doi%3D10.1210%2Fendo-94-4-1106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kowalczyk, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobolewski, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prahl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derdowska, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borovickova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slaninova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lammek, B.</span></span> <span> </span><span class="NLM_article-title">The Effects of N-Terminal Part Modification of Arginine Vasopressin Analogues with 2-Aminoindane-2-Carboxylic Acid: A Highly Potent V2 Agonist</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">2926</span>– <span class="NLM_lpage">2929</span>, <span class="refDoi"> DOI: 10.1021/jm070174s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070174s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=2926-2929&author=W.+Kowalczykauthor=D.+Sobolewskiauthor=A.+Prahlauthor=I.+Derdowskaauthor=L.+Borovickovaauthor=J.+Slaninovaauthor=B.+Lammek&title=The+Effects+of+N-Terminal+Part+Modification+of+Arginine+Vasopressin+Analogues+with+2-Aminoindane-2-Carboxylic+Acid%3A+A+Highly+Potent+V2+Agonist&doi=10.1021%2Fjm070174s"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm070174s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070174s%26sid%3Dliteratum%253Aachs%26aulast%3DKowalczyk%26aufirst%3DW.%26aulast%3DSobolewski%26aufirst%3DD.%26aulast%3DPrahl%26aufirst%3DA.%26aulast%3DDerdowska%26aufirst%3DI.%26aulast%3DBorovickova%26aufirst%3DL.%26aulast%3DSlaninova%26aufirst%3DJ.%26aulast%3DLammek%26aufirst%3DB.%26atitle%3DThe%2520Effects%2520of%2520N-Terminal%2520Part%2520Modification%2520of%2520Arginine%2520Vasopressin%2520Analogues%2520with%25202-Aminoindane-2-Carboxylic%2520Acid%253A%2520A%2520Highly%2520Potent%2520V2%2520Agonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D2926%26epage%3D2929%26doi%3D10.1021%2Fjm070174s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobolewski, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prahl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borovickova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slaninova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lammek, B.</span></span> <span> </span><span class="NLM_article-title">Arginine Vasopressin and Its Analogues - The Influence of Position 2 Modification with 3,3-Diphenylalanine Enantiomers. Highly Potent V2 Agonists</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">2862</span>– <span class="NLM_lpage">2867</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2008.12.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1016%2Fj.ejmech.2008.12.010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2009&pages=2862-2867&author=A.+Kwiatkowskaauthor=D.+Sobolewskiauthor=A.+Prahlauthor=L.+Borovickovaauthor=J.+Slaninovaauthor=B.+Lammek&title=Arginine+Vasopressin+and+Its+Analogues+-+The+Influence+of+Position+2+Modification+with+3%2C3-Diphenylalanine+Enantiomers.+Highly+Potent+V2+Agonists&doi=10.1016%2Fj.ejmech.2008.12.010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2008.12.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2008.12.010%26sid%3Dliteratum%253Aachs%26aulast%3DKwiatkowska%26aufirst%3DA.%26aulast%3DSobolewski%26aufirst%3DD.%26aulast%3DPrahl%26aufirst%3DA.%26aulast%3DBorovickova%26aufirst%3DL.%26aulast%3DSlaninova%26aufirst%3DJ.%26aulast%3DLammek%26aufirst%3DB.%26atitle%3DArginine%2520Vasopressin%2520and%2520Its%2520Analogues%2520-%2520The%2520Influence%2520of%2520Position%25202%2520Modification%2520with%25203%252C3-Diphenylalanine%2520Enantiomers.%2520Highly%2520Potent%2520V2%2520Agonists%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2009%26volume%3D44%26spage%3D2862%26epage%3D2867%26doi%3D10.1016%2Fj.ejmech.2008.12.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ben Mimoun, M.</span>; <span class="NLM_string-name">Derick, S.</span>; <span class="NLM_string-name">Andres, M.</span>; <span class="NLM_string-name">Guillon, G.</span>; <span class="NLM_string-name">Wo, N. C.</span>; <span class="NLM_string-name">Chan, W. Y.</span>; <span class="NLM_string-name">Stoev, S.</span>; <span class="NLM_string-name">Cheng, L.</span>; <span class="NLM_string-name">Manning, M.</span></span> In  <i>Vasopressin V2 Agonists: Affinities for Human and Rat V2 and V1a Receptors Reveal Surprising Species Differences</i>, Peptides 2000, Proceedings of the 26th European Peptide Symposium, Montpellier, France, September 10–15, 2000; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, J.</span>, <span class="NLM_string-name">Fehrentz, J.-A.</span></span>, Eds.; <span class="NLM_publisher-name">EDK</span>, <span class="NLM_year">2001</span>; pp  <span class="NLM_fpage">589</span>– <span class="NLM_lpage">590</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&pages=589-590&author=M.+Ben+Mimoun&author=S.+Derick&author=M.+Andres&author=G.+Guillon&author=N.+C.+Wo&author=W.+Y.+Chan&author=S.+Stoev&author=L.+Cheng&author=M.+Manningauthor=J.+Martinez&author=J.-A.+Fehrentz&title=Vasopressin+V2+Agonists%3A+Affinities+for+Human+and+Rat+V2+and+V1a+Receptors+Reveal+Surprising+Species+Differences"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DBen%2BMimoun%26aufirst%3DM.%26jtitle%3DVasopressin%2520V2%2520Agonists%253A%2520Affinities%2520for%2520Human%2520and%2520Rat%2520V2%2520and%2520V1a%2520Receptors%2520Reveal%2520Surprising%2520Species%2520Differences%26aulast%3DMartinez%26aufirst%3DJ.%26pub%3DEDK%26date%3D2001%26spage%3D589%26epage%3D590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manning, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klis, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolodziejczyk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nawrocka, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misicka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, W. H.</span></span> <span> </span><span class="NLM_article-title">Carboxy Terminus of Vasopressin Required for Activity but Not Binding</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>308</i></span>,  <span class="NLM_fpage">652</span>– <span class="NLM_lpage">653</span>, <span class="refDoi"> DOI: 10.1038/308652a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1038%2F308652a0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=308&publication_year=1984&pages=652-653&author=M.+Manningauthor=A.+Olmaauthor=W.+Klisauthor=A.+Kolodziejczykauthor=E.+Nawrockaauthor=A.+Misickaauthor=J.+Setoauthor=W.+H.+Sawyer&title=Carboxy+Terminus+of+Vasopressin+Required+for+Activity+but+Not+Binding&doi=10.1038%2F308652a0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2F308652a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F308652a0%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DM.%26aulast%3DOlma%26aufirst%3DA.%26aulast%3DKlis%26aufirst%3DW.%26aulast%3DKolodziejczyk%26aufirst%3DA.%26aulast%3DNawrocka%26aufirst%3DE.%26aulast%3DMisicka%26aufirst%3DA.%26aulast%3DSeto%26aufirst%3DJ.%26aulast%3DSawyer%26aufirst%3DW.%2BH.%26atitle%3DCarboxy%2520Terminus%2520of%2520Vasopressin%2520Required%2520for%2520Activity%2520but%2520Not%2520Binding%26jtitle%3DNature%26date%3D1984%26volume%3D308%26spage%3D652%26epage%3D653%26doi%3D10.1038%2F308652a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manning, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Przybylski, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klis, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruszynski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wo, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelton, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, W. H.</span></span> <span> </span><span class="NLM_article-title">No Requirements of Cyclic Conformation of Antagonists in Binding to Vasopressin Receptors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>329</i></span>,  <span class="NLM_fpage">839</span>– <span class="NLM_lpage">840</span>, <span class="refDoi"> DOI: 10.1038/329839a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1038%2F329839a0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=329&publication_year=1987&pages=839-840&author=M.+Manningauthor=J.+P.+Przybylskiauthor=A.+Olmaauthor=W.+A.+Klisauthor=M.+Kruszynskiauthor=N.+C.+Woauthor=G.+H.+Peltonauthor=W.+H.+Sawyer&title=No+Requirements+of+Cyclic+Conformation+of+Antagonists+in+Binding+to+Vasopressin+Receptors&doi=10.1038%2F329839a0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2F329839a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F329839a0%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DM.%26aulast%3DPrzybylski%26aufirst%3DJ.%2BP.%26aulast%3DOlma%26aufirst%3DA.%26aulast%3DKlis%26aufirst%3DW.%2BA.%26aulast%3DKruszynski%26aufirst%3DM.%26aulast%3DWo%26aufirst%3DN.%2BC.%26aulast%3DPelton%26aufirst%3DG.%2BH.%26aulast%3DSawyer%26aufirst%3DW.%2BH.%26atitle%3DNo%2520Requirements%2520of%2520Cyclic%2520Conformation%2520of%2520Antagonists%2520in%2520Binding%2520to%2520Vasopressin%2520Receptors%26jtitle%3DNature%26date%3D1987%26volume%3D329%26spage%3D839%26epage%3D840%26doi%3D10.1038%2F329839a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manning, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misicka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klis, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bankowski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nawrocka, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruszynski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolodziejczyk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, W. H.</span></span> <span> </span><span class="NLM_article-title">C-Terminal Deglycine and Deglycinamide Modifications of Arginine Vasopressin (AVP) Agonists and Antagonists. A Reevaluation</span>. <i>Pept. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_fpage">585</span>– <span class="NLM_lpage">590</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1988&pages=585-590&author=M.+Manningauthor=L.+L.+Chengauthor=A.+Misickaauthor=A.+Olmaauthor=W.+A.+Klisauthor=K.+Bankowskiauthor=E.+Nawrockaauthor=M.+Kruszynskiauthor=A.+Kolodziejczykauthor=W.+H.+Sawyer&title=C-Terminal+Deglycine+and+Deglycinamide+Modifications+of+Arginine+Vasopressin+%28AVP%29+Agonists+and+Antagonists.+A+Reevaluation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DM.%26aulast%3DCheng%26aufirst%3DL.%2BL.%26aulast%3DMisicka%26aufirst%3DA.%26aulast%3DOlma%26aufirst%3DA.%26aulast%3DKlis%26aufirst%3DW.%2BA.%26aulast%3DBankowski%26aufirst%3DK.%26aulast%3DNawrocka%26aufirst%3DE.%26aulast%3DKruszynski%26aufirst%3DM.%26aulast%3DKolodziejczyk%26aufirst%3DA.%26aulast%3DSawyer%26aufirst%3DW.%2BH.%26atitle%3DC-Terminal%2520Deglycine%2520and%2520Deglycinamide%2520Modifications%2520of%2520Arginine%2520Vasopressin%2520%2528AVP%2529%2520Agonists%2520and%2520Antagonists.%2520A%2520Reevaluation%26jtitle%3DPept.%2520Chem.%26date%3D1988%26spage%3D585%26epage%3D590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manning, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misicka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klis, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bankowski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nawrocka, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruszynski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolodziejczyk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L. L.</span></span> <span> </span><span class="NLM_article-title">C-Terminal Deletions in Agonistic and Antagonistic Analogues of Vasopressin That Improve Their Specificities for Antidiuretic (V2) and Vasopressor (V1) Receptors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">2245</span>– <span class="NLM_lpage">2252</span>, <span class="refDoi"> DOI: 10.1021/jm00395a012</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00395a012" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1987&pages=2245-2252&author=M.+Manningauthor=A.+Misickaauthor=A.+Olmaauthor=W.+A.+Klisauthor=K.+Bankowskiauthor=E.+Nawrockaauthor=M.+Kruszynskiauthor=A.+Kolodziejczykauthor=L.+L.+Cheng&title=C-Terminal+Deletions+in+Agonistic+and+Antagonistic+Analogues+of+Vasopressin+That+Improve+Their+Specificities+for+Antidiuretic+%28V2%29+and+Vasopressor+%28V1%29+Receptors&doi=10.1021%2Fjm00395a012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm00395a012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00395a012%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DM.%26aulast%3DMisicka%26aufirst%3DA.%26aulast%3DOlma%26aufirst%3DA.%26aulast%3DKlis%26aufirst%3DW.%2BA.%26aulast%3DBankowski%26aufirst%3DK.%26aulast%3DNawrocka%26aufirst%3DE.%26aulast%3DKruszynski%26aufirst%3DM.%26aulast%3DKolodziejczyk%26aufirst%3DA.%26aulast%3DCheng%26aufirst%3DL.%2BL.%26atitle%3DC-Terminal%2520Deletions%2520in%2520Agonistic%2520and%2520Antagonistic%2520Analogues%2520of%2520Vasopressin%2520That%2520Improve%2520Their%2520Specificities%2520for%2520Antidiuretic%2520%2528V2%2529%2520and%2520Vasopressor%2520%2528V1%2529%2520Receptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1987%26volume%3D30%26spage%3D2245%26epage%3D2252%26doi%3D10.1021%2Fjm00395a012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahmood, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, R. P.</span></span> <span> </span><span class="NLM_article-title">Interspecies Allometric Scaling. Part I: Prediction of Clearance in Large Animals</span>. <i>J. Vet. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">415</span>– <span class="NLM_lpage">423</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2885.2006.00786.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1111%2Fj.1365-2885.2006.00786.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=16958787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Wjtr%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2006&pages=415-423&author=I.+Mahmoodauthor=M.+Martinezauthor=R.+P.+Hunter&title=Interspecies+Allometric+Scaling.+Part+I%3A+Prediction+of+Clearance+in+Large+Animals&doi=10.1111%2Fj.1365-2885.2006.00786.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Interspecies allometric scaling. Part I: prediction of clearance in large animals</span></div><div class="casAuthors">Mahmood, I.; Martinez, M.; Hunter, R. P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Veterinary Pharmacology and Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">415-423</span>CODEN:
                <span class="NLM_cas:coden">JVPTD9</span>;
        ISSN:<span class="NLM_cas:issn">0140-7783</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Interspecies scaling is a useful tool for the prediction of pharmacokinetic parameters from animals to humans, and it is often used for estg. a first-time in human dose.  The knowledge of pharmacokinetics in veterinary species is important for dosage selection, particularly in the treatment of large zoo animal species, such as elephants, giant cats and camels, for which pharmacokinetic data are scant.  Therefore, the accuracy in clearance predictions in large animal species, with and without the use of correction factors (rule of exponents), and the impact of species selection in the prediction of clearance in large animal species was examd.  Based upon this anal., it was detd. that there is a much larger risk of inaccuracies in the clearance ests. in large animal species when compared with that obsd. for humans.  Unlike in humans, for large animal species, correction factors could not be applied because there was no trend between the exponents of simple allometry and the appropriate correction factor for improving our predictions.  Nevertheless, we did see an indication that the exponents of simple allometry may alert us as to when the predicted clearance in the large animal may be underestimated or overpredicted.  For example, if a large animal is included in the scaling, the predicted clearance in a large animal should be considered overestimated if the exponent of simple allometry is >1.3.  Despite the potential for extrapolation error, the reality is that allometric scaling is needed across many veterinary practice situations, and therefore will be used.  For this reason, it is important to consider mechanisms for reducing the risk of extrapolation errors that can seriously affect target animal safety, therapeutic response, or the accuracy of withdrawal time predictions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH5ejKuCOzn7Vg90H21EOLACvtfcHk0lgRCgYjFByT1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Wjtr%252FF&md5=5050de49ab4b41dc85948304eadfad52</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2885.2006.00786.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2885.2006.00786.x%26sid%3Dliteratum%253Aachs%26aulast%3DMahmood%26aufirst%3DI.%26aulast%3DMartinez%26aufirst%3DM.%26aulast%3DHunter%26aufirst%3DR.%2BP.%26atitle%3DInterspecies%2520Allometric%2520Scaling.%2520Part%2520I%253A%2520Prediction%2520of%2520Clearance%2520in%2520Large%2520Animals%26jtitle%3DJ.%2520Vet.%2520Pharmacol.%2520Ther.%26date%3D2006%26volume%3D29%26spage%3D415%26epage%3D423%26doi%3D10.1111%2Fj.1365-2885.2006.00786.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahmood, I.</span></span> <span> </span><span class="NLM_article-title">Application of Allometric Principles for the Prediction of Pharmacokinetics in Human and Veterinary Drug Development</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1177</span>– <span class="NLM_lpage">1192</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2007.05.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1016%2Fj.addr.2007.05.015" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2007&pages=1177-1192&author=I.+Mahmood&title=Application+of+Allometric+Principles+for+the+Prediction+of+Pharmacokinetics+in+Human+and+Veterinary+Drug+Development&doi=10.1016%2Fj.addr.2007.05.015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2007.05.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2007.05.015%26sid%3Dliteratum%253Aachs%26aulast%3DMahmood%26aufirst%3DI.%26atitle%3DApplication%2520of%2520Allometric%2520Principles%2520for%2520the%2520Prediction%2520of%2520Pharmacokinetics%2520in%2520Human%2520and%2520Veterinary%2520Drug%2520Development%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2007%26volume%3D59%26spage%3D1177%26epage%3D1192%26doi%3D10.1016%2Fj.addr.2007.05.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tahara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugimoto, T.</span></span> <span> </span><span class="NLM_article-title">1-Desamino-8-<span class="smallcaps smallerCapital">d</span>-Arginine Vasopressin (DDAVP) as an Agonist on V1b Vasopressin Receptor</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">1711</span>– <span class="NLM_lpage">1717</span>, <span class="refDoi"> DOI: 10.1016/S0006-2952(97)00070-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1016%2FS0006-2952%2897%2900070-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1997&pages=1711-1717&author=M.+Saitoauthor=A.+Taharaauthor=T.+Sugimoto&title=1-Desamino-8-d-Arginine+Vasopressin+%28DDAVP%29+as+an+Agonist+on+V1b+Vasopressin+Receptor&doi=10.1016%2FS0006-2952%2897%2900070-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2FS0006-2952%2897%2900070-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-2952%252897%252900070-1%26sid%3Dliteratum%253Aachs%26aulast%3DSaito%26aufirst%3DM.%26aulast%3DTahara%26aufirst%3DA.%26aulast%3DSugimoto%26aufirst%3DT.%26atitle%3D1-Desamino-8-d-Arginine%2520Vasopressin%2520%2528DDAVP%2529%2520as%2520an%2520Agonist%2520on%2520V1b%2520Vasopressin%2520Receptor%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1997%26volume%3D53%26spage%3D1711%26epage%3D1717%26doi%3D10.1016%2FS0006-2952%2897%2900070-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wisniewski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galyean, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tariga, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alagarsamy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croston, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitzmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisniewska, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laporte, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riviere, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schteingart, C. D.</span></span> <span> </span><span class="NLM_article-title">New, Potent, Selective, and Short-Acting Peptidic V1a Receptor Agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">4388</span>– <span class="NLM_lpage">4398</span>, <span class="refDoi"> DOI: 10.1021/jm200278m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200278m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4388-4398&author=K.+Wisniewskiauthor=R.+Galyeanauthor=H.+Tarigaauthor=S.+Alagarsamyauthor=G.+Crostonauthor=J.+Heitzmannauthor=A.+Kohanauthor=H.+Wisniewskaauthor=R.+Laporteauthor=P.+J.+Riviereauthor=C.+D.+Schteingart&title=New%2C+Potent%2C+Selective%2C+and+Short-Acting+Peptidic+V1a+Receptor+Agonists&doi=10.1021%2Fjm200278m"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjm200278m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200278m%26sid%3Dliteratum%253Aachs%26aulast%3DWisniewski%26aufirst%3DK.%26aulast%3DGalyean%26aufirst%3DR.%26aulast%3DTariga%26aufirst%3DH.%26aulast%3DAlagarsamy%26aufirst%3DS.%26aulast%3DCroston%26aufirst%3DG.%26aulast%3DHeitzmann%26aufirst%3DJ.%26aulast%3DKohan%26aufirst%3DA.%26aulast%3DWisniewska%26aufirst%3DH.%26aulast%3DLaporte%26aufirst%3DR.%26aulast%3DRiviere%26aufirst%3DP.%2BJ.%26aulast%3DSchteingart%26aufirst%3DC.%2BD.%26atitle%3DNew%252C%2520Potent%252C%2520Selective%252C%2520and%2520Short-Acting%2520Peptidic%2520V1a%2520Receptor%2520Agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4388%26epage%3D4398%26doi%3D10.1021%2Fjm200278m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wiśniewski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alagarsamy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galyean, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tariga, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ly, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiśniewska, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croston, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laporte, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivière, P. J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schteingart, C. D.</span></span> <span> </span><span class="NLM_article-title">New, Potent, and Selective Peptidic Oxytocin Receptor Agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5306</span>– <span class="NLM_lpage">5317</span>, <span class="refDoi"> DOI: 10.1021/jm500365s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500365s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADC%252BC2cXovVWhs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5306-5317&author=K.+Wi%C5%9Bniewskiauthor=S.+Alagarsamyauthor=R.+Galyeanauthor=H.+Tarigaauthor=D.+Thompsonauthor=B.+Lyauthor=H.+Wi%C5%9Bniewskaauthor=S.+Qiauthor=G.+Crostonauthor=R.+Laporteauthor=P.+J.-M.+Rivi%C3%A8reauthor=C.+D.+Schteingart&title=New%2C+Potent%2C+and+Selective+Peptidic+Oxytocin+Receptor+Agonists&doi=10.1021%2Fjm500365s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">New, Potent, and Selective Peptidic Oxytocin Receptor Agonists</span></div><div class="casAuthors">Wisniewski, Kazimierz; Alagarsamy, Sudarkodi; Galyean, Robert; Tariga, Hiroe; Thompson, Dorain; Ly, Brian; Wisniewska, Halina; Qi, Steve; Croston, Glenn; Laporte, Regent; Riviere, Pierre J.-M.; Schteingart, Claudio D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5306-5317</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mothers of preterm babies frequently have difficulty establishing or maintaining lactation, thought to be due to interference with the milk ejection reflex.  Administration of exogenous oxytocin can produce alveolar contraction and adequate breast emptying resulting in establishment of successful lactation.  The natural hormone oxytocin is not receptor-selective and may cause hyponatremia via V2 receptor mediated antidiuresis.  We have designed a series of potent oxytocin analogs contg. N-alkylglycines in position 7 with excellent selectivity vs. the related V1a, V1b, and V2 vasopressin receptors and short half-life: agonists 31([2-ThiMeGly7]dOT), 47 (carba-6-[Phe2,BuGly7]dOT), 55 (carba-6-[3-MeBzlGly7]dOT), and 57 (carba-1-[4-FBzlGly7]dOT) have EC50 values at hOTR < 0.1 nM, selectivity ratios vs. related human vasopressin receptors of >2000, IC50 at hV1aR > 500 nM, and total clearance in rats in the range of 60-80 mL min-1 kg-1.  Compd. 57 (FE 202767) is currently in clin. development for the treatment of preterm mothers requiring lactation support.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_ykZz5KXVXbVg90H21EOLACvtfcHk0ljDZDmSX9t0bQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXovVWhs78%253D&md5=8076f2bbeb06371908b462d1c8f25321</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjm500365s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500365s%26sid%3Dliteratum%253Aachs%26aulast%3DWi%25C5%259Bniewski%26aufirst%3DK.%26aulast%3DAlagarsamy%26aufirst%3DS.%26aulast%3DGalyean%26aufirst%3DR.%26aulast%3DTariga%26aufirst%3DH.%26aulast%3DThompson%26aufirst%3DD.%26aulast%3DLy%26aufirst%3DB.%26aulast%3DWi%25C5%259Bniewska%26aufirst%3DH.%26aulast%3DQi%26aufirst%3DS.%26aulast%3DCroston%26aufirst%3DG.%26aulast%3DLaporte%26aufirst%3DR.%26aulast%3DRivi%25C3%25A8re%26aufirst%3DP.%2BJ.-M.%26aulast%3DSchteingart%26aufirst%3DC.%2BD.%26atitle%3DNew%252C%2520Potent%252C%2520and%2520Selective%2520Peptidic%2520Oxytocin%2520Receptor%2520Agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5306%26epage%3D5317%26doi%3D10.1021%2Fjm500365s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Czaja, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konieczna, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lammek, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slaninova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, T.</span></span> <span> </span><span class="NLM_article-title">Analogs of Arginine-Vasopressin Substituted in Position 2 with <span class="smallcaps smallerCapital">l</span>-4-Cl-Phenylalanine or <span class="smallcaps smallerCapital">d</span>-Phenylglycine</span>. <i>Collect. Czech. Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">675</span>– <span class="NLM_lpage">680</span>, <span class="refDoi"> DOI: 10.1135/cccc19930675</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1135%2Fcccc19930675" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADyaK3sXltFOku70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1993&pages=675-680&author=M.+Czajaauthor=E.+Koniecznaauthor=B.+Lammekauthor=J.+Slaninovaauthor=T.+Barth&title=Analogs+of+Arginine-Vasopressin+Substituted+in+Position+2+with+l-4-Cl-Phenylalanine+or+d-Phenylglycine&doi=10.1135%2Fcccc19930675"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Analogs of arginine-vasopressin substituted in position 2 with L-4-Cl-phenylalanine or D-phenylglycine</span></div><div class="casAuthors">Czaja, Malgorzata; Konieczna, Ewa; Lammek, Bernard; Slaninova, Jirina; Barth, Tomislav</div><div class="citationInfo"><span class="NLM_cas:title">Collection of Czechoslovak Chemical Communications</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">675-80</span>CODEN:
                <span class="NLM_cas:coden">CCCCAK</span>;
        ISSN:<span class="NLM_cas:issn">0010-0765</span>.
    </div><div class="casAbstract">Eight new title compds. I [X = Cys, 1-mercaptocyclohexaneacetic acid (Cpp), 2-mercaptopropionic acid; X1 = L-4-chlorophenylalanine (4-ClPhe), D-phenylglycine (Phg); X2 = Gln, Val] were designed, prepd., and bioassayed as a part of a study on the structure-activity relationship of arginine-vasopressin (AVP) analogs.  All prepd. compds. but I (X = Cpp, X1 = Phg, X2 = Val) were inhibitors in a uterotonic test; however, in most cases their potency was fairly low.  The agonistic potency of I (X1 = 4-ClPhe) in a pressor activity test was essentially the same as that of I [X1 = 4-fluorophenylalanine (4-FPhe)].  Antagonists I (X1 = 4-ClPhe) showed significantly higher potency than I (X1 = 4-FPhe).  All compds. I (X1 = Phg) were inactive in the pressor test.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7xO3hB1wAILVg90H21EOLACvtfcHk0ljDZDmSX9t0bQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXltFOku70%253D&md5=48492ff581718defcd10a678c86e5c75</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1135%2Fcccc19930675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1135%252Fcccc19930675%26sid%3Dliteratum%253Aachs%26aulast%3DCzaja%26aufirst%3DM.%26aulast%3DKonieczna%26aufirst%3DE.%26aulast%3DLammek%26aufirst%3DB.%26aulast%3DSlaninova%26aufirst%3DJ.%26aulast%3DBarth%26aufirst%3DT.%26atitle%3DAnalogs%2520of%2520Arginine-Vasopressin%2520Substituted%2520in%2520Position%25202%2520with%2520l-4-Cl-Phenylalanine%2520or%2520d-Phenylglycine%26jtitle%3DCollect.%2520Czech.%2520Chem.%2520Commun.%26date%3D1993%26volume%3D58%26spage%3D675%26epage%3D680%26doi%3D10.1135%2Fcccc19930675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wisniewski, K.</span>; <span class="NLM_string-name">Stalewski, J.</span>; <span class="NLM_string-name">Jiang, G.</span></span> <span> </span><span class="NLM_article-title">Intermediates and Methods for Making Heptapeptide Oxytocin Analogs</span>. <span class="NLM_patent">WO2003072597</span>, <span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=K.+Wisniewski&author=J.+Stalewski&author=G.+Jiang&title=Intermediates+and+Methods+for+Making+Heptapeptide+Oxytocin+Analogs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWisniewski%26aufirst%3DK.%26atitle%3DIntermediates%2520and%2520Methods%2520for%2520Making%2520Heptapeptide%2520Oxytocin%2520Analogs%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linares, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doulut, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, J.</span></span> <span> </span><span class="NLM_article-title">A Facile Synthesis of Chiral N-Protected β-Amino Alcohols</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">923</span>– <span class="NLM_lpage">926</span>, <span class="refDoi"> DOI: 10.1016/S0040-4039(00)92121-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1016%2FS0040-4039%2800%2992121-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADyaK3MXitVOksb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1991&pages=923-926&author=M.+Rodriguezauthor=M.+Linaresauthor=S.+Doulutauthor=A.+Heitzauthor=J.+Martinez&title=A+Facile+Synthesis+of+Chiral+N-Protected+%CE%B2-Amino+Alcohols&doi=10.1016%2FS0040-4039%2800%2992121-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">A facile synthesis of chiral N-protected β-amino alcohols</span></div><div class="casAuthors">Rodriguez, Marc; Linares, Muriel; Doulut, Sylvie; Heitz, Annie; Martinez, Jean</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">923-6</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    </div><div class="casAbstract">Chiral N-protected β-amino alcs. are easily obtained by NaBH4 redn. of mixed anhydrides of N-protected α-amino acids in an org./aq. medium.  The alcs. obtained from side chain or main chain redn. of N-protected aspartic acid are converted in good yields into lactones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdEKziakOsFLVg90H21EOLACvtfcHk0ljDZDmSX9t0bQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXitVOksb8%253D&md5=3ddd67e6ee1c94ef4e6fee5e6cb9888b</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2800%2992121-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252800%252992121-X%26sid%3Dliteratum%253Aachs%26aulast%3DRodriguez%26aufirst%3DM.%26aulast%3DLinares%26aufirst%3DM.%26aulast%3DDoulut%26aufirst%3DS.%26aulast%3DHeitz%26aufirst%3DA.%26aulast%3DMartinez%26aufirst%3DJ.%26atitle%3DA%2520Facile%2520Synthesis%2520of%2520Chiral%2520N-Protected%2520%25CE%25B2-Amino%2520Alcohols%26jtitle%3DTetrahedron%2520Lett.%26date%3D1991%26volume%3D32%26spage%3D923%26epage%3D926%26doi%3D10.1016%2FS0040-4039%2800%2992121-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malesevic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strijowski, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachle, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sewald, N.</span></span> <span> </span><span class="NLM_article-title">An Improved Method for the Solution Cyclization of Peptides under Pseudo-High Dilution Conditions</span>. <i>J. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">73</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1016/j.jbiotec.2004.03.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1016%2Fj.jbiotec.2004.03.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=15288942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmt1Whu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2004&pages=73-77&author=M.+Malesevicauthor=U.+Strijowskiauthor=D.+Bachleauthor=N.+Sewald&title=An+Improved+Method+for+the+Solution+Cyclization+of+Peptides+under+Pseudo-High+Dilution+Conditions&doi=10.1016%2Fj.jbiotec.2004.03.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">An improved method for the solution cyclization of peptides under pseudo-high dilution conditions</span></div><div class="casAuthors">Malesevic, Miroslav; Strijowski, Ulf; Bachle, Dirk; Sewald, Norbert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biotechnology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">73-77</span>CODEN:
                <span class="NLM_cas:coden">JBITD4</span>;
        ISSN:<span class="NLM_cas:issn">0168-1656</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Depending on the ring size, the cyclization of peptides often is accompanied by dimerization or cyclodimerization.  Hence, these macrocyclizations have to be performed under high diln. conditions.  Efficient cyclization of peptides in soln. with a min. amt. of solvent succeeds, when a dual syringe pump is used to simultaneously add the linear peptide precursor and a coupling reagent from two sep. syringes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3nbSU9oZTrrVg90H21EOLACvtfcHk0lh5uV0xSmyTsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmt1Whu70%253D&md5=56eb47eff1408b726bf6cfa0724c6616</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.jbiotec.2004.03.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jbiotec.2004.03.015%26sid%3Dliteratum%253Aachs%26aulast%3DMalesevic%26aufirst%3DM.%26aulast%3DStrijowski%26aufirst%3DU.%26aulast%3DBachle%26aufirst%3DD.%26aulast%3DSewald%26aufirst%3DN.%26atitle%3DAn%2520Improved%2520Method%2520for%2520the%2520Solution%2520Cyclization%2520of%2520Peptides%2520under%2520Pseudo-High%2520Dilution%2520Conditions%26jtitle%3DJ.%2520Biotechnol.%26date%3D2004%26volume%3D112%26spage%3D73%26epage%3D77%26doi%3D10.1016%2Fj.jbiotec.2004.03.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otaka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yajima, H.</span></span> <span> </span><span class="NLM_article-title">Studies on Peptides. CLV. Evaluation of Trimethylsilyl Bromide as a Hard-Acid Deprotecting Reagent in Peptide Synthesis</span>. <i>Chem. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">3880</span>– <span class="NLM_lpage">3883</span>, <span class="refDoi"> DOI: 10.1248/cpb.35.3880</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1248%2Fcpb.35.3880" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1987&pages=3880-3883&author=N.+Fujiiauthor=A.+Otakaauthor=N.+Sugiyamaauthor=M.+Hatanoauthor=H.+Yajima&title=Studies+on+Peptides.+CLV.+Evaluation+of+Trimethylsilyl+Bromide+as+a+Hard-Acid+Deprotecting+Reagent+in+Peptide+Synthesis&doi=10.1248%2Fcpb.35.3880"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1248%2Fcpb.35.3880&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.35.3880%26sid%3Dliteratum%253Aachs%26aulast%3DFujii%26aufirst%3DN.%26aulast%3DOtaka%26aufirst%3DA.%26aulast%3DSugiyama%26aufirst%3DN.%26aulast%3DHatano%26aufirst%3DM.%26aulast%3DYajima%26aufirst%3DH.%26atitle%3DStudies%2520on%2520Peptides.%2520CLV.%2520Evaluation%2520of%2520Trimethylsilyl%2520Bromide%2520as%2520a%2520Hard-Acid%2520Deprotecting%2520Reagent%2520in%2520Peptide%2520Synthesis%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D1987%26volume%3D35%26spage%3D3880%26epage%3D3883%26doi%3D10.1248%2Fcpb.35.3880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pena, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murat, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trueba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durroux, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rognan, D.</span></span> <span> </span><span class="NLM_article-title">Mapping the Binding Site of Arginine Vasopressin to V1a and V1b Vasopressin Receptors</span>. <i>Mol. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">512</span>– <span class="NLM_lpage">523</span>, <span class="refDoi"> DOI: 10.1210/me.2006-0202</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1210%2Fme.2006-0202" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=17082326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVWisbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=512-523&author=J.+Rodrigoauthor=A.+Penaauthor=B.+Muratauthor=M.+Truebaauthor=T.+Durrouxauthor=G.+Guillonauthor=D.+Rognan&title=Mapping+the+Binding+Site+of+Arginine+Vasopressin+to+V1a+and+V1b+Vasopressin+Receptors&doi=10.1210%2Fme.2006-0202"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Mapping the binding site of arginine vasopressin to V1a and V1b vasopressin receptors</span></div><div class="casAuthors">Rodrigo, Jordi; Pena, Ana; Murat, Brigitte; Trueba, Miguel; Durroux, Thierry; Guillon, Gilles; Rognan, Didier</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Endocrinology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">512-523</span>CODEN:
                <span class="NLM_cas:coden">MOENEN</span>;
        ISSN:<span class="NLM_cas:issn">0888-8809</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Starting from the 2.8-Å resoln. x-ray structure of bovine rhodopsin, three-dimensional mol. models of the complexes between arginine vasopressin and two receptor subtypes (V1a, V1b) have been built.  Amino acid sequence alignment and docking studies suggest that four key residues (1.35, 2.65, 4.61, and 5.35) fine tune the binding of vasopressin and related peptide agonists to both receptor subtypes.  To validate these predictions, a series of single or double mutants were engineered at V1a and V1b receptor subtypes and tested for their binding and functional properties.  Two neg. charged amino acids at positions 1.35 and 2.65 are key anchoring residues to the Arg8 residue of arginine vasopressin.  Moreover, two amino acids (V4.61 and P5.35) delineating a hydrophobic subsite at the human V1b receptor are responsible for the recognition of V1b selective peptide agonists.  Last, one of the latter positions (5.35) is hypothesized to explain the pharmacol. species differences between rat and human vasopressin receptors for a V1b peptide agonist.  Altogether these refined three-dimensional models of V1a and V1b human receptors should enable the identification of further new selective V1a and V1b agonists as pharmacol. but also therapeutic tools.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiSR2zAZAfYrVg90H21EOLACvtfcHk0lh5uV0xSmyTsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVWisbg%253D&md5=3da9d009a1b55b8e9420dfba0b0b77f3</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1210%2Fme.2006-0202&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fme.2006-0202%26sid%3Dliteratum%253Aachs%26aulast%3DRodrigo%26aufirst%3DJ.%26aulast%3DPena%26aufirst%3DA.%26aulast%3DMurat%26aufirst%3DB.%26aulast%3DTrueba%26aufirst%3DM.%26aulast%3DDurroux%26aufirst%3DT.%26aulast%3DGuillon%26aufirst%3DG.%26aulast%3DRognan%26aufirst%3DD.%26atitle%3DMapping%2520the%2520Binding%2520Site%2520of%2520Arginine%2520Vasopressin%2520to%2520V1a%2520and%2520V1b%2520Vasopressin%2520Receptors%26jtitle%3DMol.%2520Endocrinol.%26date%3D2007%26volume%3D21%26spage%3D512%26epage%3D523%26doi%3D10.1210%2Fme.2006-0202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singer, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morton, A. R.</span></span> <span> </span><span class="NLM_article-title">Mouse to Elephant: Biological Scaling and Kt/V</span>. <i>Am. J. Kidney Dis.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">306</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1016/S0272-6386(00)70341-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1016%2FS0272-6386%2800%2970341-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10676731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A280%3ADC%252BD3c7jvF2jsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2000&pages=306-309&author=M.+A.+Singerauthor=A.+R.+Morton&title=Mouse+to+Elephant%3A+Biological+Scaling+and+Kt%2FV&doi=10.1016%2FS0272-6386%2800%2970341-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Mouse to elephant: biological scaling and Kt/V</span></div><div class="casAuthors">Singer M A; Morton A R</div><div class="citationInfo"><span class="NLM_cas:title">American journal of kidney diseases : the official journal of the National Kidney Foundation</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">306-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The construct Kt/V is used by the nephrology community in prescribing dialysis dose.  The concerns that have been raised as to what value of V to use in the calculation of Kt/V touch on the more central question of whether filtration rate should be normalized by a parameter other than V.  Within the animal kingdom, a number of physiological variables scale to body size according to an equation of the form Y = YoMb, where Yo is a constant, M is body mass, and b is a scaling exponent.  Glomerular filtration rate (GFR) in mammals weighing from 30 g to 503 kg scales to body weight with an exponent of 0.77.  Hence, GFR per unit body weight (or Kt/V) decreases significantly with increasing body size.  Metabolic rate also scales to body size in a wide range of mammals according to the same general equation and with a scaling exponent of 0.75.  Because GFR and metabolic rate scale to body mass with virtually the same exponent, a ratio of the two yields a constant independent of body size.  We propose that the ratio (filtration rate/metabolic rate) replace Kt/V.  Such a ratio would underscore the linkage between filtration rate (and dialysis therapy) and the metabolic demands of the body.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSei5Ve87DRUmgRQsDqrjW_fW6udTcc2eYnBNCV-NZYcrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c7jvF2jsw%253D%253D&md5=93ea81288c2d796b351ffc68e6207725</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2FS0272-6386%2800%2970341-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0272-6386%252800%252970341-6%26sid%3Dliteratum%253Aachs%26aulast%3DSinger%26aufirst%3DM.%2BA.%26aulast%3DMorton%26aufirst%3DA.%2BR.%26atitle%3DMouse%2520to%2520Elephant%253A%2520Biological%2520Scaling%2520and%2520Kt%252FV%26jtitle%3DAm.%2520J.%2520Kidney%2520Dis.%26date%3D2000%26volume%3D35%26spage%3D306%26epage%3D309%26doi%3D10.1016%2FS0272-6386%2800%2970341-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verbalis, J. G.</span></span> <span> </span><span class="NLM_article-title">Disorders of Body Water Homeostasis</span>. <i>Best Pract. Res., Clin. Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">471</span>– <span class="NLM_lpage">503</span>, <span class="refDoi"> DOI: 10.1016/S1521-690X(03)00049-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1016%2FS1521-690X%2803%2900049-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=14687585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpvVWmu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2003&pages=471-503&author=J.+G.+Verbalis&title=Disorders+of+Body+Water+Homeostasis&doi=10.1016%2FS1521-690X%2803%2900049-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Disorders of body water homeostasis</span></div><div class="casAuthors">Verbalis, Joseph G.</div><div class="citationInfo"><span class="NLM_cas:title">Best Practice & Research, Clinical Endocrinology & Metabolism</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">471-503</span>CODEN:
                <span class="NLM_cas:coden">BPRCE9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  Disorders of body fluids are among the most commonly encountered problems in the practice of clin. medicine.  This is in large part because many different disease states can potentially disrupt the finely balanced mechanisms that control the intake and output of water and solute.  It therefore behoves clinicians treating such patients to have a good understanding of the pathophysiol., the differential diagnosis and the management of these disorders.  Because body water is the primary determinant of the osmolality of the extracellular fluid, disorders of body water homeostasis can be divided into hypo-osmolar disorders, in which there is an excess of body water relative to body solute, and hyperosmolar disorders, in which there is a deficiency of body water relative to body solute.  The classical hyperosmolar disorder is diabetes insipidus (DI), and the classical hypo-osmolar disorder is the syndrome of inappropriate antidiuretic hormone secretion (SIADH).  This chapter first reviews the regulatory mechanisms underlying water and sodium metab., the 2 major determinants of body fluid homeostasis.  The major disorders of water metab. causing hyperosmolality and hypo-osmolality, DI and SIADH, are then discussed in detail, including the pathogenesis, differential diagnosis and treatment of these disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrO-tI02ZntLbVg90H21EOLACvtfcHk0lh5uV0xSmyTsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpvVWmu7w%253D&md5=8fc891633b2527c3e76f910ccfae7f58</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2FS1521-690X%2803%2900049-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1521-690X%252803%252900049-6%26sid%3Dliteratum%253Aachs%26aulast%3DVerbalis%26aufirst%3DJ.%2BG.%26atitle%3DDisorders%2520of%2520Body%2520Water%2520Homeostasis%26jtitle%3DBest%2520Pract.%2520Res.%252C%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2003%26volume%3D17%26spage%3D471%26epage%3D503%26doi%3D10.1016%2FS1521-690X%2803%2900049-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Juul, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erichsen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, G. L.</span></span> <span> </span><span class="NLM_article-title">Temporal Delays and Individual Variation in Antidiuretic Response to Desmopressin</span>. <i>Am. J. Physiol.: Renal Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>304</i></span>,  <span class="NLM_fpage">F268</span>– <span class="NLM_lpage">F278</span>, <span class="refDoi"> DOI: 10.1152/ajprenal.00502.2012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1152%2Fajprenal.00502.2012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=23136002" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2013&pages=F268-F278&author=K.+V.+Juulauthor=L.+Erichsenauthor=G.+L.+Robertson&title=Temporal+Delays+and+Individual+Variation+in+Antidiuretic+Response+to+Desmopressin&doi=10.1152%2Fajprenal.00502.2012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1152%2Fajprenal.00502.2012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajprenal.00502.2012%26sid%3Dliteratum%253Aachs%26aulast%3DJuul%26aufirst%3DK.%2BV.%26aulast%3DErichsen%26aufirst%3DL.%26aulast%3DRobertson%26aufirst%3DG.%2BL.%26atitle%3DTemporal%2520Delays%2520and%2520Individual%2520Variation%2520in%2520Antidiuretic%2520Response%2520to%2520Desmopressin%26jtitle%3DAm.%2520J.%2520Physiol.%253A%2520Renal%2520Physiol.%26date%3D2013%26volume%3D304%26spage%3DF268%26epage%3DF278%26doi%3D10.1152%2Fajprenal.00502.2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barlos, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatzi, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stavropoulos, G.</span></span> <span> </span><span class="NLM_article-title">2-Chlorotrityl Chloride Resin. Studies on Anchoring of Fmoc-Amino Acids and Peptide Cleavage</span>. <i>Int. J. Pept. Protein Res.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">513</span>– <span class="NLM_lpage">520</span>, <span class="refDoi"> DOI: 10.1111/j.1399-3011.1991.tb00769.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1111%2Fj.1399-3011.1991.tb00769.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1917309" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADyaK3MXltFGjur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1991&pages=513-520&author=K.+Barlosauthor=O.+Chatziauthor=D.+Gatosauthor=G.+Stavropoulos&title=2-Chlorotrityl+Chloride+Resin.+Studies+on+Anchoring+of+Fmoc-Amino+Acids+and+Peptide+Cleavage&doi=10.1111%2Fj.1399-3011.1991.tb00769.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">2-Chlorotrityl chloride resin.  Studies on anchoring of Fmoc-aminio acids and peptide cleavage</span></div><div class="casAuthors">Barlos, Kleomenis; Chatzi, Olga; Gatos, Dimitrios; Stavropoulos, George</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Peptide & Protein Research</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">513-20</span>CODEN:
                <span class="NLM_cas:coden">IJPPC3</span>;
        ISSN:<span class="NLM_cas:issn">0367-8377</span>.
    </div><div class="casAbstract">The esterification of 2-chlorotrityl chloride resin with 9-fluorenylmethoxycarbonyl (Fmoc) amino acids in the presence of EtN(CHMe2)2 is studied under various conditions.  High esterification yields are obtained using 0.6 equiv. Fmoc-amino acid/mmol resin in CH2Cl2 or ClCH2CH2Cl in 25 min at room temp.  The reaction proceeds without byproduct formation even in the case of Fmoc-Asn-OH and Fmoc-Gln-OH.  The quant. and easy cleavage of amino acids and peptides from 2-chlorotrityl resin using AcOH/CF3CH2OH/CH2Cl2 mixts. is accomplished within 15-60 min at room temp. while tert-Bu type protecting groups remain unaffected.  Under these exceptionally mild conditions, 2-chlorotrityl cations generated during the cleavage of amino acids and peptides from resin do not attack the nucleophilic side chains of tryptophan, methionine, and tyrosine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQ5Em66XBXF7Vg90H21EOLACvtfcHk0ljzo_CIq-aTqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXltFGjur4%253D&md5=2ac32b2f179e3b9e2a4977b6d7fa0aaa</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1111%2Fj.1399-3011.1991.tb00769.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1399-3011.1991.tb00769.x%26sid%3Dliteratum%253Aachs%26aulast%3DBarlos%26aufirst%3DK.%26aulast%3DChatzi%26aufirst%3DO.%26aulast%3DGatos%26aufirst%3DD.%26aulast%3DStavropoulos%26aufirst%3DG.%26atitle%3D2-Chlorotrityl%2520Chloride%2520Resin.%2520Studies%2520on%2520Anchoring%2520of%2520Fmoc-Amino%2520Acids%2520and%2520Peptide%2520Cleavage%26jtitle%3DInt.%2520J.%2520Pept.%2520Protein%2520Res.%26date%3D1991%26volume%3D37%26spage%3D513%26epage%3D520%26doi%3D10.1111%2Fj.1399-3011.1991.tb00769.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wisniewski, K.</span>; <span class="NLM_string-name">Schteingart, C.</span>; <span class="NLM_string-name">Riviere, P.</span></span> <span> </span><span class="NLM_article-title">Preparation of Cyclic Peptide Vasopressin-2 Receptor Agonists</span>. <span class="NLM_patent">WO2015013690A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=K.+Wisniewski&author=C.+Schteingart&author=P.+Riviere&title=Preparation+of+Cyclic+Peptide+Vasopressin-2+Receptor+Agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWisniewski%26aufirst%3DK.%26atitle%3DPreparation%2520of%2520Cyclic%2520Peptide%2520Vasopressin-2%2520Receptor%2520Agonists%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frick, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adkison, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells-Knecht, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woollard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higton, D. M.</span></span> <span> </span><span class="NLM_article-title">Cassette Dosing: Rapid in Vivo Assessment of Pharmacokinetics</span>. <i>Pharm. Sci. Technol. Today</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">12</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1016/S1461-5347(98)00010-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1016%2FS1461-5347%2898%2900010-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADyaK1cXislaks7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1998&pages=12-18&author=L.+W.+Frickauthor=K.+K.+Adkisonauthor=K.+J.+Wells-Knechtauthor=P.+Woollardauthor=D.+M.+Higton&title=Cassette+Dosing%3A+Rapid+in+Vivo+Assessment+of+Pharmacokinetics&doi=10.1016%2FS1461-5347%2898%2900010-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Cassette dosing: rapid in vivo assessment of pharmacokinetics</span></div><div class="casAuthors">Frick, Lloyd W.; Adkison, Kimberly K.; Wells-Knecht, Kevin J.; Woollard, Patrick; Higton, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Science & Technology Today</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12-18</span>CODEN:
                <span class="NLM_cas:coden">PSTTF8</span>;
        ISSN:<span class="NLM_cas:issn">1461-5347</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with 26 refs. on cassette dosing, which combines many test chems. into one dose soln. and is an attractive method for increasing the throughput of in vivo pharmacokinetic expts.  This dosing technique depends on the sensitivity and selectivity of modern anal. techniques, particularly HPLC/MS/MS.  Cassettes vary in size, but even relatively small ones greatly increase the nos. of compds. investigated by reducing the effort devoted to animal handling, sample processing and sample anal.  The major drawback of cassette dosing is the potential for drug-drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_MeQApZA877Vg90H21EOLACvtfcHk0ljzo_CIq-aTqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXislaks7o%253D&md5=2912aaa741529642959a80e409f0a7aa</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2FS1461-5347%2898%2900010-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1461-5347%252898%252900010-8%26sid%3Dliteratum%253Aachs%26aulast%3DFrick%26aufirst%3DL.%2BW.%26aulast%3DAdkison%26aufirst%3DK.%2BK.%26aulast%3DWells-Knecht%26aufirst%3DK.%2BJ.%26aulast%3DWoollard%26aufirst%3DP.%26aulast%3DHigton%26aufirst%3DD.%2BM.%26atitle%3DCassette%2520Dosing%253A%2520Rapid%2520in%2520Vivo%2520Assessment%2520of%2520Pharmacokinetics%26jtitle%3DPharm.%2520Sci.%2520Technol.%2520Today%26date%3D1998%26volume%3D1%26spage%3D12%26epage%3D18%26doi%3D10.1016%2FS1461-5347%2898%2900010-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 2 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dylan T.  Wolff</span>, <span class="hlFld-ContribAuthor ">Kerry A.  Adler</span>, <span class="hlFld-ContribAuthor ">Corey S.  Weinstein</span>, <span class="hlFld-ContribAuthor ">Jeffrey P.  Weiss</span>. </span><span class="cited-content_cbyCitation_article-title">Managing Nocturia in Frail Older Adults. </span><span class="cited-content_cbyCitation_journal-name">Drugs & Aging</span><span> <strong>2021,</strong> <em>38 </em>
                                    (2)
                                     , 95-109. <a href="https://doi.org/10.1007/s40266-020-00815-5" title="DOI URL">https://doi.org/10.1007/s40266-020-00815-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40266-020-00815-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40266-020-00815-5%26sid%3Dliteratum%253Aachs%26jtitle%3DDrugs%2520%2526%2520Aging%26atitle%3DManaging%252BNocturia%252Bin%252BFrail%252BOlder%252BAdults%26aulast%3DWolff%26aufirst%3DDylan%2BT.%26date%3D2021%26date%3D2020%26volume%3D38%26issue%3D2%26spage%3D95%26epage%3D109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Thomas F.  Monaghan</span>, <span class="hlFld-ContribAuthor ">Jeffrey P.  Weiss</span>, <span class="hlFld-ContribAuthor ">Karel  Everaert</span>, <span class="hlFld-ContribAuthor ">Alan J.  Wein</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacologic management of nocturnal polyuria: a contemporary assessment of efficacy, safety, and progress toward individualized treatment. </span><span class="cited-content_cbyCitation_journal-name">Therapeutic Advances in Urology</span><span> <strong>2021,</strong> <em>13 </em>, 175628722098843. <a href="https://doi.org/10.1177/1756287220988438" title="DOI URL">https://doi.org/10.1177/1756287220988438</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/1756287220988438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F1756287220988438%26sid%3Dliteratum%253Aachs%26jtitle%3DTherapeutic%2520Advances%2520in%2520Urology%26atitle%3DPharmacologic%252Bmanagement%252Bof%252Bnocturnal%252Bpolyuria%25253A%252Ba%252Bcontemporary%252Bassessment%252Bof%252Befficacy%25252C%252Bsafety%25252C%252Band%252Bprogress%252Btoward%252Bindividualized%252Btreatment%26aulast%3DMonaghan%26aufirst%3DThomas%2BF.%26date%3D2021%26date%3D2021%26volume%3D13%26spage%3D175628722098843" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00132/20190516/images/medium/jm-2019-001323_0010.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00132/20190516/images/large/jm-2019-001323_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00132&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00132/20190516/images/medium/jm-2019-001323_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00132/20190516/images/large/jm-2019-001323_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of reference compounds <b>1</b> (left) and <b>2</b> (right). Sequence positions are numbered at α-carbons.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00132/20190516/images/large/jm-2019-001323_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00132&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00132/20190516/images/medium/jm-2019-001323_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00132/20190516/images/large/jm-2019-001323_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Modifications of <b>2</b> explored in this study. Sequence positions are numbered at α-carbons.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00132/20190516/images/large/jm-2019-001323_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00132&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00132/20190516/images/medium/jm-2019-001323_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00132/20190516/images/large/jm-2019-001323_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Synthesis of peptide amides <b>11</b>–<b>18</b> and <b>20</b>–<b>37</b>. Synthesis of other compounds discussed in the text (<b>3</b>–<b>10</b>, <b>19</b>, and <b>38</b>–<b>43</b>) is depicted in <a href="/doi/suppl/10.1021/acs.jmedchem.9b00132/suppl_file/jm9b00132_si_001.pdf" class="ext-link">Figures S2 and S3</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00132/20190516/images/large/jm-2019-001323_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00132&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00132/20190516/images/medium/jm-2019-001323_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00132/20190516/images/large/jm-2019-001323_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Allometric scaling for selected compounds. Panel A (compound <b>31</b>, carba-6), B (<b>11</b>, disulfide), C (<b>19</b>, carba-1), and D (<b>38</b>, carba-1). The CL values used to construct the graphs are listed in the Supporting Information (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00132/suppl_file/jm9b00132_si_001.pdf" class="ext-link">Tables S1 and S2</a>). The CL values are represented by blue diamonds (rat), red dots (cyno), orange squares (dog), and green triangles (pig). Three animals per compound were used with the exception of rat experiments where four animals were used. Additional allometric scaling plots are shown in <a href="/doi/suppl/10.1021/acs.jmedchem.9b00132/suppl_file/jm9b00132_si_001.pdf" class="ext-link">Figure S1</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00132/20190516/images/large/jm-2019-001323_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00132&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00132/20190516/images/medium/jm-2019-001323_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00132/20190516/images/large/jm-2019-001323_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Comparison of in vivo antidiuretic potency and maximal effect of <b>1</b> and <b>19</b> (left graph) and <b>1</b> and <b>38</b> (right graph) in normal euvolemic rats assessed by measuring the weight of cumulative urine output at 3 h of intravenous infusion. Shown are mean ± standard error values of the mean (SEM) for urine output in <i>N</i> = 200 vehicle-treated animals and 15–20 compound-treated animals at each target <i>C</i><sub>ss</sub> (error bars that are not visible are encompassed within the symbol). Fitted parameters for dose–response are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00132/20190516/images/large/jm-2019-001323_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00132&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00132/20190516/images/medium/jm-2019-001323_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00132/20190516/images/large/jm-2019-001323_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Rat antidiuretic time course at maximally effective target <i>C</i><sub>ss</sub>. Time courses of <b>19</b> (left graph) and <b>38</b> (right graph) (30 and 100 pM) compared to <b>1</b>. Peptides were infused iv through 180 min at doses to rapidly achieve and maintain the indicated target <i>C</i><sub>ss</sub>, and cumulative urine weight was measured. At 180 min, peptide infusion was stopped and urine output was measured for an additional 300 min. Shown are the mean urine output values in <i>N</i> = 200 vehicle-treated animals and 16–20 compound-treated animals. Error bars (only shown at 60 min intervals for clarity) indicate ±SEM in each treatment group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00132/20190516/images/large/jm-2019-001323_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00132&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i40">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44483" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44483" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 57 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manigrasso, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandberg, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verbalis, J. G.</span></span> <span> </span><span class="NLM_article-title">Sex Differences in Vasopressin V(2) Receptor Expression and Vasopressin-Induced Antidiuresis</span>. <i>Am. J. Physiol.: Renal Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>300</i></span>,  <span class="NLM_fpage">F433</span>– <span class="NLM_lpage">F440</span>, <span class="refDoi"> DOI: 10.1152/ajprenal.00199.2010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1152%2Fajprenal.00199.2010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=21123493" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=300&publication_year=2011&pages=F433-F440&author=J.+Liuauthor=N.+Sharmaauthor=W.+Zhengauthor=H.+Jiauthor=H.+Tamauthor=X.+Wuauthor=M.+B.+Manigrassoauthor=K.+Sandbergauthor=J.+G.+Verbalis&title=Sex+Differences+in+Vasopressin+V%282%29+Receptor+Expression+and+Vasopressin-Induced+Antidiuresis&doi=10.1152%2Fajprenal.00199.2010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1152%2Fajprenal.00199.2010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajprenal.00199.2010%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DSharma%26aufirst%3DN.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DJi%26aufirst%3DH.%26aulast%3DTam%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DManigrasso%26aufirst%3DM.%2BB.%26aulast%3DSandberg%26aufirst%3DK.%26aulast%3DVerbalis%26aufirst%3DJ.%2BG.%26atitle%3DSex%2520Differences%2520in%2520Vasopressin%2520V%25282%2529%2520Receptor%2520Expression%2520and%2520Vasopressin-Induced%2520Antidiuresis%26jtitle%3DAm.%2520J.%2520Physiol.%253A%2520Renal%2520Physiol.%26date%3D2011%26volume%3D300%26spage%3DF433%26epage%3DF440%26doi%3D10.1152%2Fajprenal.00199.2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zaoral, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolc, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorm, F.</span></span> <span> </span><span class="NLM_article-title">Amino Acids and Peptides. LXXI. Synthesis of 1-Deamino-8-<span class="smallcaps smallerCapital">d</span>-γ-Aminobutyrine Vasopressin, 1-Deamino-8-<span class="smallcaps smallerCapital">d</span>-Lysine Vasopressin, and 1-Deamino-8-<span class="smallcaps smallerCapital">d</span>-Arginine Vasopressin</span>. <i>Collect. Czech. Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1967</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">1250</span>– <span class="NLM_lpage">1257</span>, <span class="refDoi"> DOI: 10.1135/cccc19671250</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1135%2Fcccc19671250" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADyaF1cXhtlelug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1967&pages=1250-1257&author=M.+Zaoralauthor=J.+Kolcauthor=F.+Sorm&title=Amino+Acids+and+Peptides.+LXXI.+Synthesis+of+1-Deamino-8-d-%CE%B3-Aminobutyrine+Vasopressin%2C+1-Deamino-8-d-Lysine+Vasopressin%2C+and+1-Deamino-8-d-Arginine+Vasopressin&doi=10.1135%2Fcccc19671250"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Amino acids and peptides.  LXXI.  Synthesis of 1-deamino-8-D-γ-aminobutyrine vasopressin, 1-deamino-8-D-lysine vasopressin, and 1-deamino-8-D-arginine vasopressin</span></div><div class="casAuthors">Zaoral, Milan; Kolc, Jaroslav; Sorm, Frantisek</div><div class="citationInfo"><span class="NLM_cas:title">Collection of Czechoslovak Chemical Communications</span>
        (<span class="NLM_cas:date">1967</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1250-7</span>CODEN:
                <span class="NLM_cas:coden">CCCCAK</span>;
        ISSN:<span class="NLM_cas:issn">0010-0765</span>.
    </div><div class="casAbstract">All amino acids (except glycine) are of the L-series unless stated otherwise.  A mixt. of 9.2 g. PhCH2S(CH2)2CO2H and excess SOCl2 was refluxed 20 min., evapd., the residue dissolved in 20 ml. EtOAc, and the soln. added portionwise at 0° to a mixt. of 10.86 g. tyrosine Me ester-HCl, 50 ml. H2O, and 50 ml. EtOAc; the pH was kept at 7-8 by addns. of NaHCO3 to give 16.3 g. 3-(benzylthiopropionyl)tyrosine (I) Me ester (II), m. 89-90° (EtOAc-petroleum ether), [α]25D -3.4 ± 0.5° (c 0.5, HCONMe2).  A mixt. of 15.3 g. II, 60 ml. MeOH, and 6 ml. 80% aq. N2H4 was refluxed 2 hrs. and dild. with excess H2O to give 11.95 g. I hydrazide, m. 193-4° (aq. EtOH), [α]24D -6.0 ± 0.5° (c 0.5, HCONMe2), which was converted into I azide and this condensed with phenylalanine Me ester.  The resulting BTP-Tyr-Phe-OMe (BTP = 3-benzylthiopropionyl) (III), m. 151-2° (aq. MeOH), [α]24D -17.5 ± 0.5° (c 0.5, HCONMe2), was converted to the III hydrazide, m. 249-51° (sintering from 243°) (HCONMe2-H2O), [α]24D -21.9 ± 0.5° (c 0.55, HCONMe2), which was condensed with Gln-Asn-Cys(CH2Ph)-OMe to give 76% BTP-Tyr-Phe-Gln-Asn-Cys(CH2Ph) (IV) Me ester (V), m. 253-5° (HCONMe2-H2O), [α]25D -29.6 ± 0.5° (c 0.5, HCONMe2).  A mixt. of 10.8 g. V, 160 ml. HCONMe2, and 12 ml. 80% aq. N2H4 was kept at room temp. 12 hrs. to give 6.7 g. IV hydrazide, m. 266-8° (HCONMe2-H2O), [α]25D -33.4 ± 0.5° (c 0.5, HCONMe2).  IV azide was coupled with prolyl-Nγ-tosyl-D-α,γ-diaminobutyrylglycinamide, prolyl-Nεtosyl-D-lysyl-glycinamide, and prolyl-NG-tosyl-D-arginylglycinamide, resp., to give 73% 3-benzylthiopropionyltyrosylphenylalanylglutaminylasparaginyl-S-benzylcysteinylprolyl-Nγ-tosyl-D-α,γ-diaminobutyrylglycinamide, m. 238-40° (sintering from 215°), [α]25D -22.3 ± 1° (c 0.5, HCONMe2), 74% BTP-Tyr-Phe-Gln-Asn-Cys(CH2Ph)-Pro-D-Lys(O2SC6H4Me-p)-Gly-NH2, m. 232-6°, [α]25D -18.1 ± 1° (c 0.4, HCONMe2), and 68% BTP-Tyr-Phe-Gln-Asn-Cys(CH2Ph)-Pro-D-Arg(NG-O2SC6H4Me-p)-Gly-NH2, m. 223-5°, which compds. on redn. with Na in liq. NH3 and oxidn. with K3Fe(CN)6 yielded 1-deamino-8-D-γ-aminobutyrine vasopressin (VI), 1-deamino-8-D-lysine vasopressin, [α]25D -70.4 ± 2° (c 0.27, M AcOH), and 1-deamino-8-D-arginine vasopressin (VII), [α]25D -82.5 ± 2° (c 0.2, HCONMe2).  VI and VII showed a high and specific antidiuretic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq42bs-00ljALVg90H21EOLACvtfcHk0ljmZfYhm203bQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1cXhtlelug%253D%253D&md5=b648bc14a64413812ea27b8ce4001bfd</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1135%2Fcccc19671250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1135%252Fcccc19671250%26sid%3Dliteratum%253Aachs%26aulast%3DZaoral%26aufirst%3DM.%26aulast%3DKolc%26aufirst%3DJ.%26aulast%3DSorm%26aufirst%3DF.%26atitle%3DAmino%2520Acids%2520and%2520Peptides.%2520LXXI.%2520Synthesis%2520of%25201-Deamino-8-d-%25CE%25B3-Aminobutyrine%2520Vasopressin%252C%25201-Deamino-8-d-Lysine%2520Vasopressin%252C%2520and%25201-Deamino-8-d-Arginine%2520Vasopressin%26jtitle%3DCollect.%2520Czech.%2520Chem.%2520Commun.%26date%3D1967%26volume%3D32%26spage%3D1250%26epage%3D1257%26doi%3D10.1135%2Fcccc19671250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rushton, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belman, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaontz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skoog, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sihelnik, S.</span></span> <span> </span><span class="NLM_article-title">Response to Desmopressin as a Function of Urine Osmolality in the Treatment of Monosymptomatic Nocturnal Enuresis: A Double-Blind Prospective Study</span>. <i>J. Urol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>154</i></span>,  <span class="NLM_fpage">749</span>– <span class="NLM_lpage">753</span>, <span class="refDoi"> DOI: 10.1016/S0022-5347(01)67153-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1016%2FS0022-5347%2801%2967153-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=7609170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A280%3ADyaK2MzjtlCjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=1995&pages=749-753&author=H.+G.+Rushtonauthor=A.+B.+Belmanauthor=M.+Zaontzauthor=S.+J.+Skoogauthor=S.+Sihelnik&title=Response+to+Desmopressin+as+a+Function+of+Urine+Osmolality+in+the+Treatment+of+Monosymptomatic+Nocturnal+Enuresis%3A+A+Double-Blind+Prospective+Study&doi=10.1016%2FS0022-5347%2801%2967153-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Response to desmopressin as a function of urine osmolality in the treatment of monosymptomatic nocturnal enuresis: a double-blind prospective study</span></div><div class="casAuthors">Rushton H G; Belman A B; Zaontz M; Skoog S J; Sihelnik S</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of urology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue">2 Pt 2</span>),
    <span class="NLM_cas:pages">749-53</span>
        ISSN:<span class="NLM_cas:issn">0022-5347</span>.
    </div><div class="casAbstract">To determine if urine osmolality parameters can predict whether children with primary monosymptomatic nocturnal enuresis will respond to desmopressin, we conducted a prospective, double-blind, placebo-controlled study in 96 children 8 to 14 years old.  Following a 2-week baseline screening interval patients with at least 6 of 14 net nights were randomized to double-blind regimens of desmopressin or placebo.  Urine specimens for osmolality were collected at 6 p.m. and 6 a.m. on 3 consecutive days during the baseline and the 2, 14-day treatment periods.  A significantly greater proportion of desmopressin treated children had an excellent (2 or fewer wet nights in 14 days) or good (greater than 50% reduction in wet nights) response compared with placebo treated children (p = 0.004 and p = 0.002 for treatment periods 1 and 2, respectively).  Children treated with desmopressin reported a significantly lower number of wet nights than placebo treated children during both treatment periods (p = 0.0258 and p = 0.0136, respectively).  Children treated with desmopressin had a significantly higher 6 a.m. urine osmolality during both treatment periods and a higher 6 a.m.-to-6 p.m. osmolality ratio (p = 0.004) in the first treatment period compared with the placebo group.  Within the desmopressin treatment group clinical responders had a higher 6 a.m. urine osmolality and 6 a.m.-to-6 p.m. urine osmolality ratio than nonresponders during both treatment periods but these differences did not achieve statistical significance.  In conclusion, treatment with desmopressin is associated with a significant decrease in the number of wet nights, and a significant increase in nocturnal urine osmolality and nocturnal/diurnal urine osmolality ratios.  However, clinical response was not predictable based on baseline or treatment osmolality parameters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQieP-KpA3_HVvAgqb2vdc5fW6udTcc2earjJzYF17QY7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2MzjtlCjtA%253D%253D&md5=0129432c97fb41c6ca73d90599039fa7</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS0022-5347%2801%2967153-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0022-5347%252801%252967153-2%26sid%3Dliteratum%253Aachs%26aulast%3DRushton%26aufirst%3DH.%2BG.%26aulast%3DBelman%26aufirst%3DA.%2BB.%26aulast%3DZaontz%26aufirst%3DM.%26aulast%3DSkoog%26aufirst%3DS.%2BJ.%26aulast%3DSihelnik%26aufirst%3DS.%26atitle%3DResponse%2520to%2520Desmopressin%2520as%2520a%2520Function%2520of%2520Urine%2520Osmolality%2520in%2520the%2520Treatment%2520of%2520Monosymptomatic%2520Nocturnal%2520Enuresis%253A%2520A%2520Double-Blind%2520Prospective%2520Study%26jtitle%3DJ.%2520Urol.%26date%3D1995%26volume%3D154%26spage%3D749%26epage%3D753%26doi%3D10.1016%2FS0022-5347%2801%2967153-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fralick, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kesselheim, A. S.</span></span> <span> </span><span class="NLM_article-title">FDA Approval of Desmopressin for Nocturia</span>. <i>JAMA, J. Am. Med. Assoc.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>317</i></span>,  <span class="NLM_fpage">2059</span>– <span class="NLM_lpage">2060</span>, <span class="refDoi"> DOI: 10.1001/jama.2017.4316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1001%2Fjama.2017.4316" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=317&publication_year=2017&pages=2059-2060&author=M.+Fralickauthor=A.+S.+Kesselheim&title=FDA+Approval+of+Desmopressin+for+Nocturia&doi=10.1001%2Fjama.2017.4316"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1001%2Fjama.2017.4316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2017.4316%26sid%3Dliteratum%253Aachs%26aulast%3DFralick%26aufirst%3DM.%26aulast%3DKesselheim%26aufirst%3DA.%2BS.%26atitle%3DFDA%2520Approval%2520of%2520Desmopressin%2520for%2520Nocturia%26jtitle%3DJAMA%252C%2520J.%2520Am.%2520Med.%2520Assoc.%26date%3D2017%26volume%3D317%26spage%3D2059%26epage%3D2060%26doi%3D10.1001%2Fjama.2017.4316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawler, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riddell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nitu-Whalley, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermans, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, S. A.</span></span> <span> </span><span class="NLM_article-title">Response to Desmopressin of Factors XI, X and V in Patients with Factor VIII Deficiency and Von Willebrand Disease</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">100</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2141.2004.04988.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1111%2Fj.1365-2141.2004.04988.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=15198739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtl2rt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2004&pages=100-104&author=B.+Whiteauthor=P.+Lawlerauthor=A.+Riddellauthor=I.+C.+Nitu-Whalleyauthor=C.+Hermansauthor=C.+A.+Leeauthor=S.+A.+Brown&title=Response+to+Desmopressin+of+Factors+XI%2C+X+and+V+in+Patients+with+Factor+VIII+Deficiency+and+Von+Willebrand+Disease&doi=10.1111%2Fj.1365-2141.2004.04988.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Response to desmopressin of factors XI, X and V in patients with factor VIII deficiency and von Willebrand disease</span></div><div class="casAuthors">White, B.; Lawler, P.; Riddell, A.; Nitu-Whalley, I. C.; Hermans, C.; Lee, C. A.; Brown, S. A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">100-104</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Desmopressin [1-deamino-8-D-arginine vasopressin (DDAVP)] has been successfully used in the treatment of type 1 von Willebrand disease (VWD) and mild haemophilia A (MHA).  Data suggest that DDAVP can increase factor XI (FXI) plasma levels and may represent an effective treatment for mild FXI deficiency.  We assessed the DDAVP response of FXI coagulant activity (FXI:C), FXI antigen (FXI:Ag), factor V coagulant activity (FV:C), and factor X coagulant activity (FX:C) in 33 individuals with VWD or MHA.  DDAVP did not produce a clin. significant increase in FXI:C, FXI:Ag, FX:C or FV:C in any patient.  The mean ± SD FXI:C pre-DDAVP (time 0) and at 1 h post-DDAVP was 90.7 (±22.9) U/dL and 92.1 (±20.9) U/dL, resp.  The mean (±SD) FXI:Ag at time 0 and 1 h was 92.2 (±20.1) U/dL and 89.9 (±21.3) U/dL, resp.  There was a small redn. at 1 h post-DDAVP in both FV:C, from 1018 (±20.9) U/dL to 97.2 (±21.4) U/dL (P < 0.001), and FX:C from 103 (±19.5) U/dL to 98.8 (±18.7) U/dL (P < 0.001).  No significant increase in FXI:C, FXI:Ag, FV:C or FX:C levels was seen at 4 h post-DDAVP.  This study failed to demonstrate a clin. significant increase in the levels of FXI, FX or FV following administration of DDAVP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpExbXsewqfMLVg90H21EOLACvtfcHk0ljRmbO444ppDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtl2rt7Y%253D&md5=0a58856ed1c3deadb2e9ee015ad0c3f6</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2141.2004.04988.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2141.2004.04988.x%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DB.%26aulast%3DLawler%26aufirst%3DP.%26aulast%3DRiddell%26aufirst%3DA.%26aulast%3DNitu-Whalley%26aufirst%3DI.%2BC.%26aulast%3DHermans%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DC.%2BA.%26aulast%3DBrown%26aufirst%3DS.%2BA.%26atitle%3DResponse%2520to%2520Desmopressin%2520of%2520Factors%2520XI%252C%2520X%2520and%2520V%2520in%2520Patients%2520with%2520Factor%2520VIII%2520Deficiency%2520and%2520Von%2520Willebrand%2520Disease%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2004%26volume%3D126%26spage%3D100%26epage%3D104%26doi%3D10.1111%2Fj.1365-2141.2004.04988.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mannucci, P. M.</span></span> <span> </span><span class="NLM_article-title">Treatment of Von Willebrand’s Disease</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>351</i></span>,  <span class="NLM_fpage">683</span>– <span class="NLM_lpage">694</span>, <span class="refDoi"> DOI: 10.1056/NEJMra040403</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1056%2FNEJMra040403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=15306670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADC%252BD2cXms1Okur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=2004&pages=683-694&author=P.+M.+Mannucci&title=Treatment+of+Von+Willebrand%E2%80%99s+Disease&doi=10.1056%2FNEJMra040403"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of von Willebrand's disease</span></div><div class="casAuthors">Mannucci, Pier Mannuccio</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">351</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">683-694</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  Treatment of von Willebrand's disease is reviewed here.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-Qb6sdZ6ILbVg90H21EOLACvtfcHk0ljRmbO444ppDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXms1Okur0%253D&md5=3c5c2f90538cad85ae983f9075f5ee4f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1056%2FNEJMra040403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra040403%26sid%3Dliteratum%253Aachs%26aulast%3DMannucci%26aufirst%3DP.%2BM.%26atitle%3DTreatment%2520of%2520Von%2520Willebrand%25E2%2580%2599s%2520Disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D351%26spage%3D683%26epage%3D694%26doi%3D10.1056%2FNEJMra040403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schrier, R. W.</span></span> <span> </span><span class="NLM_article-title">Body Water Homeostasis: Clinical Disorders of Urinary Dilution and Concentration</span>. <i>J. Am. Soc. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1820</span>– <span class="NLM_lpage">1832</span>, <span class="refDoi"> DOI: 10.1681/ASN.2006030240</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1681%2FASN.2006030240" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=16738014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADC%252BD28Xntlantb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2006&pages=1820-1832&author=R.+W.+Schrier&title=Body+Water+Homeostasis%3A+Clinical+Disorders+of+Urinary+Dilution+and+Concentration&doi=10.1681%2FASN.2006030240"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Body water homeostasis: clinical disorders of urinary dilution and concentration</span></div><div class="casAuthors">Schrier, Robert W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Society of Nephrology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1820-1832</span>CODEN:
                <span class="NLM_cas:coden">JASNEU</span>;
        ISSN:<span class="NLM_cas:issn">1046-6673</span>.
    
            (<span class="NLM_cas:orgname">American Society of Nephrology</span>)
        </div><div class="casAbstract">A review on the role of body water balance in the development of clin. disorders with impaired urinary diln. and concn., with emphasis on aquaporins 1, 2, 3, and 4.  These disorders include hypothyroidism, Addison's disease and hypopituitarism, primary polydipsia or compulsive water drinking, cirrhosis, pregnancy complications, and nephrogenic diabetes insipidus (genetic and acquired).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZMAWSj4lj8LVg90H21EOLACvtfcHk0lgrnT-xATZKKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xntlantb0%253D&md5=1927a02bf18d481b2f29829da3d9b0ed</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1681%2FASN.2006030240&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1681%252FASN.2006030240%26sid%3Dliteratum%253Aachs%26aulast%3DSchrier%26aufirst%3DR.%2BW.%26atitle%3DBody%2520Water%2520Homeostasis%253A%2520Clinical%2520Disorders%2520of%2520Urinary%2520Dilution%2520and%2520Concentration%26jtitle%3DJ.%2520Am.%2520Soc.%2520Nephrol.%26date%3D2006%26volume%3D17%26spage%3D1820%26epage%3D1832%26doi%3D10.1681%2FASN.2006030240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Juul, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malmberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Meulen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walle, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norgaard, J. P.</span></span> <span> </span><span class="NLM_article-title">Low-Dose Desmopressin Combined with Serum Sodium Monitoring Can Prevent Clinically Significant Hyponatraemia in Patients Treated for Nocturia</span>. <i>BJU Int.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">776</span>– <span class="NLM_lpage">784</span>, <span class="refDoi"> DOI: 10.1111/bju.13718</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1111%2Fbju.13718" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=27862898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlsleqtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2017&pages=776-784&author=K.+V.+Juulauthor=A.+Malmbergauthor=E.+van+der+Meulenauthor=J.+V.+Walleauthor=J.+P.+Norgaard&title=Low-Dose+Desmopressin+Combined+with+Serum+Sodium+Monitoring+Can+Prevent+Clinically+Significant+Hyponatraemia+in+Patients+Treated+for+Nocturia&doi=10.1111%2Fbju.13718"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Low-dose desmopressin combined with serum sodium monitoring can prevent clinically significant hyponatraemia in patients treated for nocturia</span></div><div class="casAuthors">Juul, Kristian Vinter; Malmberg, Anders; van der Meulen, Egbert; Vande Walle, Johan; Norgaard, Jens Peter</div><div class="citationInfo"><span class="NLM_cas:title">BJU International</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">776-784</span>CODEN:
                <span class="NLM_cas:coden">BJINFO</span>;
        ISSN:<span class="NLM_cas:issn">1464-410X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Objective: To explore risk factors for desmopressin-induced hyponatremia and evaluate the impact of a serum sodium monitoring plan.  Subjects and Methods: This was a meta-anal. of data from three clin. trials of desmopressin in nocturia.  Patients received placebo or desmopressin orally disintegrating tablet (ODT; 10-100 μg).  The incidence of serum sodium <130 mmol/L was recorded by age, sex and dose.  Potential predictors of clin. significant hyponatremia were identified using multivariate anal. in a Cox proportional hazards model.  Results: Dose, age, baseline serum sodium level and kidney function, according to estd. GFR clearance, were significant risk factors for hyponatremia in both sexes; similar to the known risk factors assocd. with hyponatremia in the general population.  In men, arthritis and use of drugs for bone disease were also predictive of hyponatremia, while in women, raised monocytes and absence of lipid-modifying drugs increased the risk of hyponatremia.  Use of the proposed monitoring scheme and the min. ED would have omitted all patients with clin. significant hyponatremia from further treatment.  Conclusions: The incidence of hyponatremia can be reduced by using min. effective gender-specific dosing with the ODT formulation of desmopressin (25 μg in women, 50 μg in men).  A sodium monitoring plan is proposed whereby baseline sodium must be ≥135 mmol/L (esp. important in the elderly), with addnl. monitoring at week 1 and month 1 for those at elevated risk because they are aged ≥65 years or receiving concomitant medication assocd. with hyponatremia.  This monitoring plan would help to prevent some at-risk patients developing hyponatremia; retrospective application of the monitoring plan showed that, once at-risk patients were appropriately screened out, only mild, non-clin. significant hyponatremia was obsd., within ranges of other drugs assocd. with hyponatremia and similar to the background prevalence in the treatment population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSmFFUAmtZkbVg90H21EOLACvtfcHk0lgrnT-xATZKKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlsleqtr4%253D&md5=910cc992f2d2225cbf77c48c819f211c</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1111%2Fbju.13718&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbju.13718%26sid%3Dliteratum%253Aachs%26aulast%3DJuul%26aufirst%3DK.%2BV.%26aulast%3DMalmberg%26aufirst%3DA.%26aulast%3Dvan%2Bder%2BMeulen%26aufirst%3DE.%26aulast%3DWalle%26aufirst%3DJ.%2BV.%26aulast%3DNorgaard%26aufirst%3DJ.%2BP.%26atitle%3DLow-Dose%2520Desmopressin%2520Combined%2520with%2520Serum%2520Sodium%2520Monitoring%2520Can%2520Prevent%2520Clinically%2520Significant%2520Hyponatraemia%2520in%2520Patients%2520Treated%2520for%2520Nocturia%26jtitle%3DBJU%2520Int.%26date%3D2017%26volume%3D119%26spage%3D776%26epage%3D784%26doi%3D10.1111%2Fbju.13718" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spasovski, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanholder, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allolio, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annane, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bichet, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decaux, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenske, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoorn, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joannidis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soupart, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zietse, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Veer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Biesen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagler, E.</span></span> <span> </span><span class="NLM_article-title">Clinical Practice Guideline on Diagnosis and Treatment of Hyponatraemia</span>. <i>Intensive Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">320</span>– <span class="NLM_lpage">331</span>, <span class="refDoi"> DOI: 10.1007/s00134-014-3210-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1007%2Fs00134-014-3210-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2014&pages=320-331&author=G.+Spasovskiauthor=R.+Vanholderauthor=B.+Allolioauthor=D.+Annaneauthor=S.+Ballauthor=D.+Bichetauthor=G.+Decauxauthor=W.+Fenskeauthor=E.+J.+Hoornauthor=C.+Ichaiauthor=M.+Joannidisauthor=A.+Soupartauthor=R.+Zietseauthor=M.+Hallerauthor=S.+van+der+Veerauthor=W.+Van+Biesenauthor=E.+Nagler&title=Clinical+Practice+Guideline+on+Diagnosis+and+Treatment+of+Hyponatraemia&doi=10.1007%2Fs00134-014-3210-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1007%2Fs00134-014-3210-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00134-014-3210-2%26sid%3Dliteratum%253Aachs%26aulast%3DSpasovski%26aufirst%3DG.%26aulast%3DVanholder%26aufirst%3DR.%26aulast%3DAllolio%26aufirst%3DB.%26aulast%3DAnnane%26aufirst%3DD.%26aulast%3DBall%26aufirst%3DS.%26aulast%3DBichet%26aufirst%3DD.%26aulast%3DDecaux%26aufirst%3DG.%26aulast%3DFenske%26aufirst%3DW.%26aulast%3DHoorn%26aufirst%3DE.%2BJ.%26aulast%3DIchai%26aufirst%3DC.%26aulast%3DJoannidis%26aufirst%3DM.%26aulast%3DSoupart%26aufirst%3DA.%26aulast%3DZietse%26aufirst%3DR.%26aulast%3DHaller%26aufirst%3DM.%26aulast%3Dvan%2Bder%2BVeer%26aufirst%3DS.%26aulast%3DVan%2BBiesen%26aufirst%3DW.%26aulast%3DNagler%26aufirst%3DE.%26atitle%3DClinical%2520Practice%2520Guideline%2520on%2520Diagnosis%2520and%2520Treatment%2520of%2520Hyponatraemia%26jtitle%3DIntensive%2520Care%2520Med.%26date%3D2014%26volume%3D40%26spage%3D320%26epage%3D331%26doi%3D10.1007%2Fs00134-014-3210-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vande
Walle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stockner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norgaard, J. P.</span></span> <span> </span><span class="NLM_article-title">Desmopressin 30 Years in Clinical Use: A Safety Review</span>. <i>Curr. Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">232</span>– <span class="NLM_lpage">238</span>, <span class="refDoi"> DOI: 10.2174/157488607781668891</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.2174%2F157488607781668891" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=18690973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFGqtbnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=232-238&author=J.+Vande%0AWalleauthor=M.+Stocknerauthor=A.+Raesauthor=J.+P.+Norgaard&title=Desmopressin+30+Years+in+Clinical+Use%3A+A+Safety+Review&doi=10.2174%2F157488607781668891"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Desmopressin 30 years in clinical use: a safety review</span></div><div class="casAuthors">Vande Walle, Johan; Stockner, Mette; Raes, Ann; Norgaard, Jens P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Safety</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">232-238</span>CODEN:
                <span class="NLM_cas:coden">CDSUBQ</span>;
        ISSN:<span class="NLM_cas:issn">1574-8863</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Desmopressin acetate is the synthetic analog of the antidiuretic hormone arginine vasopressin.  It has been employed clin. for >30 years in a range of formulations: intranasal soln. (since 1972), injectable soln. (since 1981), tablets (since 1987), and most recently, an oral lyophilisate (since 2005).  The antidiuretic properties of desmopressin have led to its use in polyuric conditions including primary nocturnal enuresis, nocturia, and diabetes insipidus.  While a large body of clin. data is available for desmopressin, and despite its widespread use, comprehensive reviews of the safety of desmopressin are lacking (although some case series have attempted to correlate patient and/or dosing characteristics with the occurrence of adverse reactions).  The purpose of this paper is to review the safety of desmopressin, based on analyses of both published data (MedLine) and of adverse reactions reported to Ferring Pharmaceuticals, the major manufacturer of desmopressin.  Based on the findings, suggested strategies to reduce the risk of adverse reactions are proposed.  Treatment with intranasal and oral formulations of desmopressin is generally well tolerated, and side effects are usually minor.  The risk of hyponatremia, although small, can be reduced by adhering to the indications, dosing recommendations and precautions when prescribing desmopressin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeDBlWsJBUPbVg90H21EOLACvtfcHk0litnF3IpPIraQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFGqtbnO&md5=b4d1c195dd8ca89ca81206fb34bd707e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2174%2F157488607781668891&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157488607781668891%26sid%3Dliteratum%253Aachs%26aulast%3DVande%2BWalle%26aufirst%3DJ.%26aulast%3DStockner%26aufirst%3DM.%26aulast%3DRaes%26aufirst%3DA.%26aulast%3DNorgaard%26aufirst%3DJ.%2BP.%26atitle%3DDesmopressin%252030%2520Years%2520in%2520Clinical%2520Use%253A%2520A%2520Safety%2520Review%26jtitle%3DCurr.%2520Drug%2520Saf.%26date%3D2007%26volume%3D2%26spage%3D232%26epage%3D238%26doi%3D10.2174%2F157488607781668891" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rittig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knudsen, U. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norgaard, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djurhuus, J. C.</span></span> <span> </span><span class="NLM_article-title">Abnormal Diurnal Rhythm of Plasma Vasopressin and Urinary Output in Patients with Enuresis</span>. <i>Am. J. Physiol.: Renal Physiol.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>256</i></span>,  <span class="NLM_fpage">F664</span>– <span class="NLM_lpage">F671</span>, <span class="refDoi"> DOI: 10.1152/ajprenal.1989.256.4.F664</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1152%2Fajprenal.1989.256.4.F664" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=256&publication_year=1989&pages=F664-F671&author=S.+Rittigauthor=U.+B.+Knudsenauthor=J.+P.+Norgaardauthor=E.+B.+Pedersenauthor=J.+C.+Djurhuus&title=Abnormal+Diurnal+Rhythm+of+Plasma+Vasopressin+and+Urinary+Output+in+Patients+with+Enuresis&doi=10.1152%2Fajprenal.1989.256.4.F664"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1152%2Fajprenal.1989.256.4.F664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajprenal.1989.256.4.F664%26sid%3Dliteratum%253Aachs%26aulast%3DRittig%26aufirst%3DS.%26aulast%3DKnudsen%26aufirst%3DU.%2BB.%26aulast%3DNorgaard%26aufirst%3DJ.%2BP.%26aulast%3DPedersen%26aufirst%3DE.%2BB.%26aulast%3DDjurhuus%26aufirst%3DJ.%2BC.%26atitle%3DAbnormal%2520Diurnal%2520Rhythm%2520of%2520Plasma%2520Vasopressin%2520and%2520Urinary%2520Output%2520in%2520Patients%2520with%2520Enuresis%26jtitle%3DAm.%2520J.%2520Physiol.%253A%2520Renal%2520Physiol.%26date%3D1989%26volume%3D256%26spage%3DF664%26epage%3DF671%26doi%3D10.1152%2Fajprenal.1989.256.4.F664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vande
Walle, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogaert, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattsson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schurmans, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoebeke, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deboe, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norgaard, J. P.</span></span> <span> </span><span class="NLM_article-title">A New Fast-Melting Oral Formulation of Desmopressin: A Pharmacodynamic Study in Children with Primary Nocturnal Enuresis</span>. <i>BJU Int.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">603</span>– <span class="NLM_lpage">609</span>, <span class="refDoi"> DOI: 10.1111/j.1464-410X.2006.05999.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1111%2Fj.1464-410X.2006.05999.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=16469035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADC%252BD28XjsFOqt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2006&pages=603-609&author=J.+G.+Vande%0AWalleauthor=G.+A.+Bogaertauthor=S.+Mattssonauthor=T.+Schurmansauthor=P.+Hoebekeauthor=V.+Deboeauthor=J.+P.+Norgaard&title=A+New+Fast-Melting+Oral+Formulation+of+Desmopressin%3A+A+Pharmacodynamic+Study+in+Children+with+Primary+Nocturnal+Enuresis&doi=10.1111%2Fj.1464-410X.2006.05999.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">A new fast-melting oral formulation of desmopressin: a pharmacodynamic study in children with primary nocturnal enuresis</span></div><div class="casAuthors">Vande Walle, Johan G. J.; Bogaert, Guy A.; Mattsson, Sven; Schurmans, Thierry; Hoebeke, Piet; Deboe, Veerle; Norgaard, Jens Pater; Vande Walle, Johan; Mauel, Reiner; Raes, Ann; Vande Walle, Caroline; de Lille, Sofie; Catteeuw, Julie; Audenaert, Martine; Caluwaerts, Hilde; Bogaert, Guy A.; Goeman, Lieven Joost Dieter; Goossens, Els; Cleymen, Inge; Mertens, Johan; Mattsson, Sven; Gladh, Gunilla; Persson, Dorotha; Schurmans, Thierry; Hall, Michelle; Wenderickx, Bernard; Hoebeke, Piet; Van Laecke, E.; Caluwaerts, Hilde; Audenaert, Martine; Deboe, Veerle; Depont, Saskia; Vandemaele, Kris; Van Gool, Jan D.; Wyndaele, Jean Jacques; Hauwers, Kathleen D.; van Neyghen, Ingrid</div><div class="citationInfo"><span class="NLM_cas:title">BJU International</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">603-609</span>CODEN:
                <span class="NLM_cas:coden">BJINFO</span>;
        ISSN:<span class="NLM_cas:issn">1464-4096</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Objective: To det. the pharmacodynamic properties of a new oral lyophilisate formulation of desmopressin (in single doses of 30, 60, 120, 240, 360 or 480 μg) in children with known primary nocturnal enuresis (PNE) and thus identify those dosages that could provide a duration of action corresponding to a typical length of night-time sleep in children with PNE; addnl. objectives were to det. the safety and tolerability of desmopressin in this population.  Patients and methods: Children with PNE (mean three or more wet nights/wk), aged 6-12 years, were randomized into a double-blind, placebo-controlled study.  An overhydration technique was used before dosing to suppress endogenous vasopressin prodn. and thereby ensure that any antidiuresis could be attributed to treatment.  Dosing with desmopressin or placebo occurred when urinary prodn. was >0.13 mL/min/kg.  Urinary vol., osmolality and duration of urinary-concg. action (above three threshold levels: 125, 200 and 400 mOsm/kg) were detd. as endpoints.  Results: All 72 participants receiving desmopressin had a pharmacodynamic response to the drug, while there was no change in urinary output in the 12 placebo-treated patients.  There was a clear relationship between desmopressin dose and duration of action and osmolality during action, although the three highest-dose groups had similar results.  The mean duration of action of desmopressin at the lowest osmolality threshold level was 3.6-10.6 h, according to dose; for the highest threshold, the values were 1.3-8.6 h.  Conclusion: Desmopressin, as the oral lyophilisate, causes a marked decrease in urinary output in hydrated children with PNE.  A small dose range (120-240 μg) is likely to control diuresis for a period corresponding to a night's sleep (7-11 h) in most children with PNE.  However, some patients might require a higher dose to obtain antidiuresis for the complete night.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzWkrh9fDp9bVg90H21EOLACvtfcHk0litnF3IpPIraQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjsFOqt78%253D&md5=08faba58e83013ca40c3e88daacf4a99</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1111%2Fj.1464-410X.2006.05999.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1464-410X.2006.05999.x%26sid%3Dliteratum%253Aachs%26aulast%3DVande%2BWalle%26aufirst%3DJ.%2BG.%26aulast%3DBogaert%26aufirst%3DG.%2BA.%26aulast%3DMattsson%26aufirst%3DS.%26aulast%3DSchurmans%26aufirst%3DT.%26aulast%3DHoebeke%26aufirst%3DP.%26aulast%3DDeboe%26aufirst%3DV.%26aulast%3DNorgaard%26aufirst%3DJ.%2BP.%26atitle%3DA%2520New%2520Fast-Melting%2520Oral%2520Formulation%2520of%2520Desmopressin%253A%2520A%2520Pharmacodynamic%2520Study%2520in%2520Children%2520with%2520Primary%2520Nocturnal%2520Enuresis%26jtitle%3DBJU%2520Int.%26date%3D2006%26volume%3D97%26spage%3D603%26epage%3D609%26doi%3D10.1111%2Fj.1464-410X.2006.05999.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lucchini, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonetti, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceschi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lava, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fare, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchetti, M. G.</span></span> <span> </span><span class="NLM_article-title">Severe Signs of Hyponatremia Secondary to Desmopressin Treatment for Enuresis: A Systematic Review</span>. <i>J. Pediatr. Urol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1049</span>– <span class="NLM_lpage">1053</span>, <span class="refDoi"> DOI: 10.1016/j.jpurol.2013.02.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1016%2Fj.jpurol.2013.02.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=23619353" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A280%3ADC%252BC3srosVWksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=1049-1053&author=B.+Lucchiniauthor=G.+D.+Simonettiauthor=A.+Ceschiauthor=S.+A.+Lavaauthor=P.+B.+Fareauthor=M.+G.+Bianchetti&title=Severe+Signs+of+Hyponatremia+Secondary+to+Desmopressin+Treatment+for+Enuresis%3A+A+Systematic+Review&doi=10.1016%2Fj.jpurol.2013.02.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Severe signs of hyponatremia secondary to desmopressin treatment for enuresis: a systematic review</span></div><div class="casAuthors">Lucchini Barbara; Simonetti Giacomo D; Ceschi Alessandro; Lava Sebastiano A G; Fare Pietro B; Bianchetti Mario G</div><div class="citationInfo"><span class="NLM_cas:title">Journal of pediatric urology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6 Pt B</span>),
    <span class="NLM_cas:pages">1049-53</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  Dilutional hyponatremia is a serious adverse effect of desmopressin, a vasopressin analog that is widely prescribed to manage monosymptomatic enuresis.  The presentation of hyponatremia, largely related to cerebral dysfunction, can include severe signs like altered mental status and seizures.  METHODS:  We reviewed the literature dealing with altered mental status or seizures in enuretic subjects on desmopressin.  The retained publications included patients who were described individually, revealing data on mode of administration, further identifiable factors predisposing to hyponatremia, presentation and clinical course.  RESULTS:  We found 54 cases of hyponatremia secondary to desmopressin treatment presenting with altered mental status or seizures.  In most cases the complication developed 14 days or less after starting desmopressin.  An intranasal formulation had been used in 47 patients.  Excess fluid intake was documented as a contributing factor in at least 22 cases.  In 6 cases severe signs of hyponatremia developed in the context of intercurrent illnesses.  CONCLUSION:  Altered mental status or seizures are very rare but recognized complications of desmopressin in enuresis.  This complication mostly develops in subjects managed with the intranasal formulation 14 days or less after starting the medication, following excess fluid intake and during intercurrent illnesses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTsdqMfLXLyO2BAiYWy6n3SfW6udTcc2eZEOrKYfAXBKbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3srosVWksA%253D%253D&md5=90583891b647188903327144e347e676</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.jpurol.2013.02.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpurol.2013.02.012%26sid%3Dliteratum%253Aachs%26aulast%3DLucchini%26aufirst%3DB.%26aulast%3DSimonetti%26aufirst%3DG.%2BD.%26aulast%3DCeschi%26aufirst%3DA.%26aulast%3DLava%26aufirst%3DS.%2BA.%26aulast%3DFare%26aufirst%3DP.%2BB.%26aulast%3DBianchetti%26aufirst%3DM.%2BG.%26atitle%3DSevere%2520Signs%2520of%2520Hyponatremia%2520Secondary%2520to%2520Desmopressin%2520Treatment%2520for%2520Enuresis%253A%2520A%2520Systematic%2520Review%26jtitle%3DJ.%2520Pediatr.%2520Urol.%26date%3D2013%26volume%3D9%26spage%3D1049%26epage%3D1053%26doi%3D10.1016%2Fj.jpurol.2013.02.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bosch, J. L. H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, J. P.</span></span> <span> </span><span class="NLM_article-title">The Prevalence and Causes of Nocturia</span>. <i>J. Urol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>189</i></span>,  <span class="NLM_fpage">S86</span>– <span class="NLM_lpage">S92</span>, <span class="refDoi"> DOI: 10.1016/j.juro.2012.11.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1016%2Fj.juro.2012.11.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=23234639" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=189&publication_year=2013&pages=S86-S92&author=J.+L.+H.+R.+Boschauthor=J.+P.+Weiss&title=The+Prevalence+and+Causes+of+Nocturia&doi=10.1016%2Fj.juro.2012.11.033"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.juro.2012.11.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.juro.2012.11.033%26sid%3Dliteratum%253Aachs%26aulast%3DBosch%26aufirst%3DJ.%2BL.%2BH.%2BR.%26aulast%3DWeiss%26aufirst%3DJ.%2BP.%26atitle%3DThe%2520Prevalence%2520and%2520Causes%2520of%2520Nocturia%26jtitle%3DJ.%2520Urol.%26date%3D2013%26volume%3D189%26spage%3DS86%26epage%3DS92%26doi%3D10.1016%2Fj.juro.2012.11.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hofmeester, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kollen, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffens, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosch, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drake, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanker, M. H.</span></span> <span> </span><span class="NLM_article-title">The Association between Nocturia and Nocturnal Polyuria in Clinical and Epidemiological Studies: A Systematic Review and Meta-Analyses</span>. <i>J. Urol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>191</i></span>,  <span class="NLM_fpage">1028</span>– <span class="NLM_lpage">1033</span>, <span class="refDoi"> DOI: 10.1016/j.juro.2013.10.100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1016%2Fj.juro.2013.10.100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=24184367" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A280%3ADC%252BC2c7itVCjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2014&pages=1028-1033&author=I.+Hofmeesterauthor=B.+J.+Kollenauthor=M.+G.+Steffensauthor=J.+L.+Boschauthor=M.+J.+Drakeauthor=J.+P.+Weissauthor=M.+H.+Blanker&title=The+Association+between+Nocturia+and+Nocturnal+Polyuria+in+Clinical+and+Epidemiological+Studies%3A+A+Systematic+Review+and+Meta-Analyses&doi=10.1016%2Fj.juro.2013.10.100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The association between nocturia and nocturnal polyuria in clinical and epidemiological studies: a systematic review and meta-analyses</span></div><div class="casAuthors">Hofmeester Ilse; Steffens Martijn G; Kollen Boudewijn J; Blanker Marco H; Bosch J L H Ruud; Drake Marcus J; Weiss Jeffrey P</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of urology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1028-33</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  We determined the relationship between nocturia and nocturnal polyuria.  MATERIALS AND METHODS:  The PubMed® and Embase® databases were searched for studies written in English, German, French or Dutch with original data on adult participants in an investigation of the relationship between nocturia and nocturnal polyuria.  A meta-analysis of the difference in mean nocturnal voiding frequencies between patients with and without nocturnal polyuria was conducted.  Nocturnal polyuria risk was compared between participants with and without nocturia, and the resulting odds ratio was subsequently converted to relative risk with 95% CIs.  RESULTS:  From 511 references identified we selected 78 publications of 66 studies, 15 of which met the inclusion criteria for this study.  Quality scores of studies were generally high for internal validity but low for external validity.  In 7 studies (1,416 participants) we estimated a standardized mean difference of 0.59 (95% CI 0.29-0.89) for nocturnal voids between nocturnal polyuria and nonnocturnal polyuria cases.  In 8 other studies (with 2,320 participants) we calculated a pooled OR of 4.99 (3.92-6.37) for nocturnal polyuria in individuals with nocturia.  The corresponding RR, based on a nocturnal polyuria risk in the pooled population of 63.8%, was 1.41 (1.37-1.44).  CONCLUSIONS:  The association between nocturia and nocturnal polyuria is apparent and robust.  However, the clinical importance of the association appears to be less obvious than previously suggested based on single studies.  The observed high prevalence of nocturnal polyuria, as a result of the applied International Continence Society definition, may be responsible for this discrepancy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTFyJXfa-E_NROk4JA3soTqfW6udTcc2eYI7WjhoCaAF7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c7itVCjsw%253D%253D&md5=75a0095cf6290e6e373d7f73077acf97</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.juro.2013.10.100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.juro.2013.10.100%26sid%3Dliteratum%253Aachs%26aulast%3DHofmeester%26aufirst%3DI.%26aulast%3DKollen%26aufirst%3DB.%2BJ.%26aulast%3DSteffens%26aufirst%3DM.%2BG.%26aulast%3DBosch%26aufirst%3DJ.%2BL.%26aulast%3DDrake%26aufirst%3DM.%2BJ.%26aulast%3DWeiss%26aufirst%3DJ.%2BP.%26aulast%3DBlanker%26aufirst%3DM.%2BH.%26atitle%3DThe%2520Association%2520between%2520Nocturia%2520and%2520Nocturnal%2520Polyuria%2520in%2520Clinical%2520and%2520Epidemiological%2520Studies%253A%2520A%2520Systematic%2520Review%2520and%2520Meta-Analyses%26jtitle%3DJ.%2520Urol.%26date%3D2014%26volume%3D191%26spage%3D1028%26epage%3D1033%26doi%3D10.1016%2Fj.juro.2013.10.100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
Kerrebroeck, P.</span></span> <span> </span><span class="NLM_article-title">Nocturia: Current Status and Future Perspectives</span>. <i>Curr. Opin. Obstet. Gynecol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">376</span>– <span class="NLM_lpage">385</span>, <span class="refDoi"> DOI: 10.1097/GCO.0b013e32834ac78c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1097%2FGCO.0b013e32834ac78c" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=21897234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A280%3ADC%252BC3MfhvFCntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2011&pages=376-385&author=P.+Van%0AKerrebroeck&title=Nocturia%3A+Current+Status+and+Future+Perspectives&doi=10.1097%2FGCO.0b013e32834ac78c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Nocturia: current status and future perspectives</span></div><div class="casAuthors">Van Kerrebroeck Philip</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in obstetrics & gynecology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">376-85</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE OF REVIEW:  Nocturia is a bothersome and highly prevalent condition characterized by the need to wake to void at night.  Nocturia is equally common in men and women, and although its prevalence increases with age, a significant proportion of younger people are also affected.  Nocturia leads to fragmentation of sleep and consequently to a serious decline in daytime functioning and in quality of life and health.  Its impact should not be underestimated by clinicians and therefore a review on nocturia is timely and relevant.  RECENT FINDINGS:  Traditionally, nocturia is regarded as a symptom of benign prostatic enlargement and/or overactive bladder syndrome, with treatment therefore directed toward increasing the capacity of the bladder to hold urine.  Such treatments have proven ineffective in many patients because nocturnal polyuria, an overproduction of urine at night, has been found to be present in the majority of patients.  Nocturia can be attributed to some underlying pathological factors but it can also be a distinct clinical entity with specific pathogenesis.  Frequency-volume charts are recommended for routine use in clinical practice, to determine whether nocturia is a result of excessive urine production at night, or of small voided volumes due to bladder problems, or a combination of these factors.  Desmopressin, a synthetic analogue of the antidiuretic hormone, should be considered in patients with nocturia where nocturnal polyuria is present.  SUMMARY:  Contrary to popular and medical misconception nocturia is an important condition leading to general morbidity and with serious impact on overall quality of life and health.  We advise clinicians to pay attention to nocturia and diagnostics should be offered.  Treatment modalities are available and have to be discussed with the patient.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTed0IQzZeNpmyYR5VtavbzfW6udTcc2eYI7WjhoCaAF7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MfhvFCntA%253D%253D&md5=ab34c8c6bb6c2a004cad4bea2db34578</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1097%2FGCO.0b013e32834ac78c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FGCO.0b013e32834ac78c%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BKerrebroeck%26aufirst%3DP.%26atitle%3DNocturia%253A%2520Current%2520Status%2520and%2520Future%2520Perspectives%26jtitle%3DCurr.%2520Opin.%2520Obstet.%2520Gynecol.%26date%3D2011%26volume%3D23%26spage%3D376%26epage%3D385%26doi%3D10.1097%2FGCO.0b013e32834ac78c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sand, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dmochowski, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Meulen, E. A.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Low Dose Desmopressin Orally Disintegrating Tablet in Women with Nocturia: Results of a Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study</span>. <i>J. Urol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>190</i></span>,  <span class="NLM_fpage">958</span>– <span class="NLM_lpage">964</span>, <span class="refDoi"> DOI: 10.1016/j.juro.2013.02.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1016%2Fj.juro.2013.02.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=23454404" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFCktL3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=190&publication_year=2013&pages=958-964&author=P.+K.+Sandauthor=R.+R.+Dmochowskiauthor=J.+Reddyauthor=E.+A.+van+der%0AMeulen&title=Efficacy+and+Safety+of+Low+Dose+Desmopressin+Orally+Disintegrating+Tablet+in+Women+with+Nocturia%3A+Results+of+a+Multicenter%2C+Randomized%2C+Double-Blind%2C+Placebo+Controlled%2C+Parallel+Group+Study&doi=10.1016%2Fj.juro.2013.02.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and Safety of Low Dose Desmopressin Orally Disintegrating Tablet in Women with Nocturia: Results of a Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study</span></div><div class="casAuthors">Sand, Peter K.; Dmochowski, Roger R.; Reddy, Jyotsna; van der Meulen, Egbert A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Urology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">190</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">958-964</span>CODEN:
                <span class="NLM_cas:coden">JOURAA</span>;
        ISSN:<span class="NLM_cas:issn">0022-5347</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Purpose: Previous studies suggest a lower dose of desmopressin orally disintegrating tablet may be effective in females compared to males with nocturia.  We confirm the efficacy and safety of 25 μg desmopressin orally disintegrating tablet compared to placebo in female patients.  Materials and Methods: In this 3-mo, randomized, double-blind, parallel group study 25 μg desmopressin once daily was compared to placebo in women with nocturia (2 or more nocturnal voids).  The co-primary efficacy end points were change from baseline in mean no. of nocturnal voids and proportion of patients achieving at least a 33% redn. from baseline in the mean no. of nocturnal voids (33% responders).  Results: The full anal. set comprised 261 patients (age range 19 to 87 years).  Desmopressin significantly reduced the mean no. of nocturnal voids and increased the odds of a 33% or greater response compared to placebo during 3 mo, assessed by longitudinal anal. (-0.22, p = 0.028 and OR 1.85, p = 0.006, resp.).  Desmopressin increased the mean time to first nocturnal void by 49 min compared to placebo at 3 mo (p = 0.003).  The response to desmopressin was seen by week 1 of treatment and was sustained throughout the trial.  Significant increases in health related quality of life and sleep quality were obsd. compared to placebo.  Desmopressin was well tolerated.  Serum sodium levels remained greater than 125 mmol/L throughout the trial and 3 transient decreases to less than 130 mmol/L were recorded.  Conclusions: At a dose of 25 μg, desmopressin orally disintegrating tablet is an effective and well tolerated treatment for women with nocturia.  Treatment provides rapid and sustained improvement in nocturia and quality of life.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0lJIF_Ana3rVg90H21EOLACvtfcHk0lib0U9O_cr3LA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFCktL3P&md5=0c47afe21c2de6b6fc8d92aa2f3f1dd1</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.juro.2013.02.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.juro.2013.02.037%26sid%3Dliteratum%253Aachs%26aulast%3DSand%26aufirst%3DP.%2BK.%26aulast%3DDmochowski%26aufirst%3DR.%2BR.%26aulast%3DReddy%26aufirst%3DJ.%26aulast%3Dvan%2Bder%2BMeulen%26aufirst%3DE.%2BA.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Low%2520Dose%2520Desmopressin%2520Orally%2520Disintegrating%2520Tablet%2520in%2520Women%2520with%2520Nocturia%253A%2520Results%2520of%2520a%2520Multicenter%252C%2520Randomized%252C%2520Double-Blind%252C%2520Placebo%2520Controlled%252C%2520Parallel%2520Group%2520Study%26jtitle%3DJ.%2520Urol.%26date%3D2013%26volume%3D190%26spage%3D958%26epage%3D964%26doi%3D10.1016%2Fj.juro.2013.02.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herschorn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albei, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Meulen, E. A.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Low Dose Desmopressin Orally Disintegrating Tablet in Men with Nocturia: Results of a Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study</span>. <i>J. Urol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>190</i></span>,  <span class="NLM_fpage">965</span>– <span class="NLM_lpage">972</span>, <span class="refDoi"> DOI: 10.1016/j.juro.2012.12.112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1016%2Fj.juro.2012.12.112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=23454402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFCrsr7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=190&publication_year=2013&pages=965-972&author=J.+P.+Weissauthor=S.+Herschornauthor=C.+D.+Albeiauthor=E.+A.+van+der+Meulen&title=Efficacy+and+Safety+of+Low+Dose+Desmopressin+Orally+Disintegrating+Tablet+in+Men+with+Nocturia%3A+Results+of+a+Multicenter%2C+Randomized%2C+Double-Blind%2C+Placebo+Controlled%2C+Parallel+Group+Study&doi=10.1016%2Fj.juro.2012.12.112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and Safety of Low Dose Desmopressin Orally Disintegrating Tablet in Men with Nocturia: Results of a Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study</span></div><div class="casAuthors">Weiss, Jeffrey P.; Herschorn, Sender; Albei, Cerasela D.; van der Meulen, Egbert A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Urology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">190</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">965-972</span>CODEN:
                <span class="NLM_cas:coden">JOURAA</span>;
        ISSN:<span class="NLM_cas:issn">0022-5347</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Purpose: We investigated the efficacy and safety of 50 and 75 μg desmopressin orally disintegrating tablets in men with nocturia (2 or more nocturnal voids).  Materials and Methods: In this 3-mo, randomized, double-blind, parallel study 50 and 75 μg desmopressin were compared with placebo.  The co-primary efficacy end points were changes from baseline in mean no. of nocturnal voids and proportions of patients achieving at least a 33% redn. from baseline in nocturnal voids (33% responders) during a 3-mo treatment period.  Results: The full anal. set comprised 385 men (age range 20 to 87 years).  The 50 and 75 μg doses significantly reduced the no. of nocturnal voids (-0.37, p <0.0001 and -0.41, p = 0.0003, resp.) and increased the odds of a 33% or greater response (OR 1.98, p = 0.0009 and OR 2.04, p = 0.0004, resp.) compared with placebo during 3 mo.  Desmopressin 50 and 75 μg increased the time to first void from baseline by approx. 40 min compared to placebo (p = 0.006 and p = 0.003, resp.).  The response to desmopressin was seen by 1 wk of treatment and was sustained.  Significant increases in health related quality of life and sleep quality were obsd. compared to placebo.  Desmopressin was well tolerated as only 2 subjects (age 74 and 79 years) on 50 μg had a serum sodium level of less than 130 mmol/L (vs 9 subjects on 75 μg).  Conclusions: Desmopressin (orally disintegrating tablet) is an effective and well tolerated treatment for men with nocturia.  Treatment with 50 μg desmopressin, the min. ED, provided sustained improvement of nocturia throughout the study and meaningful benefits to patients with an improved safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjfJbUfCU3aLVg90H21EOLACvtfcHk0lib0U9O_cr3LA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFCrsr7O&md5=88dd9cd6edeedab40bec2f6de726e992</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.juro.2012.12.112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.juro.2012.12.112%26sid%3Dliteratum%253Aachs%26aulast%3DWeiss%26aufirst%3DJ.%2BP.%26aulast%3DHerschorn%26aufirst%3DS.%26aulast%3DAlbei%26aufirst%3DC.%2BD.%26aulast%3Dvan%2Bder%2BMeulen%26aufirst%3DE.%2BA.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Low%2520Dose%2520Desmopressin%2520Orally%2520Disintegrating%2520Tablet%2520in%2520Men%2520with%2520Nocturia%253A%2520Results%2520of%2520a%2520Multicenter%252C%2520Randomized%252C%2520Double-Blind%252C%2520Placebo%2520Controlled%252C%2520Parallel%2520Group%2520Study%26jtitle%3DJ.%2520Urol.%26date%3D2013%26volume%3D190%26spage%3D965%26epage%3D972%26doi%3D10.1016%2Fj.juro.2012.12.112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agerso, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovgren, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senderovitz, T.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and Renal Excretion of Desmopressin after Intravenous Administration to Healthy Subjects and Renally Impaired Patients</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">352</span>– <span class="NLM_lpage">358</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.2004.02175.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1111%2Fj.1365-2125.2004.02175.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=15373927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsVSiu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2004&pages=352-358&author=H.+Agersoauthor=L.+S.+Larsenauthor=A.+Riisauthor=U.+Lovgrenauthor=M.+O.+Karlssonauthor=T.+Senderovitz&title=Pharmacokinetics+and+Renal+Excretion+of+Desmopressin+after+Intravenous+Administration+to+Healthy+Subjects+and+Renally+Impaired+Patients&doi=10.1111%2Fj.1365-2125.2004.02175.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients</span></div><div class="casAuthors">Agerso, Henrik; Larsen, Lotte Seiding; Riis, Anders; Lovgren, Ulf; Karlsson, Mats O.; Senderovitz, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">352-358</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">The aim was to evaluate the influence of renal impairment on the pharmacokinetics of desmopressin.  Twenty-four subjects were enrolled in the study, 18 with varying degrees of renal impairment and six healthy volunteers.  Each subject received a single i.v. dose of 2 pg desmopressin.  Blood and urine samples were collected for 24 h and assayed for desmopressin by RIA.  Plasma concns. and the amts. of desmopressin excreted in the urine were analyzed simultaneously by use of mixed effects modeling.  Only mild adverse events were obsd.  Both the renal and the nonrenal clearance of desmopressin were found to vary with the creatinine clearance (CrCL).  A decrease of 1.67% in the CrCL (corresponding to 1 mL min-1 from 60 mL min-1) was found to cause a 1.74% decrease in the renal clearance and a 0.93% decrease in the nonrenal clearance.  The fall in renal clearance caused the amt. of desmopressin excreted in urine to decrease from 47% in healthy subjects to 21% in the patients with severe renal impairment.  The mean systemic clearance of desmopressin was 10 L h-1 in healthy subjects and 2.9 L h-1 in patients with severe renal impairment (difference -7.5 L h-1, 95% CI [-11; -4.3] litres h-1).  Correspondingly, the mean terminal half-life, was 3.7 h in healthy subjects and 10 h in patients with severe renal impairment (difference 6.7 h, 95% CI [4.0; 9.4] h).  Although desmopressin appears to be safe and well-tolerated by patients with impaired renal function, great caution should be exercised when titrating towards an efficient dosage regimen if patients with moderately or severely impaired renal function are to be treated with desmopressin at all.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhCTemkYdoBrVg90H21EOLACvtfcHk0lib0U9O_cr3LA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsVSiu70%253D&md5=7fdf7a4ce804c9ecdf700cc453686155</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2004.02175.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2004.02175.x%26sid%3Dliteratum%253Aachs%26aulast%3DAgerso%26aufirst%3DH.%26aulast%3DLarsen%26aufirst%3DL.%2BS.%26aulast%3DRiis%26aufirst%3DA.%26aulast%3DLovgren%26aufirst%3DU.%26aulast%3DKarlsson%26aufirst%3DM.%2BO.%26aulast%3DSenderovitz%26aufirst%3DT.%26atitle%3DPharmacokinetics%2520and%2520Renal%2520Excretion%2520of%2520Desmopressin%2520after%2520Intravenous%2520Administration%2520to%2520Healthy%2520Subjects%2520and%2520Renally%2520Impaired%2520Patients%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2004%26volume%3D58%26spage%3D352%26epage%3D358%26doi%3D10.1111%2Fj.1365-2125.2004.02175.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Callréus, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, M.</span></span> <span> </span><span class="NLM_article-title">Hyponatremia in Elderly Patients Treated with Desmopressin for Nocturia: A Review of a Case Series</span>. <i>Eur. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">281</span>– <span class="NLM_lpage">284</span>, <span class="refDoi"> DOI: 10.1007/s00228-005-0919-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1007%2Fs00228-005-0919-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2005&pages=281-284&author=T.+Callr%C3%A9usauthor=E.+Ekmanauthor=M.+Andersen&title=Hyponatremia+in+Elderly+Patients+Treated+with+Desmopressin+for+Nocturia%3A+A+Review+of+a+Case+Series&doi=10.1007%2Fs00228-005-0919-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1007%2Fs00228-005-0919-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00228-005-0919-4%26sid%3Dliteratum%253Aachs%26aulast%3DCallr%25C3%25A9us%26aufirst%3DT.%26aulast%3DEkman%26aufirst%3DE.%26aulast%3DAndersen%26aufirst%3DM.%26atitle%3DHyponatremia%2520in%2520Elderly%2520Patients%2520Treated%2520with%2520Desmopressin%2520for%2520Nocturia%253A%2520A%2520Review%2520of%2520a%2520Case%2520Series%26jtitle%3DEur.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2005%26volume%3D61%26spage%3D281%26epage%3D284%26doi%3D10.1007%2Fs00228-005-0919-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fjellestad-Paulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoglund, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulsen, O.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics of 1-Deamino-8-<span class="smallcaps smallerCapital">d</span>-Arginine Vasopressin after Various Routes of Administration in Healthy Volunteers</span>. <i>Clin. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">177</span>– <span class="NLM_lpage">182</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2265.1993.tb00990.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1111%2Fj.1365-2265.1993.tb00990.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=8435898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADyaK3sXisVOqu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1993&pages=177-182&author=A.+Fjellestad-Paulsenauthor=P.+Hoglundauthor=S.+Lundinauthor=O.+Paulsen&title=Pharmacokinetics+of+1-Deamino-8-d-Arginine+Vasopressin+after+Various+Routes+of+Administration+in+Healthy+Volunteers&doi=10.1111%2Fj.1365-2265.1993.tb00990.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics of 1-deamino-8-D-arginine vasopressin after various routes of administration in healthy volunteers</span></div><div class="casAuthors">Fjellestad-Paulsen, A.; Hoeglund, P.; Lundin, S.; Paulsen, O.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Endocrinology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">177-82</span>CODEN:
                <span class="NLM_cas:coden">CLECAP</span>;
        ISSN:<span class="NLM_cas:issn">0300-0664</span>.
    </div><div class="casAbstract">The pharmacokinetics and biol. effects of 1-deamino-8-D-arginine vasopressin (dDAVP) were investigated in healthy adults after i.v. and s.c. (2 μg), intranasal and sublingual (20μg), intrarectal (50 μg), and oral (200 μg) administration.  An increase of urine osmolality was obsd. after all routes of administration, except the sublingual and intrarectal for up to 8 h after administration.  After i.v. administration, the half-life of elimination of dDVAP was 78 min.  An extensive adsorption of dDAVP to the plastic syringe was found with i.v., but not with s.c., administration.  Using the area under the curve of dDAVP from the s.c. administration as a ref., bioavailability was found to be 3.4% after intranasal administration and 0.1% after oral administration.  After sublingual and intrarectal routes of administration no detectable dDAVP was found in the blood; however, low amts. were found in the total 24-h urine.  The bioavailability of dDAVP seems lower than previously reported after intranasal and oral administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiR1LCUXrYgLVg90H21EOLACvtfcHk0lje6dY2Z8VI_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXisVOqu7c%253D&md5=a742cdc744a057c00d9df7d0c6544d99</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2265.1993.tb00990.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2265.1993.tb00990.x%26sid%3Dliteratum%253Aachs%26aulast%3DFjellestad-Paulsen%26aufirst%3DA.%26aulast%3DHoglund%26aufirst%3DP.%26aulast%3DLundin%26aufirst%3DS.%26aulast%3DPaulsen%26aufirst%3DO.%26atitle%3DPharmacokinetics%2520of%25201-Deamino-8-d-Arginine%2520Vasopressin%2520after%2520Various%2520Routes%2520of%2520Administration%2520in%2520Healthy%2520Volunteers%26jtitle%3DClin.%2520Endocrinol.%26date%3D1993%26volume%3D38%26spage%3D177%26epage%3D182%26doi%3D10.1111%2Fj.1365-2265.1993.tb00990.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Odeberg, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callreus, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoglund, P.</span></span> <span> </span><span class="NLM_article-title">A Pharmacokinetic and Pharmacodynamic Study of Desmopressin: Evaluating Sex Differences and the Effect of Pre-Treatment with Piroxicam, and Further Validation of an Indirect Response Model</span>. <i>J. Pharm. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">1389</span>– <span class="NLM_lpage">1398</span>, <span class="refDoi"> DOI: 10.1211/0022357044535</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1211%2F0022357044535" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=15525445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpvFOltb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2004&pages=1389-1398&author=J.+M.+Odebergauthor=T.+Callreusauthor=S.+Lundinauthor=E.+B.+Rothauthor=P.+Hoglund&title=A+Pharmacokinetic+and+Pharmacodynamic+Study+of+Desmopressin%3A+Evaluating+Sex+Differences+and+the+Effect+of+Pre-Treatment+with+Piroxicam%2C+and+Further+Validation+of+an+Indirect+Response+Model&doi=10.1211%2F0022357044535"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">A pharmacokinetic and pharmacodynamic study of desmopressin: Evaluating sex differences and the effect of pre-treatment with piroxicam, and further validation of an indirect response model</span></div><div class="casAuthors">Odeberg, Johanna Mercke; Callreus, Torbjoern; Lundin, Stefan; Roth, E. Bodil; Hoeglund, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacy and Pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1389-1398</span>CODEN:
                <span class="NLM_cas:coden">JPPMAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3573</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Press</span>)
        </div><div class="casAbstract">Desmopressin is a synthetic vasopressin analog mainly used in treatment of diabetes insipidus and nocturia.  Studies in rats have revealed a sex difference in the response to a vasopressin infusion, which was diminished after treatment with an NSAID.  This study was performed in man to investigate the influence of sex and concomitant treatment of piroxicam on the pharmacokinetics and dynamics of desmopressin, and to validate a previously described indirect response model.  Eight healthy males and 8 healthy females participated in the trial, which was conducted in a pharmacokinetic (PK) part followed by a pharmacodynamic (PD) part.  Desmopressin was administered i.v. as a single dose (PK = dose 2 μg, PD = dose 0.2 μg).  Piroxicam was administered to achieve steady state.  The pharmacokinetic parameters of desmopressin were estd. and calcd. by 2-compartmental anal.  In the dynamic part a study design based on an oral hydration model was used.  Parameters for urine flow and urine osmolality were estd.  Individual ests. of the pharmacokinetic parameters served as input to the indirect response model that subsequently was fitted to urine osmolality data.  The pharmacokinetics of desmopressin after a fixed bolus injection was neither influenced by piroxicam nor sex of the subject.  The pharmacodynamics of desmopressin showed a sex difference where females exhibited a more pronounced antidiuretic effect than males, which was statistically significant when the effects were submaximal (>4.5 h after dose).  The sex differences were diminished after pre-treatment with piroxicam, indicating a prostaglandin PGE2-mediated mechanism.  The indirect response model was confirmed, although the modeling could not distinguish a sex difference, indicating a limitation of this model compared with traditional descriptive statistics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhclsIssWT_7Vg90H21EOLACvtfcHk0lje6dY2Z8VI_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpvFOltb4%253D&md5=382b5ebfbddfc064c5859ae617e8499b</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1211%2F0022357044535&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1211%252F0022357044535%26sid%3Dliteratum%253Aachs%26aulast%3DOdeberg%26aufirst%3DJ.%2BM.%26aulast%3DCallreus%26aufirst%3DT.%26aulast%3DLundin%26aufirst%3DS.%26aulast%3DRoth%26aufirst%3DE.%2BB.%26aulast%3DHoglund%26aufirst%3DP.%26atitle%3DA%2520Pharmacokinetic%2520and%2520Pharmacodynamic%2520Study%2520of%2520Desmopressin%253A%2520Evaluating%2520Sex%2520Differences%2520and%2520the%2520Effect%2520of%2520Pre-Treatment%2520with%2520Piroxicam%252C%2520and%2520Further%2520Validation%2520of%2520an%2520Indirect%2520Response%2520Model%26jtitle%3DJ.%2520Pharm.%2520Pharmacol.%26date%3D2004%26volume%3D56%26spage%3D1389%26epage%3D1398%26doi%3D10.1211%2F0022357044535" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nevéus, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Läckgren, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuvemo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stenberg, A.</span></span> <span> </span><span class="NLM_article-title">Osmoregulation and Desmopressin Pharmacokinetics in Enuretic Children</span>. <i>Pediatrics</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1542/peds.103.1.65</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1542%2Fpeds.103.1.65" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=1999&pages=65-70&author=T.+Nev%C3%A9usauthor=G.+L%C3%A4ckgrenauthor=T.+Tuvemoauthor=A.+Stenberg&title=Osmoregulation+and+Desmopressin+Pharmacokinetics+in+Enuretic+Children&doi=10.1542%2Fpeds.103.1.65"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1542%2Fpeds.103.1.65&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1542%252Fpeds.103.1.65%26sid%3Dliteratum%253Aachs%26aulast%3DNev%25C3%25A9us%26aufirst%3DT.%26aulast%3DL%25C3%25A4ckgren%26aufirst%3DG.%26aulast%3DTuvemo%26aufirst%3DT.%26aulast%3DStenberg%26aufirst%3DA.%26atitle%3DOsmoregulation%2520and%2520Desmopressin%2520Pharmacokinetics%2520in%2520Enuretic%2520Children%26jtitle%3DPediatrics%26date%3D1999%26volume%3D103%26spage%3D65%26epage%3D70%26doi%3D10.1542%2Fpeds.103.1.65" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruzicka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjorkman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lethagen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sterner, G.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and Antidiuretic Effect of High-Dose Desmopressin in Patients with Chronic Renal Failure</span>. <i>Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">137</span>– <span class="NLM_lpage">142</span>, <span class="refDoi"> DOI: 10.1034/j.1600-0773.2003.920306.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1034%2Fj.1600-0773.2003.920306.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=12753429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADC%252BD3sXislOqu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2003&pages=137-142&author=H.+Ruzickaauthor=S.+Bjorkmanauthor=S.+Lethagenauthor=G.+Sterner&title=Pharmacokinetics+and+Antidiuretic+Effect+of+High-Dose+Desmopressin+in+Patients+with+Chronic+Renal+Failure&doi=10.1034%2Fj.1600-0773.2003.920306.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and antidiuretic effect of high-dose desmopressin in patients with chronic renal failure</span></div><div class="casAuthors">Ruzicka, Hana; Bjorkman, Sven; Lethagen, Stefan; Sterner, Gunnar</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Toxicology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">137-142</span>CODEN:
                <span class="NLM_cas:coden">PHTOEH</span>;
        ISSN:<span class="NLM_cas:issn">0901-9928</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishers Ltd.</span>)
        </div><div class="casAbstract">High-dose desmopressin shortens the bleeding time in uremia.  The aim of this study was to investigate the pharmacokinetics and the antidiuretic effect of desmopressin when given in a dose normally used for hemostasis to patients with reduced renal function.  Ten patients with chronic renal failure of varying etiol. were enrolled in the study.  The age was 58 (20-76) years (median and range), serum creatinine 447 (309-691) μmol/l and plasma clearance of iohexol 16 (8-19) ml/min./1.73 m2 body surface.  After baseline measurements, desmopressin was infused at a dose of 0.3 μg/kg.  The plasma concn. of desmopressin was followed for 26 h during and after the infusion and the pharmacokinetic parameters were estd. by compartmental anal.  Urine vol. and osmolality, as well as body wt., blood pressure, heart rate, hematocrit, serum osmolality, electrolytes and creatinine, were measured repeatedly during the day before and for two days after the infusion.  The total clearance of desmopressin was 0.35 (0.21-0.47) ml/min./kg, the vol. of distribution at steady state was 0.30 (0.17-0.38) l/kg and the terminal half-life 9.7 (8.4-16) hr.  After administration of desmopressin, urine osmolality increased significantly, by approx. 10%, and this increase lasted for 48 h.  Concomitantly, there was a modest but significant decrease in hematocrit.  Thus, the clearance of desmopressin was on av. decreased to approx. one quarter, and the terminal half-life was prolonged 2-3 times in the patients as compared to previously published values for healthy adults.  The single hemostatic dose of desmopressin given to patients with severe renal failure did not cause fluid overload or changes in serum electrolytes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojdxVX_ZZn6rVg90H21EOLACvtfcHk0lhiY__nHj9CSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXislOqu70%253D&md5=acc1ffec8bc3195e82ac991646feea8c</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1034%2Fj.1600-0773.2003.920306.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1034%252Fj.1600-0773.2003.920306.x%26sid%3Dliteratum%253Aachs%26aulast%3DRuzicka%26aufirst%3DH.%26aulast%3DBjorkman%26aufirst%3DS.%26aulast%3DLethagen%26aufirst%3DS.%26aulast%3DSterner%26aufirst%3DG.%26atitle%3DPharmacokinetics%2520and%2520Antidiuretic%2520Effect%2520of%2520High-Dose%2520Desmopressin%2520in%2520Patients%2520with%2520Chronic%2520Renal%2520Failure%26jtitle%3DPharmacol.%2520Toxicol.%26date%3D2003%26volume%3D92%26spage%3D137%26epage%3D142%26doi%3D10.1034%2Fj.1600-0773.2003.920306.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rembratt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graugaard-Jensen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senderovitz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norgaard, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djurhuus, J. C.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and Pharmacodynamics of Desmopressin Administered Orally Versus Intravenously at Daytime Versus Night-Time in Healthy Men Aged 55-70 Years</span>. <i>Eur. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">397</span>– <span class="NLM_lpage">402</span>, <span class="refDoi"> DOI: 10.1007/s00228-004-0781-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1007%2Fs00228-004-0781-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=397-402&author=A.+Rembrattauthor=C.+Graugaard-Jensenauthor=T.+Senderovitzauthor=J.+P.+Norgaardauthor=J.+C.+Djurhuus&title=Pharmacokinetics+and+Pharmacodynamics+of+Desmopressin+Administered+Orally+Versus+Intravenously+at+Daytime+Versus+Night-Time+in+Healthy+Men+Aged+55-70+Years&doi=10.1007%2Fs00228-004-0781-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2Fs00228-004-0781-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00228-004-0781-9%26sid%3Dliteratum%253Aachs%26aulast%3DRembratt%26aufirst%3DA.%26aulast%3DGraugaard-Jensen%26aufirst%3DC.%26aulast%3DSenderovitz%26aufirst%3DT.%26aulast%3DNorgaard%26aufirst%3DJ.%2BP.%26aulast%3DDjurhuus%26aufirst%3DJ.%2BC.%26atitle%3DPharmacokinetics%2520and%2520Pharmacodynamics%2520of%2520Desmopressin%2520Administered%2520Orally%2520Versus%2520Intravenously%2520at%2520Daytime%2520Versus%2520Night-Time%2520in%2520Healthy%2520Men%2520Aged%252055-70%2520Years%26jtitle%3DEur.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2004%26volume%3D60%26spage%3D397%26epage%3D402%26doi%3D10.1007%2Fs00228-004-0781-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caggiano, T. J.</span></span> <span> </span><span class="NLM_article-title">WAY-VNA-932</span>. <i>Drugs Future</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">248</span>– <span class="NLM_lpage">253</span>, <span class="refDoi"> DOI: 10.1358/dof.2002.027.03.659890</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1358%2Fdof.2002.027.03.659890" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADC%252BD38XkslaitL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2002&pages=248-253&author=T.+J.+Caggiano&title=WAY-VNA-932&doi=10.1358%2Fdof.2002.027.03.659890"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">WAY-VNA-932</span></div><div class="casAuthors">Caggiano, Thomas J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">248-253</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review. WAY-VNA-932 is a novel, orally active nonpeptide small mol. which exhibits vasopressin V2 receptor agonism.  In CHO cells transfected with human V1a, V2, V1b and oxytocin receptors, WAY-VNA-932 is a potent agonist at the V2 receptor, with an EC50 for 2nd messenger (cAMP) generation of 0.7 nM.  In water-loaded normotensive rats, Brattleboro rats, dogs and cynomolgus monkeys WAY-VNA-932 lowers urine output in a dose-dependent manner with a concomitant increase in osmolality.  It is expected that WAY-VNA-932 will offer several advantages over desmopressin, a peptide vasopressin V2 agonist, including greater and more consistent bioavailability and the lack of pressor activity.  WAY-VNA-932 is expected to be useful in conditions characterized by excessive prodn. and/or diln. of urine such as central diabetes insipidus and nocturnal enuresis as well as in conditions characterized by inappropriate prodn. of vasopressin.  WAY-VNA-932 is the 1st nonpeptide vasopressin V2 agonist to enter phase I trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqod3Z1TipNcrVg90H21EOLACvtfcHk0lhiY__nHj9CSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkslaitL4%253D&md5=4d8946fd3c506cd1b9d20658d5ca0d42</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1358%2Fdof.2002.027.03.659890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2002.027.03.659890%26sid%3Dliteratum%253Aachs%26aulast%3DCaggiano%26aufirst%3DT.%2BJ.%26atitle%3DWAY-VNA-932%26jtitle%3DDrugs%2520Future%26date%3D2002%26volume%3D27%26spage%3D248%26epage%3D253%26doi%3D10.1358%2Fdof.2002.027.03.659890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itoh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsujimae, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinohara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teramoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sumida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekiguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kambe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsujimoto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tominaga, M.</span></span> <span> </span><span class="NLM_article-title">Characterization of a Novel Nonpeptide Vasopressin V(2)-Agonist, OPC-51803, in Cells Transfected Human Vasopressin Receptor Subtypes</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">1700</span>– <span class="NLM_lpage">1706</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0703221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1038%2Fsj.bjp.0703221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10780976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjtV2ru7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2000&pages=1700-1706&author=S.+Nakamuraauthor=Y.+Yamamuraauthor=S.+Itohauthor=T.+Hiranoauthor=K.+Tsujimaeauthor=M.+Aoyamaauthor=K.+Kondoauthor=H.+Ogawaauthor=T.+Shinoharaauthor=K.+Kanauthor=Y.+Tanadaauthor=S.+Teramotoauthor=T.+Sumidaauthor=S.+Nakayamaauthor=K.+Sekiguchiauthor=T.+Kambeauthor=G.+Tsujimotoauthor=T.+Moriauthor=M.+Tominaga&title=Characterization+of+a+Novel+Nonpeptide+Vasopressin+V%282%29-Agonist%2C+OPC-51803%2C+in+Cells+Transfected+Human+Vasopressin+Receptor+Subtypes&doi=10.1038%2Fsj.bjp.0703221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of a novel nonpeptide vasopressin V2-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes</span></div><div class="casAuthors">Nakamura, Shigeki; Yamamura, Yoshitaka; Itoh, Shuji; Hirano, Takahiro; Tsujimae, Kenji; Aoyama, Masashi; Kondo, Kazumi; Ogawa, Hidenori; Shinohara, Tomoichi; Kan, Keizo; Tanada, Yoshihisa; Teramoto, Shuji; Sumida, Takumi; Nakayama, Sunao; Sekiguchi, Kazuo; Kambe, Toshimi; Tsujimoto, Gozoh; Mori, Toyoki; Tominaga, Michiaki</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1700-1706</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We discovered the first nonpeptide arginine-vasopressin (AVP) V2-receptor agonist, OPC-51803.  Pharmacol. properties of OPC-51803 were elucidated using HeLa cells expressing human AVP receptor subtypes (V2, V1a and V1b) and compared with those of 1-desamino-8-D-arginine vasopressin (dDAVP), a peptide V2-receptor agonist.  OPC-51803 and dDAVP displaced [3H]-AVP binding to human V2- and V1a-receptors with Ki values of 91.9±10.8 nM (n=6) and 3.12±0.38 nM (n=6) for V2-receptors, and 819±39 nM (n=6) and 41.5±9.9 nM (n=6) for V1a-receptors, indicating that OPC-51803 was about nine times more selective for V2-receptors, similar to the selectivity of dDAVP.  OPC-51803 scarcely displaced [3H]-AVP binding to human V1b-receptors even at 10-4 M, while dDAVP showed potent affinity to human V1b-receptors with the Ki value of 13.7±3.2 nM (n=4).  OPC-51803 concn.-dependently increased cyclic adenosine 3', 5'-monophosphate (cAMP) prodn. in HeLa cells expressing human V2-receptors with an EC50 value of 189±14 nM (n=6).  The concn.-response curve for cAMP prodn. induced by OPC-51803 was shifted to the right in the presence of a V2-antagonist, OPC-31260.  At 10-5 M, OPC-51803 did not increase the intracellular Ca2+ concn. ([Ca2+]i) in HeLa cells expressing human V1a-receptors.  On the other hand, dDAVP increased [Ca2+]i in HeLa cells expressing human V1a- and V1b-receptors in a concn.-dependent fashion.  From these results, OPC-51803 has been confirmed to be the first nonpeptide agonist for human AVP V2-receptors without agonistic activities for V1a- and V1b-receptors.  OPC-51803 may be useful for the treatment of AVP-deficient pathophysiol. states and as a tool for AVP researches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtP6Ey2VlQ77Vg90H21EOLACvtfcHk0lhiY__nHj9CSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjtV2ru7k%253D&md5=435c824ff32701169445cb4a1c35a94c</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0703221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0703221%26sid%3Dliteratum%253Aachs%26aulast%3DNakamura%26aufirst%3DS.%26aulast%3DYamamura%26aufirst%3DY.%26aulast%3DItoh%26aufirst%3DS.%26aulast%3DHirano%26aufirst%3DT.%26aulast%3DTsujimae%26aufirst%3DK.%26aulast%3DAoyama%26aufirst%3DM.%26aulast%3DKondo%26aufirst%3DK.%26aulast%3DOgawa%26aufirst%3DH.%26aulast%3DShinohara%26aufirst%3DT.%26aulast%3DKan%26aufirst%3DK.%26aulast%3DTanada%26aufirst%3DY.%26aulast%3DTeramoto%26aufirst%3DS.%26aulast%3DSumida%26aufirst%3DT.%26aulast%3DNakayama%26aufirst%3DS.%26aulast%3DSekiguchi%26aufirst%3DK.%26aulast%3DKambe%26aufirst%3DT.%26aulast%3DTsujimoto%26aufirst%3DG.%26aulast%3DMori%26aufirst%3DT.%26aulast%3DTominaga%26aufirst%3DM.%26atitle%3DCharacterization%2520of%2520a%2520Novel%2520Nonpeptide%2520Vasopressin%2520V%25282%2529-Agonist%252C%2520OPC-51803%252C%2520in%2520Cells%2520Transfected%2520Human%2520Vasopressin%2520Receptor%2520Subtypes%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2000%26volume%3D129%26spage%3D1700%26epage%3D1706%26doi%3D10.1038%2Fsj.bjp.0703221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yea, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allan, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashworth, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnett, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxter, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broadbridge, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franklin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hampton, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horton, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penson, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitt, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riviere, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robson, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooker, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semple, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheppard, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haigh, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roe, M. B.</span></span> <span> </span><span class="NLM_article-title">New Benzylureas as a Novel Series of Potent, Nonpeptidic Vasopressin V2 Receptor Agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">8124</span>– <span class="NLM_lpage">8134</span>, <span class="refDoi"> DOI: 10.1021/jm8008162</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8008162" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=8124-8134&author=C.+M.+Yeaauthor=C.+E.+Allanauthor=D.+M.+Ashworthauthor=J.+Barnettauthor=A.+J.+Baxterauthor=J.+D.+Broadbridgeauthor=R.+J.+Franklinauthor=S.+L.+Hamptonauthor=P.+Hudsonauthor=J.+A.+Hortonauthor=P.+D.+Jenkinsauthor=A.+M.+Pensonauthor=G.+R.+Pittauthor=P.+Riviereauthor=P.+A.+Robsonauthor=D.+P.+Rookerauthor=G.+Sempleauthor=A.+Sheppardauthor=R.+M.+Haighauthor=M.+B.+Roe&title=New+Benzylureas+as+a+Novel+Series+of+Potent%2C+Nonpeptidic+Vasopressin+V2+Receptor+Agonists&doi=10.1021%2Fjm8008162"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm8008162&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8008162%26sid%3Dliteratum%253Aachs%26aulast%3DYea%26aufirst%3DC.%2BM.%26aulast%3DAllan%26aufirst%3DC.%2BE.%26aulast%3DAshworth%26aufirst%3DD.%2BM.%26aulast%3DBarnett%26aufirst%3DJ.%26aulast%3DBaxter%26aufirst%3DA.%2BJ.%26aulast%3DBroadbridge%26aufirst%3DJ.%2BD.%26aulast%3DFranklin%26aufirst%3DR.%2BJ.%26aulast%3DHampton%26aufirst%3DS.%2BL.%26aulast%3DHudson%26aufirst%3DP.%26aulast%3DHorton%26aufirst%3DJ.%2BA.%26aulast%3DJenkins%26aufirst%3DP.%2BD.%26aulast%3DPenson%26aufirst%3DA.%2BM.%26aulast%3DPitt%26aufirst%3DG.%2BR.%26aulast%3DRiviere%26aufirst%3DP.%26aulast%3DRobson%26aufirst%3DP.%2BA.%26aulast%3DRooker%26aufirst%3DD.%2BP.%26aulast%3DSemple%26aufirst%3DG.%26aulast%3DSheppard%26aufirst%3DA.%26aulast%3DHaigh%26aufirst%3DR.%2BM.%26aulast%3DRoe%26aufirst%3DM.%2BB.%26atitle%3DNew%2520Benzylureas%2520as%2520a%2520Novel%2520Series%2520of%2520Potent%252C%2520Nonpeptidic%2520Vasopressin%2520V2%2520Receptor%2520Agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D8124%26epage%3D8134%26doi%3D10.1021%2Fjm8008162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koshio, H.</span>; <span class="NLM_string-name">Tsukamoto, I.</span>; <span class="NLM_string-name">Kakefuda, A.</span>; <span class="NLM_string-name">Akamatsu, S.</span>; <span class="NLM_string-name">Saitoh, C.</span></span> <span> </span><span class="NLM_article-title">Preparation of 4,4-Difluoro-1,2,3,4-Tetrahydro-1(5H)-Benzazepine Derivatives for Treatment of Night Pollakisuria and Diabetes Insipidus</span>. <span class="NLM_patent">WO2004096775A1</span>, <span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=H.+Koshio&author=I.+Tsukamoto&author=A.+Kakefuda&author=S.+Akamatsu&author=C.+Saitoh&title=Preparation+of+4%2C4-Difluoro-1%2C2%2C3%2C4-Tetrahydro-1%285H%29-Benzazepine+Derivatives+for+Treatment+of+Night+Pollakisuria+and+Diabetes+Insipidus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKoshio%26aufirst%3DH.%26atitle%3DPreparation%2520of%25204%252C4-Difluoro-1%252C2%252C3%252C4-Tetrahydro-1%25285H%2529-Benzazepine%2520Derivatives%2520for%2520Treatment%2520of%2520Night%2520Pollakisuria%2520and%2520Diabetes%2520Insipidus%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satoh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamagishi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furuhama, K.</span></span> <span> </span><span class="NLM_article-title">Calculation of Glomerular Filtration Rate in Conscious Rats by the Use of a Bolus Injection of Iodixanol and a Single Blood Sample</span>. <i>J. Pharmacol. Toxicol. Methods</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">64</span>, <span class="refDoi"> DOI: 10.1016/j.vascn.2009.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1016%2Fj.vascn.2009.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=19854282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1WltbnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2010&pages=59-64&author=R.+Katayamaauthor=N.+Yamaguchiauthor=T.+Yamashitaauthor=S.+Watanabeauthor=H.+Satohauthor=N.+Yamagishiauthor=K.+Furuhama&title=Calculation+of+Glomerular+Filtration+Rate+in+Conscious+Rats+by+the+Use+of+a+Bolus+Injection+of+Iodixanol+and+a+Single+Blood+Sample&doi=10.1016%2Fj.vascn.2009.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Calculation of glomerular filtration rate in conscious rats by the use of a bolus injection of iodixanol and a single blood sample</span></div><div class="casAuthors">Katayama, Rieko; Yamaguchi, Nami; Yamashita, Tetsuro; Watanabe, Shuji; Satoh, Hiroshi; Yamagishi, Norio; Furuhama, Kazuhisa</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological and Toxicological Methods</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">59-64</span>CODEN:
                <span class="NLM_cas:coden">JPTMEZ</span>;
        ISSN:<span class="NLM_cas:issn">1056-8719</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Introduction: To establish a simple and convenient procedure for the detn. of glomerular filtration rate (GFR) in conscious rats, the authors developed a single-blood-sample method, in contrast to the conventional three-sample method, using a bolus injection of the nonionic contrast medium iodixanol.  Methods: Iodixanol was i.v. administered at 1500 mg I/kg to healthy or renal-impaired rats, and blood was collected 60, 120, and 180 min later.  Serum iodixanol concns. were measured by HPLC, and serum urea nitrogen (UN) and creatinine concns. were detd. as renal function tests.  Results: In rats subjected to 1/2 and 3/4 nephrectomies, GFR values decreased significantly without and with increases in serum UN and creatinine concns., resp.  In rats treated s.c. with gentamicin sulfate (GM) at 80 mg/kg/day or puromycin aminonucleoside (PAN) at 15 mg/kg/day for 10 consecutive days, the GFR values decreased or showed a tendency to decrease before increases in serum UN and creatinine concns.  Accordingly, when the GFR decreased to more than 60% of the basal value, serum UN or creatinine concns. became elevated.  The GFR values obtained from the three-sample method were closely correlated (r = 0.83) with those calcd. from the estd. distribution vol. (V) and serum iodixanol concn. 120 min after iodixanol injection in the single-blood-sample method in which serum iodixanol concns. ranged between 20 and 250 μg I/mL.  Discussion: These results suggest that the single-blood-sample method with a bolus injection of iodixanol, allowing for the repeated use of the same animals, is an expedient procedure without ensuring accurate urine collection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDMjSYiBEq27Vg90H21EOLACvtfcHk0lgCYrQNqdwiFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1WltbnL&md5=024c608eee322fd813c550cf274bc44b</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.vascn.2009.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vascn.2009.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DYamaguchi%26aufirst%3DN.%26aulast%3DYamashita%26aufirst%3DT.%26aulast%3DWatanabe%26aufirst%3DS.%26aulast%3DSatoh%26aufirst%3DH.%26aulast%3DYamagishi%26aufirst%3DN.%26aulast%3DFuruhama%26aufirst%3DK.%26atitle%3DCalculation%2520of%2520Glomerular%2520Filtration%2520Rate%2520in%2520Conscious%2520Rats%2520by%2520the%2520Use%2520of%2520a%2520Bolus%2520Injection%2520of%2520Iodixanol%2520and%2520a%2520Single%2520Blood%2520Sample%26jtitle%3DJ.%2520Pharmacol.%2520Toxicol.%2520Methods%26date%3D2010%26volume%3D61%26spage%3D59%26epage%3D64%26doi%3D10.1016%2Fj.vascn.2009.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manning, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoev, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chini, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durroux, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mouillac, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillon, G.</span></span> <span> </span><span class="NLM_article-title">Peptide and Non-Peptide Agonists and Antagonists for the Vasopressin and Oxytocin V1a, V1b, V2 and OT Receptors: Research Tools and Potential Therapeutic Agents</span>. <i>Prog. Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>170</i></span>,  <span class="NLM_fpage">473</span>– <span class="NLM_lpage">512</span>, <span class="refDoi"> DOI: 10.1016/S0079-6123(08)00437-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1016%2FS0079-6123%2808%2900437-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=18655903" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1CjtrfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2008&pages=473-512&author=M.+Manningauthor=S.+Stoevauthor=B.+Chiniauthor=T.+Durrouxauthor=B.+Mouillacauthor=G.+Guillon&title=Peptide+and+Non-Peptide+Agonists+and+Antagonists+for+the+Vasopressin+and+Oxytocin+V1a%2C+V1b%2C+V2+and+OT+Receptors%3A+Research+Tools+and+Potential+Therapeutic+Agents&doi=10.1016%2FS0079-6123%2808%2900437-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents</span></div><div class="casAuthors">Manning, Maurice; Stoev, Stoytcho; Chini, Bice; Durroux, Thierry; Mouillac, Bernard; Guillon, Gilles</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Brain Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue">Advances in Vasopressin and Oxytocin</span>),
    <span class="NLM_cas:pages">473-512</span>CODEN:
                <span class="NLM_cas:coden">PBRRA4</span>;
        ISSN:<span class="NLM_cas:issn">0079-6123</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Oxytocin (OT) and vasopressin (AVP) mediate their biol. actions by acting on four known receptors: The OT (uterine) and the AVP V1a (vasopressor), V1b (pituitary), V2 (renal) receptors and a fifth putative AVP V1c (vasodilating) receptor.  This presentation will summarize some highlights of the recent progress, in the design and synthesis of selective peptide agonists, antagonists, radioiodinated ligands, fluorescent ligands and bivalent ligands for these receptors.  Here we present published and unpublished pharmacol. data on the most widely used agonists, antagonists and labeled ligands.  The pharmacol. properties of promising new selective OT antagonists and V1b agonists are also presented.  This review should serve as a useful guide for the selection of the most appropriate ligand for a given study.  The current status of non-peptide OT and AVP antagonists and agonists is also summarized.  The relative merits of peptide and non-peptide AVP and OT agonists and antagonists as: (1) research tools and (2) therapeutic agents will be evaluated.  Many of the receptor selective peptide agonists and antagonists from this and other labs. are far more widely used as pharmacol. tools for studies on the peripheral and central effects of OT and AVP than their non-peptide counterparts.  In addn. to OT and to a lesser extent AVP (pitressin), a no. of OT and AVP analogs; such as carbetocin (OT agonist) dDAVP (desmopressin, V2 agonist), terlipressin (V1a agonist), felypressin (V1a agonist) and atosiban (Tractocile OT antagonist) are also in clin. use.  Despite much early promise, no non-peptide V1a or OT antagonists are currently in clin. trials.  While a no. of orally active non-peptide V2 antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clin. trials; to date, only the mixed V2/V1a, antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clin. use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.  Promising new non-peptide V1b and OT antagonists, as well as non-peptide V2 and OT agonists are now in pre-clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3jiQ5LZT5gLVg90H21EOLACvtfcHk0lhEp7Cv4eUOsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1CjtrfJ&md5=c21ad467eaee4a2651232a16c7dc61c5</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2FS0079-6123%2808%2900437-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0079-6123%252808%252900437-8%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DM.%26aulast%3DStoev%26aufirst%3DS.%26aulast%3DChini%26aufirst%3DB.%26aulast%3DDurroux%26aufirst%3DT.%26aulast%3DMouillac%26aufirst%3DB.%26aulast%3DGuillon%26aufirst%3DG.%26atitle%3DPeptide%2520and%2520Non-Peptide%2520Agonists%2520and%2520Antagonists%2520for%2520the%2520Vasopressin%2520and%2520Oxytocin%2520V1a%252C%2520V1b%252C%2520V2%2520and%2520OT%2520Receptors%253A%2520Research%2520Tools%2520and%2520Potential%2520Therapeutic%2520Agents%26jtitle%3DProg.%2520Brain%2520Res.%26date%3D2008%26volume%3D170%26spage%3D473%26epage%3D512%26doi%3D10.1016%2FS0079-6123%2808%2900437-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manning, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misicka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bankowski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoev, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chini, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durroux, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mouillac, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillon, G.</span></span> <span> </span><span class="NLM_article-title">Oxytocin and Vasopressin Agonists and Antagonists as Research Tools and Potential Therapeutics</span>. <i>J. Neuroendocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">609</span>– <span class="NLM_lpage">628</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2826.2012.02303.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1111%2Fj.1365-2826.2012.02303.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=22375852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADC%252BC38XlsFKrtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2012&pages=609-628&author=M.+Manningauthor=A.+Misickaauthor=A.+Olmaauthor=K.+Bankowskiauthor=S.+Stoevauthor=B.+Chiniauthor=T.+Durrouxauthor=B.+Mouillacauthor=M.+Corbaniauthor=G.+Guillon&title=Oxytocin+and+Vasopressin+Agonists+and+Antagonists+as+Research+Tools+and+Potential+Therapeutics&doi=10.1111%2Fj.1365-2826.2012.02303.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics</span></div><div class="casAuthors">Manning, M.; Misicka, A.; Olma, A.; Bankowski, K.; Stoev, S.; Chini, B.; Durroux, T.; Mouillac, B.; Corbani, M.; Guillon, G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroendocrinology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">609-628</span>CODEN:
                <span class="NLM_cas:coden">JOUNE2</span>;
        ISSN:<span class="NLM_cas:issn">0953-8194</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  We recently reviewed the status of peptide and nonpeptide agonists and antagonists for the V1a, V1b and V2 receptors for arginine vasopressin (AVP) and the oxytocin receptor for oxytocin (OT).  In the present review, we update the status of peptides and nonpeptides as: (i) research tools and (ii) therapeutic agents.  We also present our recent findings on the design of fluorescent ligands for V1b receptor localization and for OT receptor dimerization.  We note the exciting discoveries regarding 2 novel naturally occurring analogs of OT.  Recent reports of a selective VP V1a agonist and a selective OT agonist point to the continued therapeutic potential of peptides in this field.  To date, only 2 nonpeptides, the V2/V1a antagonist, conivaptan and the V2 antagonist tolvaptan have received Food and Drug Administration approval for clin. use.  The development of nonpeptide AVP V1a, V1b and V2 antagonists and OT agonists and antagonists has recently been abandoned by Merck, Sanofi and Pfizer.  A promising OT antagonist, Retosiban, developed at Glaxo SmithKline is currently in a Phase II clin. trial for the prevention of premature labour.  A no. of the nonpeptide ligands that were not successful in clin. trials are proving to be valuable as research tools.  Peptide agonists and antagonists continue to be very widely used as research tools in this field.  In this regard, we present receptor data on some of the most widely used peptide and nonpeptide ligands, as a guide for their use, esp. with regard to receptor selectivity and species differences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvboATX-Tv3rVg90H21EOLACvtfcHk0lhEp7Cv4eUOsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlsFKrtrw%253D&md5=73b26be08e84e9daf8ac9136b472e6ad</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2826.2012.02303.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2826.2012.02303.x%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DM.%26aulast%3DMisicka%26aufirst%3DA.%26aulast%3DOlma%26aufirst%3DA.%26aulast%3DBankowski%26aufirst%3DK.%26aulast%3DStoev%26aufirst%3DS.%26aulast%3DChini%26aufirst%3DB.%26aulast%3DDurroux%26aufirst%3DT.%26aulast%3DMouillac%26aufirst%3DB.%26aulast%3DCorbani%26aufirst%3DM.%26aulast%3DGuillon%26aufirst%3DG.%26atitle%3DOxytocin%2520and%2520Vasopressin%2520Agonists%2520and%2520Antagonists%2520as%2520Research%2520Tools%2520and%2520Potential%2520Therapeutics%26jtitle%3DJ.%2520Neuroendocrinol.%26date%3D2012%26volume%3D24%26spage%3D609%26epage%3D628%26doi%3D10.1111%2Fj.1365-2826.2012.02303.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acosta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balaspiri, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judd, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, M.</span></span> <span> </span><span class="NLM_article-title">Structural Changes in the Arginine Vasopressin Molecule That Enhance Antidiuretic Activity and Specificity</span>. <i>Endocrinology</i> <span class="NLM_year" style="font-weight: bold;">1974</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">1106</span>– <span class="NLM_lpage">1115</span>, <span class="refDoi"> DOI: 10.1210/endo-94-4-1106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1210%2Fendo-94-4-1106" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1974&pages=1106-1115&author=W.+H.+Sawyerauthor=M.+Acostaauthor=L.+Balaspiriauthor=J.+Juddauthor=M.+Manning&title=Structural+Changes+in+the+Arginine+Vasopressin+Molecule+That+Enhance+Antidiuretic+Activity+and+Specificity&doi=10.1210%2Fendo-94-4-1106"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1210%2Fendo-94-4-1106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fendo-94-4-1106%26sid%3Dliteratum%253Aachs%26aulast%3DSawyer%26aufirst%3DW.%2BH.%26aulast%3DAcosta%26aufirst%3DM.%26aulast%3DBalaspiri%26aufirst%3DL.%26aulast%3DJudd%26aufirst%3DJ.%26aulast%3DManning%26aufirst%3DM.%26atitle%3DStructural%2520Changes%2520in%2520the%2520Arginine%2520Vasopressin%2520Molecule%2520That%2520Enhance%2520Antidiuretic%2520Activity%2520and%2520Specificity%26jtitle%3DEndocrinology%26date%3D1974%26volume%3D94%26spage%3D1106%26epage%3D1115%26doi%3D10.1210%2Fendo-94-4-1106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kowalczyk, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobolewski, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prahl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derdowska, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borovickova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slaninova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lammek, B.</span></span> <span> </span><span class="NLM_article-title">The Effects of N-Terminal Part Modification of Arginine Vasopressin Analogues with 2-Aminoindane-2-Carboxylic Acid: A Highly Potent V2 Agonist</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">2926</span>– <span class="NLM_lpage">2929</span>, <span class="refDoi"> DOI: 10.1021/jm070174s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070174s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=2926-2929&author=W.+Kowalczykauthor=D.+Sobolewskiauthor=A.+Prahlauthor=I.+Derdowskaauthor=L.+Borovickovaauthor=J.+Slaninovaauthor=B.+Lammek&title=The+Effects+of+N-Terminal+Part+Modification+of+Arginine+Vasopressin+Analogues+with+2-Aminoindane-2-Carboxylic+Acid%3A+A+Highly+Potent+V2+Agonist&doi=10.1021%2Fjm070174s"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm070174s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070174s%26sid%3Dliteratum%253Aachs%26aulast%3DKowalczyk%26aufirst%3DW.%26aulast%3DSobolewski%26aufirst%3DD.%26aulast%3DPrahl%26aufirst%3DA.%26aulast%3DDerdowska%26aufirst%3DI.%26aulast%3DBorovickova%26aufirst%3DL.%26aulast%3DSlaninova%26aufirst%3DJ.%26aulast%3DLammek%26aufirst%3DB.%26atitle%3DThe%2520Effects%2520of%2520N-Terminal%2520Part%2520Modification%2520of%2520Arginine%2520Vasopressin%2520Analogues%2520with%25202-Aminoindane-2-Carboxylic%2520Acid%253A%2520A%2520Highly%2520Potent%2520V2%2520Agonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D2926%26epage%3D2929%26doi%3D10.1021%2Fjm070174s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobolewski, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prahl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borovickova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slaninova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lammek, B.</span></span> <span> </span><span class="NLM_article-title">Arginine Vasopressin and Its Analogues - The Influence of Position 2 Modification with 3,3-Diphenylalanine Enantiomers. Highly Potent V2 Agonists</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">2862</span>– <span class="NLM_lpage">2867</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2008.12.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1016%2Fj.ejmech.2008.12.010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2009&pages=2862-2867&author=A.+Kwiatkowskaauthor=D.+Sobolewskiauthor=A.+Prahlauthor=L.+Borovickovaauthor=J.+Slaninovaauthor=B.+Lammek&title=Arginine+Vasopressin+and+Its+Analogues+-+The+Influence+of+Position+2+Modification+with+3%2C3-Diphenylalanine+Enantiomers.+Highly+Potent+V2+Agonists&doi=10.1016%2Fj.ejmech.2008.12.010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2008.12.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2008.12.010%26sid%3Dliteratum%253Aachs%26aulast%3DKwiatkowska%26aufirst%3DA.%26aulast%3DSobolewski%26aufirst%3DD.%26aulast%3DPrahl%26aufirst%3DA.%26aulast%3DBorovickova%26aufirst%3DL.%26aulast%3DSlaninova%26aufirst%3DJ.%26aulast%3DLammek%26aufirst%3DB.%26atitle%3DArginine%2520Vasopressin%2520and%2520Its%2520Analogues%2520-%2520The%2520Influence%2520of%2520Position%25202%2520Modification%2520with%25203%252C3-Diphenylalanine%2520Enantiomers.%2520Highly%2520Potent%2520V2%2520Agonists%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2009%26volume%3D44%26spage%3D2862%26epage%3D2867%26doi%3D10.1016%2Fj.ejmech.2008.12.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ben Mimoun, M.</span>; <span class="NLM_string-name">Derick, S.</span>; <span class="NLM_string-name">Andres, M.</span>; <span class="NLM_string-name">Guillon, G.</span>; <span class="NLM_string-name">Wo, N. C.</span>; <span class="NLM_string-name">Chan, W. Y.</span>; <span class="NLM_string-name">Stoev, S.</span>; <span class="NLM_string-name">Cheng, L.</span>; <span class="NLM_string-name">Manning, M.</span></span> In  <i>Vasopressin V2 Agonists: Affinities for Human and Rat V2 and V1a Receptors Reveal Surprising Species Differences</i>, Peptides 2000, Proceedings of the 26th European Peptide Symposium, Montpellier, France, September 10–15, 2000; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, J.</span>, <span class="NLM_string-name">Fehrentz, J.-A.</span></span>, Eds.; <span class="NLM_publisher-name">EDK</span>, <span class="NLM_year">2001</span>; pp  <span class="NLM_fpage">589</span>– <span class="NLM_lpage">590</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&pages=589-590&author=M.+Ben+Mimoun&author=S.+Derick&author=M.+Andres&author=G.+Guillon&author=N.+C.+Wo&author=W.+Y.+Chan&author=S.+Stoev&author=L.+Cheng&author=M.+Manningauthor=J.+Martinez&author=J.-A.+Fehrentz&title=Vasopressin+V2+Agonists%3A+Affinities+for+Human+and+Rat+V2+and+V1a+Receptors+Reveal+Surprising+Species+Differences"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DBen%2BMimoun%26aufirst%3DM.%26jtitle%3DVasopressin%2520V2%2520Agonists%253A%2520Affinities%2520for%2520Human%2520and%2520Rat%2520V2%2520and%2520V1a%2520Receptors%2520Reveal%2520Surprising%2520Species%2520Differences%26aulast%3DMartinez%26aufirst%3DJ.%26pub%3DEDK%26date%3D2001%26spage%3D589%26epage%3D590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manning, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klis, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolodziejczyk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nawrocka, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misicka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, W. H.</span></span> <span> </span><span class="NLM_article-title">Carboxy Terminus of Vasopressin Required for Activity but Not Binding</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>308</i></span>,  <span class="NLM_fpage">652</span>– <span class="NLM_lpage">653</span>, <span class="refDoi"> DOI: 10.1038/308652a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1038%2F308652a0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=308&publication_year=1984&pages=652-653&author=M.+Manningauthor=A.+Olmaauthor=W.+Klisauthor=A.+Kolodziejczykauthor=E.+Nawrockaauthor=A.+Misickaauthor=J.+Setoauthor=W.+H.+Sawyer&title=Carboxy+Terminus+of+Vasopressin+Required+for+Activity+but+Not+Binding&doi=10.1038%2F308652a0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2F308652a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F308652a0%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DM.%26aulast%3DOlma%26aufirst%3DA.%26aulast%3DKlis%26aufirst%3DW.%26aulast%3DKolodziejczyk%26aufirst%3DA.%26aulast%3DNawrocka%26aufirst%3DE.%26aulast%3DMisicka%26aufirst%3DA.%26aulast%3DSeto%26aufirst%3DJ.%26aulast%3DSawyer%26aufirst%3DW.%2BH.%26atitle%3DCarboxy%2520Terminus%2520of%2520Vasopressin%2520Required%2520for%2520Activity%2520but%2520Not%2520Binding%26jtitle%3DNature%26date%3D1984%26volume%3D308%26spage%3D652%26epage%3D653%26doi%3D10.1038%2F308652a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manning, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Przybylski, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klis, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruszynski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wo, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelton, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, W. H.</span></span> <span> </span><span class="NLM_article-title">No Requirements of Cyclic Conformation of Antagonists in Binding to Vasopressin Receptors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>329</i></span>,  <span class="NLM_fpage">839</span>– <span class="NLM_lpage">840</span>, <span class="refDoi"> DOI: 10.1038/329839a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1038%2F329839a0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=329&publication_year=1987&pages=839-840&author=M.+Manningauthor=J.+P.+Przybylskiauthor=A.+Olmaauthor=W.+A.+Klisauthor=M.+Kruszynskiauthor=N.+C.+Woauthor=G.+H.+Peltonauthor=W.+H.+Sawyer&title=No+Requirements+of+Cyclic+Conformation+of+Antagonists+in+Binding+to+Vasopressin+Receptors&doi=10.1038%2F329839a0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2F329839a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F329839a0%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DM.%26aulast%3DPrzybylski%26aufirst%3DJ.%2BP.%26aulast%3DOlma%26aufirst%3DA.%26aulast%3DKlis%26aufirst%3DW.%2BA.%26aulast%3DKruszynski%26aufirst%3DM.%26aulast%3DWo%26aufirst%3DN.%2BC.%26aulast%3DPelton%26aufirst%3DG.%2BH.%26aulast%3DSawyer%26aufirst%3DW.%2BH.%26atitle%3DNo%2520Requirements%2520of%2520Cyclic%2520Conformation%2520of%2520Antagonists%2520in%2520Binding%2520to%2520Vasopressin%2520Receptors%26jtitle%3DNature%26date%3D1987%26volume%3D329%26spage%3D839%26epage%3D840%26doi%3D10.1038%2F329839a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manning, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misicka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klis, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bankowski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nawrocka, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruszynski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolodziejczyk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, W. H.</span></span> <span> </span><span class="NLM_article-title">C-Terminal Deglycine and Deglycinamide Modifications of Arginine Vasopressin (AVP) Agonists and Antagonists. A Reevaluation</span>. <i>Pept. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_fpage">585</span>– <span class="NLM_lpage">590</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1988&pages=585-590&author=M.+Manningauthor=L.+L.+Chengauthor=A.+Misickaauthor=A.+Olmaauthor=W.+A.+Klisauthor=K.+Bankowskiauthor=E.+Nawrockaauthor=M.+Kruszynskiauthor=A.+Kolodziejczykauthor=W.+H.+Sawyer&title=C-Terminal+Deglycine+and+Deglycinamide+Modifications+of+Arginine+Vasopressin+%28AVP%29+Agonists+and+Antagonists.+A+Reevaluation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DM.%26aulast%3DCheng%26aufirst%3DL.%2BL.%26aulast%3DMisicka%26aufirst%3DA.%26aulast%3DOlma%26aufirst%3DA.%26aulast%3DKlis%26aufirst%3DW.%2BA.%26aulast%3DBankowski%26aufirst%3DK.%26aulast%3DNawrocka%26aufirst%3DE.%26aulast%3DKruszynski%26aufirst%3DM.%26aulast%3DKolodziejczyk%26aufirst%3DA.%26aulast%3DSawyer%26aufirst%3DW.%2BH.%26atitle%3DC-Terminal%2520Deglycine%2520and%2520Deglycinamide%2520Modifications%2520of%2520Arginine%2520Vasopressin%2520%2528AVP%2529%2520Agonists%2520and%2520Antagonists.%2520A%2520Reevaluation%26jtitle%3DPept.%2520Chem.%26date%3D1988%26spage%3D585%26epage%3D590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manning, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misicka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klis, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bankowski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nawrocka, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruszynski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolodziejczyk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L. L.</span></span> <span> </span><span class="NLM_article-title">C-Terminal Deletions in Agonistic and Antagonistic Analogues of Vasopressin That Improve Their Specificities for Antidiuretic (V2) and Vasopressor (V1) Receptors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">2245</span>– <span class="NLM_lpage">2252</span>, <span class="refDoi"> DOI: 10.1021/jm00395a012</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00395a012" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1987&pages=2245-2252&author=M.+Manningauthor=A.+Misickaauthor=A.+Olmaauthor=W.+A.+Klisauthor=K.+Bankowskiauthor=E.+Nawrockaauthor=M.+Kruszynskiauthor=A.+Kolodziejczykauthor=L.+L.+Cheng&title=C-Terminal+Deletions+in+Agonistic+and+Antagonistic+Analogues+of+Vasopressin+That+Improve+Their+Specificities+for+Antidiuretic+%28V2%29+and+Vasopressor+%28V1%29+Receptors&doi=10.1021%2Fjm00395a012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm00395a012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00395a012%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DM.%26aulast%3DMisicka%26aufirst%3DA.%26aulast%3DOlma%26aufirst%3DA.%26aulast%3DKlis%26aufirst%3DW.%2BA.%26aulast%3DBankowski%26aufirst%3DK.%26aulast%3DNawrocka%26aufirst%3DE.%26aulast%3DKruszynski%26aufirst%3DM.%26aulast%3DKolodziejczyk%26aufirst%3DA.%26aulast%3DCheng%26aufirst%3DL.%2BL.%26atitle%3DC-Terminal%2520Deletions%2520in%2520Agonistic%2520and%2520Antagonistic%2520Analogues%2520of%2520Vasopressin%2520That%2520Improve%2520Their%2520Specificities%2520for%2520Antidiuretic%2520%2528V2%2529%2520and%2520Vasopressor%2520%2528V1%2529%2520Receptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1987%26volume%3D30%26spage%3D2245%26epage%3D2252%26doi%3D10.1021%2Fjm00395a012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahmood, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, R. P.</span></span> <span> </span><span class="NLM_article-title">Interspecies Allometric Scaling. Part I: Prediction of Clearance in Large Animals</span>. <i>J. Vet. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">415</span>– <span class="NLM_lpage">423</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2885.2006.00786.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1111%2Fj.1365-2885.2006.00786.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=16958787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Wjtr%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2006&pages=415-423&author=I.+Mahmoodauthor=M.+Martinezauthor=R.+P.+Hunter&title=Interspecies+Allometric+Scaling.+Part+I%3A+Prediction+of+Clearance+in+Large+Animals&doi=10.1111%2Fj.1365-2885.2006.00786.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Interspecies allometric scaling. Part I: prediction of clearance in large animals</span></div><div class="casAuthors">Mahmood, I.; Martinez, M.; Hunter, R. P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Veterinary Pharmacology and Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">415-423</span>CODEN:
                <span class="NLM_cas:coden">JVPTD9</span>;
        ISSN:<span class="NLM_cas:issn">0140-7783</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Interspecies scaling is a useful tool for the prediction of pharmacokinetic parameters from animals to humans, and it is often used for estg. a first-time in human dose.  The knowledge of pharmacokinetics in veterinary species is important for dosage selection, particularly in the treatment of large zoo animal species, such as elephants, giant cats and camels, for which pharmacokinetic data are scant.  Therefore, the accuracy in clearance predictions in large animal species, with and without the use of correction factors (rule of exponents), and the impact of species selection in the prediction of clearance in large animal species was examd.  Based upon this anal., it was detd. that there is a much larger risk of inaccuracies in the clearance ests. in large animal species when compared with that obsd. for humans.  Unlike in humans, for large animal species, correction factors could not be applied because there was no trend between the exponents of simple allometry and the appropriate correction factor for improving our predictions.  Nevertheless, we did see an indication that the exponents of simple allometry may alert us as to when the predicted clearance in the large animal may be underestimated or overpredicted.  For example, if a large animal is included in the scaling, the predicted clearance in a large animal should be considered overestimated if the exponent of simple allometry is >1.3.  Despite the potential for extrapolation error, the reality is that allometric scaling is needed across many veterinary practice situations, and therefore will be used.  For this reason, it is important to consider mechanisms for reducing the risk of extrapolation errors that can seriously affect target animal safety, therapeutic response, or the accuracy of withdrawal time predictions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH5ejKuCOzn7Vg90H21EOLACvtfcHk0ljfHLElq71V6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Wjtr%252FF&md5=5050de49ab4b41dc85948304eadfad52</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2885.2006.00786.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2885.2006.00786.x%26sid%3Dliteratum%253Aachs%26aulast%3DMahmood%26aufirst%3DI.%26aulast%3DMartinez%26aufirst%3DM.%26aulast%3DHunter%26aufirst%3DR.%2BP.%26atitle%3DInterspecies%2520Allometric%2520Scaling.%2520Part%2520I%253A%2520Prediction%2520of%2520Clearance%2520in%2520Large%2520Animals%26jtitle%3DJ.%2520Vet.%2520Pharmacol.%2520Ther.%26date%3D2006%26volume%3D29%26spage%3D415%26epage%3D423%26doi%3D10.1111%2Fj.1365-2885.2006.00786.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahmood, I.</span></span> <span> </span><span class="NLM_article-title">Application of Allometric Principles for the Prediction of Pharmacokinetics in Human and Veterinary Drug Development</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1177</span>– <span class="NLM_lpage">1192</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2007.05.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1016%2Fj.addr.2007.05.015" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2007&pages=1177-1192&author=I.+Mahmood&title=Application+of+Allometric+Principles+for+the+Prediction+of+Pharmacokinetics+in+Human+and+Veterinary+Drug+Development&doi=10.1016%2Fj.addr.2007.05.015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2007.05.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2007.05.015%26sid%3Dliteratum%253Aachs%26aulast%3DMahmood%26aufirst%3DI.%26atitle%3DApplication%2520of%2520Allometric%2520Principles%2520for%2520the%2520Prediction%2520of%2520Pharmacokinetics%2520in%2520Human%2520and%2520Veterinary%2520Drug%2520Development%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2007%26volume%3D59%26spage%3D1177%26epage%3D1192%26doi%3D10.1016%2Fj.addr.2007.05.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tahara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugimoto, T.</span></span> <span> </span><span class="NLM_article-title">1-Desamino-8-<span class="smallcaps smallerCapital">d</span>-Arginine Vasopressin (DDAVP) as an Agonist on V1b Vasopressin Receptor</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">1711</span>– <span class="NLM_lpage">1717</span>, <span class="refDoi"> DOI: 10.1016/S0006-2952(97)00070-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1016%2FS0006-2952%2897%2900070-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1997&pages=1711-1717&author=M.+Saitoauthor=A.+Taharaauthor=T.+Sugimoto&title=1-Desamino-8-d-Arginine+Vasopressin+%28DDAVP%29+as+an+Agonist+on+V1b+Vasopressin+Receptor&doi=10.1016%2FS0006-2952%2897%2900070-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2FS0006-2952%2897%2900070-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-2952%252897%252900070-1%26sid%3Dliteratum%253Aachs%26aulast%3DSaito%26aufirst%3DM.%26aulast%3DTahara%26aufirst%3DA.%26aulast%3DSugimoto%26aufirst%3DT.%26atitle%3D1-Desamino-8-d-Arginine%2520Vasopressin%2520%2528DDAVP%2529%2520as%2520an%2520Agonist%2520on%2520V1b%2520Vasopressin%2520Receptor%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1997%26volume%3D53%26spage%3D1711%26epage%3D1717%26doi%3D10.1016%2FS0006-2952%2897%2900070-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wisniewski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galyean, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tariga, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alagarsamy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croston, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitzmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisniewska, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laporte, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riviere, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schteingart, C. D.</span></span> <span> </span><span class="NLM_article-title">New, Potent, Selective, and Short-Acting Peptidic V1a Receptor Agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">4388</span>– <span class="NLM_lpage">4398</span>, <span class="refDoi"> DOI: 10.1021/jm200278m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200278m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4388-4398&author=K.+Wisniewskiauthor=R.+Galyeanauthor=H.+Tarigaauthor=S.+Alagarsamyauthor=G.+Crostonauthor=J.+Heitzmannauthor=A.+Kohanauthor=H.+Wisniewskaauthor=R.+Laporteauthor=P.+J.+Riviereauthor=C.+D.+Schteingart&title=New%2C+Potent%2C+Selective%2C+and+Short-Acting+Peptidic+V1a+Receptor+Agonists&doi=10.1021%2Fjm200278m"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjm200278m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200278m%26sid%3Dliteratum%253Aachs%26aulast%3DWisniewski%26aufirst%3DK.%26aulast%3DGalyean%26aufirst%3DR.%26aulast%3DTariga%26aufirst%3DH.%26aulast%3DAlagarsamy%26aufirst%3DS.%26aulast%3DCroston%26aufirst%3DG.%26aulast%3DHeitzmann%26aufirst%3DJ.%26aulast%3DKohan%26aufirst%3DA.%26aulast%3DWisniewska%26aufirst%3DH.%26aulast%3DLaporte%26aufirst%3DR.%26aulast%3DRiviere%26aufirst%3DP.%2BJ.%26aulast%3DSchteingart%26aufirst%3DC.%2BD.%26atitle%3DNew%252C%2520Potent%252C%2520Selective%252C%2520and%2520Short-Acting%2520Peptidic%2520V1a%2520Receptor%2520Agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4388%26epage%3D4398%26doi%3D10.1021%2Fjm200278m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wiśniewski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alagarsamy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galyean, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tariga, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ly, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiśniewska, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croston, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laporte, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivière, P. J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schteingart, C. D.</span></span> <span> </span><span class="NLM_article-title">New, Potent, and Selective Peptidic Oxytocin Receptor Agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5306</span>– <span class="NLM_lpage">5317</span>, <span class="refDoi"> DOI: 10.1021/jm500365s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500365s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADC%252BC2cXovVWhs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5306-5317&author=K.+Wi%C5%9Bniewskiauthor=S.+Alagarsamyauthor=R.+Galyeanauthor=H.+Tarigaauthor=D.+Thompsonauthor=B.+Lyauthor=H.+Wi%C5%9Bniewskaauthor=S.+Qiauthor=G.+Crostonauthor=R.+Laporteauthor=P.+J.-M.+Rivi%C3%A8reauthor=C.+D.+Schteingart&title=New%2C+Potent%2C+and+Selective+Peptidic+Oxytocin+Receptor+Agonists&doi=10.1021%2Fjm500365s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">New, Potent, and Selective Peptidic Oxytocin Receptor Agonists</span></div><div class="casAuthors">Wisniewski, Kazimierz; Alagarsamy, Sudarkodi; Galyean, Robert; Tariga, Hiroe; Thompson, Dorain; Ly, Brian; Wisniewska, Halina; Qi, Steve; Croston, Glenn; Laporte, Regent; Riviere, Pierre J.-M.; Schteingart, Claudio D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5306-5317</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mothers of preterm babies frequently have difficulty establishing or maintaining lactation, thought to be due to interference with the milk ejection reflex.  Administration of exogenous oxytocin can produce alveolar contraction and adequate breast emptying resulting in establishment of successful lactation.  The natural hormone oxytocin is not receptor-selective and may cause hyponatremia via V2 receptor mediated antidiuresis.  We have designed a series of potent oxytocin analogs contg. N-alkylglycines in position 7 with excellent selectivity vs. the related V1a, V1b, and V2 vasopressin receptors and short half-life: agonists 31([2-ThiMeGly7]dOT), 47 (carba-6-[Phe2,BuGly7]dOT), 55 (carba-6-[3-MeBzlGly7]dOT), and 57 (carba-1-[4-FBzlGly7]dOT) have EC50 values at hOTR < 0.1 nM, selectivity ratios vs. related human vasopressin receptors of >2000, IC50 at hV1aR > 500 nM, and total clearance in rats in the range of 60-80 mL min-1 kg-1.  Compd. 57 (FE 202767) is currently in clin. development for the treatment of preterm mothers requiring lactation support.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_ykZz5KXVXbVg90H21EOLACvtfcHk0lhY_gJubDqgJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXovVWhs78%253D&md5=8076f2bbeb06371908b462d1c8f25321</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjm500365s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500365s%26sid%3Dliteratum%253Aachs%26aulast%3DWi%25C5%259Bniewski%26aufirst%3DK.%26aulast%3DAlagarsamy%26aufirst%3DS.%26aulast%3DGalyean%26aufirst%3DR.%26aulast%3DTariga%26aufirst%3DH.%26aulast%3DThompson%26aufirst%3DD.%26aulast%3DLy%26aufirst%3DB.%26aulast%3DWi%25C5%259Bniewska%26aufirst%3DH.%26aulast%3DQi%26aufirst%3DS.%26aulast%3DCroston%26aufirst%3DG.%26aulast%3DLaporte%26aufirst%3DR.%26aulast%3DRivi%25C3%25A8re%26aufirst%3DP.%2BJ.-M.%26aulast%3DSchteingart%26aufirst%3DC.%2BD.%26atitle%3DNew%252C%2520Potent%252C%2520and%2520Selective%2520Peptidic%2520Oxytocin%2520Receptor%2520Agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5306%26epage%3D5317%26doi%3D10.1021%2Fjm500365s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Czaja, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konieczna, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lammek, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slaninova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, T.</span></span> <span> </span><span class="NLM_article-title">Analogs of Arginine-Vasopressin Substituted in Position 2 with <span class="smallcaps smallerCapital">l</span>-4-Cl-Phenylalanine or <span class="smallcaps smallerCapital">d</span>-Phenylglycine</span>. <i>Collect. Czech. Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">675</span>– <span class="NLM_lpage">680</span>, <span class="refDoi"> DOI: 10.1135/cccc19930675</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1135%2Fcccc19930675" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADyaK3sXltFOku70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1993&pages=675-680&author=M.+Czajaauthor=E.+Koniecznaauthor=B.+Lammekauthor=J.+Slaninovaauthor=T.+Barth&title=Analogs+of+Arginine-Vasopressin+Substituted+in+Position+2+with+l-4-Cl-Phenylalanine+or+d-Phenylglycine&doi=10.1135%2Fcccc19930675"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Analogs of arginine-vasopressin substituted in position 2 with L-4-Cl-phenylalanine or D-phenylglycine</span></div><div class="casAuthors">Czaja, Malgorzata; Konieczna, Ewa; Lammek, Bernard; Slaninova, Jirina; Barth, Tomislav</div><div class="citationInfo"><span class="NLM_cas:title">Collection of Czechoslovak Chemical Communications</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">675-80</span>CODEN:
                <span class="NLM_cas:coden">CCCCAK</span>;
        ISSN:<span class="NLM_cas:issn">0010-0765</span>.
    </div><div class="casAbstract">Eight new title compds. I [X = Cys, 1-mercaptocyclohexaneacetic acid (Cpp), 2-mercaptopropionic acid; X1 = L-4-chlorophenylalanine (4-ClPhe), D-phenylglycine (Phg); X2 = Gln, Val] were designed, prepd., and bioassayed as a part of a study on the structure-activity relationship of arginine-vasopressin (AVP) analogs.  All prepd. compds. but I (X = Cpp, X1 = Phg, X2 = Val) were inhibitors in a uterotonic test; however, in most cases their potency was fairly low.  The agonistic potency of I (X1 = 4-ClPhe) in a pressor activity test was essentially the same as that of I [X1 = 4-fluorophenylalanine (4-FPhe)].  Antagonists I (X1 = 4-ClPhe) showed significantly higher potency than I (X1 = 4-FPhe).  All compds. I (X1 = Phg) were inactive in the pressor test.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7xO3hB1wAILVg90H21EOLACvtfcHk0lhY_gJubDqgJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXltFOku70%253D&md5=48492ff581718defcd10a678c86e5c75</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1135%2Fcccc19930675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1135%252Fcccc19930675%26sid%3Dliteratum%253Aachs%26aulast%3DCzaja%26aufirst%3DM.%26aulast%3DKonieczna%26aufirst%3DE.%26aulast%3DLammek%26aufirst%3DB.%26aulast%3DSlaninova%26aufirst%3DJ.%26aulast%3DBarth%26aufirst%3DT.%26atitle%3DAnalogs%2520of%2520Arginine-Vasopressin%2520Substituted%2520in%2520Position%25202%2520with%2520l-4-Cl-Phenylalanine%2520or%2520d-Phenylglycine%26jtitle%3DCollect.%2520Czech.%2520Chem.%2520Commun.%26date%3D1993%26volume%3D58%26spage%3D675%26epage%3D680%26doi%3D10.1135%2Fcccc19930675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wisniewski, K.</span>; <span class="NLM_string-name">Stalewski, J.</span>; <span class="NLM_string-name">Jiang, G.</span></span> <span> </span><span class="NLM_article-title">Intermediates and Methods for Making Heptapeptide Oxytocin Analogs</span>. <span class="NLM_patent">WO2003072597</span>, <span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=K.+Wisniewski&author=J.+Stalewski&author=G.+Jiang&title=Intermediates+and+Methods+for+Making+Heptapeptide+Oxytocin+Analogs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWisniewski%26aufirst%3DK.%26atitle%3DIntermediates%2520and%2520Methods%2520for%2520Making%2520Heptapeptide%2520Oxytocin%2520Analogs%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linares, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doulut, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, J.</span></span> <span> </span><span class="NLM_article-title">A Facile Synthesis of Chiral N-Protected β-Amino Alcohols</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">923</span>– <span class="NLM_lpage">926</span>, <span class="refDoi"> DOI: 10.1016/S0040-4039(00)92121-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1016%2FS0040-4039%2800%2992121-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADyaK3MXitVOksb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1991&pages=923-926&author=M.+Rodriguezauthor=M.+Linaresauthor=S.+Doulutauthor=A.+Heitzauthor=J.+Martinez&title=A+Facile+Synthesis+of+Chiral+N-Protected+%CE%B2-Amino+Alcohols&doi=10.1016%2FS0040-4039%2800%2992121-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">A facile synthesis of chiral N-protected β-amino alcohols</span></div><div class="casAuthors">Rodriguez, Marc; Linares, Muriel; Doulut, Sylvie; Heitz, Annie; Martinez, Jean</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">923-6</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    </div><div class="casAbstract">Chiral N-protected β-amino alcs. are easily obtained by NaBH4 redn. of mixed anhydrides of N-protected α-amino acids in an org./aq. medium.  The alcs. obtained from side chain or main chain redn. of N-protected aspartic acid are converted in good yields into lactones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdEKziakOsFLVg90H21EOLACvtfcHk0lh9_na9Al0gaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXitVOksb8%253D&md5=3ddd67e6ee1c94ef4e6fee5e6cb9888b</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2800%2992121-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252800%252992121-X%26sid%3Dliteratum%253Aachs%26aulast%3DRodriguez%26aufirst%3DM.%26aulast%3DLinares%26aufirst%3DM.%26aulast%3DDoulut%26aufirst%3DS.%26aulast%3DHeitz%26aufirst%3DA.%26aulast%3DMartinez%26aufirst%3DJ.%26atitle%3DA%2520Facile%2520Synthesis%2520of%2520Chiral%2520N-Protected%2520%25CE%25B2-Amino%2520Alcohols%26jtitle%3DTetrahedron%2520Lett.%26date%3D1991%26volume%3D32%26spage%3D923%26epage%3D926%26doi%3D10.1016%2FS0040-4039%2800%2992121-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malesevic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strijowski, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachle, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sewald, N.</span></span> <span> </span><span class="NLM_article-title">An Improved Method for the Solution Cyclization of Peptides under Pseudo-High Dilution Conditions</span>. <i>J. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">73</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1016/j.jbiotec.2004.03.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1016%2Fj.jbiotec.2004.03.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=15288942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmt1Whu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2004&pages=73-77&author=M.+Malesevicauthor=U.+Strijowskiauthor=D.+Bachleauthor=N.+Sewald&title=An+Improved+Method+for+the+Solution+Cyclization+of+Peptides+under+Pseudo-High+Dilution+Conditions&doi=10.1016%2Fj.jbiotec.2004.03.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">An improved method for the solution cyclization of peptides under pseudo-high dilution conditions</span></div><div class="casAuthors">Malesevic, Miroslav; Strijowski, Ulf; Bachle, Dirk; Sewald, Norbert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biotechnology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">73-77</span>CODEN:
                <span class="NLM_cas:coden">JBITD4</span>;
        ISSN:<span class="NLM_cas:issn">0168-1656</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Depending on the ring size, the cyclization of peptides often is accompanied by dimerization or cyclodimerization.  Hence, these macrocyclizations have to be performed under high diln. conditions.  Efficient cyclization of peptides in soln. with a min. amt. of solvent succeeds, when a dual syringe pump is used to simultaneously add the linear peptide precursor and a coupling reagent from two sep. syringes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3nbSU9oZTrrVg90H21EOLACvtfcHk0lh9_na9Al0gaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmt1Whu70%253D&md5=56eb47eff1408b726bf6cfa0724c6616</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.jbiotec.2004.03.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jbiotec.2004.03.015%26sid%3Dliteratum%253Aachs%26aulast%3DMalesevic%26aufirst%3DM.%26aulast%3DStrijowski%26aufirst%3DU.%26aulast%3DBachle%26aufirst%3DD.%26aulast%3DSewald%26aufirst%3DN.%26atitle%3DAn%2520Improved%2520Method%2520for%2520the%2520Solution%2520Cyclization%2520of%2520Peptides%2520under%2520Pseudo-High%2520Dilution%2520Conditions%26jtitle%3DJ.%2520Biotechnol.%26date%3D2004%26volume%3D112%26spage%3D73%26epage%3D77%26doi%3D10.1016%2Fj.jbiotec.2004.03.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otaka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yajima, H.</span></span> <span> </span><span class="NLM_article-title">Studies on Peptides. CLV. Evaluation of Trimethylsilyl Bromide as a Hard-Acid Deprotecting Reagent in Peptide Synthesis</span>. <i>Chem. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">3880</span>– <span class="NLM_lpage">3883</span>, <span class="refDoi"> DOI: 10.1248/cpb.35.3880</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1248%2Fcpb.35.3880" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1987&pages=3880-3883&author=N.+Fujiiauthor=A.+Otakaauthor=N.+Sugiyamaauthor=M.+Hatanoauthor=H.+Yajima&title=Studies+on+Peptides.+CLV.+Evaluation+of+Trimethylsilyl+Bromide+as+a+Hard-Acid+Deprotecting+Reagent+in+Peptide+Synthesis&doi=10.1248%2Fcpb.35.3880"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1248%2Fcpb.35.3880&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.35.3880%26sid%3Dliteratum%253Aachs%26aulast%3DFujii%26aufirst%3DN.%26aulast%3DOtaka%26aufirst%3DA.%26aulast%3DSugiyama%26aufirst%3DN.%26aulast%3DHatano%26aufirst%3DM.%26aulast%3DYajima%26aufirst%3DH.%26atitle%3DStudies%2520on%2520Peptides.%2520CLV.%2520Evaluation%2520of%2520Trimethylsilyl%2520Bromide%2520as%2520a%2520Hard-Acid%2520Deprotecting%2520Reagent%2520in%2520Peptide%2520Synthesis%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D1987%26volume%3D35%26spage%3D3880%26epage%3D3883%26doi%3D10.1248%2Fcpb.35.3880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pena, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murat, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trueba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durroux, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rognan, D.</span></span> <span> </span><span class="NLM_article-title">Mapping the Binding Site of Arginine Vasopressin to V1a and V1b Vasopressin Receptors</span>. <i>Mol. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">512</span>– <span class="NLM_lpage">523</span>, <span class="refDoi"> DOI: 10.1210/me.2006-0202</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1210%2Fme.2006-0202" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=17082326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVWisbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=512-523&author=J.+Rodrigoauthor=A.+Penaauthor=B.+Muratauthor=M.+Truebaauthor=T.+Durrouxauthor=G.+Guillonauthor=D.+Rognan&title=Mapping+the+Binding+Site+of+Arginine+Vasopressin+to+V1a+and+V1b+Vasopressin+Receptors&doi=10.1210%2Fme.2006-0202"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Mapping the binding site of arginine vasopressin to V1a and V1b vasopressin receptors</span></div><div class="casAuthors">Rodrigo, Jordi; Pena, Ana; Murat, Brigitte; Trueba, Miguel; Durroux, Thierry; Guillon, Gilles; Rognan, Didier</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Endocrinology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">512-523</span>CODEN:
                <span class="NLM_cas:coden">MOENEN</span>;
        ISSN:<span class="NLM_cas:issn">0888-8809</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Starting from the 2.8-Å resoln. x-ray structure of bovine rhodopsin, three-dimensional mol. models of the complexes between arginine vasopressin and two receptor subtypes (V1a, V1b) have been built.  Amino acid sequence alignment and docking studies suggest that four key residues (1.35, 2.65, 4.61, and 5.35) fine tune the binding of vasopressin and related peptide agonists to both receptor subtypes.  To validate these predictions, a series of single or double mutants were engineered at V1a and V1b receptor subtypes and tested for their binding and functional properties.  Two neg. charged amino acids at positions 1.35 and 2.65 are key anchoring residues to the Arg8 residue of arginine vasopressin.  Moreover, two amino acids (V4.61 and P5.35) delineating a hydrophobic subsite at the human V1b receptor are responsible for the recognition of V1b selective peptide agonists.  Last, one of the latter positions (5.35) is hypothesized to explain the pharmacol. species differences between rat and human vasopressin receptors for a V1b peptide agonist.  Altogether these refined three-dimensional models of V1a and V1b human receptors should enable the identification of further new selective V1a and V1b agonists as pharmacol. but also therapeutic tools.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiSR2zAZAfYrVg90H21EOLACvtfcHk0lg-DW7PnPyLkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVWisbg%253D&md5=3da9d009a1b55b8e9420dfba0b0b77f3</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1210%2Fme.2006-0202&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fme.2006-0202%26sid%3Dliteratum%253Aachs%26aulast%3DRodrigo%26aufirst%3DJ.%26aulast%3DPena%26aufirst%3DA.%26aulast%3DMurat%26aufirst%3DB.%26aulast%3DTrueba%26aufirst%3DM.%26aulast%3DDurroux%26aufirst%3DT.%26aulast%3DGuillon%26aufirst%3DG.%26aulast%3DRognan%26aufirst%3DD.%26atitle%3DMapping%2520the%2520Binding%2520Site%2520of%2520Arginine%2520Vasopressin%2520to%2520V1a%2520and%2520V1b%2520Vasopressin%2520Receptors%26jtitle%3DMol.%2520Endocrinol.%26date%3D2007%26volume%3D21%26spage%3D512%26epage%3D523%26doi%3D10.1210%2Fme.2006-0202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singer, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morton, A. R.</span></span> <span> </span><span class="NLM_article-title">Mouse to Elephant: Biological Scaling and Kt/V</span>. <i>Am. J. Kidney Dis.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">306</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1016/S0272-6386(00)70341-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1016%2FS0272-6386%2800%2970341-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10676731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A280%3ADC%252BD3c7jvF2jsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2000&pages=306-309&author=M.+A.+Singerauthor=A.+R.+Morton&title=Mouse+to+Elephant%3A+Biological+Scaling+and+Kt%2FV&doi=10.1016%2FS0272-6386%2800%2970341-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Mouse to elephant: biological scaling and Kt/V</span></div><div class="casAuthors">Singer M A; Morton A R</div><div class="citationInfo"><span class="NLM_cas:title">American journal of kidney diseases : the official journal of the National Kidney Foundation</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">306-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The construct Kt/V is used by the nephrology community in prescribing dialysis dose.  The concerns that have been raised as to what value of V to use in the calculation of Kt/V touch on the more central question of whether filtration rate should be normalized by a parameter other than V.  Within the animal kingdom, a number of physiological variables scale to body size according to an equation of the form Y = YoMb, where Yo is a constant, M is body mass, and b is a scaling exponent.  Glomerular filtration rate (GFR) in mammals weighing from 30 g to 503 kg scales to body weight with an exponent of 0.77.  Hence, GFR per unit body weight (or Kt/V) decreases significantly with increasing body size.  Metabolic rate also scales to body size in a wide range of mammals according to the same general equation and with a scaling exponent of 0.75.  Because GFR and metabolic rate scale to body mass with virtually the same exponent, a ratio of the two yields a constant independent of body size.  We propose that the ratio (filtration rate/metabolic rate) replace Kt/V.  Such a ratio would underscore the linkage between filtration rate (and dialysis therapy) and the metabolic demands of the body.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSei5Ve87DRUmgRQsDqrjW_fW6udTcc2eYH_urW7IPBjLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c7jvF2jsw%253D%253D&md5=93ea81288c2d796b351ffc68e6207725</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2FS0272-6386%2800%2970341-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0272-6386%252800%252970341-6%26sid%3Dliteratum%253Aachs%26aulast%3DSinger%26aufirst%3DM.%2BA.%26aulast%3DMorton%26aufirst%3DA.%2BR.%26atitle%3DMouse%2520to%2520Elephant%253A%2520Biological%2520Scaling%2520and%2520Kt%252FV%26jtitle%3DAm.%2520J.%2520Kidney%2520Dis.%26date%3D2000%26volume%3D35%26spage%3D306%26epage%3D309%26doi%3D10.1016%2FS0272-6386%2800%2970341-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verbalis, J. G.</span></span> <span> </span><span class="NLM_article-title">Disorders of Body Water Homeostasis</span>. <i>Best Pract. Res., Clin. Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">471</span>– <span class="NLM_lpage">503</span>, <span class="refDoi"> DOI: 10.1016/S1521-690X(03)00049-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1016%2FS1521-690X%2803%2900049-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=14687585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpvVWmu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2003&pages=471-503&author=J.+G.+Verbalis&title=Disorders+of+Body+Water+Homeostasis&doi=10.1016%2FS1521-690X%2803%2900049-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Disorders of body water homeostasis</span></div><div class="casAuthors">Verbalis, Joseph G.</div><div class="citationInfo"><span class="NLM_cas:title">Best Practice & Research, Clinical Endocrinology & Metabolism</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">471-503</span>CODEN:
                <span class="NLM_cas:coden">BPRCE9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  Disorders of body fluids are among the most commonly encountered problems in the practice of clin. medicine.  This is in large part because many different disease states can potentially disrupt the finely balanced mechanisms that control the intake and output of water and solute.  It therefore behoves clinicians treating such patients to have a good understanding of the pathophysiol., the differential diagnosis and the management of these disorders.  Because body water is the primary determinant of the osmolality of the extracellular fluid, disorders of body water homeostasis can be divided into hypo-osmolar disorders, in which there is an excess of body water relative to body solute, and hyperosmolar disorders, in which there is a deficiency of body water relative to body solute.  The classical hyperosmolar disorder is diabetes insipidus (DI), and the classical hypo-osmolar disorder is the syndrome of inappropriate antidiuretic hormone secretion (SIADH).  This chapter first reviews the regulatory mechanisms underlying water and sodium metab., the 2 major determinants of body fluid homeostasis.  The major disorders of water metab. causing hyperosmolality and hypo-osmolality, DI and SIADH, are then discussed in detail, including the pathogenesis, differential diagnosis and treatment of these disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrO-tI02ZntLbVg90H21EOLACvtfcHk0ljm-cQ5YyGH2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpvVWmu7w%253D&md5=8fc891633b2527c3e76f910ccfae7f58</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2FS1521-690X%2803%2900049-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1521-690X%252803%252900049-6%26sid%3Dliteratum%253Aachs%26aulast%3DVerbalis%26aufirst%3DJ.%2BG.%26atitle%3DDisorders%2520of%2520Body%2520Water%2520Homeostasis%26jtitle%3DBest%2520Pract.%2520Res.%252C%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2003%26volume%3D17%26spage%3D471%26epage%3D503%26doi%3D10.1016%2FS1521-690X%2803%2900049-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Juul, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erichsen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, G. L.</span></span> <span> </span><span class="NLM_article-title">Temporal Delays and Individual Variation in Antidiuretic Response to Desmopressin</span>. <i>Am. J. Physiol.: Renal Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>304</i></span>,  <span class="NLM_fpage">F268</span>– <span class="NLM_lpage">F278</span>, <span class="refDoi"> DOI: 10.1152/ajprenal.00502.2012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1152%2Fajprenal.00502.2012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=23136002" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2013&pages=F268-F278&author=K.+V.+Juulauthor=L.+Erichsenauthor=G.+L.+Robertson&title=Temporal+Delays+and+Individual+Variation+in+Antidiuretic+Response+to+Desmopressin&doi=10.1152%2Fajprenal.00502.2012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1152%2Fajprenal.00502.2012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajprenal.00502.2012%26sid%3Dliteratum%253Aachs%26aulast%3DJuul%26aufirst%3DK.%2BV.%26aulast%3DErichsen%26aufirst%3DL.%26aulast%3DRobertson%26aufirst%3DG.%2BL.%26atitle%3DTemporal%2520Delays%2520and%2520Individual%2520Variation%2520in%2520Antidiuretic%2520Response%2520to%2520Desmopressin%26jtitle%3DAm.%2520J.%2520Physiol.%253A%2520Renal%2520Physiol.%26date%3D2013%26volume%3D304%26spage%3DF268%26epage%3DF278%26doi%3D10.1152%2Fajprenal.00502.2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barlos, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatzi, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stavropoulos, G.</span></span> <span> </span><span class="NLM_article-title">2-Chlorotrityl Chloride Resin. Studies on Anchoring of Fmoc-Amino Acids and Peptide Cleavage</span>. <i>Int. J. Pept. Protein Res.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">513</span>– <span class="NLM_lpage">520</span>, <span class="refDoi"> DOI: 10.1111/j.1399-3011.1991.tb00769.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1111%2Fj.1399-3011.1991.tb00769.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1917309" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADyaK3MXltFGjur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1991&pages=513-520&author=K.+Barlosauthor=O.+Chatziauthor=D.+Gatosauthor=G.+Stavropoulos&title=2-Chlorotrityl+Chloride+Resin.+Studies+on+Anchoring+of+Fmoc-Amino+Acids+and+Peptide+Cleavage&doi=10.1111%2Fj.1399-3011.1991.tb00769.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">2-Chlorotrityl chloride resin.  Studies on anchoring of Fmoc-aminio acids and peptide cleavage</span></div><div class="casAuthors">Barlos, Kleomenis; Chatzi, Olga; Gatos, Dimitrios; Stavropoulos, George</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Peptide & Protein Research</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">513-20</span>CODEN:
                <span class="NLM_cas:coden">IJPPC3</span>;
        ISSN:<span class="NLM_cas:issn">0367-8377</span>.
    </div><div class="casAbstract">The esterification of 2-chlorotrityl chloride resin with 9-fluorenylmethoxycarbonyl (Fmoc) amino acids in the presence of EtN(CHMe2)2 is studied under various conditions.  High esterification yields are obtained using 0.6 equiv. Fmoc-amino acid/mmol resin in CH2Cl2 or ClCH2CH2Cl in 25 min at room temp.  The reaction proceeds without byproduct formation even in the case of Fmoc-Asn-OH and Fmoc-Gln-OH.  The quant. and easy cleavage of amino acids and peptides from 2-chlorotrityl resin using AcOH/CF3CH2OH/CH2Cl2 mixts. is accomplished within 15-60 min at room temp. while tert-Bu type protecting groups remain unaffected.  Under these exceptionally mild conditions, 2-chlorotrityl cations generated during the cleavage of amino acids and peptides from resin do not attack the nucleophilic side chains of tryptophan, methionine, and tyrosine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQ5Em66XBXF7Vg90H21EOLACvtfcHk0lhnayyInJQMYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXltFGjur4%253D&md5=2ac32b2f179e3b9e2a4977b6d7fa0aaa</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1111%2Fj.1399-3011.1991.tb00769.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1399-3011.1991.tb00769.x%26sid%3Dliteratum%253Aachs%26aulast%3DBarlos%26aufirst%3DK.%26aulast%3DChatzi%26aufirst%3DO.%26aulast%3DGatos%26aufirst%3DD.%26aulast%3DStavropoulos%26aufirst%3DG.%26atitle%3D2-Chlorotrityl%2520Chloride%2520Resin.%2520Studies%2520on%2520Anchoring%2520of%2520Fmoc-Amino%2520Acids%2520and%2520Peptide%2520Cleavage%26jtitle%3DInt.%2520J.%2520Pept.%2520Protein%2520Res.%26date%3D1991%26volume%3D37%26spage%3D513%26epage%3D520%26doi%3D10.1111%2Fj.1399-3011.1991.tb00769.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wisniewski, K.</span>; <span class="NLM_string-name">Schteingart, C.</span>; <span class="NLM_string-name">Riviere, P.</span></span> <span> </span><span class="NLM_article-title">Preparation of Cyclic Peptide Vasopressin-2 Receptor Agonists</span>. <span class="NLM_patent">WO2015013690A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=K.+Wisniewski&author=C.+Schteingart&author=P.+Riviere&title=Preparation+of+Cyclic+Peptide+Vasopressin-2+Receptor+Agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWisniewski%26aufirst%3DK.%26atitle%3DPreparation%2520of%2520Cyclic%2520Peptide%2520Vasopressin-2%2520Receptor%2520Agonists%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frick, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adkison, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells-Knecht, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woollard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higton, D. M.</span></span> <span> </span><span class="NLM_article-title">Cassette Dosing: Rapid in Vivo Assessment of Pharmacokinetics</span>. <i>Pharm. Sci. Technol. Today</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">12</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1016/S1461-5347(98)00010-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=10.1016%2FS1461-5347%2898%2900010-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;key=1%3ACAS%3A528%3ADyaK1cXislaks7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1998&pages=12-18&author=L.+W.+Frickauthor=K.+K.+Adkisonauthor=K.+J.+Wells-Knechtauthor=P.+Woollardauthor=D.+M.+Higton&title=Cassette+Dosing%3A+Rapid+in+Vivo+Assessment+of+Pharmacokinetics&doi=10.1016%2FS1461-5347%2898%2900010-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Cassette dosing: rapid in vivo assessment of pharmacokinetics</span></div><div class="casAuthors">Frick, Lloyd W.; Adkison, Kimberly K.; Wells-Knecht, Kevin J.; Woollard, Patrick; Higton, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Science & Technology Today</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12-18</span>CODEN:
                <span class="NLM_cas:coden">PSTTF8</span>;
        ISSN:<span class="NLM_cas:issn">1461-5347</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with 26 refs. on cassette dosing, which combines many test chems. into one dose soln. and is an attractive method for increasing the throughput of in vivo pharmacokinetic expts.  This dosing technique depends on the sensitivity and selectivity of modern anal. techniques, particularly HPLC/MS/MS.  Cassettes vary in size, but even relatively small ones greatly increase the nos. of compds. investigated by reducing the effort devoted to animal handling, sample processing and sample anal.  The major drawback of cassette dosing is the potential for drug-drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_MeQApZA877Vg90H21EOLACvtfcHk0lhnayyInJQMYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXislaks7o%253D&md5=2912aaa741529642959a80e409f0a7aa</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2FS1461-5347%2898%2900010-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1461-5347%252898%252900010-8%26sid%3Dliteratum%253Aachs%26aulast%3DFrick%26aufirst%3DL.%2BW.%26aulast%3DAdkison%26aufirst%3DK.%2BK.%26aulast%3DWells-Knecht%26aufirst%3DK.%2BJ.%26aulast%3DWoollard%26aufirst%3DP.%26aulast%3DHigton%26aufirst%3DD.%2BM.%26atitle%3DCassette%2520Dosing%253A%2520Rapid%2520in%2520Vivo%2520Assessment%2520of%2520Pharmacokinetics%26jtitle%3DPharm.%2520Sci.%2520Technol.%2520Today%26date%3D1998%26volume%3D1%26spage%3D12%26epage%3D18%26doi%3D10.1016%2FS1461-5347%2898%2900010-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i37"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00132">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_84764"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.9b00132">10.1021/acs.jmedchem.9b00132</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">In vitro, PK, PPB data with statistical parameters; analytical methods including assessment of final purity of analogues, determination of HPLC capacity factors, and high-resolution mass spectrometry; and physiochemical properties of analogues <b>1</b>–<b>43</b> as well as the description of additional synthetic methods (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00132/suppl_file/jm9b00132_si_001.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00132/suppl_file/jm9b00132_si_001.pdf">jm9b00132_si_001.pdf (280.05 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b00132&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b00132%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-10%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b00132" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                1MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679948192c1e24ad","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
